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1.6 Abstract 
1.6.1. Introduction 
The rapid growth and maturation of Information technologies over recent decades has had a 
transformative effect on healthcare delivery.  As our use of such systems increases, so too 
does the volume of routinely collected patient data.  Accessing these data with a view to 
providing meaningful information to individuals remains a challenge.  This thesis aims to assess 
the effectiveness of eHealth interventions that tailor information to users’ specific 
requirements; and describe the implementation and evaluation of a clinical decision support 
system (CDSS) for diabetes with a view to improving the care of those with diabetes. 
1.6.2. Methods 
This study consisted of two phases: 
 A systematic review was conducted for trials of tailored eHealth messaging in the 
management of chronic disease, assessing objectively measured clinical processes and 
outcomes.   
 Following this, a CDSS for diabetes was developed and implemented within a diabetes 
electronic health record.  The CDSS was evaluated via a mixed methods approach to assess 
user satisfaction and interaction with the system and to detect any changes in clinical 
processes and outcomes. 
1.6.3. Results 
The systematic review identified 22 studies that met the eligibility criteria. There was limited 
evidence that tailored eHealth messaging was associated with improved clinical processes and 
outcomes, but study quality was poor. 
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The CDSS was successfully implemented within the diabetes EHR with favourable feedback 
from users and evidence of improved efficiencies in working practices.  Adherence to 
guidelines was markedly improved when compared to a closely matched control population. 
There was an observed small but significant improvement in glycaemic control and a decrease 
in progression of kidney disease. 
1.6.4. Conclusion 
The ubiquitous nature of information technologies is testimony to the benefits that they bring 
to our everyday lives, including within the healthcare setting. 
This study has demonstrated that healthcare professionals (HCPs) caring for people with 
diabetes recognise the value of informatics in routine care via the use of a CDSS. This study has 
shown that a CDSS has the potential to improve clinical outcomes primarily by its effect on 
clinical processes i.e. adherence to guidelines. 
The diverse and complex nature of such technologies makes it difficult to assess the active 
component(s) effecting behaviour change.  Ultimately, this limits generalisability into other 
settings.  In this study, the active components of the CDSS can be identified as being improved 
efficiencies in working practices, whilst avoiding adverse effects on patient or user experience. 
It is tempting to infer that tailoring the CDSS messages to end-users (either patient or HCP) will 
improve outcomes further, however the existing evidence does not allow for this specific 
conclusion to be drawn.  It is therefore imperative that future studies attempt to address this 
by recognising the complex nature of eHealth interventions and attempting to delineate the 
active component(s). 
2. Project-related research output 
2.1 Published articles 
See appendix (section 20) for full text of published articles. 
 Conway NT, Adamson KA, Cunningham SG, Emslie Smith A, Nyberg P, Smith BH, Wales 
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 Conway NT, Webster C, Smith B, Wake, D.  eHealth and the use of individually tailored 
information: a systematic review.  Health Informatics Journal 2016 (epub):  
 Conway NT, Campbell I, Forbes P, Cunningham SG, Wake DJ. mHealth applications for 
diabetes – user preference and implications for app development. Health Informatics 
Journal 2015 (epub) 
2.2 Peer reviewed conference abstracts (*oral presentations) 
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International Diabetes Federation, World Diabetes Congress, Dubai 2017. 
 *NT Conway, SG Cunningham, A Wales, DJ Wake.  Clinical Decision Support for 
Diabetes in Scotland: evaluation of clinical processes and outcomes.  Informatics for 
Health conference, Manchester 2017. 
 NT Conway, K Adamson, SG Cunningham, A Emslie-Smith, A Wales, DJ Wake.  Clinical 
Decision Support for Diabetes in Scotland: evaluation of user attitudes and system 
usage.  Diabetes UK conference, Manchester 2017 
 NT Conway, K Adamson, SG Cunningham, A Emslie-Smith, A Wales, DJ Wake.  Clinical 
Decision Support for Diabetes in Scotland: evaluation of clinical processes and 
outcomes.  Diabetes UK conference, Manchester 2017 
 *Conway NT, Campbell I, Forbes P, Cunningham SG, Wake DJ. mHealth applications for 
diabetes – user preference and implications for app development..  Farr Institute 
International Conference, St Andrews 2015. 
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 Conway NT, Campbell I, Forbes P, Cunningham SG, Wake DJ. mHealth applications for 
diabetes – user preference and implications for app development..  International 
Diabetes Federation, World Diabetes Congress, Vancouver 2015. 
 Conway NT, Cunningham SG, Forbes P, Shaik F, Emslie-Smith A, Wales A, Wake DJ. 
Decision Support for Diabetes: Implementation and evaluation of the EBMeDS project 
within NHS Scotland. International Diabetes Federation, World Diabetes Congress, 
Vancouver 2015. 
 *Conway NT, Wales A, Cunningham S, Walker J, Locke R, Emslie-Smith A, Shaik F, Wake 
DJ.  Decision support for diabetes: embedding knowledge in care processes.  Health 
Informatics Scotland Conference, Glasgow 2014.  
 Campbell IJM, Cunningham SG, Conway NT, Wake DJ.  Mobile technology as a tool for 
patient education and self-management in the diabetic population. Diabetes UK 
Professional Conference, Liverpool 2014 
 Campbell IJM, Cunningham SG, Conway NT, Wake DJ.  Mobile technology as a tool for 
patient education and self-management in the diabetic population. International 
Conference on Advanced Technologies & Treatments for Diabetes, Vienna 2014. 
2.3 Other reports and awards 
 Final report for funders (DHI):  Project “Bain”.  Clinical decision support for diabetes in 
Scotland – implementation and evaluation of EBMeDS within SCI-Diabetes 
 Final report for NES: Clinical decision support for NHS Scotland.  Evaluation of the 
Evidence Based Medicine electronic Decision Support (EBMeDS) system within SCI-
Diabetes 
 Scottish Government eHealth website – good practice case studies: 
http://www.ehealth.nhs.scot/case-studies/clinical-decision-support-for-diabetes-in-
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 Quality in Care (Diabetes) award finalists: Clinical Decision Support for Diabetes in 
Scotland - 
http://www.qualityincare.org/diabetes/awards/results/qic_diabetes_2016_results/dig
ital_and_technology_solutions_in_the_treatment_and_management_of_diabetes 
3. Introduction 
3.1 Diabetes 
An estimated 385 million of the world’s 7 billion population have diabetes, with this number 
estimated to increase to nearly 600 million by the year 2035 3.  In the UK, nearly 3 million 
people have been diagnosed with diabetes, which accounts for over 6% of adults in the UK.  
The Scottish prevalence of diabetes is rising and is expected to double over the next 2 decades 
4–6. 
The majority of care for those with diabetes is conducted in the community via primary care 
and outpatient departments.  This care aims to improve glycaemic control, thereby reducing 
the incidence of diabetes-related complications as well as providing early detection and 
effective treatment of these complications.  Diabetes-related complications place a substantial 
burden on secondary care services.  A national English inpatient audit of over 200 hospital sites 
found that those with diabetes accounted for 15% of inpatient admissions, over half of whom 
were admitted specifically for care related to diabetes 7. 
Taking into account both direct and indirect costs, it has been estimated that the direct cost of 
diabetes care within the UK in 2010/11 was £9.8bn, equivalent to approximately 10% of NHS 
annual spending 8. Taking into account indirect costs e.g. lost earnings, the current overall cost 
to the UK economy rises to £23.7 billion per year 8.  As the burden of disease increases, it is 
estimated that by 2035/36 this proportion will rise to 17% of health spending in the UK. 
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3.2 Delivery of diabetes care – national context 
Best practice in the management of diabetes has been established by the use of national 
guidelines based on an appraisal of the available evidence 9–11.  Diabetes care in Scotland relies 
on a series of managed clinical networks supported by a national informatics platform, SCI-
Diabetes 12.  The prevalence of diabetes in Scotland has increased over the past decade 4.  
Despite this, there has been a sequential improvement in quality performance indicators and 
the incidences of diabetes-related complications have decreased 4,13,14.   
Improving the delivery of care for those with diabetes can lead to improved clinical outcomes 
15.  Specifically, interventions that involve audit tools and feedback to health professionals can 
improve diabetes outcomes (when implemented in conjunction with interventions aimed at 
patient behaviour).  In Scotland, regional and national audits are published on an annual basis 
using data extracted from SCI-Diabetes 4,16.  These audits report on a series of quality 
performance indicators (QPIs), which are agreed at a national level and allow regional and 
international comparisons to be drawn.  These QPIs (which include the monitoring of 
biochemistry, anthropometrics, and attendance at screening activities) are broadly aligned 
with the “15 care essentials” advocated by Diabetes UK, the UK’s largest charity for those with 
diabetes 17.   
In 2004, the then Scottish Executive commissioned a report into the future direction of the 
NHS in Scotland and how healthcare should be delivered 18,19.  Recommendations included a 
shift towards preventative services that are targeted towards at-risk individuals and an 
increased emphasis on self-care and intensive support for those with long-term conditions.  In 
addition, an eHealth strategy was described which recognised the importance of developing an 
electronic health record that enables integrated care across services 20.  The Scottish Diabetes 
Action plan emphasised the need for a “person-centredness” approach to allow people living 
with diabetes to be supported in managing their own condition 21.   
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In their 2008 report, the King’s Fund recognised that the NHS is slow to adopt new 
technologies and that improvements can be made at national and local levels 22.  In addition, it 
was recommended that in an effort to increase demand, clinicians should be encouraging 
patients to use available technologies.  In order to achieve this “person-centredness” approach 
these technologies should be “predictive, preventive, personal and participatory” 23. 
3.3 Turning data into information 
This lack of “patient-centredness” and the inability to access meaningful information from 
available data were recurring themes identified in the recent Francis report arising from the 
Mid Staffordshire NHS Foundation Trust Public Inquiry 24.  The report makes 290 
recommendations of which many are concerned with the transformation of data into 
meaningful information that is accessible and tailored to health professionals and patients as 
well as the local context: 
There is a need for all to accept common information practices, and to feed 
performance information into shared databases for monitoring purposes...Systems 
should be designed to include prompts and defaults where these will contribute to safe 
and effective care...[they]...should include a facility to alert supervisors where actions 
which might be expected have not occurred, or where likely inaccuracies have been 
entered...[and]...be capable of collecting performance management and audit 
information automatically, appropriately anonymised direct from entries. Systems 
must be capable of reflecting changing needs and local requirements over and above 
nationally required minimum standards 25. 
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Following the Francis report, the government commissioned the NHS confederation to 
investigate and report on how data can be used more effectively within the NHS 26.  The vast 
amount of data collected by the NHS is highlighted in the subsequent report - the authors 
estimate that that NHS clinical staff spend between 2-10 hours per week collecting, recording 
or validating data and that data collection and processing costs the NHS £300-£500 million per 
year.  These “precious” data are often inaccessible to clinicians and frontline staff and are 
therefore of little value to users.  The report found that the value of these datasets could be 
increased by: linking to patient outcomes and clinical decision making; improving feedback 
mechanisms; and increasing accessibility for staff. 
3.4 Information systems 
3.4.1. eHealth, shared clinical care records and personal health records 
The World Health organisation has defined eHealth as “the cost-effective and secure use of 
information and communication technologies in support of health and health-related fields” 
and has encouraged member states to incorporate eHealth into health systems and services 27. 
eHealth has increased the opportunity for sharing information between primary and 
secondary care via a shared clinical care record (SCCR), in the hope that this will improve 
clinical outcomes.  However, the effectiveness of such an approach has been found to be 
limited.  A Cochrane review assessing whether or not SCCRs improve clinical outcomes for 
those with long term health conditions concluded that there was insufficient evidence to 
recommend the widespread adoption of SCCR beyond the research setting 28.  The review 
identified 20 studies (19 of which were randomised controlled trials) and outcomes included 
clinical (mental or physical health); psychosocial (disability, functioning, hospital admissions); 
adherence to guidelines; service utilisation; and prescribing practice.  Of all measured 
outcomes, SCCR showed significant improvement only in prescribing practice.  However, there 
were a number of shortcomings identified in the studies included in the review including: 
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many of the studies failed to meet Cochrane’s Effective Practice and Organisation of Care 
Group (EPOC) guidelines in terms of adequate randomisation and prevention of contamination 
between intervention groups; the duration of follow up was limited (range 3-24 months); and 
participation rates were not reported making it difficult to comment on external validity. 
Three of the 20 studies eligible for inclusion in the above review were directly related to 
diabetes care 29–31.  Meta-analysis of biomedical outcomes failed to demonstrate any 
improvement in HbA1c, systolic BP or BMI between intervention and control groups.  Two of 
these studies 30,31 were also included in an earlier systematic review which concentrated 
exclusively on SCCRs in diabetes care 32.  This review included descriptive studies in addition to 
RCTs and did not include a meta-analysis.  Many of the studies included in this earlier review 
predated widespread adherence to national guidelines and so analysis was confounded by a 
lack of structured primary care in the non-intervention arm.  Common to all of the above 
evaluation of SCCRs was a lack of utilisation of electronic means in sharing the clinical record. 
A personal health record (PHR) is an electronic application through which individuals can 
manage and share their health information (and that of others for whom they are authorised) 
in a private, secure, and conﬁdential environment 33.  A PHR which is managed by the 
individual but which is interconnected with an electronic SCCR provides the optimum 
combination of patient empowerment whilst ensuring that the PHR contains validated, 
objective data that is relevant to the individual and remains up to date. 
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The concept of a PHR has been reported in the literature since the 1960’s.  With the adoption 
of electronic medical records the number of publications concerning the use of PHR has 
increased exponentially over the last decade 34.  A systematic review in 2010 35, identified 14 
studies in total, of which 3 were concerned with diabetic care (total n>3800, reported in 4 
papers 36–39).  The objective of this review was not explicitly stated, however it is inferred that 
the authors were assessing whether PHRs confer any clinical benefit.  There were some 
marginal gains in HbA1c reported, in addition to some improvement in patient knowledge and 
health-care delivery (e.g. attendance at foot clinic) however the review authors questioned the 
validity of the included studies owing to concerns regarding bias.  More recently, a further RCT 
assessing effectiveness of a PHR in diabetes found no significant difference in biomedical 
markers between study groups 40.  However, small numbers (n~100) and short duration of 
study (9 months) make a type 2 error more likely.  Of note, this study used a paper-based PHR 
whilst the authors of the systematic review also restricted the inclusion criteria to paper-based 
systems. 
3.4.2. mHealth 
Whereas eHealth technologies are based on the use of personal computing and the internet, 
the use of mobile devices to improve health outcomes, healthcare services or health related 
research has become known as mHealth 41.   
The worldwide mobile phone market continues to grow year on year with over 1.3 billion units 
being shipped in 2014, 72% of which were smartphones 42.  The World Bank estimates that in 
2013, there were 92 subscriptions to mobile phone providers per 100 people in the world 43.  
Developing countries have demonstrated the largest increase in ownership in the past few 
years and it was anticipated that ownership in these countries would exceed those in 
developed countries for the first time by the end of 2014 44. 
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The ubiquitous nature of mobile technologies across the full socio-economic spectrum has led 
to a number of public-private partnerships aiming to exploit this new area of healthcare 
delivery within both the developed and the developing world (e.g. the mHealth alliance 45).  A 
Cochrane review of the published mHealth literature with regards to health outcomes is 
currently underway 46. 
A number of smartphone and tablet apps are available for managing diabetes.  These include: 
recording and trend analysis of glucose measurements, apps aimed at improving medication 
adherence; and lifestyle modification including exercise monitors and nutritional support.  A 
2011 systematic review of apps available from online vendors as well as the published 
literature, identified over a hundred such apps 47.  By 2013, this figure had increased to over 
650.  Functionality that was most prevalent included: insulin and medication recording; data 
export and communication; recording of dietary intake; and weight monitoring.  Very few apps 
were designed to improved diabetes knowledge (in contrast to published guidelines which 
emphasise the need for patient education) and there was no identified formal evaluation of 
the role of social media in diabetes care.  Most of the commercially available apps rely on 
manual data entry, whereas the majority of published studies utilised bluetooth or wifi 
connectivity to upload personal data to a SCCR.  
Outcome data for mHealth-based interventions are mainly restricted to interventions that 
predate the advent of smartphone technology.  A systematic review of published literature 
from the 10 years preceding 2007 concluded that there were gains to be made in both 
glycaemic control and patient self efficacy and knowledge 48.  However, it should be noted that 
the interventions were primarily based on short message system (SMS) text messaging in 
response to self-reported glucose readings, as opposed to the apps described above. 
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In general, web-based interventions aimed at improving the management of type 2 diabetes 
have been shown to improve clinical outcomes when subjected to systematic review 49.  It is 
more difficult to establish which components are important to achieve these improvements 
however, due to the complex nature of each intervention.  Ramadas et al conclude that 
interventions that feature self monitoring; a local point of contact; and mobile phone 
technology would appear to be the most likely to succeed in improving clinical outcomes.  
Brown et al reach a similar conclusion in their narrative review of the same subject 50.  In 
addition, they conclude that the use of tailoring content to individuals is most likely to result in 
improvements to clinical outcomes. 
3.4.3. Clinical Decision Support Systems 
Long term conditions like diabetes, affect one in five people yet account for 80% of general 
practice consultations 51.  It is estimated that more than half of all clinical decisions fail to take 
account of the best available evidence 52.  In addition, evidence-based guidelines often do not 
accommodate co-morbidities and multiple medications 53–55.  There is a recognised need to 
find innovative ways of integrating knowledge into clinical workflow; to contextualise and 
personalise care; and to manage the complex care needs and human factors which contribute 
to unwanted variation in practice 56,57. 
Clinical Decision Support Systems (CDSS) utilise algorithms of varying complexity that are 
applied to existing eHealth systems.  CDSS can be: tools for attention focussing (flagging of 
abnormal results or investigations/management pending); patient-specific assessment and 
advice (diagnostic or prognostic inferences); or tools for critiquing and planning (sensitivity 
analysis and hypothesis testing whereby a clinician can test his/her proposed management 
plan using historical data) 58. 
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The use of automated reminders via CDSS has been shown to be one of the most consistently 
successful approaches to encourage clinicians to adopt evidence-based practice 59.  In terms of 
efficacy, a 2005 systematic review concluded that whilst a number of studies showed an 
improvement in clinical processes (e.g. adherence to guidelines), there was a lack of evidence 
demonstrating improved clinical outcomes 60.  In the same year, a separate systematic review 
found that CDSS which incorporated contemporaneous recommendations (as opposed to 
simple summaries of data) and were available within the normal work stream were more likely 
to result in improved clinical outcomes - 90% (30/32) of interventions which included these 
features demonstrated improved outcomes 61. 
3.4.4. Tailoring 
Targeted health information or education is that which is designed to reach a specific 
demographic within the population and is based on the concept of “market segmentation”, a 
decades-old device employed by business and the advertising sectors 62 .  As with all targeted 
communication, there is an underlying assumption that the target population is relatively 
homogenous in its composition i.e. similar demographics, socioeconomic status etc.  In 
addition, targeted information takes no account of the recipients’ individual circumstances e.g. 
health beliefs or health literacy.  Tailored health information takes into account of both of 
these shortcomings, whereby there is an assessment of the individual who is to receive the 
information, which is then conveyed to an individual in a manner that is specific to that 
individual 63.   
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By way of illustration, consider the BERTIE online Type 1 diabetes education programme 64.  
This could be regarded as a form of targeted education in that is designed specifically for the 
Type 1 diabetes population.  However, this is a heterogeneous population on a number of 
levels e.g. differing levels of glycaemic control, diabetes health literacy, diabetes self-efficacy 
etc.  If the intervention were to include an assessment of these variables (e.g. an individual is 
identified as having poor glycaemic control) and then deliver the information in a manner 
suited to the individual (e.g. the same individual has low levels of health literacy), then it would 
be considered to be tailored to that individual. 
The tailoring of messages to specific individuals is viewed as the most sophisticated form of 
automated communication and has been used to deliver health education and material, 
primarily for the purposes of health promotion 65.  Tailoring has been defined as: 
“any combination of strategies and information intended to reach one specific person, based 
on characteristics that are unique to that person, related to the outcome of interest, and 
derived from an individual assessment” 66. 
The theory underpinning the use of such methods draws heavily on a number of behaviour 
change theories including the Health Belief Model 67, Bandura’s Social Cognitive Theory 68 and 
Prochaska and DiClemente’s Stages of Change 69  Common to all of these models is the 
recognition that the main determinant of health-related behaviours is not a matter of simple 
demographics, but a far more complex interplay of perceived vulnerability and the anticipated 
benefits of what behaviour change can bring. 
The Health Belief Model (HBM) identified five basic cognitive dimensions as a basis for 
behaviour: perceived severity of the condition, perceived susceptibility or vulnerability to the 
disease process, perceived benefits (i.e. belief in efficacy of the intervention), costs/barriers, 
and cues to action - which may be internal (e.g. symptoms) or external (e.g. health education, 
illness of family or friend). 
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Social cognitive theory (SCT) builds on this by addressing one of the main criticisms of the HBM  
- a lack of consideration of an individual’s past experiences and social environment 68.  A key 
construct of SCT is an individual’s self-efficacy.  Self-efficacy is the confidence that an individual 
has in his/her ability to successfully complete a task and is influenced by past experience, as 
well as current facilitators and barriers, and can be measured using validated tools 70. 
In contrast to HBM and SCT that concentrate on the cognitive processes associated with 
behaviour change, Prochaska and DiClemente’s Stages of Change concentrates on the 
behavioural aspects of behaviour change as well as considering time as a key determinant 69.  It 
does so by describing a series of key stages that are common to all individuals when 
attempting to change their behaviour  .  Theses stages range from the pre-contemplative (i.e. 
not ready to make any changes) through to acting and maintaining the change in behaviour.  
During this process, individuals may recycle through stages or demonstrate regression to 
earlier stages. Again, validated tools can determine which stage an individual is at any given 
time, with a view to tailoring interventions appropriately 71 
As previously stated, an integral component of a tailored intervention is that it incorporates an 
individual-level assessment of the recipient.  This assessment is dependent on the type of 
intervention and the target audience, but could be based on routinely collected data (e.g. 
professional role; socioeconomic status; health records; or clinical parameters) or data 
collected from the individual with the specific intention of formulating a tailored message (e.g. 
health literacy; self-efficacy; or pre-existing attitudes and knowledge).  Interventions that 
utilise tailored messages tend to involve the distribution of printed material aimed at primary 
health promotion e.g. dietary advice 72–74, smoking cessation 75,76, or uptake of screening 77. 
Reviewers of these and other studies conducted in the late 20th century concluded that 
tailored print communication was more effective than non-tailored interventions, however the 
lack of a systematic approach by the reviewers limits the generalizability of the findings 78,79.   
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More recently, systematic reviews (some utilising meta-analysis) have reached similar 
conclusions with regards to tailored interventions aimed at improving physical activity, 
ambulatory care, health care practitioner behaviour (HCP), smoking cessation, and 
communication of risk to improve uptake of screening tests  80–84.  A meta-analysis of studies 
utilising paper-based tailored communications identified 57 studies in total, of which 40 
compared tailored with non-tailored/generic communication 85.  The combined mean sample 
size-weighted effect size was r = 0.058, equivalent to an odds ratio of 1.21 (no confidence 
interval provided).  The authors conclude that these results suggest paper-based tailored 
communications confer a small but significant benefit over the generic equivalent, however 
the do also concede that the stated effect size falls below the threshold for what is considered 
a “small” effect size (r = 0.1) 86.  Furthermore, the meta-analysis identified significant effect 
modifiers using regression techniques.  Factors that were predictive of greater effect included 
patients with higher socioeconomic status (SES), printed material of shorter length and 
repeated messages through time.  In addition, effect size increased with the number of 
theoretical constructs that were used in the assessment of the individual e.g. self-efficacy, 
stage of change etc. 
There is a lack of literature concerning the use of tailored messages aimed at changing health 
care practitioner (HCP) behaviour.  There is also a lack of evidence to inform the design and 
modality of tailored messaging, and whether the effectiveness of existing eHealth technologies 
(e.g. CDSS) can be improved were they to incorporate tailored messaging. 
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3.4.5. Barriers to adopting systems 
Assessing how and why individuals and groups choose to adopt new information systems has 
been the subject of much research 87.  Various factors that can influence this process have 
been identified including individuals’ attitudes to new technology; their intention to use such 
systems; and organisational or environmental conditions required to increase uptake.  As a 
result, several models have been proposed which include some or all of these factors.  The 
Unified Theory of Acceptance and Use of Technology (UTAUT) model was formulated by 
identifying the similarities between 8 different models, combining them and then validating 
the resultant model 88.  This model has been used to predict the likelihood that a new 
technology will be adopted by users, as well as allowing organisations to identify user groups 
that may require additional support during the implementation phase.  The model consists of 
four key determinants: Performance expectancy (how much an individual believes the 
technology will assist them); effort expectancy (how much an individual perceives the 
technology will be easy to use); social influence; and other facilitating conditions (e.g. 
organisational factors) 88, in addition to a number of demographic modifiers.  The model is 
widely cited, however the applicability to academic or health environments is still not known 
87.  More recently, Venkatesh tested the UTAUT within the healthcare setting and found that 
the primary determinant of adoption of a new electronic health record by HCPs was age (as 
opposed to the constructs cited above), highlighting the importance of context when 
evaluating adoption of new systems 89. 
3.4.6. Safety and risk 
Developing a new drug from “bench to bedside” is a notoriously expensive and time 
consuming process.  The pharmaceutical industry estimates that the average new drug takes 
12 years to develop, at a cost of over £1 billion 90.  This cost is partly due to the necessary 
pharmacovigilance associated with developing a new product, but also due to the high 
attrition rate of new drugs during this process – only 1/5000 new compounds developed in the 
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lab will make the successful journey to the healthcare market, with the remainder discarded 
owing to concerns related to efficacy, safety, or both 90.   
In contrast, the development of mHealth apps available to consumers takes place in a largely 
unregulated environment, resulting in concerns regarding conflicts with current guidance 47 
and the efficacy of such products 91.  In a systematic review of mHealth apps designed to 
calculate doses of insulin boluses, Huckvale et al demonstrated inherent risks in the majority of 
available apps 92.  Nearly all (91%) of the 46 apps that met the inclusion criteria failed to 
validate inputted data, resulting in potentially lethal insulin dosage advice being given, whilst 
half (48%) of the apps assessed gave advice that violated basic clinical assumptions (e.g. in the 
event of missing blood glucose data, blood glucose was assumed to be 0 mmol/l) 92. 
These identified risks have led to calls for greater regulation of the market in general, and the 
need for regulation to take into account the safety and efficacy of such products 93.  The U.S. 
Department of Health and Human Services Food and Drug Administration (FDA) have recently 
issued advice on what types of mHealth apps constitute a “medical device”, thereby requiring 
them to adhere to necessary regulatory standards 94.  In the UK, the Medicines & Healthcare 
products Regulatory Agency (MHRA) provide similar advice on how to ensure mHealth apps 
meet regulatory requirements, thereby allowing them to be marketed to users throughout the 
EU 95.   It should be noted that neither US nor UK regulatory authorities consider a product’s 
efficacy as part of this process. 
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3.5 Summary 
Diabetes represents a growing public health problem that currently places a large burden on 
healthcare spending and is projected to grow in the coming years.  Effective diabetes care can 
reduce the risk of developing diabetes-related complications and that care can be improved 
with the use of emerging technologies.  However, owing to the complex nature of 
interventions that use new technologies, it is difficult to identify which components can 
effectively be implemented and which are effective in improving care.   
Both government and opinion leaders have articulated the need to explore the use of new 
technologies in improving the “patient-centredness” of care and the transformation of clinical 
data into meaningful information.  Furthermore, there is the potential to tailor this 
information to specific user groups including patient sub-populations and health care 
professionals.  This study will test whether either approach results in improved healthcare 
processes and/or clinical outcomes for those with diabetes. 
4. Aims and objectives 
4.1 Aims 
The study aims to: 
1. Determine the effectiveness of eHealth interventions designed to improve the 
management of chronic diseases by providing tailored information to health care 
practitioners, patients and/or carers 
2. Describe the implementation and evaluation of a clinical decision support system (CDSS) 
within a shared clinical care record (SCCR) for those with diabetes 
4.2 Objectives 
In order to achieve these aims, the study will be conducted in three main parts and will 
address the following objectives: 
1. Evaluation of the literature: 
 Conduct a systematic review of the published literature on of eHealth interventions 
designed to improve the management of chronic diseases by providing tailored 
information to health care practitioners, patients and/or carers 
2. Implementing and evaluating a CDSS: 
 Describe the development and testing of a CDSS to be integrated within an existing 
SCCR 
 Develop a framework to evaluate the CDSS 
 Within that framework: 
o Conduct focus groups of system users to assess the acceptability of the CDSS 
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o Develop and distribute a questionnaire survey to users of the CDSS to assess 
the usefulness and usability of the CDSS and to identify barriers and facilitators 
to widespread adoption 
o Develop and distribute a questionnaire survey of patients subject to the 
intervention to ensure that the CDSS has no adverse impact on the 
consultation process 
o Conduct a case-control comparison of system usage to assess whether the 
CDSS changes user behaviour 
o Conduct a case-control comparison of clinical outcomes to assess whether the 
CDSS improves clinical outcomes 
o Make recommendations for the future development of the CDSS 
Finally, this thesis will apply the findings from all of the above to propose how current systems 
could be adapted to take full advantage of tailoring and CDSS to improve patient care. 
5. Systematic review 
5.1 Abstract 
5.1.1. Background 
Tailored messages are those that specifically target individuals following an assessment of 
their characteristics and can influence health-related decisions when delivered using 
traditional media. 
5.1.2. Purpose 
This systematic review aims to assess the evidence regarding the effectiveness of tailoring 
within eHealth interventions aimed at improving the management of chronic diseases. 
5.1.3. Data Sources 
OVID Medline and Embase databases were searched from inception to May 2014, without 
language restriction, for trials of tailored eHealth messaging. 
5.1.4. Study Selection 
Randomised controlled trials; controlled clinical trials; controlled before-after studies; and 
interrupted time series analyses were considered.  Objectively measured clinical processes or 
outcomes were considered where comparison was made with no intervention and/or existing 
practice. 
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5.1.5. Data Extraction and synthesis 
Two reviewers independently extracted data and assessed quality.  The review included 22 
papers: 6 studies with fully tailored messaging; 16 studies that included partially tailored 
messages.  Two studies isolated tailored messages as the active component.  The remainder 
compared intervention with standard care.  Twelve of 16 studies measuring clinical processes 
reported positive outcomes; and 2 of 6 studies reporting clinical outcomes showed 
improvements.  Positive findings were reported for interventions aimed at both patients and 
healthcare practitioners. 
5.1.6. Limitations 
Overall, study quality was low.  Study design did not allow for identification of the 
interventions’ active component.  Study heterogeneity precluded quantitative or meta-
analysis. 
5.1.7. Conclusion 
There is evidence that tailored eHealth messaging improves clinical processes/outcomes, 
however this review was unable to demonstrate that tailoring itself has specific additional 
benefit owing to limited quality and quantity of evidence. Future studies are needed to 
improve quality in this area.  Studies that allow for isolation of the intervention’s active 
component and are designed to reduce potential bias will support the evidence base. 
5.2 Objective 
This systematic review aimed to assess the published evidence regarding the effectiveness of 
eHealth interventions designed to improve the management of chronic diseases by providing 
information or advice that has been tailored to the recipients i.e. health care practitioners or 
patients.   
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The research question was:  Does the cumulative published research evidence support the 
hypothesis that a system that incorporates messages specifically tailored to an individual 
(health care practitioner or patient) results in improve clinical processes or outcomes in the 
management of long term conditions? 
5.3 Method 
5.3.1. Types of studies 
Randomised controlled trials, controlled clinical trials, controlled before and after studies and 
interrupted time series analyses were considered for inclusion in the review.  Studies 
published in any language were considered. 
5.3.2. Types of recipients 
Studies that involved patients with a specified long term condition receiving health care (any 
setting), and/or health care practitioners responsible for the care of those with long term 
conditions (any setting), were considered. 
5.3.3. Types of interventions 
We considered interventions that used eHealth technologies to deliver tailored information to 
patients or HCPs within the care setting.  The search strategy therefore included a combination 
of terms relating to eHealth, health records and communication strategies (including tailoring 
of information). 
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5.3.4. Types of outcomes 
Any outcome was considered where a comparison was drawn between the intervention and 
no intervention and/or existing practice with regards to objectively measured professional 
performance, clinical outcome, or patient behaviour.  The study’s stated primary outcome was 
our main outcome of interest, with consideration also given to any stated secondary outcomes 
or post hoc analyses.  Patient and professional satisfaction was also recorded, but studies were 
not included if this was the sole outcome. 
5.3.5. Search strategy 
A search strategy was devised to include keywords and text words relating to the following 
terms: chronic disease; methodology; eHealth; health records; communication; and user 
groups (see appendix - section 10).  Text words were appropriately truncated to maximise 
returns.  Terms were combined using Boolean logic.  There was no keyword identified for 
tailored messaging and so we adopted a broad search strategy.  As well as including variations 
of tailored messaging as text words, we included an exploded search of other communication-
related keywords in an effort to capture studies that utilised tailored messages but did not 
refer to it as such (see appendix - section 10).  The search was run against both Ovid Medline 
(1946-present) and Embase (1974-present), with no restrictions placed on language. 
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5.3.6. Eligibility criteria for inclusion 
Studies that were RCTs or CCTs were deemed eligible if the other criteria mentioned above 
were met.  Additional methodologies (controlled before-after studies and interrupted time 
series analyses) were considered if they met quality criteria specified by the Cochrane Effective 
Practice and Organisation of Care Group (EPOC) data collection checklist 96.  In accordance with 
the EPOC criteria the quality criteria for inclusion of both types of studies were as follows:  
 Controlled before-after studies were only eligible if the control site was deemed 
suitable; there was evidence of contemporaneous data collection; and there were ≥2 
intervention and ≥2 control sites.   
 Interrupted time series analyses were included if there was a clearly recorded point in 
time when the intervention began and where there were ≥3 data points recorded both 
before and after the intervention commenced.  Given the potential heterogeneity of 
the studies relevant to the review, study inclusion was not based on a minimum cut-
off for methodological quality. 
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5.3.7. Data collection and analysis 
Titles and abstracts were initially reviewed by a single reviewer (NTC) and discarded if deemed 
not to be relevant to the research question.  A shortlist was then compiled (for which full text 
articles were sought) and independently reviewed by 2 reviewers - NTC and CW*.  Any 
discrepancies were resolved by consensus.  An online data abstraction form (modified from 
the EPOC data collection checklist 96) was used for data collection 97.  An overall quality rating 
was assigned to RCTs based on the following criteria: allocation concealment; blinded or 
objective assessment of primary outcome(s); completeness of follow up; reliable primary 
outcome; and protection against bias.  In accordance with previously published EPOC 
systematic reviews 98,99, studies were rated as being of high quality if the first 3 criteria were 
met with no additional concerns.  Studies were of moderate quality if ≤2 criteria were “not 
done” or “not clear” and of low quality if this applied to >2 criteria.  Results were presented in 
accordance with the standards set out by the Preferred Reporting Items for Systematic 
Reviews and Meta-Analyses (PRISMA) statement 100.  The PRISMA checklist is shown in the 
appendix (see section 9). 
5.3.8. Assessing tailoring 
Kreuter et al 66 judged that an intervention incorporated tailored messaging if the intervention 
included both: 
1. An assessment of individual patient characteristics; and 
2. Communication that was specifically targeted at that individual. 
Owing to the limited number of published studies that the search strategy returned, we 
accepted interventions that included either of these criteria, as agreed by the two reviewers. 
                                                          
 
*
 NTC = Dr Nicholas Conway, consultant paediatrician (author).  CW = Dr Clare Webster, 
consultant paediatrician. 
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5.4 Results 
5.4.1. Search results 
The search strategy was run twice - September 2013 and again in May 2014.  The final yield 
from both searches was 1074 returns, of which 89 were duplicates.  Of the remaining 985 
studies, 818 were initially rejected based on title alone, with a further 112 discarded after 
review of the abstract (see Figure 1).  Full text papers were sought for the provisional shortlist 
of 55 studies and were available for 45 of these.  The abstracts of the remaining 10 studies 
were assessed, and included if there was sufficient information to meet the inclusion criteria.  
Fifteen papers were rejected owing to the absence of any tailoring component in the 
intervention.  The remaining 40 papers were then reviewed by the 2 reviewers.  A further 18 
papers were then rejected as they failed to meet (or had insufficient detail to satisfy) the 
eligibility criteria, leaving 22 papers to be considered in the review. 
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Figure 1. PRISMA diagram of literature search 
 
These 22 studies are shown in Table 1 (sorted by first author).  All of the studies were 
published since 2002 and most were conducted in North America 101–116.  The majority were 
RCTs 101,103,105–109,111,112,114–120. The clinical problem addressed by the various interventions 
varied, but the most common applications were diabetes 101,102,110,111,114,119, cardiovascular 
disease 107,110,114,118, and the prescribing of medication 105,106,112,121. 
Duplicates removed (n= 985) 
PUBMED and/or EMBASE search (n=1074) 
Duplicates (n=89) 
Title and/or abstract 
not relevant (n=930) 
Full text available (n=45) 
Abstracts only (n=10) 
Studies included in qualitative synthesis 
(n=22) 
Ineligible articles 
(n=33) 
Reason for rejection: 
 No tailoring (n=15) 
 Descriptive paper 
only (n=3) 
 CBA - insufficient 
sites (n=3) 
 ITS - insufficient 
data points (n=3) 
 Review paper (n=2) 
 Abstracts with 
insufficient 
information (n=7) 
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Table 1.  Studies eligible for inclusion in the review. 
*Denotes abstract only.  RCT = Randomised controlled trial, ITS = interrupted time series analysis, CCT = controlled 
clinical trial 
First Author [ref] Year Design Country Clinical speciality Clinical problem 
Avery 121 2012 RCT UK General/family practice Medication prescribing 
Boukhors 101 2003 RCT Canada General/family practice Diabetes 
Cafazzo 102 2012 ITS Canada Paediatrics Diabetes 
Carroll 103 2012 RCT USA Psychiatry Maternal depression 
Cruz-Correia 117 2007 RCT Portugal Other Asthma 
Epstein 104 2011 RCT USA Paediatrics ADHD 
Field 105 2009 RCT Canada General/family practice Medication prescribing 
Fossum 122 2011 CCT Norway Other Pressure ulcers 
Gurwitz 106 2008 RCT USA/Canada Other Medication prescribing 
Jones 123 2011 ITS UK General medicine Acute medicine 
Kinn 107 2002 RCT USA Other Hypertension 
Mcdonald 108 2005 RCT USA Paediatrics preventative service 
Nagykaldi 109 2012 RCT USA General/family practice preventative care 
Persell 110 2010 ITS USA General medicine CVD, diabetes and cancer 
Persell 118 2013 RCT USA General/family practice CVD 
Pinnock 120 2013 RCT UK General medicine COPD 
Quinn 111 2008 RCT USA Other Diabetes 
Raebel 112 2007 RCT USA Obstetrics and Gynaecology Medication prescribing 
Ross 119 2006 RCT USA General medicine Diabetes 
Sequist 114 2005 RCT USA General medicine CVD and diabetes 
Tierney 115 2005 RCT USA General medicine Asthma 
Vollmer 116 2011 RCT USA NOT CLEAR Asthma 
5.4.2. Setting and characteristics of participating health care providers 
Most studies were undertaken in either an outpatient or community-based setting and 
involved physicians – see Table 2.  Other professional groups included nurses and pharmacists.  
The studies were undertaken in both academic and non-academic settings.  There was a 
general lack of information describing the experience or qualifications of the various 
professional user groups. 
5.4.1. Characteristics of the intervention 
Thirteen of the studies directed the intervention at HCPs 103–107,110,112,114,115,120–123.  The 
remainder directed the intervention at patients 102,108,109,116–119, or at both HCPs and patients 
111.  Each of the interventions is described in detail in the appendix (see section 11).  
5.4.2. Influence of tailoring component on intervention design 
All of the studies included in the review incorporated some degree of individual patient 
assessment.  This assessment was made via automated data queries of routinely-collected 
clinical datasets or via additional data entry completed by patient and/or HCP – see Table 3.
 Table 2.  Clinical setting and characteristics of providers 
First Author Location of 
care 
Academic status Profession 
involved 
Level of 
training 
Mean 
age (yr) 
Years in 
practice 
Avery 121 Community 
based care 
- Physicians, 
Pharmacists 
- - - 
Boukhors 101 Outpatient care - Physicians - - - 
Cafazzo 102 Outpatient care - Physicians - - - 
Carroll 103 Outpatient care University /teaching 
setting 
Physicians - - - 
Cruz-Correia 
117 
Outpatient care - Physicians - - - 
Epstein 104 Community 
based care 
- Physicians Accredited 
and/or licensed 
47 - 
Field 105 Community 
based care 
Non-teaching setting Physicians - - - 
Fossum 122 nursing home Non-teaching setting Nurses Accredited 
and/or licensed 
- - 
Gurwitz 106 Inpatient care University /teaching 
setting 
Physicians, 
Nurses 
- - - 
Jones 123 Inpatient care University /teaching 
setting 
Physicians, 
Nurses 
- - - 
Kinn 107 Outpatient care - Physicians Accredited 
and/or licensed 
- - 
Mcdonald 108 Outpatient care University /teaching 
setting 
Physicians Accredited 
and/or licensed 
- post grad 
level 1-3 
Nagykaldi 109 Community 
based care 
Non-teaching setting Physicians, 
Nurses 
- - - 
Persell 110 Community 
based care 
University /teaching 
setting 
Physicians - - - 
Persell 118 Inpatient care University /teaching 
setting 
Physicians In training - - 
Pinnock 120 Outpatient care - Physicians - - - 
Quinn 111 Outpatient care - Physicians - - - 
Raebel 112 Pharmacy Non-teaching setting Pharmacists - - - 
Ross 119 Outpatient care - - - - - 
Sequist 114 Outpatient care University /teaching 
setting 
Physicians Mixed 40 - 
Tierney 115 Outpatient care Non-teaching setting Physicians, 
Pharmacists 
Mixed - - 
Vollmer 116 Community 
based care 
- - - - - 
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Table 3.  Role of tailoring in the interventions. 
“Tailored assessment” relates to the assessment of individual patient characteristics and how that data was 
collated.  “Tailored communication” describes whether or not communication was specifically targeted to an 
individual.  HCP= Healthcare professional 
First Author 
[ref] 
Tailored assessment Tailored 
communication 
Recipient of 
communication 
Tailored communication detail 
Avery 121 Automated data 
query 
None HCP Message contents dependent on data 
Boukhors 101 Data from patient None Patient Message contents dependent on data 
Cafazzo 102 Data from patient Tailored to user Patient Message contents dependent on data 
and tailored to user requirements (trend 
wizard) 
Carroll 103 Data from parent and 
HCP 
None HCP Message contents dependent on data 
Cruz-Correia 
117 
Data from patient 
and HCP 
None Patient Message contents dependent on data 
Epstein 104 Data from patient 
and HCP 
None HCP Message contents dependent on data 
Field 105 Automated data 
query 
None HCP Message contents dependent on data 
Fossum 122 Automated data 
query 
None HCP Message contents dependent on data 
Gurwitz 106 Automated data 
query 
None HCP Message contents dependent on data 
Jones 123 Automated data 
query 
None HCP Message contents dependent on data 
Kinn 107 Automated data 
query 
None HCP Message contents dependent on data 
Mcdonald 108 Data from patient Tailored to user Patient Message contents dependent on 
individual data taking into account 
individual circumstances 
Nagykaldi 109 Data from patient 
and HCP 
Tailored to user Patient Message contents dependent on 
individual data taking into account 
individual circumstances 
Persell 110 Automated data 
query 
None HCP Message contents dependent on data 
Persell 118 Automated data 
query 
Tailored to user Patient Message contents dependent on 
individual data taking into account 
individual circumstances 
Pinnock 120 Data from patient None HCP Message contents dependent on data 
Quinn 111 Data from patient 
and HCP 
None Patient and HCP Message contents dependent on data 
Raebel 112 Automated data 
query 
None HCP Message contents dependent on data 
Ross 119 Automated data 
query 
Tailored to user Patient Message contents dependent on 
individual data taking into account 
individual circumstances 
Sequist 114 Automated data 
query 
None HCP Message contents dependent on data 
Tierney 115 Automated data 
query 
None HCP Message contents dependent on data 
Vollmer 116 Automated data 
query 
Tailored to user Patient Message contents dependent on 
individual data taking into account 
individual circumstances 
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The use of individually tailored communication was only evident in a minority of studies 
102,108,109,116,118,119.  All of these studies delivered messages to individual patients based on data 
specific to that patient e.g. risk of illness/injury and how this might be modified for the 
individual 108,109,118; individualised educational content 116,119; or individualised clinical results 
102.  For the remainder of studies, the content of communication was dictated by automated 
algorithms based on the individual assessment rather than the specific circumstances of the 
end-user.  For example, it was common that automated CDSS aimed at HCPs would provide 
prompts based on an assessment of a patient’s data, but the prompt provided by the system 
was generic to the system and not tailored to the HCPs job-description or clinical context. 
Of the 6 studies that fulfilled both criteria for having used tailored communication (as dictated 
by Kreuter et al 66), the primary outcomes (where stated) were patient self-care (improved) 102, 
serum lipids (no difference) 118 and medication adherence (better than control but reduced 
overall) 116.  The remainder of studies did not state the primary outcome, but reported on 
service uptake (improved in intervention group) 119, patient knowledge (improved in 
intervention group, but multiple comparisons made) 108, patient centredness (improved in 
intervention group) 109. 
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5.4.3. Comparison – tailored intervention versus non-tailored intervention 
Two studies compared an intervention which utilised tailoring with an intervention that 
included untargeted activity 108,119 (see appendix – section 11).  Neither study specified the 
primary outcome of interest in the methods.  Both studies provided tailored educational 
material to patients and compared outcomes with patients who had received non-tailored 
material.  For example in one study 108, parents completed a questionnaire designed to assess 
previous injuries sustained by their child as well as parental perceptions of their child’s current 
risk of injury.  The educational material then incorporated the events previously described as 
well as addressing any misconceptions in injury risk identified from parental responses.  
Tailoring resulted in an increase in patient service uptake in one study 119, with multiple 
comparisons being made in the other, introducing the possibility of a type 1 error 108. 
5.4.4. Comparison – intervention versus no intervention 
The primary outcome was not overtly stated in 8 of the studies.  Of the 22 studies included in 
the review, the main outcome of interest related to clinical processes and performance in 14, 
with the remainder concerned with clinical outcomes– see Table 4. 
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Table 4.  Reported outcomes and main results from studies included in the review. 
A more detailed version of this table detailing all comparisons made is available in the appendix (see section 12).  
Study quality score compiled for RCTs only – see appendix (section 11) for study characteristics used for grading.  AE 
= adverse event; HbA1c = glycated haemoglobin; LoS = Length of stay; EWS = Early Warning Score; LDL = low density 
lipoprotein; QPI = Quality performance indicators; COPD = Chronic obstructive pulmonary disease; QoL = Quality of 
life, BP = blood pressure; IQR = interquartile range; SD = standard deviation; ITS = interrupted times series analysis;  
*Denotes primary outcome(s) where stated. 
Study Study quality Outcome(s) Main results of the 
outcome(s) 
Avery 121 Moderate Number of potential drug AE* Intervention group 
significantly less likely to have 
been prescribed 
contraindicated medication 
(all 3 measures) 
Boukhors 101 Low Number of hypoglycaemic events* No significant difference in 
incidence of hypoglycaemia 
Cafazzo 102  ITS Number of blood glucose tests 
Glycaemic control (HbA1c)* 
Number of blood glucose tests 
increased with intervention. 
No difference in secondary 
outcomes - incidence of 
hyperglycaemia & glycaemic 
control 
Carroll 103 Low Number of mothers identified as having 
depressive symptoms, Number of mothers 
referred for psychiatric assessment 
Intervention groups more 
likely to have depression 
detected and more likely to be 
referred to specialist 
Cruz-Correia 117 Low Patient satisfaction, 
Patient adherence to recommended 
monitoring 
Patients were satisfied with 
system 
Patients adherence was not 
altered with electronic system 
- if anything adherence 
improved with paper system 
Epstein 104 Low Proportion using recommended diagnostic 
tools at follow up* 
Significant increase in use of 
diagnostic questionnaires 
Field 105 Moderate Alert rate*, Type of alert* - incorrect dose, 
incorrect frequency, drug should be avoided, 
incomplete clinical information (creatinine) 
Overall, no difference in rate 
of alerts between groups. 
Fossum 122 Low Proportion with malnourishment,  
Proportion at risk of malnourishment and 
pressure ulcer 
no change in risk of PU 
no change in prevalence of PU 
No change in prevalence of 
malnourishment 
Gurwitz 106 Low Number of drug-related AE* No significant difference in 
AE's between intervention and 
control 
Jones 123  ITS Length of stay (LoS)*, Accuracy of early 
warning score (EWS), Adherence to protocol, 
Clinical response to EWS alert, Rate of cardiac 
arrests, Number of critical care bed days, 
Mortality rate 
Significant decrease in LoS 
during intervention period 
Kinn 107 Low Likelihood of being diagnosed with 
hypertension, Likelihood of receiving ≥1 
antihypertensive, 
Number of antihypertensives per patient, Use 
of combination therapy, BP 
Significantly more patients 
receiving appropriate 
diagnosis in intervention 
group; Intervention group 
significantly more likely to be 
on anti-hypertensive.  
Intervention group had 
significantly less 
antihypertensive agents 
prescribed. 
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Table 4 (cont.).  Reported outcomes and main results from studies included in the review. 
QoL = quality of life; ITS = interrupted time series analysis; QPI = quality performance indicator; COPD = chronic 
obstructive pulmonary disease; LDL = low density lipoprotein; HCP = healthcare professional 
Study Study quality Outcome(s) Main results of the 
outcome(s) 
Mcdonald 108 Low Parent safety knowledge, prevention beliefs, 
and safety behaviours 
Improved safety knowledge at 
follow up. 
Nagykaldi 109 Low Provision of preventative services, Number of 
log ins to portal, Patient centredness 
Minimal use of portal 
Patient centredness score 
improved in intervention 
group 
Persell 110 Low LDL cholesterol*, Change in BP, Smoking 
cessation, Prescription of a statin, Number of 
office visits 
No significant difference in 
rate of lowered LDL 
No significant difference in 
attendance at clinic 
Significantly more statins 
prescribed in intervention 
group 
Persell 118  ITS 16 quality performance indicators (QPIs) - 
prescribing for chronic disease and screening 
procedures* 
Performance measures 
improved 
Pinnock 120 High Time to admission to hospital with 
exacerbation of COPD*, Time to admission, 
number and duration of admissions, deaths, 
QoL, number of patient contacts 
No significant difference in 
admission rate or quality of 
life in those receiving 
intervention. 
Quinn 111 Low Physician satisfaction, Diabetes self-care, 
Glycaemic control 
Physicians satisfied 
Glycaemic control improved 
Patients self-care improved 
Raebel 112 Low Proportion of pregnant women dispensed a 
contraindicated medication* 
Intervention group were 
significantly less likely to be 
prescribed a contraindicated 
medication 
Ross 119 Low System usage Intervention group had 
greater usage of system 
Sequist 114 Low Receipt of recommended care*, HCP 
perceptions surrounding guideline adherence 
Patients in intervention group 
significantly more likely than 
control patients to receive 
recommended diabetes care 
and CAD care 
Tierney 115 Low Percentage adherence to management 
recommendations* 
No significant differences in 
adherence to guideline 
between groups 
Vollmer 116 Low Patient adherence to medication*, Patient 
QoL, Reliever medication use, Asthma control, 
Healthcare utilisation 
Small but significant increase 
in adherence 
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Studies where the stated primary outcome related to clinical processes included: HCP 
adherence to existing guidelines 104,110,114,115; avoidance of adverse drug events 105,106,112,121; 
patient adherence to medication 116; and patients’ frequency of clinical testing 102.  Of the 6 
studies which failed to stipulate the primary outcome, one measured HCP adherence to an 
existing guideline aimed at improving diagnosis rates 111. 
Twelve of the 16 studies concerned with clinical processes reported a favourable outcome.  
For those studies aiming to assess HCP adherence to guidelines, most reported an 
improvement 103,104,107,110,114; however one of these studies also noted a pre-intervention 
improvement in the ITS analysis, introducing the possibility that secular change was 
responsible for the observed improvement 110.  The rate of potential adverse drug events was 
significantly reduced in half of the relevant studies 112,121.  When compared with controls, 
patient medication adherence was said to be higher, however the actual difference was small 
and both groups’ overall adherence fell during the study period 116.  The other measures of 
patient-driven clinical processes also improved (blood sugar testing 102 and service uptake 119). 
Two of the 6 studies concerned with clinical outcomes reported positive findings.  Four studies 
measured clinical parameters as the primary outcome which included glycaemic control  
(unchanged) 101; length of hospital stay (improved) 123; change in serum lipids (unchanged) 118; 
and time to admission to hospital (unchanged) 120.  Clinical parameters were also measured in 
two further studies and included glycaemic control (improved) 111; and presence of 
malnourishment and/or pressure ulcers (unchanged) 122. 
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5.4.5. Comparing patient-orientated interventions with HCP-orientated 
interventions 
Eight of the studies targeted patients with the intervention 101,102,108,109,116–119, one study 
involved an intervention aimed at both HCPs and patients 111 and the remainder focussed 
solely on HCPs – see Table 2.      
For the 8 studies where the intervention targeted patients, five (63%) reported that the 
intervention produced a positive effect.  This included increased patient satisfaction 117; 
monitoring of blood glucose 102; adherence to medication 116;  system usage 119; and knowledge 
108 – see Table 4. 
For the 14 studies where the intervention was targeted at HCPs, a similar proportion reported 
positive findings (8/14, 57%).   These included improved adherence to guidelines 104,110,114; 
detection of morbidity 103,107 decreased adverse drug events 112,121; and length of hospital stay 
123 – see Table 4. 
5.4.6. Risk of bias in included studies 
There was a high risk of bias for all studies included in the review, with the exception of one 
high quality study 120 – see Table 4.  Three studies were assessed as having concealed 
allocation adequately 112,115,120.  The remaining studies either failed to do so or did not provide 
sufficient information.  Four studies reported that the assessors were sufficiently blinded to 
allocation group 105,106,115,120.  Of the remainder, 10 studies derived outcome data from 
automated data queries, making assessment bias unlikely 103,104,107,112,114–116,118,119,122.  Seven 
studies were assessed as having adequate follow up of professionals and/or patients 
105,107,108,116,120–122. 
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Three of the studies were interrupted time series analyses 102,110,123.  All three used a reliable 
outcome measure.  It was unclear how either of these studies protected against detection bias 
(in terms of either data collection or blinded assessment) or secular changes in the population 
being studied.  One study reported on the completeness of the dataset which was assessed as 
being satisfactory 110. 
5.5 Discussion 
In order to assess the effectiveness of tailored messages within eHealth interventions, a 
comparison needs to be made between outcomes of tailored interventions and non-tailored 
interventions.  However, based on the results of this review, the research question remains 
incompletely answered for a number of reasons. 
First, any direct comparison between tailored and non-tailored interventions was limited to a 
minority of the included studies.  Nearly all studies compared the intervention to a no 
change/standard practice control group as opposed to a non-tailored intervention.  This makes 
it impossible to ascertain whether any improvements were secondary to the tailoring 
component of the intervention per se.   
Secondly, the outcome of either of these comparisons presented a mixed picture.  A number 
of studies concluded there was improvement in clinical processes e.g. adherence to guidelines; 
avoidance of prescription errors; and increased service uptake when compared to no 
intervention.  However, most of these studies presented methodological weaknesses meaning 
that these conclusions should be met with caution. 
Thirdly, only a minority of studies included in the review included an intervention that fulfilled 
both criteria for what is considered to be tailoring of information.  All of the other studies 
included in the review incorporated only one of the two components that define true tailoring.  
The adoption of studies meeting this less strict definition increased the number of studies 
eligible for inclusion but made it difficult to address the research question specifically. 
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Finally, the quality of most of the included studies was assessed as low.  However, the 
introduction of methodological quality as an eligibility criterion for inclusion would have 
excluded almost all of the studies identified.  Meta-analysis was not possible owing to the 
heterogeneous nature of the interventions and outcomes of the studies reviewed. 
5.6 Significance 
Despite these limitations, some limited conclusions can be drawn.  Irrespective of the degree 
to which the intervention incorporated tailoring, or the degree to which tailoring was 
responsible for the observed outcomes, it is notable that 14 of the 22 studies included 
reported positive findings.  These improvements were largely limited to clinical processes as 
opposed to clinical outcomes and were observed in interventions aimed at both patients and 
HCPs.  This study restricted analysis to quantifiable outcomes and so it not know why there 
was an observed improvement in outcome.  Whilst it could be inferred that this is a direct 
result of HCP behaviour change, this remains conjecture.  It is also notable that none of the 
included studies reported any harm.  Again, this could lead to the suggestion that personalised 
eHealth interventions (aimed at either patients or HCPs) can safely effect behaviour change, 
however it is acknowledged that the studies did not specifically aim to measure harm, 
therefore absence of evidence cannot be regarded as equivalent to evidence of absence in this 
case. 
The lack of studies that combine eHealth technologies with interventions that utilise tailoring 
of information is surprising, given the evidence that tailoring is effective when used in 
conjunction with traditional media and the ease with which tailoring algorithms can be 
incorporated into new technologies 66.  This may reflect the fact that both are relatively recent 
innovations.  Given the existing evidence that tailored messages via traditional media can 
effect behaviour change it would seem a logical extension to incorporate them into eHealth 
interventions.  Clearly, there is a need for additional work in this area.  Future research should 
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delineate the role of tailoring in eHealth by comparing it with non-tailored interventions as 
opposed to no intervention or standard care. 
5.7 Conclusion 
Tailoring of information to recipients has previously been shown to be an effective way of 
changing behaviour when used with traditional media.  This review suggests that eHealth 
tailored information delivery may improve clinical care, but there is currently a lack of 
evidence to conclude that the use of tailoring within an eHealth context confers any benefits 
over non-tailored eHealth interventions.  This lack of evidence reflects the low number of good 
quality studies in this area.  It is only by designing studies where the role of tailoring is isolated 
as the active component in the intervention, that the effectiveness of tailoring can be 
adequately assessed. 
6. Clinical Decision Support systems 
6.1 Abstract 
6.1.1. Introduction 
Clinician Decision Support Systems (CDSS) provide health care professionals (HCPs) with 
automated advice about best practice patient care.  Prompts are provided via IT software and 
are tailored to the individual patient based on the real time data available.  CDSS have been 
shown to effectively influence HCP behaviour, in terms of adherence to guidelines and 
avoidance of drug errors.  The Evidence Based Medicine electronic Decision Support (EBMeDS) 
system is a CDSS that was developed in conjunction with health care providers, in line with the 
best evidence base (including SIGN guidelines) and was successfully implemented within SCI-
Diabetes, the Scottish national electronic health record for diabetes. 
6.1.2. Methods 
EBMeDS has been live to users within NHS Tayside and NHS Lothian since December 2013 
onward (serving a combined diabetes population of approximately 30,000).  An evaluation was 
undertaken over two quality improvement cycles adopting a mixed methods approach to: 
assess users' and patients' reaction to the EBMeDS system; to demonstrate that there are no 
unintended adverse effects attributable to the system; and to quantify any change in clinical 
processes and/or outcomes.  The evaluation was based on NHS Education for Scotland’s 
Knowledge into Action framework. 
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6.1.3. Results 
The use of the EBMeDS system had no adverse effects on patient experience, clinic 
consultation or working practices.  The system was associated with improved efficiency in 
working practices, but at the same time has resulted in a dramatic improvement in adherence 
to national guidelines e.g. patients were 3-4 times more likely to receive appropriate screening 
for diabetes-related complications.  There were modest, but significant, improvements in 
blood glucose control. 
6.1.4. Discussion 
The CDSS in its current form prompts HCPs to consider screening for complications as well as 
optimisation of current management.  If our findings were replicated across Scotland, 
thousands more individuals would receive screening for complications in accordance with 
national guidelines.  These evidence-based, early interventions can significantly impact on 
costly and devastating complications such as foot ulcers, amputations, cardiovascular disease, 
renal failure and death. 
Future work will aim to: a) develop and implement additional rule-based algorithms based on 
user feedback and emerging literature/guidelines; b) tailor messages to user group (HCPs and 
patients), c) improve the integration of the system within primary care systems and d) roll out 
CDSS to all users of SCI-Diabetes (patients and HCPs) across the whole of NHS Scotland. 
Not only does the study add to the evidence-base for CDSS, it serves as an exemplar for 
decision support across healthcare systems in Scotland, including primary care.  Therefore, the 
potential benefits of this project extend beyond the Scottish diabetes population, as NHS 
Scotland considers how best to realise the full potential of CDSS described in the national 
eHealth strategy. 
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6.2 Introduction 
As previously discussed, Clinical Decision Support Systems (CDSS) have been shown to be one 
of the most consistently successful approaches to encourage clinicians to adopt evidence-
based practice 59.  The Evidence Based Medicine electronic Decision Support (EBMeDS) system 
is an example of a CDSS and is currently integrated within the Finnish national electronic 
healthcare record (EHR).  It provides decision support to healthcare professionals and 
members of the public on a wide variety of health-related issues.  EBMeDS has been 
developed by the Finnish Medical Society, Duodecim 124.  This project arose via a collaboration 
between Duodecim and NHS Education for Scotland (NES), whereby NES are actively exploring 
CDSS options for NHS Scotland, in accordance with the refreshed national eHealth strategy  57.  
This strategy envisages that by 2020, healthcare professionals will have access to “…increasing 
amounts of clinical guidance and decision support that is relevant to the specific patient 
context, including highlighting any substantial variation from expectations, and generating 
appropriate prompts and alerts.”  NES and Duodecim entered into a service level agreement in 
March 2013, whereby EBMeDS would be implemented and evaluated within SCI-Diabetes  
(Scotland’s national informatics platform and EHR for people with diabetes), by way of a 
service improvement project assessing the feasiblity and utility of such a system within the 
Scottish context.  A project team was formed, comprising the author; a project manager; local 
clinicians; SCI-Diabetes developers; and representatives from Duodecim.  The project team 
met regularly via teleconference on a 1-2 monthly basis to discuss progress, review timelines 
and agree content of the CDSS.  The author was responsible for much of the development 
work and testing of the system as well as conducting all activities related to evaluation. 
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6.2.1. EBMeDS architecture 
EBMeDS relies on the ability of an EHR to summarise clinical data in a structured way.  When a 
patient record is opened, the EHR sends an individual’s clinical data to the EBMeDS server 
(hosted by Duodecim).  These data are initially converted into a standardised coded structure 
before being run through the EBMeDS “engine”.  This “engine” consists of a series of 
algorithms based on boolean logic, each written to address a specific clinical problem.  There 
are approximately 1000 such scripts, covering a wide variety of clinical specialities.  If the 
algorithm (or “script”) returns a positive result, then this clinical problem is identified as being 
an active issue.  A decision support message is then generated and transmitted back to the 
EHR, for displaying to the end user via the EHR user interface (UI).  If the script returns a 
negative result, then no such message is generated.  The system is summarised in Figure 2. 
 
Figure 2.  EBMeDS system architecture 
EBMeDS = Evidence Based Medicine electronic Decision Support 
 
EBMeDS is a “system-agnostic” service whereby it can be integrated into any EHR containing 
coded data.  There is no “front-end” to the system, so the appearance and behaviour of the 
end message is dictated by the EHR system administrators and developers. 
  
Electronic 
health record 
Coded data Database 
EBMeDS 
Engine 
Healthcare system Web server 
 58 
6.2.2. SCI-Diabetes architecture 
The SCI-Diabetes informatics platform has evolved from what was initially a local diabetes 
registry linking data from a number of sources 125 into a more comprehensive electronic health 
record, serving the whole of Scotland 12.  The Scottish Care Information – Diabetes 
Collaboration (SCI-DC) system was initially composed of a collection of informatics products 
designed to retrieve individual patient data from a number of sources and link these data using 
the community health index unique identifier 126.  These products were consolidated in 2011 
and renamed SCI-Diabetes 127.  SCI-Diabetes is built upon a healthcare domain model, with 
each domain being based on geography, service provider, or demographics.  For example, NHS 
Tayside (one of 14 geographical health boards in Scotland) comprises one tertiary centre; 
three district general hospitals; 67 primary care practices; and a number of health and 
community care centres.  The number of SCI-Diabetes healthcare domains within NHS Tayside 
reflects this diversity e.g. individual hospital clinic; primary care; paediatric population etc. 
HCP users are granted access to the domains that are deemed relevant to their role, thereby 
allowing access to all patient records attributed to that specific domain.  This 
compartmentalisation of the national register can then be exploited for the purposes of audit, 
data backup and the phased implementation of updates to the system. 
  
 59 
6.2.3. NHS Education for Scotland 
This project was sponsored by NHS Education for Scotland, who have proposed a new model 
to promote the integration of knowledge from research, practice and experience into everyday 
clinical practice - the NHSScotland Knowledge into Action framework 128.  The overall ambition 
of this strategy is to embed knowledge in care processes in real-time, making the EBMeDS 
system an ideal exemplar of this approach.  The framework has been adopted as a way to 
structure the evaluation of this project and involves a mixed methods approach – see Figure 3. 
 
Figure 3.  NES Knowledge into action framework. 
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6.3 Aims and objectives 
The project aims to implement decision support scripts derived from the SIGN guideline and 
local handbook information for diabetes, within the SCI-Diabetes system in NHS Tayside and 
West Lothian. This will serve as a demonstrator to inform recommendations for the 
implementation of decision support systems at a national level. 
The evaluation of this project aims to assess users' and patients' reaction to the EBMeDS 
system;  to demonstrate that there are no unintended adverse effects attributable to the 
system; and to quantify any change in clinical processes and/or outcomes. 
The objectives of the evaluation are: 
1. To describe users' navigation of the SCI-Diabetes system and to quantify changes in 
usage patterns following an EBMeDS prompt.  
2. To record Patient Reported Experience Measures (PREM's) for those attending the 
diabetes clinics during the demonstrator project and to compare PREM's for patients 
that were subject to an EBMeDS alert with those that weren't. 
3. To quantify whether or not the use of EBMeDS is associated with changes in clinical 
process measures and clinical outcomes (blood glucose control, renal disease,  and risk 
of cardiovascular disease). 
 61 
6.4 Methods - implementation 
6.4.1. Script selection 
The EBMeDS system in Finland contains approximately 1000 scripts, each targeting a specific 
clinical problem within a variety of clinical specialities.  Approximately 100 of these scripts 
relate directly to diabetes and were identified using associated metadata.  Following review by 
the project group, a decision was made to select those scripts that aligned most closely to 
diabetes care in Scotland.  This pragmatic choice was made in an effort to maximise the 
efficiency in which the scripts could be adapted to local use.  The scripts were selected using a 
Delphi type approach, whereby a document describing each script was circulated to all 
clinicians within the project group and local diabetes team for comment.  A consensus was 
reached and the chosen scripts were then amended to conform to national guidelines.  This 
process was completed by the author over a number of weeks and involved a variety of steps 
including: changing of scientific notation; altering of value thresholds; amending text of 
decision support messages; and identifying the relevant evidence behind each decision 
support message.  See appendix (section 13) for a summary and full details of each script. 
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6.4.2. User interface 
Decisions on how EBMeDS message was to appear within the SCI-Diabetes UI were made in 
conjunction with project team members; SCI-Diabetes developers; and SCI-Diabetes users.  
Again, email correspondence sought opinion from all stakeholders, with various proposed 
“mock ups” circulated for comment.  At the outset, it was acknowledged that any automated 
reminders need to be suitably placed so that users are aware of them, whilst avoiding user-
fatigue and annoyance.  The use of a “pop-up” dialogue box that appears on opening an 
individual patient record before automatically disappearing after a predetermined period, was 
felt to offer this correct balance.   Following user feedback, there have been a couple of 
iterations of the behaviour and appearance of the UI over the course of the project.  Further 
details on this feedback are available in sections 6.6 and 6.7.  Figure 4 shows the UI displaying 
the “pop-up” dialogue box.   
 
Figure 4.  Screenshot of SCI-Diabetes user interface showing EBMeDS short message pop up dialogue box. 
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In addition to this initial short message, users have the option to seek further information 
behind the decision support message.  This is achieved by navigating to a “long message” 
within SCI-Diabetes, that contains further details behind the clinical guidance, as well as a 
hyperlink to the relevant evidence (e.g. national guidelines) – see Figure 5. 
 
Figure 5.  Screenshot of SCI-Diabetes user interface showing EBMeDS long message and links to relevant evidence 
6.4.3. System testing 
Once the scripts were amended to reflect national clinical practice, they were implemented 
within the EBMeDS server.  A system of testing was devised to ensure that the scripts behaved 
as expected within SCI-Diabetes.  This process involved the creation of multiple fictitious 
patients within a testing environment.  The clinical data associated with each of these fictitious 
patients were designed to either trigger or suppress each of the scripts.  Due to the large 
number of variables and threshold values contained within each script, this dataset contained 
a large number of dummy patients (approximately 1500).  Each of these dummy patient 
records was manually opened, in turn, with the tester noting how the system behaved.  Scripts 
that were not suppressed or triggered as expected were then reviewed and amended as 
appropriate. 
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 64 
The work described above represented a significant proportion of the overall project with the 
author dedicating approximately 9 months to the process prior to the implementation of the 
live system (see Figure 6). 
 
Figure 6. Timeline illustrating the process by which the EBMeDS scripts were developed to the local context and 
tested prior to implementation.  Further script development and testing was required in response to user feedback – 
see figure 7. 
 
6.4.4. Implementation 
The SCI-Diabetes healthcare domain architecture allows EBMeDS to be switched on or off to 
specific user groups (see section 6.2.1).  Prior to being switched on in any given domain, a 
series of awareness-raising activities took place, including: questionnaire distribution; focus 
groups; email updates; and departmental presentations (see sections 6.6 to 6.7).   
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6.4.5. Participants 
Implementation adopted a quality improvement approach whereby the system was 
introduced to a limited number of users; evaluated for acceptability; adapted in light of user 
feedback; and then introduced more widely.  Two such “improvement cycles” ran over the 
course of an 18 month period: cycle 1 - implementation and evaluation in Ninewells Hospital 
(NWH) and one primary care general practice in Dundee (16 weeks); and cycle 2 - 
implementation and evaluation throughout the Tayside area (including Perth and Kinross and 
Angus) and St John’s Hospital (SJH), Livingston (16 weeks) – see Figure 7 
.  
 
Figure 7.  Project timeline.   
NWH= Ninewells Hospital; GP= General Practice; SJH=St John's Hospital; NHST=NHS Tayside (primary and secondary 
care) 
  
Dec Jun Dec 
Analysis 
Adapt 
Analysis 
Phase 1(NWH + 1 x GP) 
Phase 2 (NWH + SJH) 
2014 2013 
Jun 
2015 
Mar Sep Mar Sep Dec 
“Phase 2b” (NHST + SJH) 
Analysis 
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Cycle 1 
Participants included HCP users of the SCI-Diabetes system in NHS Tayside secondary care.  
The total number of users registered within NHS Tayside secondary care is 157.  This includes 
all health care professionals, of which approximately 25 use the system regularly within the 
NWH diabetes outpatient clinic.  In NWH, there are approximately 170 patients appointed to 
attend a diabetes clinic per week (4 doctor-led clnics with 18 patients/doctor and 1 nurse-led 
clinic with 10/nurse). 
Cycle 2 
Participants included all HCP users of the SCI-Diabetes system throughout NHS Tayside primary 
and secondary care as well as SJH, Livingston.  The number of registered users in each area is 
known, but it is less clear which of these are regular users.  It was estimated that cycle 2 would 
involve approximately 120 users, based on the following: 
 Number of NHS Tayside primary care practices = 67 (assuming 1 regular user per 
practice of the 98 registered doctors in primary care) 
 Number of NHS Tayside secondary care registered users = 157 (of which it was 
estimated there would be 40 regular users across all sites) 
 Number of NHS Lothian secondary care registered users = 12 (assuming all are regular 
users) 
Approximately 500 patients were appointed to the diabetes clinic in SJH, Livingston for both of 
the 3-month improvement cycles that they participated in.  Quantifying patient numbers for 
the whole of NHS Tayside primary and secondary care requires extrapolation from aggregate 
figures.  Based on 2013 data, there were approximately 20,800 patients with diabetes living in 
NHS Tayside 16.  Assuming all of these patients visit an HCP at least once during a 12 month 
period, we can expect approximately half will be seen during the 3 months of cycle two and 3 
months of cycle 3 combined i.e. approximately 10,000 patients. 
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6.4.6. Evaluation 
The evaluation adopted a mixed methods approach, and included 6 different components.  
Each component is described in the following sections (sections 6.5 to 6.10 where methods 
and results are reported concurrently. 
6.5 Patient reported experience measures (PREMs) 
6.5.1. Abstract 
6.5.1.1. Introduction 
The clinical consultation and the “doctor-patient” relationship can be influenced by the way in 
which computers are used by the health care professional (HCP).  The Evidence Based 
Medicine electronic Decision Support (EBMeDS) clinical decision support system (CDSS) is 
designed to provide health care professionals with advice within the normal workflow and 
does so by providing messages to the HCP during the consultation.    This study was designed 
to evaluate patient reported experience measures (PREMs) for patients attending a diabetes 
clinic, and to assess whether or not the EBMeDS system affects patient experience. 
6.5.1.2. Methods 
A PREMs questionnaire was devised and distributed to patients attending diabetes clinics at 
three sites: Ninewells hospital, Dundee; St John’s hospital, Livingston; and a primary care 
diabetes clinic within Dundee city.  Questionnaires were distributed at 2 time points, 
December 2013-February 2014 (improvement cycle 1) and August 2014-February 2015 
(improvement cycle 2), with dedicated research staff employed during cycle 2.  The 
questionnaire consisted of a series of closed, 5-point Likert scale items grouped within 
different domains: interaction with doctors; interaction with nurses; use of medication; and 
general satisfaction.  A score was calculated for each domain and used as a dependent variable 
in a multivariable linear regression analysis.  Predictors included demographic variables and 
the presence or absence of a CDSS message. 
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6.5.1.3. Results 
A total of 359 questionnaire responses were received from cycle 1 and 2 combined, from a 
total population of 2,072 clinic attendances (17%).  Response rates were higher for cycle 2 
(281/471, 60%).  Responses to all domains were overwhelmingly favourable with >90% or 
respondents reporting positively to each item.  Owing to data availability, regression analysis 
was limited to a subset of 71 patients from cycle 1.  Within this subset, there was no significant 
association between presence or absence of a CDSS message and domain score in either 
domain.  Various demographic variables were predictive of domain scores e.g. greater 
deprivation was associated with less satisfaction with doctor interaction (=0.04, p=0.01). 
6.5.1.4. Conclusion 
In general, patients reported high rates of satisfaction with the service that they received.  
There was no association between presence or absence of a CDSS message and patient 
satisfaction.  This would imply that the EBMeDS system is having no adverse impact on the 
consultation. 
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6.5.2. Introduction 
The role of the computer within the consultation and the potential for both positive and 
negative effects on the doctor-patient relationship has been widely discussed 129.  In Scotland, 
computer use is an integral part of the consultation with patients with diabetes owing to the 
widespread use of the SCI-Diabetes electronic health record.  The EBMeDS clinical decision 
support system has been implemented within SCI-Diabetes to provide users with prompts and 
reminders via the user interface.  EBMeDS is primarily aimed at health care practitioners as an 
additional tool that seamlessly integrates into the normal consultation.  There is no patient-
orientated interface or communication from EBMeDS.  From the patients’ perspective, the 
implementation of EBMeDS should therefore have no adverse effects on the consultation.  
Patient reported experience measures (PREMs) are an integral part of quality assurance for the 
NHS in the UK 56,130,131.  Both NHSScotland and the NHS in England regularly survey large 
samples of the population to gain insight into patients’ experiences at both primary and 
secondary care and publish these results annually 132,133.  Questions have been written to 
assess PREMs following consultation with stakeholders, and have been cognitively tested with 
the public to ensure their validity 134.  These questions are freely available for local use thereby 
allowing for comparison with results obtained nationally 134,135.  The NHSScotland patient 
survey is primarily aimed at assessing patients’ experience of visiting the GP but is easily 
adapted to the outpatient setting.   
6.5.3. Aims 
 To record patient reported experience measures (PREMs) following a visit to the 
diabetes clinic where EBMeDS was introduced 
 To compare PREMs between those patients whose health care practitioner (HCP) 
received an EBMeDS prompt and those whose HCP didn’t. 
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6.5.4. Methods 
6.5.4.1. PREMs questionnaire 
The NHSScotland PREMs questionnaire was adapted for use in both outpatient and primary 
care settings and consists of 32 items within 4 domains: interaction with the doctor; 
interaction with the nurse; understanding of medication; and overall satisfaction. The final 
questionnaire is available in the appendix (see section 14), as well as online at 
http://tinyurl.com/zd8sxwz.  Respondents were given the opportunity to complete and 
anonymously return the survey immediately.  Alternatively, respondents could return the 
completed questionnaire to the postal address provided (postal costs were not covered).  The 
online version was also made available to respondents.  
The questionnaire was distributed during both improvement cycle 1 and 2 during the EBMeDS 
project.  Cycle 1 took place in the NWH diabetes outpatient clinic between December 2013 
and February 2014 whilst cycle 2 involved the whole of NHS Tayside plus SJH, Livingston during 
August 2014 to February 2015.  The questionnaire was initially distributed via outpatient 
clerical staff with the aim to offer it to all patients attending the outpatient clinic for the 3 
months of cycle 1.  Patients were issued with a questionnaire on arrival by reception staff and 
asked to return the completed form at the end of their appointment.  These methods were 
adapted in light of a poor response rate and for cycle 2, a research assistant was employed to 
distribute the questionnaire for a more concentrated period.  All patients waiting in the 
outpatient clinic were approached by the research assistant and were invited them to take 
part. 
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6.5.4.2. Sample size 
From national results, we initially expected that approximately 90% of patients will be positive 
about their clinic experience 132. In cycle 1, approximately 95% of respondents to the question 
“Overall, how would you rate the care provided by the diabetes clinic?” gave an “excellent” or 
“good” response.  The null hypothesis is that there is no difference in overall rating between 
those whose HCP received an EBMeDS notification and those that didn’t.  The alternative 
hypothesis is that there is a difference between the two groups. 
In the event of 320 responses being received, it was estimated that approximately 100 will be 
in the intervention group (assuming 20-30% of consultations will be subject to an EBMeDS 
prompt).  If the proportion of patients who rate overall care as “good” or “excellent” fell to 
85% in the intervention group, then the null hypothesis would be rejected with 82% power 
(alpha error 5%). 
Approximately 320 patients visit the diabetes clinics involved in the project every week.  
Assuming a 10% non-attendance rate 136 and a return rate of 60%, questionnaires were 
distributed within NHS Tayside for 2 weeks and SJH for 1 week (total anticipated n=540).  
Distribution was not on consecutive days, but all clinics were equally covered to ensure 
adequate representation of all patient groups. 
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6.5.4.3. Statistical analysis 
Responses to questions containing a 5 point Likert scale were recoded into “positive”, 
“neutral” or “negative” responses for the purposes of graphical representation.  Control and 
intervention group demographics were compared using Chi Square.  A domain score for each 
individual was calculated by summing the total for each domain, before dividing by the highest 
possible score available in that domain to give a total out of 1.  Comparison between control 
and intervention groups was made using these domain scores.  The domain scores were 
considered as the dependent variable.  Demographic variables were considered potential 
confounders and so each were entered into a univariable linear regression model.  These 
independent variables were retained if p<0.1 for the final model, containing presence or 
absence of DSS prompt. 
6.5.4.4. Approval 
Permission was granted by the national Caldicott Guardian to collect identifiable information.  
Probabilistic matching was completed to match respondents with CHI data, which in turn 
allowed individuals’ SCI-Diabetes data to be accessed.  All resultant data queries were 
provided in a pseudo-anonymised format. 
6.5.5. Results 
Analysis of both cycle 1 and cycle 2 data was restricted to aggregate data only.  The planned 
regression to compare responses between intervention and control groups was limited to 
cycle 1 data owing to a lack of data at the individual level – cycle 2 demographic variables were 
not available at the time of analysis. 
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6.5.5.1. Aggregates 
During cycle 1, 78 responses were obtained from a total of 1601 attendances (5%).  During 
cycle 2, 221 responses were obtained from a total of 391 attendances in NHS Tayside 
secondary care (57%) and an additional 20 responses were obtained from 2 primary care 
diabetes clinics (100% response rate). 40 responses were obtained from a total of 60 
attendances in SJH (60%). Data were combined from cycles 1 and 2 to provide a total of 359 
responses.  201 (56%) of total responses were from males, 341 (95%) described themselves as 
“white” ethnicity and 144 (40%) described their general health as “good”.  
PREMs for each of the 4 domains was overwhelmingly positive, reflecting high patient 
satisfaction with the service that they received (see Figure 8 to Figure 11).  233 (65%) of 
patients had a consultation with a doctor; 217 (60%) had a consultation with a nurse; and 95 
(26%) had their medication changed (resulting in questions being answered on the use of 
medications). 
 
Figure 8.  Stacked bar charts for responses to items relating to interaction with doctors.   
5 point Likert scale was collapsed into positive, neutral or negative responses. 
 
0% 10% 20% 30% 40% 50% 60% 70% 80% 90% 100% 
The doctor listened to me 
I felt that the doctor had all the information … 
The doctor was considerate and understanding 
The doctor talked in a way that helped me … 
I felt confident in the doctor’s ability to treat me 
I had enough time with the doctor 
Interaction with doctors (n=233) 
positive neutral negative 
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Figure 9.  Stacked bar charts for responses to items relating to interaction with nurses.   
5 point Likert scale was collapsed into positive, neutral or negative responses. 
 
 
Figure 10.  Stacked bar charts for responses to items relating to use of medication.   
5 point Likert scale was collapsed into positive, neutral or negative responses. 
 
0% 10% 20% 30% 40% 50% 60% 70% 80% 90% 100% 
The nurse listened to me 
I felt that the nurse had all the information … 
The nurse was considerate and understanding 
The nurse talked in a way that helped me … 
I felt confident in the nurse’s ability to treat me 
I had enough time with the nurse 
Interaction with nurses (n=217) 
positive neutral negative 
0% 10% 20% 30% 40% 50% 60% 70% 80% 90% 100% 
I knew enough about what my medicines were 
for 
I knew enough about how and when to take my 
medicines 
I knew enough about possible side effects of my 
medicines 
I would know what to do if I had any problems 
with my medicines 
I took my prescription as I was supposed to 
Use of medications (n=95) 
positive neutral negative 
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Figure 11.  Stacked bar charts for responses to items relating to overall satisfaction.  
5 point Likert scale was collapsed into positive, neutral or negative responses. 
 
In keeping with the above, the domain scores were similarly positive (see Figure 12).  
 
Figure 12.  Mean score for each of the 4 questionnaire domains.   
Score calculated as a proportion of highest total possible.  Error bars show 95% CI. 
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Are you involved as much as you want to be in 
decisions about your care and treatment? 
I am treated with dignity and respect 
I am treated with kindness and understanding 
Overall, how would you rate the care provided 
by the diabetes clinic? 
General satisfaction (n=359) 
positive neutral negative 
0.8 
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1 
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6.5.5.2. Comparison 
Of the 78 respondents in cycle 1, 71 were successfully identified within SCI-Diabetes.  The HCP 
opening the patient record received a DSS message in 25/71 (35%) cases i.e. similar to the 
overall proportion of patient records subject to a DSS prompt (see section 6.8).  Demographic 
variables were very similar between respondents whose HCP received a prompt and those 
whose HCP didn’t (see Table 5).  Unsurprisingly, those that did receive a prompt had greater 
comorbidity (see section 6.8.4 for comorbidity score description). 
Table 5.  Demographic variables for cycle 1 PREMs respondents. 
Comparison made using Chi Square 
 DSS message received  
 Yes  (n (% of N)) No (n (% of N)) p 
Total N 46 25 0.439 
Male 18 (39%) 7 (29%) 1 
Age >=60 years 20 (47%) 11 (50%) 0.282 
Ethnic group "white"  45 (98%) 23 (96%) 0.594 
Most deprived SIMD quintile 12 (26%) 8 (32%) 1 
Self reported health "good" 17 (37%) 9 (36%) 0.307 
High comorbidity score 5 (11%) 5 (20%) 0.256 
Type 2 diabetes 32 (70%) 21 (84%) 0.576 
Insulin therapy 35 (76%) 17 (68%) 0.131 
 
When subject to univariable analysis, a few demographic variables reached significance and so 
were entered into the multivariable model in conjunction with presence or absence of a DSS 
prompt (see Table 6 and Table 7). 
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Table 6.  PREMS respondents - univariable significance of each predictor variable for domain scores. 
*Denotes predictors reaching significance <0.1.  B = correlation coefficient 
Predictor variables (univariable) Domain 
Doctor Nurse Medication General satisfaction 
B p value B p value B p value B p value 
gender -0.21 0.698 0.07 0.138 0.09 0.159 0.04 0.125 
Age category (decades) -0.01 0.729 -0.03 0.188 0.06 0.084 -0.01 0.151 
Ethnic group 0.03 0.599 -0.08 0.076 0.01 0.93 -0.06 0.176 
SIMD quintile 0.04 0.01 0 0.938 -0.01 0.745 0 0.858 
Self reported health status -0.03 0.375 -0.02 0.614 0.07 0.151 0.04 0.023 
Comorbidity group -0.02 0.635 -0.07 0.079 0.02 0.732 -0.01 0.597 
Diabetes type 0.05 0.435 -0.04 0.508 0.29 0.001 0 0.881 
DSS message displayed 0.02 0.709 0 0.967 0.04 0.575 0.01 0.829 
 
 
Table 7.  PREMS respondents - significant univariable predictors entered into a multivariable model. 
NB. presence or absence of DSS message retained as a predictor.  B= correlation coefficient 
Predictor variables (multivariable) Domain 
Doctor Nurse Medication General satisfaction 
B p value B p value B p value B p value 
gender - - - - - - - - 
Age category (decades) - - - - 0.03 0.301 - - 
Ethnic group - - -0.08 0.076 - - - - 
SIMD quintile 0.04 0.01 - - - - - - 
Self reported health status - - - - - - 0.07 0.14 
Comorbidity group - - - - - - - - 
Diabetes type - - - - 0.26 0.015 - - 
DSS message displayed 0.03 0.476 0.03 0.606 0 0.942 0.05 0.465 
 
Of note from the above tables: 
 Domain scores were not significantly predicted by presence or absence of a DSS 
message. 
 Greater deprivation was predictive of a lower doctor domain score.   
 Ethnicity as a predictor of nursing score approached significance, however, actual 
numbers of non-white ethnic groups were extremely low (2 in total).   
 Presence of Type 1 diabetes was predictive of a lower medication score.  
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 Lower self reported health status showed some association with overall lower 
satisfaction with the service. 
6.5.6. Discussion 
Patient satisfaction was generally high for those attending the diabetes clinics during the 
period of assessment and were in keeping with results obtained from a similar PREMs 
questionnaire distributed to primary care users 132.  This analysis has demonstrated no 
difference in patient satisfaction between patients whose HCP received a CDSS message, and 
those that did not.  There are several limitations in study design, making it difficult to draw 
firm conclusions. 
Despite the improved response rate demonstrated within cycle 2, the regression analysis is 
limited to cycle 1 data (71/299 total responses).  This decision was based on data availability, 
whereby at the time of writing, the data custodians lacked sufficient capacity to make the 
requisite query.  It is acknowledged that this invalidates the initial power calculation that 
assumed 320 questionnaires would be returned.  It is anticipated that future multivariable 
analysis will include all respondents’ data once these data are available. The smaller patient 
numbers (and less representative sample) limits the conclusions that can be drawn in terms of 
statistical inference.  However, the aggregate statistics from cycle 2 were very similar to those 
obtained in cycle 1, and it is not anticipated that future analyses will arrive at a different 
conclusion. 
The questionnaire itself was adapted from a similar instrument used for a national survey 134.  
This national survey was developed following a consultation process with patients and HCPs 
and was “cognitively validated” with regards to language and structure.  However, the national 
questionnaire was not used to calculate “domain scores” as per the methods employed in this 
study.  The use of this domain score in this study is, therefore, not a validated measure with 
which to compare patient sub-groups and may not be discriminatory.  The results obtained in 
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this study were similar to the national survey, in that both demonstrated high rates of patient 
satisfaction.  Whilst this is obviously encouraging from a service delivery perspective, these 
high satisfaction rates may be further compounding this lack of discrimination, by masking any 
difference between patients whose HCP received a CDSS message and those that didn’t. 
The potential for respondent bias is acknowledged, whereby respondents may be self-
selecting, following a particularly good (or bad) experience.  This was of concern during cycle 1, 
where response rates were particularly low.  However, the targeted approach adopted during 
cycle 2, (whereby a dedicated research assistant approached patients within the clinic) 
improved response rates markedly. 
Despite these limitations, it is notable that presence or absence of a CDSS prompt had no 
bearing on patients’ self-reported experience with doctors or nurses, nor did the CDSS impact 
upon overall satisfaction.  Given the high levels of satisfaction demonstrated, this is perhaps 
unsurprising and would suggest that the CDSS is having no adverse effects on the consultation.  
It is also notable that, despite the small numbers included within the regression analysis, 
patients with more complex needs had lower satisfaction with the service.  In addition, 
patients with greater deprivation were less positive about their experience with the doctor.  
National patient surveys have previously demonstrated a negative correlation between 
deprivation and satisfaction 137,138.  The cause of such an association remains speculative, 
however it may be both measures would improve with appropriate targeting of the relevant 
patient and HCP groups. 
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6.5.7.  Conclusion 
This study has demonstrated that there are high rates of patient satisfaction with the care 
received within primary and secondary care diabetes clinics.  Despite the fact that a similar 
analysis has not yet been completed with cycle 2 data, the high levels of satisfaction would 
suggest that the EBMeDS system is not having an adverse effect on the consultation process, 
and it would seem unlikely that future analysis will detect any significant difference between 
intervention and control groups. 
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6.6 Health Care Professional (HCP) user opinion survey 
6.6.1. Abstract 
6.6.1.1. Introduction 
There are a variety of factors that can potentially influence the uptake and use of a new information 
system, including performance expectancy (i.e. the degree to which an individual believes the 
system will help them with their work); effort expectancy (i.e. perceived ease of use); social 
influence; and facilitating conditions.  The Evidence Based Medicine electronic Decision Support 
(EBMeDS) system was introduced to SCI-Diabetes as a clinical decision support system (CDSS).  This 
study aimed to describe users’ attitudes to the use of CDSS prior to, and following, implementation 
of EBMeDS with a view to identifying facilitators and barriers to system uptake and usage. 
6.6.1.2. Methods 
Two questionnaires were developed for distribution to health care professional (HCP) users of SCI-
Diabetes.  They were distributed to HCPs prior to, and at the end of each 3-month quality 
improvement cycle in both primary and secondary care.  The questionnaires were available in 
electronic and paper versions and consisted of a series of closed 5-point Likert scale questions 
grouped by theoretical construct.  Theoretical constructs were derived from the Unified Theory of 
Acceptance and Use of Technology (UTAUT) model, that aims to predict whether or not new 
technology will be adopted by users.  A score was calculated for each construct and was used as a 
dependent variable in a multivariable linear regression analysis with users’ demographics entered as 
the independent predictors. 
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6.6.1.3. Results 
The response rate for pre and post intervention questionnaires was 57/105 (54%) and 39/105 (37%), 
respectively.  Respondents tended to be more senior members of staff.  Prior to the intervention, 
HCPs reported that most reading of literature and guidelines occurred after or unrelated to the 
consultation and attitudes to a CDSS were mixed.  Post-intervention attitudes to the EBMeDs system 
were similarly mixed. The majority of respondents had a positive or neutral response to the content 
of the reminders in terms of relevance, clarity and quality.  Similarly, most respondents were 
positive or neutral to questions relating to ease of use.  Despite this, self reported use of the system 
was low.  Work role predicted users’ performance expectancy (i.e. the degree to which an individual 
believes the system will help them with their work), which was significantly higher for nurses. 
6.6.1.4. Conclusion 
In general, HCPs expressed positive attitudes to the use of CDSS, however self reported use was low.  
This may reflect users’ pre-existing work patterns and may also be attributed to the relative seniority 
of respondents.  Actual use of the system was the subject of further quantitative research.  In 
addition, further qualitative work with users was required to identify any particular 
barriers/facilitators that may improve uptake. 
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6.6.2. Introduction 
When implementing any new information system, it is essential that there is clear understanding of 
the factors that may influence potential users to successfully adopt it.  The decision whether or not 
to do so is highly subjective.  Various factors that can influence this process have been identified 
including: individuals’ attitudes to new technology; their intention to use such systems; and 
organisational or environmental conditions required to increase uptake.  As a result, several models 
have been proposed which include some or all of these factors.  These include the Theory of 
Reasoned Action 139; the Technology Acceptance Model 140; and Social Cognition Theory 141 amongst 
others.  The Unified Theory of Acceptance and Use of Technology (UTAUT) model was formulated by 
identifying the similarities between eight different models, combining them and then validating the 
resultant model 88.  This model can be used to evaluate the likelihood of whether a new technology 
will be adopted by users as well as allowing organisations to identify user groups that may require 
additional support during the implementation phase.  The UTAUT has been used in a variety of 
contexts to explore user acceptance of new technologies, including the adoption of electronic health 
records 89,142 and the use of telemedicine in diabetes care 143 
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The UTAUT identifies four main constructs (common to all the previous models), which were found 
to be significant predictors of user acceptance and usage behaviour.  These are: performance 
expectancy (i.e. the degree to which an individual believes the system will help them with their 
work); effort expectancy (i.e. perceived ease of use); social influence; and facilitating conditions (see 
Figure 13). These in turn are influenced by a number of independent variables including gender, age 
and experience. 
 
Figure 13.  The Unified Theory of Acceptance and Use of Technology.   
Adapted from Venkatesh et al 
88
  (putative modifiers omitted). 
6.6.3. Objectives 
The objectives of this study were to: 
 Describe HCPs’ use of evidence based medicine (EBM) resources prior to and following 
implementation of the CDSS 
 Explore HCPs’ attitudes to the use of a CDSS prior to and following implementation 
 Identify potential facilitators/barriers to HCPs’ use of CDSS elsewhere 
Social 
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Effort 
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6.6.4. Methods 
The UTAUT model was used to develop a user experience questionnaire aimed at users of the clinical 
decision support system (CDSS) implemented within SCI-Diabetes.  Additional constructs were also 
added including: attitude to CDSS reminders; general satisfaction; and perceived use of the system.  
This work drew on the experience of Heselmans et al who have previously assessed the use of the 
Evidence Based Medicine electronic Decision Support system (EBMeDS) within their local context 144.  
An additional, pre-implementation questionnaire was also developed for this study that aimed to 
assess users’ attitudes to CDSS prior to the implementation of EBMeDS.  This would allow 
comparisons of user attitudes before and after the introduction of the CDSS. 
The resultant two questionnaires consisted of: a 37-item baseline questionnaire (see section 15 
appendix or http://tinyurl.com/zmsp7tk for the online version); and a 42-item follow up 
questionnaire (see section 16 appendix or http://tinyurl.com/hqsdztz for the online version). 
SCI-Diabetes users were emailed links to the online version of the questionnaire and paper copies 
were made available at departmental meetings.  Secondary care users were contacted via grouped 
email lists held by the managed clinical network manager.   
In secondary care, there were 22 registered users during cycle 1 (Ninewells Hospital (NWH)) and 16 
users during cycle 2 (SJH).  Primary care users were included in cycle 2.  The total number of 
registered users in the NHS Tayside primary care domain was 97, distributed amongst 67 primary 
care health centres.  Practice managers for each health centre were contacted via an email asking 
them to forward the invitation to the most appropriate user in the practice.  For the purposes of 
analysis, it was therefore assumed that one user per practice was invited to respond (n=67).  
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The email to the secondary care team was also used to invite recipients to take part in focus groups 
(see section 6.7, HCP user opinion focus groups).  When tested prior to administering, both pre and 
post-intervention questionnaires took less than 5 minutes to complete.  In an effort to improve 
response rates, the cycle 1 post-implementation questionnaire included the option to be entered 
into a prize draw (for a £50 shopping voucher), as a contingent incentive. No personal identifiable 
information was collected. 
Both questionnaires consisted of mainly closed questions with the option for additional free text 
comments.  Responses to questions containing a 5 point Likert scale were recoded into “positive”, 
“neutral” or “negative” responses for the purposes of graphical representation2. Items 
corresponding to UTAUT constructs were grouped to allow a construct score for each individual to 
be calculated.  This construct score was calculated by summing the total for each construct, before 
dividing by the highest possible score available in that construct to give a total out of 13.  Unless 
otherwise stated, the cycle 1 and 2 responses to both pre and post-implementation questionnaire 
were combined for analysis.  Multivariable linear regression was used to look for significant 
demographic predictors of each construct score.  The independent predictors entered were age 
category; workplace (primary or secondary care); number of years’ experience; and work role 
(doctor or nurse). 
                                                          
 
2
 Scores 1-2 = “positive”, score 3 = “neutral”, score 4-5 = “negative” 
3
 Scoring for negatively worded questions was reversed by using the following equation: 5+1-score (where 5 is the maximum value of 
response scale and "score" is the individual's response.  This results in a reversal of scores i.e. 1=5, 2=4 and vice versa). 
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6.6.5. Results 
Pre-intervention questionnaires were returned by 57 users (cycle 1=9/22 (response rate 41%), cycle 
2=48/83 (58%) whilst 39 users responded to the post-intervention questionnaire (cycle 1=5/22(23%), 
cycle 2=34/83(41%)).  Demographic variables were similar between pre and post intervention 
respondents.  The majority of respondents were 50 years or older (pre-intervention=35/57 (61%), 
post-intervention 23/39 (59%)) and worked in primary care (pre-intervention=35/57 (61%), post-
intervention=30/39 (77%)).  Most respondents were nurses (pre-intervention=30/57 (53%), post-
intervention=24/39 (62%)) and most had >10 years’ experience of working with patients with 
diabetes (pre-intervention=44/57 (77%), post-intervention=29/39 (74%) – see Table 8. 
Table 8.  Demographic variables of respondents to pre and post intervention questionnaires. 
NB. Data are combined from cycles one and two 
 Pre-intervention 
(n=57) 
Post-intervention 
(n=39) 
n % n % 
Age 20-29 years 1 1.8% 0 0.0% 
30-39 years 4 7.0% 4 10.3% 
40-49 years 17 29.8% 12 30.8% 
50-59 years 34 59.6% 23 59.0% 
60+ years 1 1.8% 0 0.0% 
Role AHP 2 3.5% 0 0.0% 
Doctor 24 42.1% 12 30.8% 
Nurse 30 52.6% 24 61.5% 
Specialist practitioner 1 1.8% 0 0.0% 
Administrator 0 0.0% 3 7.7% 
Setting Primary care 35 61.4% 30 76.9% 
Secondary care 16 28.1% 5 12.8% 
Both primary and secondary care 6 10.5% 4 10.3% 
Average hours worked per 
week 
<17 hours 1 1.8% 1 2.6% 
17-32 hours 19 33.3% 15 38.5% 
33+ hours 36 63.2% 21 53.8% 
Experience <5 years 8 14.0% 4 10.3% 
5-10 years 5 8.8% 6 15.4% 
10+ years 44 77.2% 29 74.4% 
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Respondents to both pre- and post-intervention questionnaires were asked about their use of 
guidelines and literature during a typical working week.  Over half of respondents to either 
questionnaire (52/96, 54%) spent <1 hour per week doing so, whilst the remainder spent 1-5 
hours/week.  The most commonly used guideline was the local diabetes handbook (85/96, 86%), 
followed by guidance from the Scottish Intercollegiate Guidelines Network (SIGN) (80/96, 83%) and 
the National Institute for Health and Care Excellence (NICE) (43/96, 45%).  A minority (7/96, 7.3%) 
sought guidance from elsewhere.   
6.6.5.1. Pre-intervention questionnaire 
Respondents to the pre-intervention questionnaire were asked about when they accessed these 
resources (relative to the clinical consultation).  Most reading took place either after or unrelated to 
the consultation.  Prior to and during the consultation, guidelines were more commonly accessed 
than other literature (e.g. journal articles) – see Figure 14. 
 
Figure 14.  Respondents’ access to guidelines and literature, relative to the clinical consultation (n=57) 
 
0% 
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Clinical queries that emerge were usually answered by either searching the literature/guidelines or 
by asking a colleague for advice.  The majority of respondents to the pre-intervention questionnaire 
reported that they had adequate time to search the literature and that their reading usually resulted 
in the query being answered.   This reading was often not recorded for continuing professional 
development (CPD) purposes, and the majority of respondents agreed that a system that could do 
this automatically would be worth considering – see Figure 15. 
 
Figure 15.  Pre-intervention access to literature and guidelines (n=57). 
5 point Likert scale was collapsed into positive, neutral or negative responses. 
 
0% 10% 20% 30% 40% 50% 60% 70% 80% 90% 100% 
I would like it if my CPD is automatically recorded 
when I read literature and/or guidelines. 
When I search for relevant literature and/or 
guidelines, I would like this to count towards my … 
When I search for relevant literature and/or 
guidelines, I always record it as CPD. 
I feel comfortable overriding a guideline if I feel it is 
not in the patient's best interests. 
When I have a clinical query, I usually ask a colleague 
for advice 
When I have a clinical query, I usually look for the 
answer in the literature and/or guidelines. 
When I have a clinical query, I usually manage to find 
the time to find the answer. 
When I search for relevant literature and/or 
guidelines, I usually find what I am looking for. 
positive neutral negative 
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Prior to the intervention, attitudes to CDSS were mixed.  Over half of respondents either disagreed 
or were not sure that a CDSS would lead to better quality care – see Figure 16.  Similarly, most 
respondents did not feel that they could trust a CDSS and would want to know the underlying 
evidence behind the CDSS message.  Over half of respondents were also fearful that users would 
become reliant on the system.   A similar proportion hoped that they would be given the opportunity 
to turn the CDSS off. 
 
Figure 16.  Pre-intervention attitudes to CDSS (n=57).   
5 point Likert scale was collapsed into positive, neutral or negative responses. *Denotes negatively worded stems where 
scoring was reversed – see methods. 
 
0% 10% 20% 30% 40% 50% 60% 70% 80% 90% 100% 
If a CDSS was implemented, I would like the option to 
turn it off. 
*I would find messages from a CDSS annoying after a 
while 
*I would worry that some people might come to rely 
on messages from the CDSS. 
I would feel comfortable choosing to ignore the 
advice from the CDSS if I felt it was justified. 
*I worry that messages from a CDSS might affect the 
consultation and/or my relationship with the patient. 
I would trust the advice given by an automated 
message delivered by a clinical decision support … 
I would want to know the evidence behind the advice 
given by the CDSS. 
I think that CDSS could help me when prescribing 
medication. 
I think that CDSS could help me when deciding 
when/when not to request investigations. 
I think that using a CDSS will lead to a better quality 
of care. 
positive neutral negative 
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6.6.5.2. Post-intervention questionnaire 
Responses to the post-intervention questionnaire are displayed in Figure 17 to Figure 21, grouped by 
questionnaire construct.  Responses to items within each construct followed a similar pattern, 
whereby most respondents gave a neutral response to statements and those with either positive or 
negative attitudes were in the minority.  For example, 4/18 (22%) agreed that the CDSS has 
“changed my way of working”, whereas 5/18 (28%) disagreed with this statement – the remainder 
(9/18, 50%) had a neutral attitude to the statement. 
6.6.5.2.1. Attitudes to reminders (Figure 17) 
Attitudes to the CDSS in the post-implementation questionnaire were similar to those expressed 
prior to implementation.  The majority of respondents had a positive or neutral response to the 
actual content of the reminders in terms of relevance, clarity and quality.  In accordance with the 
pre-implementation questionnaire, users felt comfortable in overriding the advice if it was felt to be 
not relevant.  The option to turn off reminders polarised opinion, but 5 individuals only answered 
this - 3/5 (60%) would like the option to do so whilst 2/5 (40%) did not.
 
Figure 17.  Post-intervention attitudes to CDSS – attitude towards reminders 
5 point Likert scale was collapsed into positive, neutral or negative responses. *Denotes negatively worded stems where 
scoring was reversed – see methods.  n=18,  denotes n=5.   
  
0% 10% 20% 30% 40% 50% 60% 70% 80% 90% 100% 
I would like the option to turn off the EBMeDS system 
The EBMeDS clinical alerts are relevant to my 
practice. 
*The EBMeDS clinical alerts are not specific enough. 
I feel comfortable overriding the advice given by the 
EBMeDS system if I feel it is not in the patient's best … 
*I don't think the information provided by EBMeDS is 
of sufficient quality. 
The EBMeDS clinical alerts communicate the message 
in a clear way. 
I would prefer it if the guidelines referred to by the 
clinical alert were available within SCI-Diabetes (as … 
Attitude towards reminders 
positive neutral negative 

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6.6.5.2.1. UTAUT constructs (Figure 18 to Figure 21) 
Social influence – a minority of respondents felt that their decision to use the CDSS was affected by 
whether or not colleagues were using the system. 
Performance expectancy – a minority of respondents felt that the CDSS conferred benefit in terms 
of time to complete task or improving clinical knowledge.   
Facilitating conditions – The majority of respondents did not experience technical problems. A 
minority of respondents felt that they were given insufficient information and a minority also did not 
feel that technical support was available when needed.   
Effort expectancy – the system was easy to use, with only a minority finding it difficult to adapt to. 
 
Figure 18.  Post-intervention attitudes to CDSS – social influence on decision to use CDSS (n=18) 
5 point Likert scale was collapsed into positive, neutral or negative responses. 
 
 
Figure 19.  Post-intervention attitudes to CDSS – users’ perception of performance expectancy (n=18) 
5 point Likert scale was collapsed into positive, neutral or negative responses. 
 
0% 10% 20% 30% 40% 50% 60% 70% 80% 90% 100% 
I use the EBMeDS system mainly because my 
colleagues do. 
Social influence 
positive neutral negative 
0% 10% 20% 30% 40% 50% 60% 70% 80% 90% 100% 
I think that using the EBMeDS system improves 
my clinical knowledge. 
The use of the EBMeDS clinical alerts system 
could lead to better quality of care. 
Using the EBMeDS clinical alerts system enables 
me to accomplish my tasks more quickly. 
Performance expectancy 
positive neutral negative 
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Figure 20.  Post-intervention attitudes to CDSS – conditions that may facilitate adoption (n=18). 
5 point Likert scale was collapsed into positive, neutral or negative responses. *Denotes negatively worded stems where 
scoring was reversed – see methods. 
 
 
 
Figure 21.  Post-intervention attitudes to CDSS – effort expectancy (n=18).   
5 point Likert scale was collapsed into positive, neutral or negative responses.*Denotes negatively worded stems where 
scoring was reversed – see methods. 
 
  
0% 10% 20% 30% 40% 50% 60% 70% 80% 90% 100% 
I felt that I was given sufficient information … 
Technical support is available when I need it. 
Using the system fits in well with the way I like … 
*I regularly experience technical problems when … 
Facilitating conditions 
positive neutral negative 
0% 10% 20% 30% 40% 50% 60% 70% 80% 90% 100% 
The EBMeDS clinical alerts system is easy to use. 
I quickly adapted to using the EBMeDS clinical 
alerts 
*The EBMeDS system is too slow. 
Effort expectancy 
positive neutral negative 
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The construct scores were moderate for all areas (see Figure 22).  Comparison between cycle 1 and 
cycle 2 was not possible owing to low numbers of respondents in cycle 1 (n=5), and so data were 
combined for analysis. 
Figure 22.  UTAUT and other construct scores from post-implementation questionnaire. 
cycles 1 and 2, n=18. Error bars show 95% CI. 
There were no obvious demographic predictors for either of these construct scores, with the 
exception of work role.  Nurses’ scoring of performance expectancy was significantly higher than 
that given by doctors – see Table 9.
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6.6.5.2.2. Perceived use and influence (Figure 23 and Figure 24) 
Perceived use - two items recorded perceived use of the CDSS.  It is notable that the majority of 
respondents gave a negative response to both, however this was in response to absolute statements 
(“I always read the EBMeDS clinical alerts...” and “I always read the guidelines cited by EBMeDS...”). 
Perceived influence – The CDSS only influenced a minority of people in terms of self-reported 
prescribing practices; requesting investigations; and their way of working. 
Figure 23.  Post-intervention attitudes to CDSS – users’ reported use of the system (n=18). 
5 point Likert scale was collapsed into positive, neutral or negative responses. 
Figure 24.  Post-intervention attitudes to CDSS - perceived influence of the alerts (n=18) 
5 point Likert scale was collapsed into positive, neutral or negative responses. 
0% 10% 20% 30% 40% 50% 60% 70% 80% 90% 100% 
I always read the EBMeDS clinical alerts (these 
are the messages shown in the yellow pop-up 
box). 
I always read the guidelines cited by EBMeDS 
(these are accessed by using the links contained 
within the case record clinical alerts page). 
Perceived use 
positive neutral negative 
0% 10% 20% 30% 40% 50% 60% 70% 80% 90% 100% 
The clinical alerts have changed my way of 
working. 
The clinical alerts have made me more careful 
when prescribing medication. 
The clinical alerts have influenced my decision 
when/when not to request investigations. 
Perceived influence 
positive neutral negative 
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6.6.5.2.3. General satisfaction (Figure 25) 
Respondents were more negative than positive with regards to the content of the alerts and the 
reliability of the system.  Only a minority of respondents intended to keep using the system and 
most would not recommend it to colleagues. 
Figure 25.  Post-intervention attitudes to CDSS – general satisfaction with CDSS (n=18) 
5 point Likert scale was collapsed into positive, neutral or negative responses. 
6.6.6. Discussion 
Respondents to both pre- and post-intervention questionnaires reported regular use of literature 
and guidelines to support clinical decision-making – most of this knowledge acquisition took place 
out with the clinical consultation.  Prior to the intervention, the idea of using a CDSS was met with a 
favourable response with very few misgivings being expressed.  However, despite expressing 
satisfaction with the content of the CDSS alerts, the majority did not find the system useful and 
reported that they were unlikely to continue using it in the future. 
0% 10% 20% 30% 40% 50% 60% 70% 80% 90% 100% 
Overall, I am satisfied with the EBMeDS system. 
I would recommend the use of the EBMeDS system … 
I intend to keep using the EBMeDS system. 
I am satisfied with the clinical alerts that EBMeDS … 
I am satisfied with the reliability of the EBMeDS … 
I am satisfied with the guidelines suggested by … 
General satisfaction 
positive neutral negative 
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The UTAUT constructs provide a useful model to conceptualise possible facilitators and barriers to 
system usage.  Previous studies have reported on user experience with EBMeDS which serve as a 
useful comparison to these local results, aided by the fact that the present study adopted the 
questionnaire used by Heselmans et al 144.  Despite a small number of respondents, the 
questionnaire developed by this Belgian research team proved to be reliable with Cronbach’s alpha 
for the various constructs ranging between 0.65 and 0.95 144.  
Construct scoring was comparable across these two studies, suggesting a similar user experience 
with EBMeDS.  That being said, all of the construct scores in this study were similar, making it 
difficult to identify any particular aspects that require further investigation.  Of note, nurses’ scoring 
of items related to performance expectancy was significantly higher than doctors.  This would 
suggest that the former group are more likely to view the CDSS as a way of improving job 
performance.  There were no other significant demographic predictors of UTAUT score. 
It is notable that age was not a significant predictor of any of the constructs, including perceived use.  
The UTAUT was developed within the context of the computer sciences and it is only recently that it 
has been tested within a healthcare setting 89.  Venkatesh et al found that the primary predictor of 
adoption of a new electronic health record was user age, resulting in modifications being made to 
the model for future use within a health context 89.   
6.6.6.1. Limitations 
The lack of a robust denominator with regards to SCI-Diabetes users made response rates difficult to 
calculate.  Whilst a user may be registered on the system, they may have very little day-to-day 
interaction with SCI-Diabetes.  This was of particular issue when distributing the questionnaire to 
primary care users.  In primary care, most system access and data entry is carried out by practice 
nurses, however some general practitioners may use the system more extensively (if, for example, 
they have a special interest in diabetes). 
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Neither pre nor post-intervention questionnaires were validated.  The post-intervention 
questionnaire had been adapted from a previous study by translating from Flemish into English by 
the authors.  The questionnaire constructs in the original questionnaire demonstrated good internal 
consistency, but neither Flemish or English versions of questionnaire were validated.  This makes it 
difficult to draw any firm conclusions when analysing construct scores – it may be that the lack of 
significant findings simply reflects lack of face validity.  The decision to adapt the Flemish 
questionnaire was made with a view to allowing future collaboration between study groups, making 
validation a future possibility. 
The low number of respondents made it difficult to draw any statistical inference.  This was in part a 
reflection of the low number of users to whom the questionnaire was distributed.  Whilst not 
particularly high, the response rate was comparable to other electronic questionnaires 145.  The 
chosen medium of distribution affects response rate, with online questionnaires resulting in one of 
the lowest rates 146.  Financial inducements have been shown to improve response rates 145,however 
these vary depending on how the inducement is made – prepaid, small, monetary incentives have 
been shown to significantly increase response rates in comparison to rewards made contingent on 
return of the questionnaire 147, and this is worth considering in the future. 
The lack of identifiers meant that analysis was unable to draw any paired comparisons between 
before and after EBMeDS implementation.  The decision to only collect anonymous data was made 
from an information governance perspective.  This allowed the use of a cloud-based server (Google 
Drive) to distribute the questionnaire and collect responses electronically, with a view to improving 
response rates. 
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6.6.6.2. Conclusion 
There would appear to be a degree of mismatch between HCPs’ positive attitudes to the use of a 
CDSS and low reported usage once the system was implemented.  This is perhaps unsurprising given 
that reported access to EBM prior to the intervention was mostly outwith the clinical consultation.  
The relative seniority of the HCPs that took part in this study may also influence system usage, in 
that the CDSS may have less utility for this group. 
The moderate scoring within each of the questionnaire’s constructs meant that the theoretical 
model failed to identify any particular facilitators or barriers to uptake.  These scores are consistent 
with EBMeDS evaluations reported elsewhere.   
Most users expressed ambivalence to the system (as opposed to complete rejection).  Further 
qualitative work was therefore required to identify which aspects of the system were most useful to 
users and which, less so (see section 6.7).
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6.7 User opinion focus groups - Health Care Professionals 
6.7.1. Abstract 
6.7.1.1. Introduction 
Clinical Decision Support Systems (CDSS) offer automated prompts to Health Care Professionals 
(HCPs) via the electronic health record (EHR), within the normal clinical workflow.  There is a lack of 
published literature concerning factors that influence CDSS uptake.  This study adopts a qualitative 
approach to explore attitudes to CDSS within a diabetes EHR and to identify facilitators and barriers 
to effective uptake of the CDSS.  This study forms one aspect of a wider quality improvement project 
assessing the effectiveness of the CDSS. 
6.7.1.2. Methods 
Three focus groups were conducted, each comprising 8-9 HCPs of varying roles within the diabetes 
departments taking part in the study.  The first focus group explored attitudes to CDSS and the use 
of guidelines in general prior to implementation of the CDSS.  The second group gave initial reaction 
and feedback following the first improvement cycle.  The system was amended in light of this 
feedback and the third focus group gave their reaction to these changes.   A constant comparative 
approach identified emergent themes, which were then related to a recently published theoretical 
model describing the differing attitudes to CDSS adoption. 
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6.7.1.3. Results 
Prior to implementation, HCPs were generally receptive to the idea of a CDSS and could appreciate 
its utility.  There were concerns regarding: user fatigue; insufficient tailoring to role; covert 
surveillance of system use; and the applicability of guidelines in general to a complex patient 
population.  Following implementation, there was evidence of early adopters using the system 
within their normal clinical workflow in order to improve the efficiency of their EHR use.  However, 
most users reported minimal usage, despite seeing the potential advantages of the system.  
Amongst the secondary care specialist team, It was felt that the CDSS had greatest utility in an 
educational capacity for other, less experienced HCPs. Barriers to adoption included: lack of time; 
fatigue at the number of messages displayed; problems with the underlying EHR (e.g. data feed); and 
the user interface (UI).  The UI was amended prior to the second improvement cycle and subsequent 
feedback was positive. 
6.7.1.4. Conclusion 
Whilst the CDSS has become part of the normal workflow for some users, for most, engagement is 
limited.  Users acknowledged that the CDSS has its merits, thereby making it likely that usage will 
increase as content and functionality improve in light of feedback. 
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6.7.2. Introduction 
There are a number of technical features within clinical decision support systems (CDSS) that have 
been found to be associated with successful adoption 61.  These facilitators include the automatic 
provision of treatment/management recommendations (as opposed to simple assessments), via 
computer systems that act within the normal workflow.   There is a paucity of published studies 
assessing cultural/sociological factors that lead to successful adoption of CDSS.  This study sought to 
build upon this limited evidence by engaging with health care professionals (HCPs) in an effort to 
identify facilitators and barriers to using a CDSS. 
6.7.3. Objectives 
Prior to implementation of the CDSS, a focus group was convened in order to: 
 Describe the role that clinical guidelines and other resources currently play in clinical 
decision-making and practice, and how these are accessed. 
 Explore attitudes to the possibility of embedding automated, tailored clinical decision 
support tools within the SCI-Diabetes electronic health record 
Following each improvement cycle a further focus group was held with users of the system.  There 
was a degree of overlap with the pre-implementation focus groups in that they were designed to: 
 Explore attitudes to using the Evidence Based Medicine electronic Decision Support 
(EBMeDS) system 
 Identify potential barriers/facilitators to effective adoption elsewhere 
 Identify potential improvements to the system 
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6.7.4. Methods 
Participants were identified as a convenience sample of workers within the NHS Tayside and NHS 
Lothian diabetes teams.  Participants were invited to attend by an email that contained a participant 
information sheet.  Attendance was voluntary, with the meetings held in place of regular, lunchtime 
departmental meetings and took place in a variety of venues within the relevant hospital. Consent 
was obtained from all participants to retain and use their anonymised data for research and 
publication. 
There were 3 focus groups held in total – one prior to implementation (NWH) and one each at the 
end of improvement cycles 1 (NWH) and 2 (SJH).  For the pre-implementation focus group, seating 
was arranged in a semi-circle with the moderator seated in the centre, and lunch was not provided.  
Both of the subsequent focus groups took place round a table, over lunch that was provided for 
participants.  Participants for the pre-implementation focus group were 4 Diabetes Specialist Nurses 
(DSNs); 3 consultant physicians; 1 GP; and 1 specialist trainee.  The post-cycle 1 focus group 
comprised: 3 DSNs; 1 consultant physician; and 2 specialist trainees.  Additional feedback was 
provided, via a trainee, from a consultant who gave his apologies.  Finally, the post-cycle 2 focus 
group comprised: 4 DSNs; 2 consultant physicians; 1 staff grade physician; and 1 podiatrist.  There 
were two additional observers from the project group present at focus groups 1&2 and one 
additional observer at focus group 3 who help with administrative tasks and took contemporaneous 
field notes. 
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Meetings lasted for approximately 45 min.   A topic guide was prepared prior to the meetings that 
were facilitated by the moderator (researcher) - see appendix (section 17) for the pre-
implementation topic guide. Discussions were digitally recorded via a laptop computer.  Field notes 
were taken and summarised by the moderator immediately after each meeting.  The audio files 
were later analysed in greater depth by the researcher using a constant comparative approach 
whereby data were grouped into themes and categorised 148. This was achieved using audio file 
annotation software (Sonocent, audionotaker) that parsed the recording into manageable sections 
that could then be classified and extracted according to category 149.  Data from both post-
implementation focus groups were considered together to identify emergent themes. Quotes of 
interest were initially highlighted using the audio annotation software before being transcribed by 
the researcher to be included in the final report.  Anonymised identifiers were generated for each 
participant and consisted of two parts: the focus group that the participant took part in (e.g. FGx) 
and the role of the participant (e.g. DSNy). 
6.7.5. Results: focus group 1 (pre implementation) 
6.7.5.1. General support 
There was general support for the idea of a CDSS, so long as it did not detract from the consultation 
or become intrusive.  In particular, there were a number of possible advantages identified, including 
its use to encourage holistic care: 
“One of the good things about this will not be so much the decision support, but the reminder 
to act…Quite often people [HCPs] are not doing the things that are seen as important, 
because other things are taking priority, but if a patient leaves having had a more holistic 
care package offered to them, then that’s beneficial”.  FG1 GP. 
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Another potential advantage was that the system could be used when training junior members of 
staff.  For example, the resources referred to by the CDSS could be used to justify/explain why a 
particular management decision has been made.  However, the use of the system in this way would 
again be dependent on how much time the clinician had within the outpatient clinic: 
“If you had a student in with you in clinic, and you had lots of time [laughter], and you 
weren’t seeing lots of patients, then you could say “this is how we managed Mr X and the 
blood pressure target was based upon that guideline or this guideline and you could refer 
them to it.  So there it would be great, useful tool.  But you could have that as a separate 
lane that may be used for teaching purposes” FG1 Consultant 2. 
In response to the problem of time, it was suggested that a “dummy”, training SCI-Diabetes 
environment could be used.  Not only would this allow new SCI-Diabetes users to practice using SCI-
Diabetes, but it would enable them to use the CDSS and access the additional resources that it links 
to. 
There was a lack of enthusiasm for the CDSS to play a role in recording Continuing Professional 
Development (CPD).  This was partly as there were concerns that the recording of reading for CPD 
purposes does not reflect whether or not the individual has learnt to apply their knowledge: 
“It just tells you that you’ve read it, it doesn’t tell you if you’ve learnt it” FG1 DSN2 
There were also concerns regarding the surveillance of users and if this information could be used in 
a negative way: 
“It’s a good thing if it records it, but it’s a bad thing if when you go for your appraisal they 
say ”well, actually, it looks like you haven’t looked at these guidelines at all, whereas you 
may well have looked at them in a different context. So it’s a good idea, so long as it doesn’t 
work against you”.  FG1 Consultant 1. 
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6.7.5.2. Tailoring 
All participants agreed that the typical patient that is seen in a secondary care clinic differs from that 
seen in primary care.  In the latter setting, it was considered that the majority of patients seen with 
diabetes are those with T2D who are on minimal medication and have little co-morbidity, whereas 
those seen in secondary care tend to have more complex medical issues and poorer control.  It was 
argued that many guideline suggestions are not applicable for a lot of these patients, and that 
management should be guided primarily by clinical expertise: 
“In hospitals, it’s almost a license not to practise guidelines and to use your expertise to say 
that the guidelines are going to be inappropriate for this individual, for whatever reason.  Or, 
not aggressive enough for this individual, because they are actually 16 and you want them to 
spend their entire life at much, much lower levels” FG1 Consultant2 
This contrast was one of the reasons why a “one size fits all” approach would not be welcomed, as 
targets for clinical outcomes may be unachievable in certain patient groups. 
6.7.5.3. Facilitators 
The concept of tailoring message to professional role was raised as a possible way to avoid user 
fatigue: 
“Could the system depend on which clinician is using the system? Say for example [name] 
was doing her clinic and she felt that she was overseeing this patient that she knew, but me 
as a member of staff would actually like all these clinical alert messages coming, so that I 
gained that experience.  So I have the alerts switched on, but [name] has the alerts switched 
off” FG1 DSN1 
However, it was pointed out by others that this may impact on the users’ awareness of clinical 
targets in that users may become “a bit blasé” about targets in general. 
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Another possible solution to user fatigue was colour-coding alerts to differentiate between 
important safety issues (“red alerts”) and more general reminders. 
6.7.5.4. Interface between primary and secondary care 
There was a tension between primary and secondary care that emerged when discussing the role of 
reminders for screening tests e.g. blood pressure or urinary samples.  There are prescribed intervals 
for each of these investigations (described in national guidelines) that form the basis of quality 
performance indicators (QPI).  These QPIs form the basis of the primary care Quality & Outcomes 
Framework 150 which provides a financial incentive for primary care practitioners to adhere to best 
practice.  As a result, it was felt that those working in secondary care are perhaps not as aware of 
the importance of QPIs, to the detriment of patient care and efficient working practices: 
“What primary care would say, is that they get distressed for contractual reasons when 
people are seen at the hospital and don’t get their feet checked for example, or don’t get a 
urinary ACR [Albumin Creatinine Ratio] checked and we have to pull them back in just for 
that, so from my perspective, something that works effectively to remind [name] to check the 
ACR, or [name] to check the feet.  But then that’s because primary care has a performance 
related pay issue.  But it’s also good for the patient.  So if there are aspects of what’s 
considered to be “good quality review” that are being forgotten and can be reminded, that, 
to me, is good”. FG1 GP 
In mitigation, those in secondary care argued that often a test is not completed owing to other 
uncontrollable (i.e. patient) factors and this does not necessarily reflect a lack of awareness by the 
diabetes specialist; that“It’s not usually because we are being negligent about not doing it…” (FG1 
consultant 1) 
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6.7.5.5. Limitations of guidelines 
One of the main limitations of a CDSS from the perspective of the participants was its reliance on 
clinical guidelines that are not always applicable to certain patient groups: 
“I think it [CDSS] is a reasonable approach, I think the limitation of a clinical decision making 
system is that it is based upon guidelines, which are in themselves limited - they’re based 
upon populations and not individuals…  Within the specialist setting…there is a need to 
individualise therapy.  We’re all aware of guidelines, we have to adapt those guidelines to 
suit the individual” FG1 Consultant 2. 
As well as being population-based, it was suggested that guidelines are quickly rendered out of date; 
are unable to be updated timeously; that supporting evidence is often from trials involving a cohort 
that is unrepresentative of the average clinic patient (e.g. the frail elderly with co-morbidity); and 
that the evidence base is lacking due to the tendency for industry-sponsored clinical trials being 
designed to show lack of harm as opposed to clinical benefit.  
Unsurprisingly, the decision to override a guideline was something that more senior members of the 
team were more comfortable with.  Less experienced staff (e.g. trainees) and those from non-
medical backgrounds (e.g. DSNs) would consult with their senior colleagues before making such 
decisions, in recognition that the resultant advice may not only differ from the guideline (“you have 
to weigh up experience, that carries a lot of weight” FG1 StR) but may differ between individuals: 
“If you ask several seniors, then you might get different answers…because if it’s not within 
the guideline, then it will be “expert opinion” which will therefore vary, but doesn’t mean to 
say that one’s right or wrong” FG1 DSN3 
Again, the contrast between this arrangement and the circumstances of those working in isolation 
was made: 
“I think we’re very fortunate in that we are surrounded by experts who are very experienced, 
but I think it would be a very different story in primary care.” FG1 DSN1 
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“We are much more reliant on local or national guidelines and would follow them 
moderately slavishly.” FG1 GP 
Whilst it was noted that strictly following guidelines has the potential to prompt GPs to adopt a 
more aggressive treatment option that may not be in the patients’ best interests, there was 
agreement that this is a limitation of guidelines and not the CDSS per se and that CDSS may confer 
additional advantages to the lone worker in primary care: 
“So that’s no worse than the situation at the moment. Whereas at the moment we would try 
and find out what the guideline said, and that might not be very easy to do and we might 
also miss situations that we should have picked up on if they weren’t pointed out to us”. FG1 
GP 
6.7.5.6. Fatigue 
Owing to the complex nature of the patients seen in secondary care, there was an anxiety that alerts 
would be triggered for almost all patients attending clinic.  As a result, it was feared that the alerts 
would initially be “intrusive” before being “devalued” as users start to ignore them.  This could 
potentially impact upon patient safety if users fail to differentiate between types of alerts e.g. if “the 
ones [alerts] that are focused on targets may put at risk the ones that perhaps are more to do with 
clinical safety” (FG1 GP).  Again, this led to the suggestion that the CDSS may be more applicable to 
primary care patients with less complicated disease.  An alternative to CDSS was also mooted, 
whereby the existing SCI-Diabetes audit system was used more effectively e.g. monthly QPI reports. 
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6.7.5.7. Other risks 
There was agreement that users should not infer that absence of a prompt is indicative of no active 
clinical problems.  The risk of others doing so was felt to be low. 
Of greater concern was the question of clinical responsibility for those that receive prompts from the 
CDSS. The DSNs are the most frequent users of SCI-Diabetes and access the system in a variety of 
settings, including telephone contacts.  It was suggested that the presence of a CDSS alert, that is 
unrelated to the task in hand, may introduce an unsustainable increase in DSN’s workload, as they 
may feel that failure to act on the advice may be construed as being negligent: 
“Potentially the nurses could have all these alerts coming up, but it’s not appropriate for 
them to deal with them at that time, but they might feel that actually they need to do 
something about this.” FG1 DSN1 
This, in turn, introduces an additional problem for the DSN, as it may not be immediately clear which 
clinician they should liaise with (e.g. GP, consultant or trainee).  There is also the potential for 
patient anxiety, if the DSN chooses to share the information with the patient when it may not be 
appropriate to do so. 
Similarly, non-clinical staff (e.g. administrators) accessing the system may also be confronted with 
alerts, which may place them in the vulnerable position of being unable to assess which alerts 
require immediate action (e.g. those related to patient safety). 
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6.7.6. Results: focus groups 2&3 – post implementation 
6.7.6.1. Use of CDSS and SCI-Diabetes in general 
When assessing reaction towards the CDSS, consideration must be given to the context in which SCI-
Diabetes is being used.  For example, the greatest users of SCI-Diabetes are the DSNs and much of 
their time using the system is in order to answer quick queries about a specific problem (e.g. 
telephone advice regarding blood glucose readings), as opposed to more involved use when patients 
are inpatient or in clinic. 
SCI-Diabetes is also used for retrospective data entry following a clinical encounter.  In these cases 
the CDSS message is no longer relevant to the task in hand. 
All users observed that a CDSS message was triggered in the vast majority of patients (“I haven’t 
opened a record and it hasn’t had an alert” FG2 DSN3).  As a result, the absence of an alert was 
considered unusual4: 
“I’ve occasionally had a patient that hasn’t had an alert, and I’ve thought, “why’s he not got 
an alert?” FG2 C3. 
The most useful component of the CDSS system was the short message displayed in the initial pop 
up window.  It was felt to contain sufficient information was easy to refer to.  Users (nurses and 
doctors) reported using this to guide the subsequent consultation by briefly noting the contents: 
 “I give it a quick scan” (FG3 DSN1) 
                                                          
 
4
 In light of these observations, script thresholds and content were reviewed, resulting in a reduction in 
the number of messages being triggered. 
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 There was no evidence of the CDSS adversely affecting the consultation or normal workflow.  Some 
SCI-Diabetes users open the patient record prior to seeing a patient, in which case they have time to 
consider the recommendations and, if appropriate, guide the subsequent consultation to address 
them.  Further navigation within an individual’s clinical record does not result in the short message 
being displayed again (unless the user floats over the alert icon).  This was considered a good thing 
(FG3 DSN1). 
It was rare for users to report navigating to the long message and no users used the hyperlink to 
navigate to the underlying guidelines.   
“We generally know why it’s prompting us…you know, I think we know what we should be 
doing…and sometimes it doesnae get done when it should get done…but I think we generally 
know the evidence behind it” (FG3 DSN2) 
The participants were keen to feedback on their experience of SCI-Diabetes in general as there were 
obvious frustrations with the existing system (unrelated to the CDSS).  It was noted that if the 
system were to be broadened to other health boards and clinical settings, uptake would vary 
markedly owing to differing usage of SCI-Diabetes and varying levels of IT literacy. 
6.7.6.2. Facilitators to using the CDSS 
6.7.6.2.1. Clinically useful 
There was some evidence that the CDSS messages are influencing clinician behaviour by highlighting 
issues that may not have been addressed. 
“I generally have gone into the alerts and had a look at them, and most of the stuff is stuff 
that I would have picked up on anyway, but there has been the occasional thing that has 
prompted me to ask an additional question or two.” (FG2 C3) 
 115 
For example, reminding the clinician of a possible use for metformin in specific patients.  In practice, 
all patients that were asked had a good reason for why they are not on it, but “it was probably still 
useful to go through the process” (FG2 C3) 
Clinicians reported that the CDSS is enabling users to make targeted data queries for items that they 
currently find it difficult to locate within SCI-Diabetes: 
“one of the things that I find more useful is the things that I’m not very good at 
…[finding]…so, I’ll see someone’s blood pressure, and I’ll know it’s high, but if the computer is 
prompting me that they’ve also got microalbuminuria then it, kind of, saves me looking it 
up…and if it’s prompting me that they’ve got a high cholesterol and they’re not on a statin, 
it’s, again, it’s something that’s just an extra prompt for things that I kind of forget.” (FG3 
C1) 
“It then saves you going into all the individual screens and looking at things, and, you know, 
SCI-Diabetes is getting bigger and bigger all the time and so there’s more to look at, so it lets 
you be more…choosy about what you look at” (FG3 DSN2) 
Despite the fact that some messages were not directly applicable to the user’s role within the 
multidisciplinary team, it was felt that this was still useful information as it may serve to guide 
subsequent clinical decisions.  For example, nurses who do not prescribe are still involved in the 
decision to commence/discontinue medication - “we advise [laughs] doctors what to prescribe” 
(DSN2). 
6.7.6.2.2. Educational role 
The CDSS messages were felt to be of greatest utility to someone who is new to the team and who 
has not previously worked with SCI-Diabetes. 
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“Because we’ve not had alerts before, I’ve got into the habit that when you open up the 
record, you scan down: when did they last get they’re feet screened; when did they last get 
their last diabetes eye check done, and you almost go through an automatic 
process….whereas somebody new who is not tuned into that way…[of working]…they may go 
straight into an alert and the alert tells them all of that information” (FG2 C3) 
If I was new into the team, I’d probably be wanting to read all of these things to make sure I 
wasn’t missing anything…[I wonder]…if our response is because we’re maybe a bit more 
familiar with what we are looking for.” (FG2 DSN3) 
There was little use of the CDSS for medical education purposes, mainly due to time constraints 
within the clinical context. 
 “Generally yeah, it’ll lead you onto something else...it was highlighting something to 
you…but then the link that you are going into is also time consuming” (FG2 DSN4) 
6.7.6.3. Barriers to using the CDSS 
6.7.6.3.1. Time and fatigue 
A recurring them between both focus groups was one of user fatigue:  
 “I think I’ve started to ignore them” (FG2 DSN3) 
“Because there’s too many?” (moderator) 
“Yeah” (FG2 DSN3) 
“Is it annoying?” (moderator) 
“I just don’t bother with it now” (FG2 DSN3) 
…and lack of time: 
“It’s time consuming, doing SCI-Diabetes, at the best of times…with those popping up, it’s 
just something else that you’ve got to look at, and sometimes I look at them, but generally…” 
(FG2 DSN4) 
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6.7.6.3.2. Context 
As mentioned above, usage of SCI-Diabetes varies and so the CDSS message may not be appropriate 
to the context in which it is being used.  For example the CDSS message may remind the HCP to 
check the patient’s feet during a phone call related to glucose control.  In this example, there is very 
little the HCP can do other than to recommend a visit to the GP.  In other instances, the CDSS 
message is directly relevant to the clinical encounter, however the consultation has been planned in 
advance to address the very issues identified by the CDSS message e.g. an annual review 
appointment: 
 “the annual review stuff I find less helpful because usually we’re doing it anyway...there are 
too many things…and you won’t look at it…and if it alerts every single time that you open it 
up, you kind of think, “oh, it’s just alerting me again because it’s a year since I last saw them” 
(FG3 C1) 
In addition to problem of lack of relevance to the clinical context, the messages are not always 
relevant to the clinical role.  Whilst it is acknowledged that messages can influence the working of 
the multidisciplinary team (MDT) beyond traditional roles (see above), not all users find all messages 
to be of utility e.g. a podiatrist using SCI-Diabetes. 
6.7.6.3.3. Data 
It was noted that there is a lag period between data being entered into the SCI-Diabetes system and 
the CDSS considering these new data, however this is related to the SCI-Diabetes data feed and not a 
problem inherent with the CDSS per se.  
6.7.6.3.4. User interface (UI) 
The appearance of the CDSS message evolved during the course of the study in response to user 
feedback.  Initially, the short CDSS message appeared as a yellow box in the bottom right of the 
screen.  Whilst this was easily visible  (“Well you certainly can’t miss it!” FG2 DSN3), there was a lack 
of awareness as to how to access further content once the initial message had disappeared: 
 118 
“[Once the short message has faded away] I don’t know where to go…” (FG2 StR2) 
The behaviour of the short message was altered in response to this initial feedback - the short 
message was reconfigured to appear as a tool tip, associated with an alert icon in the top right 
corner of the screen.  This change resulted in most focus group 3 users expressing satisfaction with 
the UI.  However the change was problematic for some as the tool tip temporarily covers a 
commonly used tab (tab to navigate to clinical comments page).  As a result, some users had 
developed workarounds in order to navigate past the CDSS message quickly. 
The time that the short message is displayed (default is 5 seconds) was not always ideal.  For some it 
is too short:  
“It pops up and it disappears quite quickly, usually in the time that I haven’t read all of the 
things it suggests, but I guess it’s usually stuff that you would be, hopefully, thinking about 
anyway” (FG3 C2). 
“I rarely have time to read it, probably because I open someone’s record whilst talking to 
them…and when I turn back to the screen, that’s usually gone…it’s good that it comes up 
because it will remind me to click on the clinical alert [icon]…It jogs my memory, but I rarely 
have time to read it before it goes” (FG2 C3) 
Whereas for others, the 5 seconds default is too long.  This latter group are mainly the nursing staff 
that would like to access parts of the UI that are obscured by the message:  
“[the short message] gets in the way…[of]…clinical comments and new comments” (FG3 
DSN1)  
“The alert is always where you want to click on to make a new contact!” (FG3 DSN2) 
Users were seemingly unaware of the option to configure the behaviour of the short message 
(available under user settings) that would solve this issue. 
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6.7.6.4. Possible amendments 
Participants were asked for possible changes that could make the system better.  One such change 
has already been mentioned (appearance of the short message).  Other suggestions included: 
 Flagging of recent adverse events e.g. recent hospital admissions; hypoglycaemic events 
 Data entry validation for data items that require manual entry e.g. a reminder to record 
when a patient has taken part in an educational course. 
 Development of algorithms that process blood glucose data with the aim to improve 
glycaemic control 
 Avoidance of repetition  (“the trouble is that during the next consultation they’ll probably get 
asked the same question again.” FG2 C3) 
 Greater user control over system behaviour 
 Tailoring of system to user role and context 
6.7.7. Discussion 
The emergent themes from both pre and post-implementation focus groups are presented in 
Table 10. 
Table 10.  Emergent themes from focus groups 
Pre-implementation Post-implementation 
General support for concept of  CDSS Facilitators: 
Possible facilitators: Clinically useful and relevant 
Educational role – staff induction Educational role 
Tailor messages to role Barriers: 
Colour coding of message importance Lack of time 
Possible barriers: User fatigue 
Surveillance of use Lack of clinical context 
Limitation of guidelines Data feed issues 
User fatigue User interface 
Inappropriate responsibility to take action  
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Prior to implementation, there was a general consensus that the concept of CDSS was a valid and 
potentially useful addition to the clinician’s toolkit.  There were some minor concerns expressed e.g. 
user fatigue; covert monitoring of system usage; and concerns regarding the messages not taking 
into account user role.  There were no concerns that the CDSS would have an adverse effect on the 
consultation or doctor-patient relationship.  The biggest shortcomings identified were actually 
unrelated to the CDSS per se.  Firstly, there was an obvious tension between the perceived 
contrasting working practices in primary and secondary care.   Secondly, there was an acceptance 
that the guidelines on which the CDSS is based are themselves limited in terms of applicability to the 
more complex patients seen in secondary care. 
The post-implementation focus groups demonstrated general support for the CDSS with some 
suggested amendments to improve functionality.  There was also a desire for the system to be more 
tailored to clinical context and role, thereby echoing the pre-implementation focus group findings.  
Again, there were issues identified that were unrelated to the CDSS per se and were principally 
related to the SCI-Diabetes data feeds, whereby certain data items were not updated in real time.  It 
should be acknowledged that the CDSS relies on contemporaneous data to deliver relevant advice.  
For example, when metformin is indicated, the relevant script makes an assessment of renal status 
and advises a dose reduction if function is impaired.  If an individual’s renal function has recently 
deteriorated, the absence of the relevant biochemistry results could result in an inappropriately high 
dose of metformin being prescribed.  Whilst this could be viewed as a clinical risk, it could also be 
argued that this risk is not increased by the use CDSS – the prescriber needs to take account of renal 
function before prescribing the drug and should, therefore, review the most recent results before 
doing so. 
 Some of the suggested amendments from focus group 2 were implemented prior to focus group 3.  
These changes mostly related to the UI and included: 
 The short message was amended to include colour coding of message importance 
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 Users could now choose the duration that the short message is displayed prior to fading 
automatically 
 The short message was moved to become associated with a CDSS icon that persists after the 
message fades 
 “Floating” over the CDSS icon will result in the short message being viewed again. 
 Removal of scripts that, although different in their logic, resulted in similar advice to the user 
e.g. the prescription of antihypertensive medication for patients with renal disease and/or 
hypertension.  In the event of both clinical entities, messages were displayed in duplicate. 
Following these changes, the feedback was generally positive.  Users within focus group 3 reported 
that the system supported more efficient working practices by enabling them to quickly identify 
problem areas.  There was clear evidence of fatigue, however, with most users reporting that their 
use of the system was limited to the short initial message as opposed to looking at the longer 
message or the evidence behind the prompt.  It was felt that this latter feature was perhaps more 
suited to an educational context where there was greater time available to the individual.   
Studies concerning CDSS tend to concentrate on describing the practical and technical nature of the 
intervention and the subsequent effect on clinical processes and outcomes.  There are very few 
studies examining why and how CDSS become adopted by users.  The generalisability of such studies 
is limited owing to the differing nature of the CDSS; the clinical context; and the setting 151–155.  In 
accordance with previous qualitative work assessing HCPs’ views on CDSS (and the practice of 
evidence based medicine (EBM) in general) 151,152,156, all users reported a lack of time to fully engage 
with the CDSS when seeing patients.  In their recently published qualitative study of Italian HCPs 
working with a CDSS, Liberati et al identified six distinct groupings of attitude 153.  These groupings 
were dependent on two main factors – acceptance of technology and readiness to accept evidence 
based medicine – and were arranged along a spectrum ranging from complete rejection to 
successful integration of CDSS into the clinical workflow (see Figure 26).  These 6 groups are 
described as being: 
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1. Total rejection – EBM is not useful and technology is viewed as a threat to status 
2. Threatened control – CDSS could be adopted, but this would usurp all expertise, resulting in 
a dichotomy of total rejection or total acceptance towards all CDSS advice.  
3. Distrust of the evidence – The technology is seen as less of a threat, however users feels that 
the evidence is potentially flawed e.g. distrust of guidelines. 
4. Instrument of the other – The usefulness and applicability of the CDSS is acknowledged, but 
is seen as a something of use to someone else. 
5. Potential recognised – The CDSS content is accepted but technological competence acts as a 
barrier. 
6. Fully integrated and competent – The user has fully adopted the CDSS within the normal 
workflow and the CDSS becomes an instrument of a “shared community of practice” 
whereby users collaborate to improve the system. 
 
Figure 26.  Theoretical model for identifying users' readiness to adopt CDSS.   
Adapted and translated from Liberati et al 
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Total rejection 
Threatened control 
Distrust of the evidence Instrument of the other 
Potential recognised 
Fully integrated and competent 
Technology acceptance 
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When relating this model to the focus group discussions, it was clear that, aside from a few early 
adopters, most participants were in the “instrument of the other” group whereby the usefulness of 
the system is acknowledged, but it was felt to not apply directly to their own work.  Instead, the 
participants of the focus group felt that the CDSS had greater applicability to the stand-alone general 
practitioner who may not be as familiar with current guidelines.  This may well be the case, however 
it would be wrong to suggest that there is no room for improvement in clinical care provided by the 
participating secondary care teams.  It is, therefore, incumbent upon system developers to ensure 
that all users can realise the potential of the system – by adapting content and/or functionality 
improving functionality, it is hoped that the CDSS will become part of normal working patterns. 
6.7.7.1. Limitations 
The decision to adopt a convenience sample for the focus groups was made out of necessity, owing 
to participant numbers.  Nevertheless, it was felt that data saturation had been reached and there 
were no new, emergent themes by the end of the third focus group.  It is acknowledged that within 
this sample of workers from within the same organisation, there are likely to be power differentials 
that may affect how ideas are expressed and may also skew findings.  Nevertheless, it was felt that 
all participants were given equal opportunity to contribute, and the multidisciplinary nature of the 
clinical team meant that participants were used to contributing to group discussions amongst 
colleagues. 
There was a tendency for senior clinicians to contribute more to the discussion than their nursing 
colleagues.  This was especially evident during the pre-implementation focus group.  The decision to 
provide lunch and arrange seating around a table had a positive effect in encouraging all to 
participate as the tone of the meeting became more relaxed and less staid. 
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Finally, it is acknowledged that there is a high probability for observer bias.  The researcher who 
moderated and analysed the focus groups has also worked on developing and implementing the 
CDSS.  The inclusion of additional observers from the project team allowed field notes to be 
compared.  In addition, user questionnaires were also distributed (see section 6.6) in an effort to 
triangulate the measurement processes.  
6.7.8. Conclusion 
The focus group findings suggest that there is evidence of the CDSS becoming part of the normal 
workflow for some users.  For most, however, their engagement with the system is currently limited.  
Users acknowledge that the CDSS has its merits and so there is the potential for increasing system 
use.  It is incumbent on system developers to improved content and functionality in line with user 
feedback.  In particular, there would seem to be less demand for greater access to the evidence 
underpinning the CDSS recommendations and it may be that consideration should be given to 
reconfiguring this particular aspect of the system in an effort to improve accessibility and increase 
uptake. 
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6.8 Use of the system 
6.8.1. Abstract 
6.8.1.1. Introduction 
System usage is an important consideration in the evaluation of whether or not an information 
system (i.e. EBMeDS) has been successfully adopted.  The SCI-Diabetes audit trail allows for 
interrogation of user behaviour within the system.  This study aimed to characterise usage patterns 
for different health care professional (HCP) roles; to quantify time spent accessing clinical records 
with respect to these different user groups; and to compare usage patterns between instances 
where users received a clinical decision support system (CDSS) with instances where no such 
message was displayed. 
6.8.1.2. Methods 
Data were extracted from the SCI-Diabetes audit trail for all users of the system within the Ninewells 
diabetes clinic domain, over a 3-month period, commencing December 2013.  The primary outcomes 
were number of user “clicks” within patient record and duration of time that the patient record 
opened.  Comparison was made between presence or absence of EBMeDS message using 
multivariable generalised estimating equations.  Possible confounders included within the model 
were: number of EBMeDS messages; patient comorbidity score; diabetes type; insulin therapy and 
socioeconomic status. 
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6.8.1.3. Results 
The SCI-Diabetes audit trail contained 760,666 rows of data for the time period being considered.  
Within these data, 17,280 patient records were opened, belonging to 5355 unique patients.  The 
median number of times a record was opened was 3 (range 2-56, IQ range 4).  A CDSS message was 
displayed on opening 6665/17280 patient records (39%).  When displayed, the median number of 
messages was 3 (range 1-12).  Presence of a CDSS message had no association on the duration that 
the record was viewed by nurses, however the number of mouse clicks made by nurses within the 
patient record was significantly increased when a CDSS message was displayed (median number of 
clicks (IQ range) 19 (8-37) versus 16 (7-32), adjusted p=0.014).  For doctors, the duration that the 
record was viewed was significantly reduced when a DSS message was displayed (median duration 
(IQ range) 33 sec (5-86) vs 38 sec (12-97), adjusted p=0.032), with no other significant confounders.  
The presence or absence of a CDSS message had no relationship with number of clicks made by 
doctors.  
6.8.1.4. Conclusion 
This analysis has quantified system usage by members of the multidisciplinary team in terms of 
duration that the record is viewed and the number of user clicks within that record.  The presence of 
a message was associated with some differences in user behaviour, but this was dependent on user 
role.  The clinical significance of these observed difference remain unknown and inference is limited 
by study design.  Further analysis is required to assess whether these differences translate into 
changes in clinic processes and outcomes. 
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6.8.2. Introduction 
When determining how succesful an information system is, attention must be given to what defines 
success.  DeLone and McLean attempted to do so by developing their model of information systems 
success, based on a review of the literature from the preceding two decades 157.  The resultant 
debate amongst sociologists regarding the validity of their proposed model is well documented by 
the original authors in further updates 158, but it would appear that consensus has emerged that it is 
a valid approach 159.  The model identifies 6 main dimensions that are postulated as being causal 
determinants of success: system quality; information quality; system usage; user satisfaction; 
individual impact and organisational impact (see Figure 27). 
 
Figure 27.  DeLone and McLean’s Model of information systems success.   
Adapted from original paper 
157
 
 
The previously  described qualitative work assessed attitudes to (and satisfaction with) the clinical 
decision support system (CDSS) - questionnaires described self-reported indvidual use (section 6.6), 
whilst focus groups explored use of the system at the group level (section 6.7).  This study is 
designed to further describe individual usage of the CDSS by quantifying users’ behaviour within the 
SCI-Diabetes electronic health record (EHR), with a view to assessing whether or not the CDSS had 
any effect on this (in terms of navigation through the system).   
User 
satisfaction 
Use 
Information 
quality 
System quality 
Information 
quality 
Organisational 
impact 
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The SCI-Diabetes audit trail allows remote observation of users' interaction with the system.  Users 
consent to remote monitoring when agreeing to the terms and conditions of use.  Log files 
prospectively collect usage data and record when users retrieve or submit clinical information and 
how they navigate through the system.  These files contain a large dataset, comprising a logged 
event(s) for every interaction that users have with SCI-Diabetes.  These data were used to address 
the question – is the CDSS associated with a change in system usage? 
6.8.3. Objectives 
 To characterise typical usage patterns within SCI-Diabetes within different user groups (e.g. 
doctor, nurse etc.) 
 To quantify time spent accessing clinical records with respect to these different user groups 
 To compare usage patterns between instances where a CDSS message was displayed and 
when there was no CDSS message. 
6.8.4. Methods 
Data were extracted for the relevant SCI-Diabetes domains that took part in improvement cycle one.  
This included the NWH diabetes outpatient clinic and one primary care practice within NHS Tayside 
between 2/12/13 and 1/3/14 inclusive. 
Owing to the large amount of extraneous data the files requiring extensive data cleaning prior 
analysis.  Data cleaning was conducted using SPSS syntax written by the author (see appendix - 
section 18). 
The data cleaning process reduced the file down to the following variables: 
 User ID – anonymised HCP identifier 
 User role – HCP discipline 
 Patient ID – anonymised patient identifier 
 Time when patient record opened 
 Number of user “clicks” within patient record 
 Duration of time that patient record opened 
 Presence or absence of EBMeDS message 
 Number of EBMeDS messages displayed 
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In addition to navigation data, a separate data query was made with respect to potential patient 
confounders.  These included: 
 Diabetes type 
 Diabetes treatment 
 Co-morbidities 
 Deprivation category (SIMD) 
Co-morbidity was considered a confounder as this has the potential to influence consultation time 
and management – it was assumed that a patient with much co-morbidity is more likely to have 
active medical problems, necessitating a longer consultation time.  SCI-Diabetes data were used to 
construct a “comorbidity score”, which was calculated using a modified version of the Charlson Co-
morbidity Index (CCI) 160.  SCI-Diabetes routinely records 7 of the 19 conditions that contribute to the 
CCI – see Table 11. 
Table 11.  Charlson co-morbidity index and the availability of these data within SCI-Diabetes 
Score Condition SCI-Diabetes data item 
1 
 
 
 
 
Myocardial Infarction Yes 
Congestive heart failure Yes 
Peripheral vascular disease Yes 
Cerebrovascular disease Yes 
Dementia No 
Chronic pulmonary disease Yes 
Connective tissue disease No 
Peptic ulcer disease No 
Mild liver disease No 
Diabetes with no complications Yes 
2 Hemiplegia No 
Moderate or severe renal disease Yes 
Diabetes with end organ damage Yes 
Tumour (without metastases) No 
Leukaemia No 
Lymphoma No 
3 Moderate or severe liver disease No 
6 Metastatic solid tumour No 
Aids (not simply HIV+) No 
 
Not all of the SCI-Diabetes data items were exact matches for the CCI and so some inference was 
required to attribute scores.  In particular, diabetes with “end organ damage” was inferred present if 
any of the following were recorded in the patient record: retinopathy; maculopathy; foot risk score 
of medium, high or active foot disease (or amputation). 
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A modified comorbidity score was then calculated out of a possible total of 9 based on presence or 
absence of the conditions listed in Table 11.  An analysis of frequencies was used to determine 
appropriate bins for score (e.g. tertiles versus quartiles). 
Generalised estimating equations were used to allow for analysis of repeated measures.  There were 
2 potential dependent variables of interest that could be used to address the research question – 
number of user “clicks” in patient record and duration that patient record opened. The independent 
variables of interest include user role; presence or absence of EBMeDS message; number of EBMeDS 
messages; patient comorbidity; diabetes type; insulin therapy and socioeconomic status. 
Univariable analysis was initially undertaken for each dependent variable, with a view to including all 
independent variables with significance to p<0.1 within the multivariable analysis.  In an effort to 
achieve a model with best fit, both poisson and gamma distributions were considered for the 
dependent variables as was the use of log transformation.  Assessment of residuals for evidence of 
random distribution determined the model of best fit. 
6.8.5. Results 
The cycle 1 raw data file contained 760,666 rows of data.  After cleaning, the dataset contains 
17,280 rows – each one representing a patient record being opened.  The 17,280 records being 
opened were for 5355 unique patients.  The median number of views of each patient record was 3 
(range 2-56, IQ range 4). 
Patient records were viewed for a median duration of 38 seconds (IQ range: 11-94 seconds).  Whilst 
open, the median number of user clicks within each patient record was 13 (IQ range: 6-27).  Most 
records were opened between the hours of 11:00 and 15:00 (Median 12:46, IQ range 08:32-17:00) 
Diabetes Specialist Nurses (DSNs) were the most frequent users of SCI-Diabetes, opening 
9107/17280 patient records (53%).  Doctors opened 2709/17280 (16%) of records and Allied Health 
Professionals (AHPs) opened 472/17280 (2.7%) of records.  The remainder of records were opened 
by admin staff or those with unknown role (3151/17280, 18% and 1217/17280, 7% respectively). 
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A CDSS message was displayed when opening 6665/17280 patient records (39%).  When displayed, 
the median number of messages was 3 (range 1-12) - see Figure 28. 
Figure 28.  Number of CDSS messages displayed to user on opening each clinical record.  n=17,280. 
1352/5355 (25.2%) of patients had T1D and 3777(70.5%) had T2D.  3421/5355 (63.9%) were treated 
with insulin, with a small minority using pump therapy (138/3421, 4%).  
4293/5355 (83%) of patients had a co-morbidity score of 2/9 or less and so patients were grouped 
pragmatically into low (score <2/9, n=2012/5355 38%), moderate (score=2/9, n=2475/5355, 46%) 
and high (score>2/9, n=859/5355, 16%) co-morbidity groups. 
There were higher numbers of those from more deprived areas, however all socio economic groups 
were represented – see Figure 29. 
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Figure 29.  Deprivation categories for patients seen in the NWH diabetes outpatient clinic during improvement cycle 1 
Deprivation categories expressed as SIMD quintiles.  Dec 13 - Feb 14: N=5355 
Both dependent variables (duration that patient record viewed and number of user clicks within 
each patient record) showed clear left skew with significant outliers – see figure 30 and figure 31. 
Figure 30. Histogram showing duration that each patient record was viewed.  Filtered for outliers (SDS>3 and non – clinical 
users. N= 12,756. 
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Figure 31.  Histogram of number of user clicks within each patient record viewed. N=17,280. 
Outliers were subsequently removed from analysis by filtering for records that were viewed for a 
duration >3SD greater than the mean (n=231).  Records opened by administrative staff and unknown 
users were also filtered from further analysis, reducing the total number of opened records included 
in the analysis to 12,756. 
The univariable analysis for each dependent variable is provided in Table 12.
Ta
b
le
 1
2
.  
D
u
ra
ti
o
n
 t
h
a
t 
p
a
ti
en
t 
re
co
rd
 v
ie
w
ed
 w
it
h
in
 S
C
I-
D
ia
b
et
es
 a
n
d
 n
u
m
b
er
 o
f 
u
se
r 
cl
ic
ks
 w
it
h
in
 p
a
ti
en
t 
re
co
rd
. 
St
ra
ti
fi
ed
 b
y 
in
d
ep
en
d
en
t 
va
ri
a
b
le
s 
a
n
d
 a
n
a
ly
se
d
 b
y 
G
en
er
a
lis
ed
 E
st
im
a
ti
n
g
 E
q
u
a
ti
o
n
s.
  I
n
d
ep
en
d
en
t 
va
ri
a
b
le
s 
en
te
re
d
 in
to
 m
u
lt
iv
a
ri
a
b
le
 a
n
a
ly
si
s 
if
 u
n
iv
a
ri
a
b
le
 p
<0
.1
.  
*D
en
o
te
s 
in
d
ep
en
d
en
t  
va
ri
a
b
le
 w
it
h
h
el
d
 f
ro
m
 m
u
lt
iv
a
ri
a
b
le
 a
n
a
ly
si
s 
d
u
e 
to
 c
o
lin
ea
ri
ty
.  
D
SS
 =
 d
ec
is
io
n
 s
u
p
p
o
rt
 s
ys
te
m
; S
IM
D
 =
 S
co
tt
is
h
 in
d
ex
 o
f 
m
u
lt
ip
le
 d
ep
ri
va
ti
o
n
; S
D
 =
 s
ta
n
d
a
rd
 d
ev
ia
ti
o
n
; I
Q
 =
 in
te
rq
u
a
rt
ile
 
n
 
D
u
ra
ti
o
n
 r
e
co
rd
 o
p
e
n
ed
 
N
u
m
b
e
r 
o
f 
cl
ic
ks
 
m
ea
n
 (
SD
) 
m
ed
ia
n
 (
IQ
 
ra
n
ge
) 
p
 
(u
n
iv
ar
ia
b
le
) 
p
 
(m
u
lt
iv
ar
ia
b
le
) 
m
ea
n
 (
SD
) 
m
ed
ia
n
 (
IQ
 
ra
n
ge
) 
p
 
(u
n
iv
ar
ia
b
le
) 
p
 
(m
u
lt
iv
ar
ia
b
le
) 
D
SS
 m
e
ss
ag
e
 d
is
p
la
ye
d
 
ye
s 
6
1
5
5 
6
2
 (
7
7
) 
3
2
 (
8
-8
6
) 
0
.0
6
1 
0
.2
8
0 
2
5
 (
2
6
) 
1
5
 (
7
-3
4
) 
0
.0
0
1 
0
.2
0
2 
n
o
 
6
6
0
1 
6
7
 (
7
7
) 
3
9
 (
1
4
-9
0
) 
2
2
 (
2
4
) 
1
4
 (
6
-2
9
) 
N
u
m
b
e
r 
o
f 
D
SS
 m
e
ss
ag
e
s 
m
ea
n
 (
SD
) 
1
.8
 (
2
.3
) 
- 
- 
0
.0
3
8 
0
.1
7
6 
0
.0
0
9 
0
.6
6
4 
U
se
r 
ro
le
 
A
ss
o
ci
at
e 
sp
ec
ia
lis
t 
2
4
4 
6
5
 (
7
8
) 
3
4
 (
5
-9
8
) 
<0
.0
0
1 
<0
.0
0
1 
8
 (
5
) 
6
 (
4
-1
0
) 
<0
.0
0
1 
<0
.0
0
1 
C
o
n
su
lt
an
t 
1
4
6
3 
6
4
 (
7
8
) 
3
6
 (
8
-8
9
) 
6
 (
4
) 
5
 (
3
-8
) 
D
ie
ti
ci
an
 
4
6
4 
6
5
 (
7
8
) 
3
6
 (
8
-9
4
) 
2
0
 (
1
4
) 
1
7
 (
1
0
-2
9
) 
D
SN
 
9
0
1
2 
6
5
 (
8
0
) 
3
7
 (
1
1
-8
8
) 
2
8
 (
2
7
) 
1
9
 (
9
-3
7
) 
G
P
 
7
4
5 
6
7
 (
8
0
) 
3
7
 (
1
1
-9
3
) 
1
0
 (
8
) 
8
 (
5
-1
3
) 
P
ra
ct
ic
e 
n
u
rs
e
 
8
0
 
4
4
 (
7
9
) 
2
2
 (
7
-3
8
) 
6
 (
2
) 
5
 (
4
-8
) 
R
es
ea
rc
h
 n
u
rs
e
 
5
4
1 
5
2
 (
6
9
) 
2
5
 (
8
-6
0
) 
1
4
 (
1
6
) 
5
 (
3
-2
3
) 
St
R
 
2
0
7 
6
0
 (
7
8
) 
2
7
 (
5
-8
9
) 
1
0
 (
8
) 
8
 (
4
-1
5
) 
*U
se
r 
ro
le
 c
o
lla
p
se
d
 
D
o
ct
o
r 
2
6
5
9 
6
5
 (
7
9
) 
3
6
 (
8
-9
0
) 
0
.9
2
7 
- 
8
 (
6
) 
6
 (
4
-9
) 
<0
.0
0
1 
- 
A
H
P
 
4
6
4 
6
5
 (
7
8
) 
3
6
 8
-9
4
) 
2
0
 (
1
4
) 
1
7
 (
1
0
-2
9
) 
N
u
rs
e
 
9
6
3
3 
6
4
 (
7
6
) 
3
6
 (
9
-3
7
) 
2
8
 (
2
7
) 
1
9
 (
9
-3
7
) 
m
o
rb
id
it
y 
gr
o
u
p
 
Lo
w
 
4
6
5
5 
6
4
 (
7
7
) 
3
6
 (
1
0
-9
0
) 
0
.3
6
6 
- 
2
7
 (
3
0
) 
1
6
 (
7
-3
5
) 
0
.0
7
9 
0
.0
2
5 
M
o
d
er
at
e
 
5
8
8
8 
6
5
 (
7
8
) 
3
6
 (
1
1
-8
9
) 
2
2
 (
2
4
) 
1
3
 (
6
-2
9
) 
H
ig
h
 
2
2
1
3 
6
2
 (
7
4
) 
3
5
 (
1
1
-8
4
) 
2
1
 (
1
8
) 
1
4
 (
7
-3
1
) 
SI
M
D
 
1
 
3
1
2
4 
6
3
 (
7
5
) 
3
5
 (
1
1
-8
6
) 
0
.5
3
9 
- 
2
6
 (
2
7
) 
1
5
 (
7
-3
4
) 
0
.2
3 
- 
2
 
2
2
2
8 
6
6
 (
7
9
) 
3
6
 (
1
1
-9
0
) 
2
1
 (
2
0
) 
1
5
 (
7
-3
0
) 
3
 
2
1
3
8 
6
3
 (
7
7
) 
3
4
 (
1
0
-8
3
) 
2
2
 (
2
4
) 
1
3
 (
6
-3
1
) 
4
 
3
3
0
7 
6
4
 (
7
7
) 
3
6
 (
1
0
-8
9
) 
2
4
 (
2
5
) 
1
4
 (
6
-3
2
) 
5
 
1
8
6
2 
6
7
 (
7
9
) 
3
7
 (
9
-9
7
) 
2
4
 (
2
6
) 
1
3
( 
6
-3
1
) 
D
ia
b
e
te
s 
ty
p
e 
T1
D
 
3
8
0
9 
6
4
 (
7
7
) 
3
7
 (
1
1
-8
8
) 
0
.1
5
4 
- 
2
3
 (
2
6
) 
1
3
 (
6
-2
9
) 
0
.0
0
4 
0
.2
0
4 
T2
D
 
8
4
2
8 
6
4
 (
7
7
) 
3
5
 (
1
0
-8
8
) 
2
4
 (
2
4
) 
1
5
 (
7
-3
2
) 
O
th
er
 d
ia
b
e
te
s 
4
0
8 
7
0
 (
8
4
) 
3
8
 (
1
3
-9
8
) 
3
1
 (
2
8
) 
1
9
 (
7
-4
4
) 
U
n
kn
o
w
n
 
1
0
3 
4
7
 (
5
4
) 
3
0
 (
1
1
-6
9
) 
1
7
 (
9
) 
1
7
 (
1
0
-2
5
) 
In
su
lin
 
ye
s 
9
8
7
1 
6
4
 (
7
7
) 
3
6
 (
1
1
-8
8
) 
0
.2
9
6 
- 
2
4
 (
2
5
) 
1
4
 (
7
-3
2
) 
<0
.0
0
1 
<0
.0
0
1 
n
o
 
2
8
8
5 
6
3
 (
7
7
) 
3
4
 (
9
-8
5
) 
1
6
 (
2
0
) 
8
 (
4
-2
0
) 
135 
For duration of record viewed, the following independent variables were entered simultaneously: 
presence or absence of a CDSS message; number of CDSS messages; and user role.  Of these, user 
role exerted a highly significant effect on the final model (p<0.001) (see Table 12). 
The dependent factors that were significantly associated with number of user clicks on univariable 
analysis were: presence or absence of a CDSS message; number of CDSS messages; user role; 
morbidity group; diabetes type and insulin therapy.  Of these, user role (p<0.001); morbidity group 
(p=0.025); and presence of insulin therapy (p<0.001) were retained within the final model (see Table 
12). 
Given the strong effect that user role exerted on both of these models, the multivariable analysis for 
both dependent variables was repeated for each collapsed user role category i.e. doctor, nurse and 
AHP.  For doctors, the duration that the record was viewed was significantly reduced when a DSS 
message was displayed (p=0.032), with no other significant confounders (see Table 13).  There was 
no significant association between the independent variables and the number of clicks that a doctor 
made within the patient record (see Table 14). 
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Table 13.  Duration (seconds) that patient record viewed by doctors.   
Mulitvariate analysis of main effects on doctors’ interaction with SCI-Diabetes.  DSS = decision support system; SIMD = 
Scottish index of multiple deprivation; SD = standard deviation; IQ = interquartile 
Doctor  n mean (SD) median (IQ range) p (univariable) p (mulitvariate) 
DSS message displayed Yes 1280 61 (76) 33 (5-86) <0.001 0.032 
No 1379 69 (83) 38 (12-97) 
Number of DSS reminders mean (SD) 2 (2) - - 0.016 0.85 
Co-morbidity group Low 945 63 (76) 36 (9-88) 0.43 - 
Moderate 1297 67 (83) 36 (8-93) 
High 417 62 (76) 36 (7-92) 
Insulin Yes 1902 65 (79) 36 (8-90) 0.768 - 
No 757 66 (82) 35 (7-93) 
Diabetes type T1D 827 67 (80) 37 (11-92) 0.13 - 
T2D 1773 64 (80) 34 (7-92) 
Other diabetes 44 65 (69) 46 (12-95) 
Unknown 15 42 (37) 34 (10-66) 
SIMD 1 658 62 (76) 36 (9-88) 0.641 - 
2 439 63 (78) 32 (9-86) 
3 444 70 (87) 37 (9-95) 
4 663 65 (80) 36 (6-93) 
5 437 65 (78) 36 (7-94) 
 
Table 14.  Number of user clicks within each patient record - doctors.   
Mulitvariate analysis of main effects on doctors’ interaction with SCI-Diabetes.  DSS = decision support system; SIMD = 
Scottish index of multiple deprivation; SD = standard deviation; IQ = interquartile 
Doctor  n mean (SD) median (IQ range) p (univariable) p (mulitvariate) 
DSS message displayed yes 1280 7 (5) 6 (4-9) 0.929 - 
no 1379 7 (6) 6 (3-9) 
Number of CDSS reminders mean (SD) 2 (2) - - 0.765 - 
Comorbidity group low 945 7 (5) 6 (4-9) 0.212 - 
moderate 1297 7 (5) 6 (4-9) 
high 417 8 (7) 6 (4-9) 
Insulin yes 1902 8 (6) 6 (4-9) 0.026 0.164 
no 757 7 (5) 6 (4-9) 
Diabetes type T1D 827 8 (6) 6 (4-10) 0.124 - 
T2D 1773 7 (5) 6 (4-9) 
Other diabetes 44 5 (3) 5 (3-7) 
Unknown 15 15 (13) 10 (4-32) 
SIMD 1 658 8 (7) 7 (4-10) 0.014 0.070 
2 439 7 (5) 6 (4-9) 
3 444 7 (5) 6 (3-8) 
4 663 7 (6) 6 (3-9) 
5 437 7 (6) 6 (3-9) 
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When nurses used SCI-Diabetes, the duration that the record was viewed was significantly different 
between the different SIMD categories (p=0.031), but this effect did not follow a socioeconomic 
gradient (see Table 15).  The number of mouse clicks made by nurses within the patient record was 
significantly increased when a CDSS message was displayed (p=0.014).  Nurses had more interaction 
with the system if patients had a low comorbidity score (p<0.001); the patient had type 1 diabetes 
(p<0.001); and they were receiving insulin (p<0.001) (see Table 16). 
Table 15.  Duration that patient record viewed by nurses.   
Mulitvariate analysis of main effects on nurses’ interaction with SCI-Diabetes.  DSS = decision support system; SIMD = 
Scottish index of multiple deprivation; SD = standard deviation; IQ = interquartile 
Nurse  n mean (SD) median (IQ range) p (univariable) p (mulitvariate) 
DSS message displayed Yes 4585 62 (77) 31 (8-84) 0.128 - 
No 5048 66 (76) 39 (14-88) 
Number of DSS reminders mean (SD) 2 (2) - - 0.119 - 
Co-morbidity group Low 3515 65 (77) 36 (10-90) 0.543 - 
Moderate 4369 64 (76) 36 (11-85) 
High 1749 61 (73) 34 (11-82) 
Insulin Yes 7574 64 (76) 36 (11-87) 0.243 - 
No 2059 62 (76) 34 (10-83) 
Diabetes type T1D 2701 64 (76) 37 (11-87) 0.083 0.075 
T2D 6484 63 (76) 34 (10-86) 
Other diabetes 353 75 (86) 45 (15-99) 
Unknown 87 57 (70) 34 (14-73) 
SIMD 1 2384 63 (75) 35 (11-87) 0.024 0.031 
2 1705 65 (79) 36 (11-88) 
3 1598 60 (72) 34 (10-79) 
4 2518 65 (77) 37 (11-89) 
5 1356 64 (78) 35 (9-88) 
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Table 16.  Number of user clicks within each patient record - nurses.   
Mulitvariate analysis of main effects on nurses’ interaction with SCI-Diabetes.  DSS = decision support system; SIMD = 
Scottish index of multiple deprivation; SD = standard deviation; IQ = interquartile 
Nurse  n mean (SD) median (IQ range) p (univariable) p (mulitvariate) 
DSS message displayed yes 4585 28 (18) 19 (8-37) 0.001 0.014 
no 5048 24 (24) 16 (7-32) 
Number of CDSS reminders mean (SD) 2 (2) - - 0.004 0.545 
Comorbidity group low 3515 29 (30) 19 (8-37) 0.017 <0.001 
moderate 4369 25 (25) 16 (8-33) 
high 1749 22 (18) 16 (8-33) 
Insulin yes 7574 28 (27) 19 (9-37) <0.001 <0.001 
no 2059 20 (22) 12 (5-26) 
Diabetes type T1D 2701 27 (29) 17 (7-36) <0.001 <0.001 
T2D 6484 26 (25) 17 (8-34) 
Other diabetes 353 25 (23) 16 (7-37) 
Unknown 87 16 (9) 16 (7-24) 
SIMD 1 2384 27 (27) 17 (8-36) 0.094 0.080 
2 1705 23 (20) 17 (8-33) 
3 1598 24 (25) 16 (8-32) 
4 2518 27 (28) 17 (8-35) 
5 1356 28 (27) 18 (8-40) 
 
In contrast to doctors and nurses, AHPs had much less interaction with SCI-Diabetes in general, with 
only 464 patient records being viewed during the period of study.  The duration that these records 
were viewed was significantly longer when a CDSS message was displayed; the patient had less 
comorbidities; the patient had type 2 diabetes; the patient was on insulin; and they were from a 
more deprived background (all p<0.001 – see Table 17).  The presence of a CDSS message had no 
effect on the number of clicks that AHPs made within the patient record (see Table 18). 
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Table 17.  Duration that patient record viewed by AHPs.   
Mulitvariate analysis of main effects on AHPs’ interaction with SCI-Diabetes.  DSS = decision support system; SIMD = 
Scottish index of multiple deprivation; SD = standard deviation; IQ = interquartile 
AHP  n mean (SD) median (IQ range) p (univariable) p (mulitvariate) 
DSS message displayed Yes 290 72 (85) 39 (8-105) <0.001 <0.001 
No 174 50 (57) 31 (8-72) 
Number of DSS reminders mean (SD) 2 (2) - - 0.095 <0.001 
Co-morbidity group Low 195 65 (79) 35 (8-90) 0.031 <0.001 
Moderate 222 62 (77) 32 (7-94) 
High 47 61 (57) 49 (16-93) 
Insulin Yes 395 65 (78) 36 (8-93) <0.001 <0.001 
No 69 55 (66) 29 (7-92) 
Diabetes type T1D 281 64 (80) 33 (8-93) <0.001 <0.001 
T2D 171 64 (71) 42 (9-96) 
Other diabetes 11 35 (48) 10 (5-46) 
Unknown 1 - - 
SIMD 1 82 66 (92) 31 (7-73) 0.867 <0.001 
2 84 64 (73) 36 (7-97) 
3 96 62 (71) 37 (9-89) 
4 126 62 (72) 38 (10-90) 
5 69 62 (77) 30 (7-104) 
 
Table 18.  Number of user clicks within each patient record - AHPs.   
Mulitvariate analysis of main effects on AHPs’ interaction with SCI-Diabetes.  DSS = decision support system; SIMD = 
Scottish index of multiple deprivation; SD = standard deviation; IQ = interquartile 
AHP  n mean (SD) median (IQ range) p (univariable) p (mulitvariate) 
DSS message displayed yes 290 21 (14) 16 (10-33) 0.007 0.362 
no 174 17 (13) 13 (6-24) 
Number of CDSS reminders mean (SD) 2 (2) - - 0.349 - 
Comorbidity group low 195 17 (11) 14 (8-23) <0.001 <0.001 
moderate 222 19 (14) 15 (8-29) 
high 47 31 (19) 34 (13-36) 
Insulin yes 395 20 (14) 17 (10-29) <0.001 <0.001 
no 69 16 (14) 9 (5-23) 
Diabetes type T1D 281 19 (13) 15 (9-33) <0.001 <0.001 
T2D 171 21 (16) 16 (9-26) 
Other diabetes 11 7 (5) 4 (3-9) 
Unknown 1 - - 
SIMD 1 82 16 (13) 12 (5-23) <0.001 0.087 
2 84 16 (10) 15 (9-26) 
3 96 25 (18) 19 (12-36) 
4 126 23 (14) 20 (11-35) 
5 69 12 (7) 11 (6-17) 
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6.8.6. Discussion 
In terms of typical SCI-Diabetes usage, this analysis has demonstrated the following: 
 Nurses are the most frequent users of the system in terms of number of patient records 
viewed. 
 Nurses and AHP’s use of the system involves greater interaction (as measured by number of 
user clicks).  This could be due to either more pages being viewed within the patient record 
and/or greater volume of data entry. 
 Regardless of user role, the median time that a patient record is viewed is 30-40 seconds, 
whilst outliers increase the average time to just over a minute. 
 Comorbidity and socioeconomic status are associated with differences in system usage by 
nurses and AHP’s (but not doctors).  These differences are inconsistent and do not follow 
any particular gradient. 
The CDSS displayed a message in approximately 40% of patient records that were opened.  It should 
be noted that this was in contrast to earlier observations made within the focus groups, whereby it 
was felt that messages were displayed for nearly all patients (section  6.7.6.1).  The presence of a 
message was associated with some differences in user behaviour, but this was dependent on user 
role.  When doctors received a CDSS message, the duration that the record was viewed reduced by 
an average of 8 seconds.  Whilst statistically significant, it could be argued that this has little clinical 
significance.  That being said, this may reflect observations made by senior medical staff that the 
system enables a more targeted approach to consultations (see section 6.7).  These results are in 
keeping with previous studies that found CDSS was related to increased efficiencies in working 
practices, although the level of evidence to support this hypothesis remains low 161,162.  It is 
important to note, that the improved efficiencies in working patterns was not at the expense of 
patient satisfaction as measured by PREMs (see section 6.5).  Again, this reflects previous (low 
quality) studies that demonstrated no negative impact on patient satisfaction 162. 
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In contrast to doctors, when nurses received a CDSS message there was no difference in the 
duration that the record was viewed, but the number of user clicks was significantly greater for both 
nurses (and AHPs) when a CDSS message was displayed (by approximately 25%).  Again, it is difficult 
to see how clinically significant this difference is without greater insight into the underlying clinical 
processes (e.g. adherence to guidelines) and clinical outcomes.  One possible explanation is that the 
CDSS may be the catalyst for users to increase their data entry, but this remains speculative at this 
stage. 
Patient socioeconomic class and morbidity exerted an inconsistent effect on system usage by nurses 
and AHPs.  Greater co-morbidity is closely associated with deprivation 163, however lower 
socioeconomic class is not necessarily associated with greater health care utilisation 164.  In 
particular, deprivation is associated with less use of preventative services.  Given that much of 
diabetes care is concerned with the prevention of secondary complications, it is less surprising that 
there is a lack of a clear gradient between socioeconomic class (or morbidity) and system usage by 
HCPs. 
SCI-Diabetes is an electronic health record that is accessed by a wide variety of health professionals 
for various reasons.  Whilst an audit trail exists for every user interaction within the system, these 
data are not specifically collected to assess user behaviour.  Certain assumptions must therefore be 
made in order to use these data in such a way.  The duration that the patient record was viewed and 
number of user clicks within the patient record were used as proxies for user behaviour.  These 
somewhat crude measures assume that each time a patient record is opened, the user is doing so 
for reasons related to clinical management (as opposed to e.g. answering simple queries, data entry 
etc).  There is also an assumption that the duration that the record is opened represents active use 
by the HCP, however it is clear from the large number of outliers that in many cases a patient record 
is left open indefinitely (until the user is automatically logged out of the system). 
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Despite these limitations, these proxy measures of user behaviour do serve as an objective measure 
by which to characterise an individuals’ system use and to compare the effects of the CDSS in 
general.  Filtering by user role and the removal of outliers goes some way to addressing the above 
limitations. In addition, the “noise” created by everyday use (e.g. patient record left open for 
prolonged periods of time) is independent of the presence or absence of a CDSS message and so 
does not introduce bias into the analysis.  System usage has previously been quantified via duration 
of use and number of interactions with the system in question 159.  The EBMeDS intervention is an 
adjunct to an existing information system and so it impossible to compare our findings with these 
previous studies that are largely concerned with the evaluation of newly implemented systems 
where success is determined by the fact that the system is being used at all. 
This study has characterised individual system usage of an existing EHR.  It has demonstrated that a 
CDSS may have some impact on user behaviour, but the clinical significance of these changes 
remains unknown.  The following chapters attempt to resolve this unanswered question by 
investigating whether the CDSS has resulted in any change in clinical processes and outcomes.
 6.9 Clinical processes 
6.9.1. Abstract 
6.9.1.1. Introduction 
The main determinant of the success of an information system is the impact that the system has on 
the organisation itself.  Routine diabetes care is informed by national evidence-based guidelines.  
These include recommendations for the screening and treatment of diabetes-related 
complications. This study will assess whether the CDSS intervention resulted in change at an 
organisational level, by measuring the impact (if any) on a range of quality performance indicators 
(QPIs) derived from national guidelines.  
6.9.1.2. Methods 
Data were extracted from the SCI-Diabetes electronic health record for both improvement cycle 
one (Ninewells hospital diabetes clinic and one NHS Tayside primary care diabetes clinic, Dec 13 – 
Feb 14) and cycle two (St John’s hospital diabetes clinic, Aug 14 – Nov 14).  Cases were all patients 
attending the diabetes clinic whose health care professional (HCP) received a CDSS message during 
this time.  Control were matched in a ratio of 1:2 for age; sex; type and duration of diabetes; BMI; 
and attendance at a clinic not taking part in the study. 
Improvement in adherence to the QPIs served as the primary outcomes.  These included screening 
for: foot disease (standardised foot screening); hyperlipidaemia (serum cholesterol); thyroid 
disease (serum thyroid stimulating hormone (TSH)); and kidney disease (serum creatinine and 
urinary albumin/creatinine ratio (UACR)).  Adherence was considered to be improved if patients 
with no recorded results within the previous 15 months (24 months for TSH) proceeded to have the 
screening test done within 30 days post-appointment.  Cases and controls were compared by 
multivariable linear regression taking into account potential demographic confounders. 
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6.9.1.3. Results 
An EBMeDS prompt was displayed to an HCP in 1883 cases attending the clinic (cycle 1 = 1116, 
cycle 2 = 767 cases).  Prior to the intervention, adherence to each of the QPIs was greater than 
60%.  Patient group (i.e. case or control) was a significant predictor of whether or not a patient 
received appropriate screening following a clinic appointment for each of the QPIs.   
Improvement cycle one: the intervention was significantly associated with increased uptake of 
screening for foot disease (adjusted OR 1.4, 95%CI: 1.0-2.1, p=0.045) and urinary protein (2.0 (1.5-
2.7), p<0.001) and decreased uptake of screening for thyroid disease (0.2 (0.1-0.2) p<0.001) when 
compared to controls.   
Improvement cycle two: patients were significantly more likely than matched controls to undergo 
screening for all of the outcomes, the odds of which were far greater than those observed in cycle 
1.  Cases were over 4 times more likely than cases to have their feet, cholesterol and creatinine 
checked (adjOR (95%CI): 4.5 (3.2-6.3); 4.5 (2.3-8.6); 4.2 (2.7-6.5) respectively, all p<0.001); 9 times 
more likely to have TSH checked (9.1 (6.2-13.2) p<0.001); and twice as likely to have UACR checked 
(2.7 (2.0-3.6) p<0.001) compared with the control group. 
6.9.1.4. Conclusion 
The study has demonstrated a large improvement in adherence to current guidelines, when 
compared to a closely matched control population.  This improvement was more marked within 
improvement cycle two, which may reflect improved functionality of the system following 
iterations made in light of user feedback, however it is acknowledged that clinical practices will 
differ between sites.   It is hoped that improved adherence to guidelines will translate to improved 
clinical outcomes in due course.  The limitations of the study preclude any causal inference, but 
would support the on going use of the CDSS system 
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6.9.2. Introduction 
As previously discussed, DeLone and McLean’s model of information systems success 157 attempts 
to define by which criteria a new information system can be considered to be effective (see section 
6.8.2).  The model was initially developed within a business management context, but has since 
been applied to medical information systems 159.  Ultimately, the model describes a new 
information system as being a success if it is associated with a positive effect on the organisation 
itself.  From the perspective of a diabetes clinic, the metrics by which organisational performance 
can be quantified fall into two key areas: clinical processes and clinical outcomes.  Clinical 
processes include tasks undertaken by HCPs in an effort to provide effective healthcare, ideally in 
accordance with evidence-based clinical guidelines.  Adherence to these guidelines can therefore 
be regarded as a metric of success and are used as quality performancy indicators (QPIs) of regional 
and national performance 4.  It is hoped that by improving clinical processes, clinical outcomes will 
improve.  Clinical outcomes for diabetes principally include glycaemic control as well as a range of 
other measures that serve to characterise levels of morbidity amongst the population.  Both 
processes and outcomes have the potential to be indirectly influenced by improvements to the 
information system (see section 6.2.3), and it is the former that proves most amenable to 
improvement by the introduction of a CDSS 162. 
This study will assess whether the intervention has resulted in change at an organisational level, by 
measuring the impact (if any) on clinical processes, as measured by a range of QPIs.  These include 
screening for thyroid, kidney and foot disease; as well as hyperlipidaemia. 
6.9.3. Methods 
Data were extracted from those attending the NWH diabetes outpatient clinic and one primary 
care practice within NHS Tayside between 2/12/13 and 1/3/14 inclusive (improvement cycle 1).  In 
addition, data from those attending the SJH diabetes clinic between 18/08/14 and 15/11/14 
(improvement cycle 2) were also included in the analysis. 
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Cases were defined as those patients who attended the diabetes clinic within the specified date 
and whose HCP received an EBMeDS alert on that date.  Controls were selected from the SCI-
Diabetes Scottish national dataset from geographical areas not exposed to the intervention.  
Controls were matched to cases based on the following criteria: age (2 years); gender; diabetes 
type; duration of diabetes (2 years); BMI (2 kg/m2); and attendance at clinic between January to 
December 2014.  If an individual had multiple appointments during these 12 months, data were 
extracted relative to the earliest appointment during the year. 
Where possible, 2 controls were matched to each case (however, a ratio of 1:1 was accepted in 
order to improve case retention).  The dependent variables were not considered when matching 
controls to cases.   Demographic features were compared between cases and controls using 
Student’s t test and Chi-square as appropriate. 
Improvement in adherence to the QPIs served as the primary outcomes.  The QPIs were : 
 Proportion of patients where foot risk screening was completed within 15 months of the 
clinic appointment. 
 Proportion of patients where serum thyroid stimulating hormone (TSH) was measured 
within 24 months of the clinic appointment. 
 Proportion of patients where serum creatinine was measured within 15 months of the 
clinic appointment. 
 Proportion of patients where serum cholesterol was measured within 15 months of the 
clinic appointment. 
 Proportion of patient where urinary albumin creatinine ratio (ACR) was measured within 15 
months of the clinic appointment. 
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Patients in whom the above screening tests were not completed within the preceding specified 
period were considered to be non-adherent to current guidelines 9, and were included in the 
subsequent analysis – see Figure 32.  In each instance, cases’ HCP received a CDSS message alerting 
them to this fact, whereas no such message was displayed to controls’ HCP.  Adherence was 
considered improved if these patients proceeded to have the screening test done within 30 days 
post-appointment.  
  
Figure 32. Schema demonstrating selection of cases and controls included in the analysis of clinical processes. 
The foot screening QPI is used as an example, with the same attrition methods used for the other QPIs. 
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The secondary outcomes related to prescribed medication in the 30 days following a clinic 
consultation.  Individuals were considered naïve to oral hypoglycaemics if they had had not been 
prescribed Metformin, Glibenclamide, Gliclazide, Glipizide, Glimepiride, or Tolbutamide prior to the 
consultation.  The proportion of oral hypoglycaemic drug naïve patients that went on to receive 
one of these drugs in the 30 days following the consultation was then compared between cases 
and controls. 
6.9.3.1. Statistical analysis 
All outcomes were initially cross-tabulated and compared using Chi-square.  Patients’ data were 
entered into a logistical regression analysis if they were non-adherent to the QPI prior to the clinic 
appointment.  The dichotomous dependent variable was whether or not they went on to receive 
screening within 0-30 days following the appointment date.  Intervention group and demographics 
were considered as independent variables and entered on a univariable basis.  All variables 
significant to p<0.3 were retained and entered simultaneously in the multivariable analysis.  
Previous analyses used a more stringent cut off of p<0.1 (see section 6.5.4.3), however a more 
liberal approach was adopted in this instance to ensure potentially important demographic 
predictors were included in the multivariable analysis. 
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Power calculations were made based on the foot-screening primary outcome within the context of 
the NWH diabetes clinic.  The proportion of those in whom this was done within the preceding 15 
months was 62% of those with T1D and 85% of those with T2D - equivalent to 82% overall 165.  It 
was anticipated that 1200 patients would attend NWH during the three-month period of 
improvement cycle 1.  Of these, it was anticipated that HCPs would receive a foot-screening 
prompt indicating that the patient had not had his/her feet screened in approximately 216 
consultations (18% of 1200 = 216 patients).  In order to maintain a steady state of 82% patients 
screened within the past 15 months, an average of 12 of these 216 patients who are over the 15-
month threshold are screened every month, regardless of the intervention (i.e. 82% of 216 divided 
by 15 months = 11.8) - failure to do so would result in the proportion of individuals not screened 
for the past 15 months growing ever larger through time.  If the clinical alert provoked the HCP to 
complete foot screening for an additional 8 patients per month (equivalent to a 67% increase) then 
over the course of the 3-month period, 60 patients who had not received foot screening for 15-
months (i.e. 3*(8+12)) would receive foot screening in the intervention clinic (60/1200 = 5%).  It 
was assumed that the control patient group (anticipated n=2400) was subject to the same 
background rate of foot screening.  This would result in 24 patients per month who had not 
received screening in the past 15-months, receiving foot screening through routine care - 
equivalent to 72/2400 (3%) over the three-month period.  The resulting difference between the 2 
samples (5% of 1200 vs. 3% of 2400) would allow the null hypothesis that there is no difference 
between the 2 groups to be rejected with 90% power. 
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6.9.4. Results 
6.9.4.1. Matching 
During the two improvement cycles, 5692 patients were the subject of an EBMeDS prompt when 
their patient record was opened.  These were successfully matched to 10,677 controls (see section 
6.10.5.1 for further details).  Of these, the date of the EBMeDS prompt corresponded with a clinic 
appointment date in 1883 cases, matched to 3557 controls (1674 cases were matched to two 
controls, 209 cases were matched to one control patient).  As expected, for each of the matching 
variables there were no significant differences between cases and controls (see Table 19). 
Table 19.  Demographic characteristics of cases and controls 
No significant differences demonstrated between either group (continuous variables compared with Student's t test, 
categorical variables compared with Chi Square).  BMI = body mass index; SD = standard deviation 
  Cases Controls p 
n 1883 3557 - 
Male 1072 (57%) 2045 (58%) 0.708 
Type 1 Diabetes 588 (31%) 1103 (31%) 0.878 
Type 2 Diabetes 1269 (67%) 2450 (69%) 0.27 
Duration of diabetes [years] (SD) 17.9 (12.5) 17.5 (11.6) 0.32 
BMI [kg/m2] (SD) 30.6 (6.8) 30.5 (6.3) 0.5 
Mean age [years] (SD) 59.8 (16.5) 59.5 (16.4) 0.63 
 
Improvement cycle 1 (NWH) contributed 1116/1883 cases (59%), whilst improvement cycle 2 (SJH) 
involved 767 cases (41%). 
6.9.4.2. Quality performance indicators 
Prior to the intervention, adherence to each of the QPIs was greater than 60% (see Figure 33).  The 
proportion of all cases that had had foot screening in the previous 15 months was significantly 
greater amongst cases (76.5% versus 73.4%, p<0.001), whereas controls had significantly greater 
adherence to screening for TSH, creatinine and cholesterol. 
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Figure 33. Pre-intervention adherence to Quality Performance Indicators (QPIs).   
See methods for definition of QPIs.  * denotes p<0.05, ** denotes p<0.001.  Cases n=1883, controls n=3557. 
 
Of those patients attending clinic that had not received screening within the recommended period, 
significantly more received screening for foot disease, renal disease and hypercholesterolaemia in 
the intervention sites in the 30 days following the clinic appointment where an EBMeDS message 
was received.  TSH monitoring was significantly more prevalent in the control population (see Table 
20). 
Table 20. Adherence to Quality Performance Indicators in the 30 days following a clinic appointment 
  Cases requiring screening Controls requiring screening 
  n Received screening, n(%) n Received screening, n(%) p 
Foot screening 443 243 (54.9%) 945 281 (29.7%) <0.001 
TSH 707 229 (32.4%) 1100 408 (37.1%) 0.02 
Creatinine 206 168 (81.6) 252 162 (64.3%) <0.001 
Cholesterol 342 236 (69.0%) 442 213 (48.2%) <0.001 
UACR 678 277 (40.9%) 1252 287 (22.9%) <0.001 
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6.9.4.3. Univariable and multivariable analysis 
Patient group (i.e. case or control) was a significant predictor of whether or not a patient received 
appropriate screening following a clinic appointment for each of the QPIs – see Figure 34.  During 
cycle 1 (NWH), the intervention was significantly associated with increased uptake of screening for 
foot disease and urinary protein and decreased uptake of thyroid disease when compared to 
matched controls.  Patients attending clinic in cycle 2 (SJH) were significantly more likely than 
matched controls to undergo screening for all of the outcomes, the odds of which were far greater 
than those observed in cycle 1 - see Figure 34. 
Figure 34. Adjusted odds ratios for each of the primary outcomes, by site 
Odds represent the probability of a case receiving screening for the complications of diabetes following a clinic 
appointment, compared with controls.  Adjusted for Age, diabetes type and duration, gender and BMI. 
Intervention group compared with controls.  Note log scale on y axis. 
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6.9.4.3.1. Cycle 1 – Ninewells hospital, Dundee 
For those patients whose HCP received an EBMeDS alert prompting the need for foot screening, 
the adjusted odds of subsequently receiving that screening were 1.4 when compared with the 
control population (95%CI: 1.01-2.07, p=0.045) – see Table 21. 
Table 21. Logistic regression showing significant predictors of foot screening in NWH.   
Cases n=170, controls n=561.  All univariable predictors significant to p<0.3 entered simultaneously.  OR = Odds ratio; BMI 
= body mass index; CI = 95% confidence interval. 
 
Univariable Multivariable 
  OR CI p OR CI p 
Group 1.448 1.012-2.072 0.043 1.444 1.009-2.068 0.045 
Age 1.007 0.999-1.015 0.102 1.007 0.999-1.015 0.107 
T2D 0.982 0.717-1.344 0.993 -     
Gender 0.858 0.627-1.176 0.342 -     
Duration of diabetes 1.002 0.992-1.013 0.67 -     
BMI 0.992 0.969-1.016 0.532 -     
 
The adjusted odds for receiving screening for thyroid disease following an EBMeDS prompt were 
significantly reduced in the intervention group, when compared to controls (OR 0.15, 95%CI: 0.11-
0.21, p<0.001). 
Table 22. Logistic regression showing significant predictors of TSH screening in NWH.   
Cases n=473, controls n=658.  All univariable predictors significant to p<0.3 entered simultaneously.  OR = Odds ratio; BMI 
= body mass index; CI = 95% confidence interval. 
 
Univariable Multivariable 
  OR CI p OR CI p 
Group 0.15 0.108-0.210 <0.001 0.15 0.107-0.209 <0.001 
Age 0.995 0.988-1.002 0.182 0.993 0.986-1.001 0.092 
T2D 0.844 0.649-1.097 0.309 -     
Gender 1.112 0.857-1.443 0.425 -     
Duration of diabetes 0.994 0.984-1.005 0.267 0.996 0.985-1.008 0.53 
BMI 0.999 0.980-1.020 0.958 -     
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The intervention was not associated with increased odds of having serum creatinine or cholesterol 
checked in clinic – see Table 23 and Table 24.  Increasing age was associated with increased odds of 
having creatinine checked (OR 1.02, 95%CI: 1.00-1.04, p=0.036).  Similarly, those with a higher BMI 
were more likely to have cholesterol checked (OR 1.05, 95%CI: 1.02-1.09, p=0.007). 
Table 23. Logistic regression showing significant predictors of creatinine screening in NWH.   
Cases n=81, controls n=131.  All univariable predictors significant to p<0.3 entered simultaneously.  OR = Odds ratio; BMI = 
body mass index; CI = 95% confidence interval. 
 
Univariable Multivariable 
  OR CI p OR CI P 
Group 1.246 0.663-2.341 0.494 -     
Age 1.024 1.007-1.042 0.007 1.019 1.001-1.038 0.036 
T2D 1.069 0.581-1.967 0.831 -     
Gender 0.843 0.457-1.554 0.583 -     
Duration of diabetes 1.013 0.988-1.038 0.325 -     
BMI 1.078 1.016-1.144 0.013 1.059 0.996-1.125 0.065 
 
Table 24. Logistic regression showing significant predictors of cholesterol screening in NWH.   
Cases n=142, controls n=252.  All univariable predictors significant to p<0.3 entered simultaneously.  OR = Odds ratio; BMI 
= body mass index; CI = 95% confidence interval. 
 
Univariable Multivariable 
  OR CI P OR CI P 
Group 1.219 0.805-1.847 0.35 -     
Age 1.01 1.000-1.020 0.062 1.004 0.993-1.015 0.446 
T2D 1.104 0.741-1.644 0.823 -     
Gender 0.75 0.501-1.121 0.16 1.467 0.968-2.224 0.071 
Duration of diabetes 1.016 0.998-1.034 0.08 1.016 0.999-1.034 0.071 
BMI 1.05 1.014-1.088 0.006 1.053 1.015-1.094 0.007 
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An HCP receiving an EBMeDS prompt to check urinary ACR were twice as likely to receive this test 
in comparison to the control group (OR 2.01, 95%CI: 1.51-2.67, p<0.001) – see Table 25.  Increasing 
age and female sex were also significantly associated with increased odds of having UACR checked. 
Table 25. Logistic regression showing significant predictors of UACR screening in NWH.   
Cases n=322, controls n=739.  All univariable predictors significant to p<0.3 entered simultaneously.  OR = Odds ratio; BMI 
= body mass index; CI = 95% confidence interval. 
 
Univariable Multivariable 
  OR CI P OR CI P 
Group 1.951 1.472-2.586 <0.001 2.011 1.511-2.676 <0.001 
Age 1.013 1.005-1.021 0.001 1.014 1.006-1.022 0.001 
T2D 1.158 0.881-1.523 0.323 -     
Gender 0.738 0.562-0.968 0.028 1.435 1.085-1.898 0.011 
Duration of diabetes 1.001 0.991-1.011 0.856 -     
BMI 1.011 0.991-1.032 0.296 1.007 0.985-1.029 0.561 
 
Of the 491 cases not previously prescribed oral hypoglycaemic agents prior to the consultation, 5 
(1.0%) were started on this medication following an appointment.  Of the 1036 controls, 24 (2.3%) 
were started on hypoglycaemics following an appointment.  Patient group (i.e. cases or controls) 
was not associated with receiving a new prescription for oral hypoglycaemics, whereas shorter 
duration of diabetes and increased BMI were significantly associated with receiving a prescription – 
see Table 26. 
Table 26.  Logistic regression showing significant predictors of starting an oral hypoglycaemic following appointment in 
NWH. 
Cases n=491, controls n=1036.    All univariable predictors significant to p<0.3 entered simultaneously.  OR = Odds ratio; 
BMI = body mass index; CI = 95% confidence interval. 
 Univariable Multivariable 
  OR CI P OR CI P 
Group 0.434 0.165-1.144 0.091 0.513 0.193-1.366 0.182 
Age 1.009 0.989-1.029 0.389 - - - 
Gender 1.353 0.649-2.823 0.42 - - - 
Duration of diabetes 0.925 0.883-0.97 0.001 0.922 0.877-0.969 0.001 
BMI 1.091 1.038-1.146 0.001 1.089 1.035-1.146 0.001 
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6.9.4.3.2. Cycle 2 – St John’s hospital, Livingston 
Patients attending the SJH diabetes clinic whose HCP received an EBMeDS prompt for foot 
screening were over 4 times more likely to receive this when compared to their closely matched 
controls (OR 4.52, 95%CI: 3.22-6.34, p<0.001).  Increased duration of diabetes and higher BMI were 
also significantly associated with receiving the test – see Table 27. 
Table 27. Logistic regression showing significant predictors of foot screening in SJH.   
Cases n=273, controls n=384.  All univariable predictors significant to p<0.3 entered simultaneously.  OR = Odds ratio; BMI 
= body mass index; CI = 95% confidence interval. 
 
Univariable Multivariable 
  OR CI P OR CI P 
Group 4.494 3.224-6.263 <0.001 4.522 3.224-6.344 <0.001 
Age 1.014 1.005-1.022 0.002 1.008 0.998-1.018 0.112 
T2D 0.945 0.693-1.289 0.721 -     
Gender 0.963 0.708-1.311 0.811 -     
Duration of diabetes 1.017 1.004-1.031 0.011 1.021 1.006-1.035 0.005 
BMI 1.037 1.013-1.061 0.002 1.028 1.001-1.055 0.04 
 
Similarly, patients were 9 times more likely to receive screening for thyroid disease if their HCP 
received a prompt for this (OR 9.05, 95%CI: 6.22-13.18, p<0.001) – see Table 28. 
Table 28. Logistic regression showing significant predictors of TSH screening in SJH.   
Cases n=234, controls n=442.  All univariable predictors significant to p<0.3 entered simultaneously.  OR = Odds ratio; BMI 
= body mass index; CI = 95% confidence interval. 
 
Univariable Multivariable 
  OR CI P OR CI P 
Group 8.743 6.047-12.642 <0.001 9.053 6.217-13.183 <0.001 
Age 0.994 0.984-1.003 0.186 1 0.987-1.014 0.945 
T2D 0.669 0.489-0.914 0.012 0.587 0.377-0.914 0.061 
Gender 1.073 0.787-1.462 0.655 -     
Duration of diabetes 0.998 0.985-1.011 0.781 -     
BMI 1.001 0.978-1.025 0.917 -     
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The odds of a patient receiving screening for kidney disease (via serum creatinine and urinary ACR) 
were also greatly increased in the intervention group (OR 4.47, 95%CI: 2.34-8.55, p<0.001 and OR 
2.65, 95%CI 1.96-3.59, p<0.001 respectively) – see Table 29 and Table 30.  Increasing age was 
predictive of both tests being completed and females were more likely to have UACR checked than 
males. 
Table 29. Logistic regression showing significant predictors of creatinine screening in SJH.   
Cases n=125, controls n=121.  All univariable predictors significant to p<0.3 entered simultaneously.  OR = Odds ratio; BMI 
= body mass index; CI = 95% confidence interval. 
 
Univariable Multivariable 
  OR CI P OR CI P 
Group 4.48 2.421-8.291 <0.001 4.468 2.335-8.550 <0.001 
Age 1.033 1.016-1.051 <0.001 1.025 1.001-1.049 0.037 
T2D 1.81 1.001-3.272 0.146 0.768 0.299-1.970 0.582 
Gender 0.99 0.568-1.726 0.971 -     
Duration of diabetes 1.042 1.101-1.075 0.01 1.035 1.000-1.071 0.05 
BMI 1.071 1.017-1.127 0.01 1.038 0.974-1.107 0.252 
 
Table 30. Logistic regression showing significant predictors of UACR screening in SJH.   
Cases n=356, controls n=513.  All univariable predictors significant to p<0.3 entered simultaneously.  OR = Odds ratio; BMI 
= body mass index; CI = 95% confidence interval. 
 
Univariable Multivariable 
  OR CI P OR CI P 
Group 2.793 2.076-3.757 <0.001 2.653 1.961-3.588 <0.001 
Age 1.011 1.002-1.020 0.021 1.013 1.001-1.024 0.029 
T2D 1.146 0.851-1.543 0.144 0.726 0.484-1.090 0.115 
Gender 0.715 0.535-0.957 0.024 1.496 1.102-2.031 0.01 
Duration of diabetes 0.999 0.988-1.011 0.908 -     
BMI 1.023 1.002-1.045 0.029 1.024 0.999-1.049 0.056 
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The odds of having serum cholesterol measured following an EBMeDS prompt were 4 times greater 
than the control population (OR 4.19, 95%CI: 2.68-6.55, p<0.001).  Increasing age was again 
predictive of receiving the test – see Table 31. 
Table 31. Logistic regression showing significant predictors of cholesterol screeningin SJH.   
Cases n=200, controls n=190.  All univariable predictors significant to p<0.3 entered simultaneously.  OR = Odds ratio; BMI 
= body mass index; CI = 95% confidence interval. 
 
Univariable Multivariable 
  OR CI P OR CI P 
Group 4.674 3.021-7.231 <0.001 4.188 2.679-6.549 <0.001 
Age 1.024 1.012-1.035 <0.001 1.017 1.003-1.03 0.014 
T2D 1.349 0.897-2.029 0.355 -     
Gender 0.921 0.615-1.379 0.688 -     
Duration of diabetes 0.999 0.984-1.015 0.924 -     
BMI 1.052 1.018-1.087 0.003 1.013 0.976-1.052 0.492 
 
Of the 397 cases not receiving an oral hypoglycaemics prior to the consultation, 8 (2%) were 
started on this medication following an appointment.  Of the 641 controls, 16 (2.5%) were started 
on hypoglycaemics following the consultation.  Patient group was not significantly associated with 
the odds of receiving this prescription.  Again, shorter duration of diabetes and increasing BMI 
were significant predictors of receiving an oral hypoglycaemic – see Table 32. 
Table 32. Logistic regression showing significant predictors of receiving a new oral hypoglycaemic following appointment 
at SJH. 
Cases n=397, controls n=641.  All univariable predictors significant to p<0.3 entered simultaneously.  OR = Odds ratio; BMI 
= body mass index; CI = 95% confidence interval. 
 Univariable Multivariable 
  OR CI P OR CI P 
Group 0.803 0.341-1.895 0.617 - - - 
Age 1.015 0.992-1.039 0.197 1.016 0.99-1.043 0.226 
Gender 0.545 0.231-1.286 0.166 0.476 0.195-1.16 0.102 
Duration of diabetes 0.947 0.906-0.99 0.016 0.936 0.899-0.985 0.011 
BMI 1.098 1.043-1.156 <0.001 1.091 1.031-1.155 0.002 
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6.9.5. Discussion 
This study has demonstrated a large improvement in nearly all of the QPIs in the month following a 
clinic appointment, when compared to closely matched controls.  The early detection of diabetes-
related complications via these secondary prevention interventions is associated with reduced 
morbidity and are associated with substantial economic savings 8.  This is discussed in greater detail 
later – see section 6.11.1.  The improved adherence to clinical guidelines is consistent with 
previously studied CDSS 162, however the observed improvements in this study are of a far greater 
magnitude. 
The study failed to show any difference between cases and controls in the odds of receiving a 
newly commenced oral hypoglycaemic in the month following a consultation.  Perhaps 
unsurprisingly, shorter duration of diabetes (i.e. more recently diagnosed) and higher BMI (i.e. 
greater insulin resistance) were highly significant predictors of starting this medication.  The CDSS 
included HCP prompts to consider ways of improving glycaemic control, but these would have 
appeared to have no effect on prescribing practices.  It could be argued that decision support has 
less value in this context as the primary drivers of HCP behaviour within clinic is the need to 
improve glycaemic control, therefore reminders to consider this are perhaps less warranted.   
An additional secondary outcome to be considered was the prescription of antihypertensive agents 
(Angiotensin-converting enzyme inhibitors and Angiotensin-II receptor antagonists) in the month 
following a clinic appointment.  There is perhaps greater scope for improvements in this area – 
guidelines suggest that patients with positive screening results (i.e. albuminuria) are commenced 
on these drugs, yet this is often overlooked 166.   Unfortunately, these data were not yet available at 
the time of writing. 
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A note of caution must be struck when interpreting the above findings, owing to limitations in 
study design.  For example, the QPI improvements observed in cases during cycle two were far 
greater than those in cycle one.  It is tempting to infer that these observed differences were as a 
result of system iterations (in response to user feedback).  However, it is far more likely that local 
variation in clinical practices was responsible for the observed differences.  It transpired that in the 
Livingston clinic (cycle 2), health care assistants responsible for identifying patients requiring 
screening tests during their clinic visit were using the CDSS for this specific task as a way of quickly 
interrogating the EHR [K Adamson, email communication].  This serves as a reminder that the 
effects of a CDSS are limited/enhanced by human factors and the processes in place around the 
system.  In this context, the CDSS could be viewed as an enhancement to an existing system, 
resulting in behaviour change within the MDT. 
Matching between cases and controls did not include the dependent variables at baseline e.g. the 
presence or absence of pre-existing foot screening was not considered.  This pragmatic decision 
was based upon the need to improve the probability of a successful match and to allow the same 
control population to be used throughout the investigation.  Ultimately, this resulted in a large 
control population, closely matched for a variety of demographics.  The observed differences 
between cases and controls in the primary outcomes prior to the intervention were therefore 
unavoidable but unsurprising, given the likelihood of local variation in practice.  The proportion of 
cases that went on to receive screening in the month following a clinic appointment was several 
magnitudes greater that those controls that were due screening (with the exception of thyroid 
disease), and remained highly significant after correcting for potential confounders.  This would 
suggest that the intervention played a greater role than any baseline differences between the two 
groups. 
These findings are consistent with the substantial body of evidence suggesting that a CDSS can 
result in improvements in clinical processes 167. What remains more challenging is converting this 
improved health care delivery into meaningful improvements in clinical outcomes.  
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6.10 Clinical outcomes 
6.10.1. Abstract 
6.10.1.1. Introduction 
The Evidence Based Medicine electronic Decision Support system (EBMeDS) delivers a clinical 
decision support system (CDSS) that is available to clinicians within the normal work stream.  This 
type of CDSS has been shown to result in positive behaviour change by health care professionals 
(HCPs), but there is a lack of evidence that this translates into improved patient outcomes.  This 
case-control study utilises data from improvement cycles one and two of the EBMeDS project to 
quantify changes in glycaemic control (and a range of other secondary outcomes) through time and 
to compare these outcomes between cases and controls. 
6.10.1.2. Methods 
Data were extracted from the SCI-Diabetes electronic health record for patients attending the 
Ninewells hospital diabetes clinic between 2/12/13 and 1/3/14 inclusive (improvement cycle 1) and 
the St John’s hospital diabetes clinic between 18/08/14 and 15/11/14 (improvement cycle 2).  
Cases were all patients whose health care professional (HCP) received a CDSS message during this 
time.  Control data were anonymously extracted from SCI-Diabetes and matched in a ratio of 1:2 
for age; sex; type and duration of diabetes; BMI; and attendance at a clinic not taking part in the 
study.  Paired data were obtained for each dependent variable from baseline and follow up at 9-15 
months.  The primary outcome was change in HbA1c at one year.  Secondary outcomes included 
change in serum cholesterol, blood pressure and urinary albumin/creatinine ratio (UACR).  Cases 
and controls were compared by multivariable linear regression taking into account potential 
demographic confounders. 
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6.10.1.3. Results 
During the 3-month period of study, CDSS messages were generated for 5,692 cases, of which 
5,432 were matched to 10,667 controls.  There were no significant differences between the groups 
in terms of demographic variables.  Paired baseline-follow up HbA1c values were available for 
2662/5432 (47%) cases and 6203/10,677 (58%) controls.  Both cases and controls showed small, 
but significant improvements in HbA1c (mean change in HbA1c: -2.3 mmol/l vs. -1.1, B 1.2 95% CI 
0.4 to 2.0, p=0.003).  There were no significant differences in cholesterol and diastolic blood 
pressure between the groups.  Systolic blood pressure improved more in the control group (mean 
change in SBP: -1.3 mmHg vs. -3.3, B -2.0, 95%CI: -3.0 to -1.0, p<0.001).  UACR increased in both 
groups but significantly more in the control group (mean change in UACR: 1.6 vs. 4.4, B 2.9, 95%CI 
0.7 to 5.1, p=0.01). 
6.10.1.4. Conclusion 
The study has demonstrated a small improvement in glycaemic control and a decrease in 
progression of kidney disease when compared to a closely matched control population.  The 
limitations of the study preclude any causal inference, but would support the ongoing use of the 
CDSS system.  This study has shown how a national informatics platform can be readily utilised to 
evaluate research questions arising from quality improvement interventions.  
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6.10.2. Introduction 
The use of automated reminders via a Clinical Decision Support System (CDSS) has been shown to 
be one of the most consistently successful approaches to encourage clinicians to adopt evidence-
based practice 59.  Whilst a number of studies have demonstrated improvements in clinical 
processes (e.g. adherence to guidelines), there is a lack of evidence for improved clinical outcomes 
60.  The Evidence Based Medicine electronic Decision Support system (EBMeDS) delivers CDSS that 
incorporates contemporaneous recommendations (as opposed to simple summaries of data) 
within the normal work stream.  Interventions of this kind are more likely than other forms of CDSS 
to result in behaviour change 61. 
The long term medical management of diabetes is aimed at maintaining normoglycaemia and 
reducing cardiovascular risk factors, in an effort to reduce the risk of long term complications 
9,168,169.  The risk of microvascular complications (e.g. kidney disease) is greatly reduced by reducing 
instances of hyperglycaemia170 and controlling other cardiovascular risk factors9 .  Screening tests 
are undertaken regularly to detect such complications (e.g. urinary protein to detect kidney 
disease). In the event of a positive screening result, early intervention can halt progress (e.g. ACE 
inhibitors in patients with urinary microalbuminuria). 
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For the purposes of this study, the metrics by which clinical outcomes were assessed reflect 
diabetes control (glycated haemoglobin [HbA1c] as a measure of average blood glucose); risk of 
diabetes-related complications (hyperlipidaemia and hypertension as risk factors for cardiovascular 
disease); and presence of diabetes-related morbidity (microalbuminuria as a measure of kidney 
disease and an indicator of micro-vascular complications).  A variety of CDSS messages are 
displayed for each of these clinical outcomes within the EBMeDS system.  In the absence of a 
recent result, the message prompts health care professionals (HCPs) to offer/suggest the test to 
the patient.  In the presence of an abnormal result, the message suggests possible medical 
interventions.  The chosen thresholds for when a message is displayed and the advice contained 
therein varies according to potential clinical outcome and are based on the national guideline 9.  
For example, it is recommended that urinary albumin/creatinine ratio (UACR) should measured on 
an annual basis in all patients over the age of 12 years – a message is triggered if there is no record 
of this being done within the last 13 months.  If the UACR is raised, then it is recommended that an 
adult with diabetes is commenced on a specific type of antihypertensive drug (ACE inhibitor) – a 
message to this effect is triggered in the presence of a raised UACR and the absence of ACE 
inhibitors being already prescribed. 
6.10.3. Aims 
 To identify a cohort of patients who were the subject of a CDSS prompt (by virtue of their 
HCP opening the patient’s electronic health record during the period of study). 
 To identify appropriate controls from elsewhere in Scotland, matched to cases on the basis 
of age, sex, type and duration of diabetes, BMI and recent clinic attendance. 
 To quantify change in glycaemic control through time for this case group and compare this 
change with the control population. 
 To quantify change in a range of secondary clinical outcomes through time and similarly 
compare cases with controls. 
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6.10.4. Methods 
Data were extracted from those attending the NWH diabetes outpatient clinic and one primary 
care practice within NHS Tayside between 2/12/13 and 1/3/14 inclusive (improvement cycle 1).  In 
addition, data from those attending the SJH diabetes clinic between 18/08/14 and 15/11/14 
(improvement cycle 2) were also included in the analysis.  Cases were defined as those patients 
whose HCP received a CDSS message when their clinical record was opened during the above 
period.    Controls were selected from the SCI-Diabetes Scottish national dataset from geographical 
areas not exposed to the intervention.  Further details on matching procedures are contained in 
the previous chapter (see section 6.9.3). 
The primary outcome was change in HbA1c (mmol/mol).  Secondary outcomes included changes in 
total cholesterol (mmol/l)); systolic blood pressure (SBP, mmHg); diastolic blood pressure (DBP, 
mmHg); and urinary albumin/creatinine ratio (UACR, mg/mmol). Baseline data were taken from the 
last available value for each patient seen during the three months of data capture.  Baseline data 
were considered eligible for inclusion if they were recorded  1 month from the date of the clinical 
record being opened.  This was to ensure that investigations completed prior to, or as a result of 
attending the clinic (e.g. blood tests done in primary care) were included in the analysis.  Follow up 
data were taken as the last available value for each patient within 9-15 months following the data 
of the initial clinical consultation. 
Data validation within SCI-Diabetes ensured that all clinical data entered onto the system by an 
HCP are biologically plausible values.  Similarly, biochemical data extracted from clinical systems 
(via an existing data feed) are subject to strict clinical and information governance practices 
thereby minimising the risk of incorrect values being recorded. 
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6.10.4.1. Statistical analysis 
The change in absolute value was calculated for each dependent variable.  Cases and controls were 
excluded from analysis in the absence of paired data.   Groups were initially compared using 
Student’s t test and Chi Square, as appropriate.  Multivariable analysis was then undertaken, taking 
into account potential confounders, using linear regression.  Variables with significance of p<0.3 on 
initial univariable regression were retained in the final model. 
Statistical power was calculated prior to the study, based on a number of assumptions.  It was 
anticipated that up to 1,200 patients would be seen in the outpatient clinic during the 60 day 
demonstrator period, of which it was assumed that a prompt would be displayed to the HCP in 20% 
of cases (n=240).  Prior to the study, the mean HbA1c for patients in Tayside was 59 mmol/mol 165.  
A 2 mmol/mol reduction in mean HbA1c in cases, with no observed difference in controls at follow 
up would result in the rejection of the null hypothesis that there was no difference between the 
groups with 81% power (assuming SD=10). 
Post hoc comparison between groups was undertaken using Chi Square, assessing the proportion of 
patients with glycaemic control within a target range of 53 mmol/mol (as defined by national 
guidance 9) at baseline and follow up.  Further comparison was made between groups using Cox 
Regression, assessing the proportion of patients in each group moving from above target HbA1c to 
within target HbA1c range. 
6.10.5. Results 
6.10.5.1. Matching 
A CDSS message was generated for 5,692 cases in total (including the 1,883 cases visiting clinic).  Of 
these, 5,245 were successfully matched to two controls.  An additional 187 cases were matched to 
one control, resulting in a total control population of 10,677.  The remaining 260 cases were unable 
to be matched on the defined criteria and so were excluded from analysis. 
There were no significant differences between cases and controls in terms of demographic 
variables.  Similarly, there was no significant difference in HbA1c between cases and controls at 
baseline (71.4mmol/mol (6.5%) vs. 70.6 (6.5%), p=0.086).  Baseline cholesterol, SBP and UACR were 
significantly greater in controls (p<0.001, p<0.001, p=0.028 respectively) and baseline DBP was 
significantly higher in cases (p<0.001) – see Table 33. 
 
6.10.5.2. Data completeness 
Paired baseline-follow up HbA1c values were available for 2,662/5,432 (47%) cases and 
6203/10,677 (58%) controls.  Data were more complete for the sub-group of patients who 
attended clinic during the period of study (n=1,883).  In this group, the majority of cases and 
controls had paired data available for baseline and follow up (937/1116 NWH cases; 558/767 SJH 
cases; 2649/3557 controls).  The least well-captured dependent variable was UACR (539/1116 
NWH cases; 319/767 SJH cases; 1199/3557 controls) – see Figure 35. 
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Figure 35. Data completeness for each dependent variable in those attending clinic (n=1,883).   
Cases and control included in analysis if paired data available and baseline data recorded 1 month of initial clinical 
consultation.  SBP = systolic blood pressure; DBP = diastolic blood pressure; UACR = urinary albumin creatinine ratio. 
6.10.5.3. Clinical outcomes 
Cases were compared with controls at 9-15 months following the initial consultation.  There were 
small improvements observed within the intervention group (NWH and SJH combined) for HbA1c, 
cholesterol, and systolic & diastolic blood pressure – see Table 33.  In contrast, UACR increased in 
both groups.  When compared with controls, the reduction in mean HbA1c was significantly greater 
at follow up (mean change in HbA1c: -2.3 mmol/l vs. -1.1, p=0.002).  The increase in mean UACR 
was less pronounced in cases compared with controls (mean change in UACR: 0.6 vs. 4.6, p=0.025).  
Systolic blood pressure showed significantly greater improvements in the control group (mean 
change in SBP: -1.3 mmHg vs. -3.3, p<0.001).  The difference in change in diastolic blood pressure 
and cholesterol did not reach significance. 
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Table 33.  Univariable comparison of dependent outcomes. 
SBP = systolic blood pressure; DBP = diastolic blood pressure; UACR = urinary albumin creatinine ratio;  SD = standard 
deviation. *UACR presented as median (IQR) with comparison made between mean change in UACR (change in UACR is 
normally distributed). 
 
Cases, mean(SD) Controls, mean (SD) 
Mean difference (95% CI), p 
 
Baseline Follow up Change Baseline Follow up Change 
HbA1c (mmol/mol) 71.4 (19.7) 69.1 (17.9) -2.3 (16.8) 70.6 (19.8) 69.5 (18.2) -1.1 (17.3) -1.2 (-2.0 to -0.4), p=0.002 
Cholesterol (mmol/l) 4.2 (1.1) 4.1 (1.1) -0.1 (0.8) 4.3 (1.1) 4.3 (1.1) -0.05 (0.0) 0.0 (-0.1 to 0.0), p=0.549 
SBP (mmHg) 136.5 (18.5) 135.2 (17.6) -1.3 (19.5) 137.8 (19.9) 134.5 (8.1) -3.3 (20.4) 2.0 (1.0 to 2.9), p<0.001 
DBP (mmHg) 75.7 (10.8) 75.0 (10.6) -0.8 (11.2) 74.5 (12.0) 73.4 (10.9) -1.1 (12.4) 0.4 (-0.2 to 0.9), p=0.244 
UACR* 1.5 (4.5) 1.6 (6.3) 0.0 (2.3) 2.2 (6.7) 2.6 (9.0) 0.2 (3.5) -4.0 (-7.5 to -0.5), p=0.025 
 
Patient group (i.e. case or control) remained a significant predictor of change in HbA1c (p=0.003), 
when adjusted for potential confounders – see Table 34.  Of the potential confounders, increased 
duration of diabetes and lower BMI was associated with significant reductions in HbA1c (p<0.001 
and p=0.022, respectively). 
Table 34.  Linear regression showing predictors of change in HbA1c.   
All univariable predictors significant to p<0.3 entered simultaneously.  B = correlation coefficient; 95% CI = 95% confidence 
interval; BMI = body mass index. 
HbA1c Univariable Multivariable 
 
B CI p B CI p 
Group 1.208 0.429 - 1.987 0.002 1.198 0.418 - 1.978 0.003 
Age 0.012 -0.01 - 0.34 0.277 -0.006 -0.035 - 0.024 0.703 
Diabetes type -0.568 -1.344 - 0.208 0.151 0.499 -0.637 - 1.635 0.389 
Gender -0.286 -1.004 - 0.432 0.435 - 
  
Duration of diabetes 0.112 0.076 - 0.148 <0.001 0.114 0.073 - 0.155 <0.001 
BMI -0.078 -0.133 - -0.024 0.005 -0.069 -0.128 - -0.010 0.022 
 
Change in cholesterol values between the intervention and follow up periods was independent of 
patient group.  Similarly, none of the potential confounders were found to be significant – see 
Table 35. 
.
Table 35.  Linear regression showing predictors of change in cholesterol.   
All univariable predictors significant to p<0.3 entered simultaneously.  B = correlation coefficient; 95% CI = 95% confidence 
interval; BMI = body mass index. 
Cholesterol Univariable Multivariable 
 
B CI p B CI p 
Group 0.016 -0.037 - 0.069 0.549 - 
  
Age 0 -0.002 - 0.001 0.831 - 
  
Diabetes type -0.055 -0.106 - -0.003 0.037 -0.037 -0.095 - 0.020 0.203 
Gender 0.043 -0.003 - 0.090 0.069 0.045 -0.002 - 0.092 0.059 
Duration of diabetes 0.003 0.000 - 0.005 0.027 0.002 0.000 - 0.004 0.102 
BMI -0.002 -0.006 - 0.001 0.232 -0.001 -0.005 - 0.003 0.716 
 
There was an observed decrease in systolic blood pressure that was significantly greater in the 
control group.  This remained highly significant, once adjusted for potential confounders (p<0.001) 
– see Table 36.  Age was the only significant confounder, whereby reductions in SBP were greater 
with increased age (p<0.001).  In contrast, changes in diastolic blood pressure were unrelated to 
patient group or any of the independent variables entered – see Table 37. 
Table 36.  Linear regression showing predictors of change in systolic blood pressure.   
All univariable predictors significant to p<0.3 entered simultaneously.  .  B = correlation coefficient; 95% CI = 95% 
confidence interval; BMI = body mass index. 
SBP Univariable Multivariable 
 
B CI p B CI p 
Group -1.953 -2.184 - -0.503 0.002 -1.987 -2.975 - -1.000 <0.001 
Age -0.066 -0.094 - -0.037 <0.001 -0.07 -0.107 - -0.033 <0.001 
Diabetes type -0.969 -1.933 - -0.005 0.049 0.486 -0.917 - 1.889 0.497 
Gender 0.012 -0.867 - 0.890 0.979 - 
  
Duration of diabetes -0.035 -0.079 - 0.009 0.114 -0.018 -0.069 - 0.032 0.475 
BMI -0.049 -0.118 - 0.020 0.161 -0.058 -0.133 - 0.017 0.127 
 
Table 37.  Linear regression showing predictors of change in diastolic blood pressure.   
All univariable predictors significant to p<0.3 entered simultaneously.  .  B = correlation coefficient; 95% CI = 95% 
confidence interval; BMI = body mass index. 
DBP Univariable Multivariable 
 
B CI p B CI p 
Group -0.757 -1.262 - -0.52 0.244 -0.367 -0.960 - 0.226 0.226 
Age -0.021 -0.807 - 1.354 0.619 - 
  
Diabetes type -0.601 -1.008 - 1.064 0.958 - 
  
Gender -0.228 -1.278 - -0.503 0.396 - 
  
Duration of diabetes 0.026 -0.001 - 0.052 0.055 0.024 -0.003 - 0.051 0.076 
BMI -0.022 -0.063 - 0.019 0.294 -0.02 -0.061 - 0.022 0.359 
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As previously noted, observed increases in urinary ACR were greater in controls compared with 
cases.  This difference remained significant once adjustment was made for potential confounders – 
see Table 38.  None of these potential confounders significantly predicted change in urinary ACR. 
 
Table 38.  Linear regression showing predictors of change in urinary albumin/creatinine ratio.   
All univariable predictors significant to p<0.3 entered simultaneously. B = correlation coefficient; 95% CI = 95% confidence 
interval; BMI = body mass index. 
UACR Univariable Multivariable 
 
B CI p B CI p 
Group 4.003 0.494 – 3.787 0.025 3.931 0.419 – 7.443 0.028 
Age 0.094 0.000-0.187 0.049 0.035 -0.086 – 0.155 0.573 
Diabetes type 2.799 -0.364 – 5.962 0.083 2.516 -1.950 – 6.983 0.269 
Gender 0.854 -1.932 – 3.640 0.548 - - 
 
Duration of diabetes 0.121 -0.021 – 2.64 0.096 0.160 -0.002 – 0.322 0.053 
BMI 0.150 -0.072 – 0.371 0.186 0.101 -0.139 – 0.340 0.409 
6.10.5.4. Cycle one – Ninewells Hospital, Dundee 
In the 9-15 month period following the initial consultation, both mean HbA1c and mean blood 
pressure (systolic and diastolic) reduced slightly in cases and controls – see Table 39.  UACR 
increased in both groups, whilst cholesterol was largely unchanged. 
Table 39. Improvement cycle one - baseline and follow up values for dependent variables, by intervention group. 
SBP = systolic blood pressure; DBP = diastolic blood pressure; UACR = urinary albumin creatinine ratio;  SD = standard 
deviation. *UACR presented as median (IQR) with difference between cases and controls as mean (SD) (change in UACR is 
normally distributed) 
 
Cases Controls 
 
Baseline 
mean(SD) 
Follow up 
mean (SD) 
Mean difference 
(SD) 
Baseline 
mean(SD) 
Follow up mean 
(SD) 
Mean 
difference 
(SD) 
HbA1c (mmol/mol) 72.3 (19) 70.4 (17.2) -1.3 (14.8) 71.7 (19.9) 70.8 (18.9) -0.8 (16.9) 
Cholesterol (mmol/l) 4.1 (1) 4.1 (1) 0 (0.7) 4.4 (1.2) 4.3 (1.1) 0 (0.9) 
SBP (mmHg) 138.4 (19.2) 137.2 (17.6) -1.4 (19.7) 134.4 (19.2) 133.7 (17.9) -2.1 (19.9) 
DBP (mmHg) 75.7 (11.2) 75.7 (10.6) -0.2 (11.2) 74 (11.9) 73.3 (10.9) -0.8 (12.3) 
UACR* (mg/mmol) 1.3 (4.5) 1.3 (6.5) 0.0 (2,1) 2.2 (6.7) 2.5 (8.9) 3.3 (35.0) 
 
There was no statistically significant observed difference between cases and controls for any of the 
dependent variables – see Table 40 to Table 44.  Increased duration of diabetes was associated 
with a significant improvement in HbA1c (Table 40), whilst increasing BMI was associated with a 
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deterioration in UACR (Table 44). 
Table 40. Linear regression showing cycle one predictors of change in HbA1c.   
All univariable predictors significant to p<0.3 entered simultaneously.  B = correlation coefficient; 95% CI = 95% confidence 
interval; BMI = body mass index. 
HbA1c Univariable Multivariable 
  B 95% CI p B 95% CI p 
Group 0.55 -0.76-1.87 0.408  -     
Age (years) 0.03 -0.01-0.07 0.101 0.03 -0.15-0.065 0.218 
Diabetes type 0.16 -1.2-1.53 0.813  -     
Gender 0 -1.29-1.28 0.996  -     
Duration of diabetes (years) 0.08 0.02-0.15 0.013 0.07 0.01-0.14 0.025 
BMI -0.04 -0.14-0.06 0.433  -     
 
Table 41. Linear regression showing cycle one predictors of change in cholesterol.   
All univariable predictors significant to p<0.3 entered simultaneously.  B = correlation coefficient; 95% CI = 95% confidence 
interval; BMI = body mass index. 
Cholesterol Univariable Multivariable 
  B 95% CI p B 95% CI p 
Group -0.04 -0.12-0.04 0.329  -     
Age (years) 0 0-0 0.322  -     
Diabetes type -0.01 -0.09-0.08 0.908  -     
Gender 0.07 -0.01-0.15 0.085 0.07 -0.01-0.15 0.085 
Duration of diabetes (years) 0 0-0.01 0.686  -     
BMI 0 -0.01-0.01 0.882  -     
 
Table 42. Linear regression showing cycle one predictors of change in systolic blood pressure (SBP)   
All univariable predictors significant to p<0.3 entered simultaneously.  B = correlation coefficient; 95% CI = 95% confidence 
interval; BMI = body mass index. 
SBP Univariable Multivariable 
  B 95% CI p B 95% CI p 
Group -0.75 -2.37-0.87 0.363  -     
Age (years) -0.05 -0.09-0 0.067  -     
Diabetes type -1.23 -2.91-0.45 0.151 -0.8 -2.64-1.05 0.398 
Gender 0.01 -1.58-1.59 0.995  -     
Duration of diabetes (years) -0.03 -0.11-0.05 0.458  -     
BMI -0.1 -0.22-0.02 0.114 -0.08 -0.21-0.06 0.277 
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Table 43. Linear regression showing cycle one predictors of change in diastolic blood pressure (DBP).   
All univariable predictors significant to p<0.3 entered simultaneously.  B = correlation coefficient; 95% CI = 95% confidence 
interval; BMI = body mass index. 
DBP Univariable Multivariable 
  B 95% CI p B 95% CI p 
Group -0.58 -1.56-0.39 0.239 -0.61 -1.59-0.36 0.216 
Age (years) 0.02 -0.01-0.05 0.2 0.02 -0.01-0.05 0.257 
Diabetes type -0.2 -1.21-0.8 0.691  -     
Gender 0.02 -0.93-0.97 0.968  -     
Duration of diabetes (years) 0.03 -0.02-0.07 0.274 0.02 -0.03-0.07 0.379 
BMI -0.03 -0.1-0.05 0.458  -     
 
Table 44. Linear regression showing cycle one predictors of change in urinary albumin creatinine ratio (UACR).   
All univariable predictors significant to p<0.3 entered simultaneously.  B = correlation coefficient; 95% CI = 95% confidence 
interval; BMI = body mass index. 
UACR Univariable Multivariable 
  B 95% CI p B 95% CI p 
Group 2.17 -1.64 – 5.97 0.264 2.28 -1.52 – 6.08 0.239 
Age (years) 0.08 -0.05 – 0.21 0.202 0.06 -0.07 – 0.19 0.330 
Diabetes type 1.36 -2.93 – 5.65 0.534 -     
Gender 2.27 -1.58 – 6.12 0.248 2.52  -1.34 – 6.38 0.201 
Duration of diabetes (years) 0.09 -0.10 – 0.29 0.352  - 
  
BMI 0.37 0.08 - -0.67 0.014 0.38  0.08 – 0.68 0.013 
 
6.10.5.5. Cycle two – St John’s Hospital, Livingston 
During the 9-15 months following the initial outpatient appointment, there were small reductions 
in HbA1c in both cases and controls – see Table 45.  Cholesterol remained relatively stable in both 
groups.  Systolic and diastolic BP increased in cases, whilst a decrease was observed in controls.  
UACR increased in both groups, but more so in cases. 
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Table 45. Improvement cycle two - baseline and follow up values for dependent variables, by intervention group.  SBP = 
systolic blood pressure; DBP = diastolic blood pressure; UACR = urinary albumin creatinine ratio;  SD = standard deviation.  
*UACR presented as median (IQR) with difference between cases and controls as mean (SD) (change in UACR is normally 
distributed) 
 
Cases 
 
Controls 
 
 
Baseline 
mean(SD) 
Follow up mean 
(SD) 
Mean 
difference 
(SD) 
Baseline 
mean(SD) 
Follow up 
mean (SD) 
Mean 
difference 
(SD) 
HbA1c (mmol/mol) 68.5 (18.3) 68.2 (17.6) -0.4 (16.4) 71.4 (19.3) 70.4 (18.1) -0.8 (18) 
Cholesterol (mmol/l) 4.4 (1.1) 4.4 (1.1) 0 (0.9) 4.4 (1.1) 4.3 (1.1) -0.1 (0.8) 
SBP (mmHg) 131.1 (17.1) 134.1 (17.3) 2.7 (19.3) 136.5 (19.6) 133.9 (18) -2.2 (20.6) 
DBP (mmHg) 75.3 (10.8) 75.3 (10.3) 0.4 (11) 75.2 (11.4) 73.9 (10.8) -0.8 (12.3) 
UACR* (mg/mmol) 1.7 (4.5) 2.3 (6.2) 0.1 (2.4) 2.4 (8.7) 2.7 (8.5) 6.8 (41.1) 
 
The presence of an EBMeDS prompt was not associated with improvements in any of the 
dependent variables (see Table 46 to Table 50).  The observed decrease in blood pressure within 
the control group was highly significant (see Table 48 and Table 49).  Mirroring cycle one results, 
increased duration of diabetes was associated with improved HbA1c (Table 46) as well as 
worsening UACR (Table 50).  Type 2 diabetes was also significantly associated with worsening 
UACR. 
Table 46. Linear regression showing cycle two predictors of change in HbA1c.   
All univariable predictors significant to p<0.3 entered simultaneously.  B = correlation coefficient; 95% CI = 95% confidence 
interval; BMI = body mass index. 
HbA1c Univariable Multivariable 
  B 95% CI p B 95% CI p 
Group -1.15 -2.93-0.63 0.205 -1.15 -2.94-0.63 0.206 
Age (years) -0.04 -0.1-0.01 0.132 -0.06 -0.13-0.01 0.116 
Diabetes type -1.61 -3.37-0.15 0.072 1.19 -1.4-3.78 0.368 
Gender 0.24 -1.46-1.94 0.78  -     
Duration of diabetes (years) 0.1 0.01-0.18 0.025 0.11 0.01-0.21 0.025 
BMI -0.19 -0.32--0.05 0.006 -1.18 -0.32--0.03 0.019 
 
  
 175 
Table 47. Linear regression showing cycle two predictors of change in cholesterol.   
All univariable predictors significant to p<0.3 entered simultaneously.  B = correlation coefficient; 95% CI = 95% confidence 
interval; BMI = body mass index. 
Cholesterol Univariable Multivariable 
  B 95% CI p B 95% CI p 
Group -0.05 -0.15-0.05 0.325 -     
Age (years) 0 -0.01-0 0.272 0 -0.01-0 0.343 
Diabetes type -0.04 -0.14-0.06 0.413 
-
  
    
Gender 0.04 -0.06-0.13 0.463 -     
Duration of diabetes (years) 0 0-0.01 0.533 -     
BMI 0 -0.01-0 0.294 0 -0.01-0 0.373 
 
Table 48. Linear regression showing cycle two predictors of change in SBP.   
All univariable predictors significant to p<0.3 entered simultaneously. B = correlation coefficient; 95% CI = 95% confidence 
interval; BMI = body mass index. 
SBP Univariable Multivariable 
  B 95% CI p B 95% CI p 
Group -4.93 -7.11--2.76 0 -4.92 -7.1--2.73 <0.001 
Age (years) -0.06 -0.13-0.01 0.087 -0.06 -0.13-0.01 0.076 
Diabetes type 0.32 -1.79-2.44 0.764  -     
Gender 0.42 -1.63-2.48 0.686  -     
Duration of diabetes (years) -0.06 -0.16-0.04 0.238 -0.05 -0.15-0.05 0.312 
BMI -0.02 -0.18-0.14 0.807  -     
 
Table 49. Linear regression showing cycle two predictors of change in DBP.   
All univariable predictors significant to p<0.3 entered simultaneously.  B = correlation coefficient; 95% CI = 95% confidence 
interval; BMI = body mass index. 
DBP Univariable Multivariable 
  B 95% CI p B 95% CI p 
Group -1.28 -2.56-0 0.05 -1.3 -2.58--0.02 0.047 
Age (years) -0.03 -0.07-0.01 0.091 -0.03 -0.07-0.01 0.084 
Diabetes type -0.63 -1.87-0.61 0.317  -     
Gender -0.56 -1.76-0.64 0.36  -     
Duration of diabetes (years) 0.03 -0.03-0.09 0.358  -     
BMI -0.02 -0.12-0.07 0.645  -     
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Table 50. Linear regression showing cycle two predictors of change in UACR.   
All univariable predictors significant to p<0.3 entered simultaneously.  B = correlation coefficient; 95% CI = 95% confidence 
interval; BMI = body mass index. 
UACR Univariable Multivariable 
  B 95% CI p B 95% CI p 
Group 5.82 -0.64 – 12.29 0.077 4.76 -1.55 – 11.07 0.139 
Age (years) 0.11 -1.11 – 0.32 0.326 -     
Diabetes type 6.31 -0.412 – 13.03 0.066 9.16 2.24 – 16.08 0.010 
Gender -2.11 -8.60 – 4.38 0.523  -     
Duration of diabetes (years) 0.41 0.08 – 0.73 0.014 0.55 0.20 – 0.89 0.002 
BMI -0.02 -0.51 – 0.48 0.942  -     
 
6.10.5.6. Post hoc analysis 
Cases from both cycle one and cycle two were considered within the post hoc analysis, which 
compared the proportion of cases and controls moving from above to within target HbA1c 
(53mmol/mol).  There was a slightly greater proportion in the intervention group, but this failed 
to reach significance – see Table 51. 
Table 51.  Proportion of cases and controls with HbA1c above and within target range (53mmol/mol) at baseline and 
follow up. 
HbA1c 
Baseline Follow up 
Cases Controls Cases Controls 
above target 2081 (82.4%) 5014 (81.0%) 20159 (81.5%) 5082 (82.1%) 
within target 446 (17.6%) 1174 (19.0%) 468 (18.5%) 1106 (17.9%) 
Total 2527 6188 2527 6188 
 
Of those cases that had an HbA1c above target at baseline, 208/2,527 (8.2%) moved to within 
target at follow up.  In contrast, 468/6188 (7.6%) controls moved from above to within target 
HbA1c during the period of study.  Multivariable cox regression did not demonstrate any significant 
difference between study groups (B 0.932, 95%CI 0.791-1.099, p=0.404, see Figure 36. 
Those with T2D were 1.3 times more likely than those with T1D to move within the target range 
(95%CI: 1.076-1.606, p=0.007)).  Duration of diabetes was also predictive of moving into the target 
range – the probability decreased by 1.7% for every year of having diabetes (Exp(B) 0.983, 95%CI: 
0.975-0.992, p<0.001).  There was no association between the probability of moving into target 
range and gender or BMI. 
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Figure 36.  Probability of HbA1c moving from above target to within target through time. 
Time=0 is the date the clinical record was opened.  Target HbA1c defined as 53mmol/mol. 
 
6.10.6. Discussion 
The analysis has demonstrated a significant improvement in glycaemic control in the patients for 
whom the HCP received a CDSS message, when compared with matched controls living elsewhere 
in Scotland.  In addition, patients who were subject to a CDSS message showed significantly less 
deterioration in kidney disease when compared to control subjects.  Both patient groups showed 
small decreases in SBP, however the improvement in SBP shown in the control group was 
significantly greater than in the cases.  It is difficult to compare these findings with previous studies 
owing to heterogeneity of interventions.  With regards to diabetes care specifically, most studies 
(included in a systematic review that evaluated computerised prompting of diabetes care) limit 
their analyses to clinical processes (e.g. adherence to guidelines) as opposed to clinical outcomes 
171.  Studies included in this systematic review that did include glycaemic control as an outcome 
measure failed to demonstrate any improvement. 
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It should be acknowledged that the mean improvement in glycaemic control amongst cases is 
probably of little clinical significance.  This is demonstrated by the post hoc analysis that failed to 
demonstrate any significant improvement in the proportion of patients in whom glycaemic control 
could be considered within target.  The chosen target of HbA1c 53mmol/mol was based on 
available national guidance for those with T2D 9 which, in turn, is based on evidence that an HbA1c 
53mmol/mol is associated with improved clinical outcomes 170. 
It is plausible that the lack of deterioration in kidney disease observed in cases could be a direct 
result of the CDSS – many of the messages prompt users to screen for and treat microalbuminuria.  
It is more difficult to provide an explanation for the observed improvements in control group SBP, 
which may be accounted for by one or more of the limitations in this study that will now be 
considered.  
6.10.6.1. Power calculation 
Patient numbers used within the pre-study power calculation were based on data derived from 
outpatient clinic information systems.  In addition, the anticipated CDSS message frequency was a 
rough approximation based on no empirical data. As demonstrated previously (see section 6.8), the 
most frequent users of SCI-Diabetes are nursing staff.  These users often open patient records in a 
non-clinical context e.g. retrospective data entry, audit, telephone queries etc.  In addition, the 
CDSS message frequency was approximately double that expected (39% of all records opened – see 
section 6.8).  All of these factors contributed to far higher patient numbers than were initially 
anticipated, producing results that in some instances are statistically, but not clinically significant.  
Future analyses could limit cases to those whose electronic health record was opened within a 
clinical context e.g. outpatient clinic. 
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6.10.6.2. Selection bias 
Despite the high numbers of cases, this patient group may not be representative of the wider 
diabetes community.  The mean HbA1c for both cases and controls was higher than the regional 
average4  which is unsurprising, given that both groups are attending secondary care clinics (where 
there tends to be more complex disease).  There was also a greater proportion of those with T1D 
compared with the national average4, however age and sex distributions were similar to national 
averages, as was duration of diabetes.  Inclusion relied on clinic attendance, therefore non-
attenders/less engaged patients were less likely to be included due to their records not being 
opened.  The analysis also relied on paired data samples, measured at baseline and follow up.  This 
resulted in significant attrition and further increased the risk of selection bias.  Imputation was not 
considered appropriate, owing to the lack of repeat measures from which to impute. 
6.10.6.3. Study design 
Whilst controls were closely matched to cases by demographic variables, there was no ability to 
match local clinical practice.  Most diabetes centres work to  national guidelines, however it is 
highly likely that there will be variation in practice across the country, thereby limiting the ability to 
infer that the intervention is responsible for observed differences.  Another consideration is the 
matching of cases to controls on demographics alone.  A more sophisticated approach would be to 
also match controls on the dependent outcome at baseline i.e. the controls’ data would have 
triggered the same CDSS message if the system was operating in their locality.  Unfortunately, this 
was not technically feasible. 
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Patients were assigned to being a “case” if the HCP received a CDSS message on opening their 
record.  The subject of that message was not considered in this analysis and may not have been 
related to the primary outcome (e.g. the message may have been a reminder to assess foot risk 
score i.e. unrelated to glycaemic control).  This was a pragmatic decision based on data availability, 
and it is acknowledged that future analyses should address this shortcoming.  This could be 
achieved by including CDSS message relevance to the outcome being considered, as a dichotomous 
independent variable within the multivariable analysis which would delineate the impact of the 
intervention more clearly. 
6.10.6.4. Study implications 
Despite these limitations, it is notable that this study has provided evidence that the CDSS is 
associated with improvements in clinical outcomes – an important finding given the lack of 
evidence in this area 60. Whilst the modest improvement in glycaemic control is thought to be of 
little clinical significance in this study population, there are potential gains to be made at a 
population level.  Small improvements in glycaemic control are associated with considerable long-
term savings due to reduced complications.  For example, if the current UK Type 1 diabetes 
population reduced their HbA1c by 4mmol/mol (0.4%) the estimated saving would be £39m over 5 
years (£995m after 25 years)172. 
Our findings demonstrated a non-significant increase in the proportion of cases with an HbA1c 53 
mmol/mol  - increasing from 17.6% to 19.0%.  If this improvement were replicated at a national 
level (276,430 people diagnosed with diabetes in Scotland 4), this could potentially account for 
nearly 4,000 individuals reducing their HbA1c to 53 mmol/mol.  An HbA1c within this range is 
associated with a 35-76% decrease in microvascular complications compared to those with poorer 
glycaemic control (median HbA1c 74 mmol/mol) at long term follow up 170. 
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The lack of progression in kidney disease (as measured by UACR) amongst cases compared to 
controls is also worth noting.  Approximately three quarters of patients with diabetes in England & 
Wales have some form of chronic kidney disease (CKD), the vast majority of whom have early onset 
disease (CKD stages 1-2) 173.  Treatment with ACE inhibitors can not only prevent microalbuminuria 
from progressing to macroalbuminuria, but can also induce regression to no albuminuria 174.  CKD is 
a risk factor for cardiovascular disease (CVD) and people with CKD are more likely to die of CVD 
than end stage renal failure 175.  Therefore, any reduction in incidence or progression of CKD has 
the potential to not only improve morbidity but also to reduce all cause mortality for a substantial 
proportion of people with diabetes. 
With regards to other cardiovascular risk factors, it is notable that whilst both cases and controls 
demonstrated a reduction in systolic blood pressure, this decrease was significantly greater in 
controls.  Again, is arguable that the magnitude of the observed reduction is such that this is 
probably of little clinical significance at an individual level.  However, at a population level, small 
reductions in mean blood pressure can result in large improvements in the risk of an adverse 
cardiovascular event 176.  It is unclear as to why such a difference was observed and the study 
methodology does not allow for this question to be answered.  Blood pressure was chosen as a 
secondary outcome as many of the CDSS messages are concerned with the initiation of blood 
pressure lowering therapy.  At the very least, it could be argued that these messages have had little 
effect in changing user behaviour and that the observed differences are a result of variation in local 
practice.  Perhaps more importantly, consideration should be given to the possibility that the CDSS 
is having an adverse effect on user behaviour e.g. the multiple messages displayed by the CDSS 
may distract a user from their normal clinical practice, resulting in a lack of attention being paid to 
management of hypertension.  Whilst it is acknowledged that the existing system is associated with 
a degree of user fatigue (see sections 6.6 and 6.7), questionnaire respondents and focus group 
contributors did not report any adverse effects.   
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Further work is required in this area.  The analysis above was unable to take account of message 
contents.  It is therefore not known if the observed difference in Systolic BP can be attributed to 
the contents of the message per se.  There is scope to consider message contents and the other 
potential distractors (i.e. additional messages) in the analysis of clinical outcomes, and it could be 
argued that this is essential from a quality assurance and safety perspective. 
6.10.7. Conclusion 
The study has demonstrated a small improvement in glycaemic control and a decrease in 
progression of kidney disease when compared to a closely matched control population.  The 
limitations of the study preclude any causal inference and the observed differences are of limited 
clinical significance (but may have implications at the population level).  This study has shown how 
a national informatics platform can be readily utilised to evaluate research questions arising from 
quality improvement interventions. 
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6.11 Summary of EBMeDS project findings 
The use of the EBMeDS system had no adverse effects on patient experience, clinic consultation or 
working practices.  Quantification of system usage supports users’ assertion that the system 
encourages more efficient working practices.  For clinical processes, the odds of a patient receiving 
an appropriate screening investigation following a clinic appointment were significantly raised.  With 
regards to clinical outcomes, the presence of an EBMeDS message was associated with small 
improvements in glycaemic control.    
6.11.1. Implications 
Aside from the health benefits afforded by early intervention, there are considerable potential 
economic savings.  This is explored in greater depth using foot screening as an example. 
Diabetes-related foot complications currently account for nearly £1 billion per year of UK healthcare 
spending8.  In Scotland, approximately one quarter of patients with diabetes (n70,000) have not 
received foot screening in the past 15 months4. If the observed improvement in screening were 
extrapolated to the whole country, an additional 15,000 patients would receive foot screening every 
year.  Screening for foot disease reduces the risk of ulceration by approximately a third177.  Taking 
into account the current prevalence of foot disease, 750 of this 15,000 cohort are at risk of 
developing ulceration in the absence of screening.  Screening could therefore prevent ~250 episodes 
of ulceration per year.  Assuming that patients with ulceration require at least one admission to 
hospital per year178, this represents an annual saving of ~£500k per year.  Those with a history of 
ulceration are also at high-risk of future amputation.  For each high-risk patient identified and 
effectively managed, it is estimated that ~£1000-1500 is saved per year179.  Taking into account the 
above assumptions, if the system was available on a national basis it is estimated that an additional 
~500 high-risk patients would be identified per annum.  Effective management of this cohort would 
therefore save an additional £500k-£750k per year i.e. a potential total saving of £1m per year for 
NHS Scotland. 
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Similar magnitudes of improvement were observed in screening for kidney disease and serum 
cholesterol.  Extrapolated to the Scottish population, this would result in an additional ~15,000 
patients having UACR checked and ~4,000 individuals having serum creatinine and cholesterol 
measured annually, increasing the potential for early intervention to prevent costly cardiovascular 
events and renal disease. 
Despite the observed modest improvements in glycaemic control it is worth noting that even small 
improvements in glycaemic control are associated with considerable long-term savings due to 
reduced complications.  For example, if the current UK Type 1 diabetes population reduced their 
HbA1c by 4mmol/mol (0.4%) the estimated saving is £39m over 5 years (£995m after 25 years)180. 
6.11.2. Risks 
Just as small improvements in glycaemic control can improve long term outcomes, so too can small 
reductions in blood pressure result in improved cardiovascular outcomes.  In one randomised 
controlled trial conducted over a period of 4 years, there was a twofold increase in risk of a major 
cardiovascular event in those assigned to a diastolic BP of less than 90mmHg versus the group 
assigned to less than 80mmHg, despite relatively small differences in the observed BP (mean 
achieved BP 85mmHG versus 81mmHg)176.  In this study, the control population systolic BP improved 
significantly more than cases (see section 6.10).  Given the long-term effects of such an 
improvement, this observed difference should not simply be attributed to methodological weakness 
– further investigation is required. 
This study did not demonstrate any adverse effects on patient satisfaction, as measured by PREMs 
(see section 6.5).  It is acknowledged that this analysis was conducted on a sub-population of 
respondents and that in order to satisfy the initial power calculation, further analysis is required.  In 
general, the impact of computer use and electronic medical records on the doctor-patient 
relationship remains a much debated phenomenon 129.  Whilst some studies have demonstrated an 
adverse effect on the clinical encounter (e.g. decreased patient-centredness), the evidence also 
 185 
points to improvements in the consultation (e.g. communication of information and patient 
reported satisfaction) 129,181 
More broadly, consideration should also be given to both the regulatory framework within which 
CDSS is developed, as well as the legal liabilities of developers and users of such systems.  According 
to MHRA definitions, CDSS is considered a medical device and is therefore subject to the same 
oversight as any other physical device 95.  What is less clear is who is liable for such devices if (and no 
doubt when) they go wrong.  There are three main stakeholders in the successful implementation 
and use of a CDSS – software developers; purchasing organisations who implement the system; and 
health care practitioners who use the system 182.  Fox et al note there is an absence of case law 
precedent in the UK, but that it is reasonable to assume that developers of CDSS have a legal duty of 
care to the users of such systems 183.  Accordingly, it is incumbent on developers to develop CDSS in 
accordance with appropriate quality and safety protocols and to risk assess each constituent part of 
the system 183.  Risk management of such systems rely on a trade off between maximising safety and 
minimising additional use of finite resources, with the aim to achieve a risk that is “as low as is 
reasonably practical” 183.  Quality assurance is recommended at all stages of a product’s life cycle, 
but until recently, there had been little practical guidance as to how best to achieve this 184. The 
GUIDES project has convened a panel of internationally sourced experts, and aims to address this 
shortfall this by providing explicit advice on the development and implementation of CDSS via a 
checklist of essential considerations (contributing author - article in press) 185. 
6.11.3. Benefits 
6.11.3.1. Academic 
This study demonstrated improved HCP adherence to guideline-driven care and directly contributes 
to the evidence base for CDSS in general.  To date, the work has been presented at national and 
international conferences, and has been accepted for publication by peer-reviewed journals.  The 
project has been selected as a finalist for the 2016 Quality in Care, Diabetes awards 186. 
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It is envisaged that the system will be adapted to provide tailored decision support for patients, 
delivered through the patient portal, mydiabetesmyway187,188.  This will include decision support 
based on self-monitored blood glucose uploaded from home.  Future research will aim to identify 
the role of tailoring of messages to individuals, by taking account of medical co-morbidities, health 
literacy and levels of engagement with the service 
6.11.3.2. Civic 
This project was a collaboration between Duodecim, NES and the Digital Health & Care Institute 
(DHI)1, which funded the project.  Further funding from DHI has been established to define the 
system architecture necessary to integrate with existing primary care systems and to provide 
patient-directed decision support.  There is widespread awareness and clinical support through the 
Scottish Diabetes Group and Diabetes Managed Clinical Networks throughout Scotland.  
The CDSS in its current form prompts HCPs to consider screening for complications as well as 
optimisation of current management.  These evidence-based, early interventions can significantly 
impact on costly and devastating complications such as foot ulcers, amputations, cardiovascular 
disease, renal failure and death. 
There may also be potential efficiencies and wider cost savings by decision prompts which negate 
the need for wider interrogation of the medical record.  Not only does the study add to the 
evidence-base for CDSS, it serves as an exemplar for decision support across healthcare systems in 
Scotland, including primary care 189.  Therefore, the potential benefits of this project extend beyond 
the Scottish diabetes population, as NHS Scotland considers how best to realise the full potential of 
CDSS described in the national eHealth strategy 57. 
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6.11.3.3. Business 
The CDSS is an example of a “system-agnostic” tool, which can be integrated into any EHR. System 
behaviour is dictated by administrators and advice is customisable to local context.  The various 
algorithms that have been developed locally can be implemented into any CDSS, making 
commercialisation of the system a realistic prospect. 
The SCI-diabetes project has been instrumental in guiding the Scottish government in assessing the 
benefits of decision support and is driving the wider use of CDSS across national healthcare systems 
189.  Long term funding and wider procurement of decision support systems across NHS Scotland are 
currently being secured with Scottish Government support 190. 
The diabetes digital landscape continues to evolve at a rapid pace. Scotland’s national informatics 
platform for diabetes ensures that widespread implementation is technically straightforward. This 
work could easily be adapted in other areas of the UK and beyond. This project can be viewed as an 
exemplar of good practice for other healthcare organisations considering such innovations, 
potentially improving the safety, quality and standardisation of diabetes care. 
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7. Overall discussion 
7.1 Summary of Findings 
The overarching aims of this investigation were to: 
1. Determine the effectiveness of eHealth interventions designed to improve the management 
of chronic diseases by providing tailored information to health care practitioners, patients 
and/or carers 
2. Describe the implementation and evaluation of a clinical decision support system (CDSS) 
within an electronic health record for those with diabetes 
The investigation found that: 
1. Information provided to individuals in a tailored way through traditional media is more 
effective at effecting behaviour change than generic information.  However, there is a lack of 
evidence to suggest that similar tailoring of information within eHealth systems provides 
added benefit. 
2. The CDSS that was successfully implemented within the SCI-Diabetes electronic health 
record was well received by staff, with no adverse effects on the clinical consultation.  The 
system was associated with greatly improved adherence to guidelines.  There were modest 
improvements in some clinical outcomes, of limited clinical significance. 
7.2 Strengths of the investigation 
The investigation has provided a wealth of evidence to support the assertion that decision support 
can improve clinical care, by demonstrating large improvements in adherence to clinical guidelines 
and significant improvements in clinical outcomes.  As previously discussed (see section 6.11), 
extrapolating these findings to a national level highlights the potential for the prevention of 
diabetes-related complications in a sizable proportion of the diabetes population.  The investigation 
has also identified research questions that remain unanswered, and has highlighted the need for a 
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rigorous approach to governance and quality assurance when developing and implementing any 
system that has implications for patient safety. 
The investigation has benefitted from a multi-faceted approach, utilising both quantitative and 
qualitative methodologies.  This is borne out in the findings of the main body of the work - the 
implementation and evaluation of the CDSS.  The use of a theoretical framework for evaluation 
ensured that these methods (and the wealth of data that they generated) created a rich picture of 
how people interact with the system and the effects that this has on patient management.  The 
system was implemented at a population level (in more than one health board), thereby further 
adding to the sheer volume of data that were successfully exploited for the purposes of assessing 
efficacy. 
The collaboration with private industry and national governmental agencies has ensured that the 
project remained achievable and relevant to the national context.  As the study draws to a close, the 
reported results have contributed to on going government support of CDSS within diabetes care.  
Furthermore, the investigation is serving as an exemplar for decision support more widely within 
NHS Scotland. 
7.3 Weaknesses of the investigations 
The systematic review was conducted prior to the CDSS being fully developed and implemented.  At 
its inception, the research question posed by the systematic review was designed to inform CDSS 
development.  It was envisaged that the CDSS that was developed would have provided tailored 
information to the recipient.  However, owing to the lack of evidence demonstrated by the 
systematic review, a pragmatic decision was made to limit the scope of the CDSS to providing non-
tailored messages.  This could be viewed as a missed opportunity to add to the evidence base in this 
area, but can be justified in terms of ensuring that the project was achievable within the given 
constraints. 
The CDSS system can be adapted to provide tailored advice based on user role (e.g. doctor, nurse 
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etc.) and can also be adapted to provide patient advice via the MyDiabetesMyWay patient portal.  It 
is therefore conceivable that future work can address the question as to whether or not tailoring 
provides added benefit. 
Whilst the collaboration with multiple agencies added value to the investigation, the logistics of 
project management were sometimes made more difficult.  Different partners had differing 
priorities with regards to their involvement in developing and evaluating the CDSS, and these 
priorities often shifted throughout the course of the investigation.  The various agencies were often 
limited in terms of resources and time, with a knock-on effect on the project timeline.  For example, 
recruitment to focus groups was limited by staff availability; data acquisition was delayed owing to 
lack of resource etc.  Nevertheless, the completion of the investigation represents an example of 
successful cross-sector working that positively impacted upon patient care. 
There are various methodological weaknesses noted throughout the investigation, discussed within 
the appropriate chapters.  Whilst these methodological weaknesses limit both inference and 
generalisability of the findings, it is difficult to envisage how they could be avoided.  This service 
improvement project was conducted within a real-life working clinical environment with limited 
resources, as opposed to a fully funded, carefully controlled, multicentre trial.  From a personal 
perspective, this work will directly inform future study design in this area, in order to address these 
weaknesses. 
7.4 Issues for further research 
7.4.1. Turning data into information 
The scope for developing and improving the CDSS is huge.  It is technically possible to make the 
system available to the whole of NHS Scotland, with immediate effect.  Before doing so, 
consideration must be given to the governance and quality assurance of the system.  This 
investigation did not identify any safety concerns nor any negative impact on patient experience.  
However, it did demonstrate a significant improvement in systolic blood pressure when controls 
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were compared with cases.  The chosen methods did not allow further investigation of this 
observation and future work should delineate whether the system had a causative role (see section 
6.10.6.4 for further discussion).  Furthermore, it could be argued that oversight of the system should 
embed quality improvement methods, whereby automated reports could be used to identify 
unforeseen adverse impacts on clinical processes and outcomes. 
National roll out of the system will no doubt result in additional user feedback, with the possibility of 
the need to develop additional rule-based algorithms in response to this.  In addition, the algorithms 
will need to be continually updated as new evidence and guidelines emerge.  This could potentially 
reduce the observed delay in translating new evidence into everyday practice 191.  
Ultimately, the aim would be to develop algorithms that cross reference different guidelines 
simultaneously.  Given the prevalence of multi-morbidity in the diabetes population, this would 
seem to be an area where the CDSS has greatest relevance 55.  The CDSS could also potentially be 
adapted to other chronic illness for integration within the relevant electronic health record.   
Each of the iterations described above represents an opportunity to test whether clinical care and 
outcomes improve as a result.  Prospective trials, using cluster randomisation of geographical areas 
would overcome many of the methodological weaknesses identified within the current study. 
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Clinical decision-making by HCPs is a complex process that has been the subject of much research 
192.   For example, diagnostic reasoning requires the clinician to formulate a list of differential 
diagnoses.  When doing so, the clinician must first use the available clinical data to form a hypothesis 
(via a process of abstraction and abduction) then test that hypothesis (via deduction and inductive 
reasoning).  Hypothesis testing relies on the clinician using a combination of working memory and 
long-term memory.  The clinicians’ long-term memory can be viewed as a biomedical repository that 
is stored in an ontological manner.  As experience grows, pattern recognition ensures the system 
becomes more efficient, resulting in differing cognitive processes being employed by experts and 
non-experts in any given specialty 192.  Just as the cognitive processes employed by experts and non-
experts differ when making clinical decisions, so too does the way in which they utilise clinical 
guidelines.  Whilst the former tend to use the guidance as an aide memoir, the latter use guidelines 
to fill gaps in their own knowledge base 193. 
Given the complexity of human clinical reasoning, it is perhaps unsurprising that CDSS in general 
(including that which was developed in this study) do not attempt to replicate this approach.  
Instead, the CDSS will typically consist of a decision tree (based on a pre-existing clinical guideline) 
which employs Boolean logic to convert clinical data into a suggested outcome 61.   However, this 
simplistic approach fails to take into account the vast number of data points relevant to the 
individual patient that are stored within the electronic health record (as well as other data silos) – 
data that is stored in both structured (i.e. coded) and unstructured (e.g. free text) formats.  In 
addition, the increasing use of biomedical sensors within wearable technology (e.g. fitness devices) 
represents additional opportunity to mine data for useful information 194,195. 
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The increased prevalence of multi-morbidity presents a challenge to clinicians, whereby they must 
navigate several clinical guidelines in order to make informed decisions 55.  Added to which, the 
clinician is increasingly being asked to consider genomic and other lab-based data as diagnostic 
procedures become increasingly sophisticated and personalised.   A CDSS that relies primarily on 
Boolean logic within a decision tree will soon become unfeasibly complex as the programmer tries to 
take account of the multiple disease combinations and permutations that any given patient may be 
experiencing.  Instead, consideration must be given to the use of artificial intelligence (AI) as a 
means to process such volumes of data. 
Machine learning is a form of AI that enables computer systems to learn to perform tasks from data 
as opposed to relying on specific programmes.  In recent years, machine learning has been 
increasingly used within medical research and care.  For example, the Cochrane library are 
developing machine learning techniques to construct search strategies 196.  There are also a number 
of disease-specific instances where machine learning has been employed to provide decision 
support 197.  To date, there are very few instances where AI has been used in order to improve care 
to those with multimorbidity 198.  Ultimately, an AI system should be capable of processing both 
structured and unstructured data to arrive at clinically relevant and informative decisions.  
Significant advances have already been made in this area, however these remain largely 
experimental 199.  Just as “Moore’s law” predicted the exponential rise in computing processing 
power 200, so too is it likely that the scope and complexity of CDSS will increase in the coming years.  
Machine learning may well provide a means to realise this, and should be explored within future 
clinical research. 
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7.4.2. Turning information into action 
In addition to considering how the CDSS can be optimised in terms of data usage and processing, it is 
clear that additional work is required in deciding how the resultant information is best 
communicated to service users.  This investigation has demonstrated that within eHealth 
interventions, there is a lack of evidence for tailoring of eHealth information to user group.  In 
addition, this study has demonstrated a mismatch between the scope of existing diabetes-related 
mHealth apps and the priorities of the user. 
The CDSS that was developed has the capability to provide a degree of tailoring to user group, be it 
professional role or patient.  In effect, the clinical advice that is provided can be configured to be 
more relevant to the user e.g. medication advice to prescribers; screening advice for primary care 
etc.  For patients, tailored advice can be delivered via the MyDiabetesMyWay patient portal, thereby 
empowering the “expert patient” to share in decision making with their clinician.   
However, any such intervention is complicated by the need to consider how best to convey these 
messages so that they have maximum impact.  Diabetes outcomes are poorer in those with lower 
health literacy 201,202, yet there is a lack of understanding as to how best to address this inequality203.  
Given that decision support messages have the potential to convey relatively abstract concepts (e.g. 
perception of risk), it is imperative that any future developments consider the role of health literacy 
when tailoring messages to patients (and HCPs). 
Similarly, when developing mHealth apps (regardless of whether or not they incorporate an element 
of decision support), consideration must be given to users’ literacy levels, in addition to stakeholder 
opinion.  Failure to do so would only serve to widen the health inequality gap further 204.  Each of 
these potential developments offers a multitude of research opportunities from the qualitative work 
required in developing content and evaluating acceptability, to the quantitative assessment of how 
such changes can impact upon clinical outcomes.  
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10. Appendix: Systematic review - exact search strings and results
 Search ran on 9th May 2014 
<chronic disease terms> Results 
1 exp long-term care/ 970678 
2 exp chronic disease/ 367248 
3 (continuity adj3 care).tw. 10514 
4 (long adj term).tw. or chronic.tw. 2804248 
5 exp diabetes mellitus/ 899426 
6 exp hypertension/ 694011 
7 exp asthma/ 292761 
8 exp pulmonary disease chronic obstructive/ or 
(chronic adj2 obstructive adj2 pulmonary).tw. 
122429 
9 exp thyroid diseases/ 290518 
10 exp hyperlipidemia/ 164759 
11 exp arthritis rheumatoid/ 239948 
12 exp mental disorders/ 2473309 
13 exp substance-related disorders or exp substance 
abuse/ 
472702 
14 exp hiv infections/ 527209 
15 or/1-14 8184509 
<methodology terms> 
16 randomized controlled trial.pt. 372741 
17 controlled clinical trial.pt. 88283 
18 randomized controlled trials/ 143696 
19 random allocation/ 142234 
20 random assignment/ 0 
21 comparative study/ 2306285 
22 exp evaluation studies/ 197553 
23 intervention studies/ 25984 
24 follow-up studies/ 1284534 
25 prospective studies/ 613217 
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26 (randomised or randomized).tw. 832198 
27 (random$ adj1 (allocat$ or assign$)).tw. 191822 
28 (control$ or prospectiv$ or volunteer$).tw. 6517515 
29 experiment$.tw. 2849094 
30 (time adj series).tw. 31318 
31 ((pre adj test) or pretest or (post adj test) or 
posttest).tw. 
34916 
32 or/16-31 11821519 
 <eHealth terms>  
33 exp Telemedicine/ 34575 
34 (telemedicine OR telehealth).tw. 15255 
35 exp computer communication networks/ 75077 
36 (ict or information communication technolog$).tw. 5865 
37 exp Medical Informatics/ 334389 
38 (digital OR technol$ OR online OR tele$ OR ehealth 
OR e-health OR mhealth OR m-health OR computer$ 
OR cloud OR (web ADJ site$) OR (web site$) OR 
internet).tw 
1450716 
39 Patient Identification Systems/ 7738 
40 (blog$ or weblog$ or web-log$).tw. 1745 
41 (bulletin board$ or bulletinboard$ or 
messageboard$ or message board$ or forum$).tw. 
23032 
42 OR/33-41 1765310 
 <health record terms>  
43 exp Medical Records/ 223046 
44 exp Nursing Records/ 143949 
45 exp Hospital Records/ 140812 
46 ((medical OR health) AND Record$).tw. 322918 
47 (case ADJ (note$ OR Record$)).tw 30879 
48 (log-book$ OR logbook$).tw 2095 
49 (personal ADJ3 health ADJ3 record).tw 675 
50 (passport$ OR kiosk$ OR portal$).tw 136970 
51 OR/43-50 637032 
 <communication terms>  
52 exp computer literacy/ 6065 
53 exp information literacy/ 1809 
54 exp access to information/ 17586 
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55 exp information dissemination/ 23788 
56 exp Information storage and retrieval/ 328 
57 exp Information services/ 877443 
58 exp health communication/ 51670 
59 (tailor$ adj4 (messag$)).tw. 606 
60 (Information adj4 (need$ or seek$ or us$ or util$ or 
literac$)).tw. 
223643 
61 communicat$.tw. 375054 
62 exp user-computer interface/ 48968 
63 exp attitude to computers/ 6387 
64 OR/52-63 1569294 
 <user groups terms>  
65 Caregivers/ 60200 
66 exp disabled persons/ 71277 
67 exp patients/ 1291601 
68 (Patient$ or consumer$ or carer$ or caregiver$ or 
lay$).mp 
11746992 
69 exp health personnel/ 1271329 
70 or/65-69 12545531 
 <combinations>  
71 AND/15,32,42,51,64,70 1073 
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11. Appendix: Systematic review - characteristics of the interventions. 
Means and proportions are approximations only, based on published data. 
Avery 121  
Design RCT 
Follow up of professionals Done 
Follow up of patients or episodes of care Done 
Blinded assessment of primary outcome(s) Done 
Baseline measurement Done 
Reliable primary outcome measure(s) Done 
Power calculation Done 
Concealment of allocation Not done 
Protection against contamination Not done 
Profession group Physicians, Pharmacists 
Patients - number Not clear 
Patients - age (mean(yrs)) Not clear 
Patients - gender (% female) Not clear 
Patients - predominant ethnic group (%) Not clear 
Total number of intervention groups 1 
Type of targeted behaviour Prescribing 
Control groups used standard practice plus verbal feedback 
type of intervention Professional 
intervention sub category educational outreach visits 
intervention further details Pharmacist led information technology complex 
intervention 
Primary outcome Adverse drug event 
Health professional outcomes/process 
measures 
Not done 
Patient outcomes number of drug-related adverse events 
 
Boukhors 101  
Design RCT 
Follow up of professionals Not clear 
Follow up of patients or episodes of care Not clear 
Blinded assessment of primary outcome(s) Not clear 
Baseline measurement Done 
 216 
Reliable primary outcome measure(s) Done 
Power calculation Done 
Concealment of allocation Not clear 
Protection against contamination Not clear 
Profession group Physicians 
Patients - number 10 
Patients - age (mean(yrs)) 39 
Patients - gender (% female) not clear 
Patients - predominant ethnic group (%) not clear 
Total number of intervention groups 1 
Type of targeted behaviour General management of a problem, Patient 
education/advice, Professional-patient 
communication, Record keeping 
Control groups used cross over trial - normal care as control 
type of intervention Professional 
intervention sub category patient mediated 
Audit and feedback 
intervention further details Patient mediated - SMBG levels 
Audit and feedback – automated advice based on 
glucose readings 
Primary outcome clinical outcome 
Health professional outcomes/process 
measures 
Not done 
Patient outcomes primary outcome - number of hypoglycaemic 
events 
secondary outcomes - number of hypers, 
glycaemic control, behaviour and knowledge 
change, change in insulin doses 
 
Cafazzo 102  
Design ITS 
Follow up of professionals NA 
Follow up of patients or episodes of care NA 
Blinded assessment of primary outcome(s) NA 
Baseline measurement NA 
Reliable primary outcome measure(s) NA 
Power calculation Not done 
Concealment of allocation NA 
Protection against contamination NA 
 217 
Profession group Physicians 
Patients - number 12 
Patients - age (mean(yrs)) 15 
Patients - gender (% female) 50% 
Patients - predominant ethnic group (%) NOT CLEAR 
Total number of intervention groups 1 
Type of targeted behaviour Patient education/advice, Professional-patient 
communication, Record keeping 
Control groups used NA 
type of intervention Organisational 
intervention sub category Patient orientated intervention 
intervention further details mHealth app providing tailored communication 
Primary outcome Self care 
Health professional outcomes/process 
measures 
Not done 
Patient outcomes primary - number of blood glucose tests 
secondary - HbA1c 
 
Carroll 103  
Design RCT 
Follow up of professionals Not clear 
Follow up of patients or episodes of care Not clear 
Blinded assessment of primary outcome(s) Not done 
Baseline measurement Not done 
Reliable primary outcome measure(s) Done 
Power calculation Done 
Concealment of allocation Not clear 
Protection against contamination Not clear 
Profession group Physicians 
Patients - number 3520 
Patients - age (mean(yrs)) Not clear 
Patients - gender (% female) 100% 
Patients - predominant ethnic group (%) Hispanic (40%) 
Total number of intervention groups 2 
Type of targeted behaviour Diagnosis, Referrals, Patient education/advice 
Control groups used Generic information 
type of intervention Professional 
 218 
intervention sub category Distribution of educational materials 
Patient mediated interventions 
intervention further details Group 1: Recommendation to refer to psychiatry 
based on depression score plus patient education. 
Group 2: Recommendation to refer to psychiatry 
based on depression score only. 
Primary outcome Not stated 
Health professional outcomes/process 
measures 
Number of mothers referred for psychiatric 
assessment 
Patient outcomes Number of mothers identified as having 
depressive symptoms 
 
Cruz-correia 117  
Design RCT 
Follow up of professionals Not clear 
Follow up of patients or episodes of care Not clear 
Blinded assessment of primary outcome(s) Not clear 
Baseline measurement Done 
Reliable primary outcome measure(s) Done 
Power calculation Not done 
Concealment of allocation Not done 
Protection against contamination Not done 
Profession group Physicians 
Patients - number 21 
Patients - age (mean(yrs)) 29 
Patients - gender (% female) 71% 
Patients - predominant ethnic group (%) Not clear 
Total number of intervention groups 1 
Type of targeted behaviour Patient education/advice 
Professional-patient communication 
Control groups used cross over trial with paper system 
type of intervention Professional 
intervention sub category patient mediated interventions 
intervention further details asthma self monitoring - data upload and analysis 
Primary outcome Not stated 
Health professional outcomes/process 
measures 
Not done 
Patient outcomes patient satisfaction 
patient adherence to recommended monitoring 
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Epstein 104  
Design RCT 
Follow up of professionals Not clear 
Follow up of patients or episodes of care Not clear 
Blinded assessment of primary outcome(s) Not clear 
Baseline measurement Done 
Reliable primary outcome measure(s) Done 
Power calculation Not done 
Concealment of allocation Not done 
Protection against contamination Not clear 
Profession group Physicians 
Patients - number 238 
Patients - age (mean(yrs)) not clear 
Patients - gender (% female) not clear 
Patients - predominant ethnic group (%) not clear 
Total number of intervention groups 1 
Type of targeted behaviour Diagnosis 
Control groups used No intervention control group 
type of intervention Professional 
intervention sub category Educational outreach  
Educational materials 
intervention further details Internet based educational programme plus face-
face didactic teaching/workshop 
Primary outcome Adherence - guidelines 
Health professional outcomes/process 
measures 
Proportion using recommended diagnostic tools at 
follow up 
Patient outcomes Not done 
 
Field 105  
Design RCT 
Follow up of professionals Not done 
Follow up of patients or episodes of care Done 
Blinded assessment of primary outcome(s) Done 
Baseline measurement Not done 
Reliable primary outcome measure(s) Done 
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Power calculation Not done 
Concealment of allocation Not done 
Protection against contamination Not done 
Profession group Physicians 
Patients - number 833 
Patients - age (mean(yrs)) 86 
Patients - gender (% female) 68% 
Patients - predominant ethnic group (%) NOT CLEAR 
Total number of intervention groups 1 
Type of targeted behaviour Prescribing 
Control groups used No intervention control group 
type of intervention Professional 
intervention sub category Reminders 
intervention further details Clinical alert displayed when prescribing 
medication, based on patient's calculated 
creatinine clearance. 
Primary outcome Adverse drug event 
Health professional outcomes/process 
measures 
Alert rate  
Type of alert - incorrect dose, incorrect frequency, 
drug should be avoided, incomplete information 
(creatinine) 
Patient outcomes Not done 
 
Fossum 122  
Design CCT 
Follow up of professionals Not clear 
Follow up of patients or episodes of care Done 
Blinded assessment of primary outcome(s) Not clear 
Baseline measurement Done 
Reliable primary outcome measure(s) Done 
Power calculation Done 
Concealment of allocation Not clear 
Protection against contamination Not clear 
Profession group Nurses 
Patients - number 491 
Patients - age (mean(yrs)) 85 
Patients - gender (% female) 75% 
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Patients - predominant ethnic group (%) NOT CLEAR 
Total number of intervention groups 2 
Type of targeted behaviour Clinical prevention services, Diagnosis 
Control groups used Standard practice control group 
type of intervention Professional 
intervention sub category Educational 
Reminders 
intervention further details Intervention 1 - CDSS within EHR plus educational 
meeting/info Intervention 2 - educational 
meeting/info only 
Primary outcome Not stated 
Health professional outcomes/process 
measures 
Not done 
Patient outcomes Proportion of patients: with malnourishment, at 
risk of malnourishment, with PU and at risk of PU 
 
Gurwitz 106  
Design RCT 
Follow up of professionals Not done 
Follow up of patients or episodes of care Not clear 
Blinded assessment of primary outcome(s) Done 
Baseline measurement Done 
Reliable primary outcome measure(s) Done 
Power calculation Done 
Concealment of allocation Not done 
Protection against contamination Not done 
Profession group Physicians, Nurses 
Patients - number 1118 
Patients - age (mean(yrs)) 87 
Patients - gender (% female) 1 
Patients - predominant ethnic group (%) Not clear 
Total number of intervention groups 1 
Type of targeted behaviour Prescribing 
Control groups used Standard practice control group 
type of intervention Professional 
intervention sub category Reminders 
intervention further details prescribing, electronic 
 222 
Primary outcome Adverse drug event 
Health professional outcomes/process 
measures 
Not done 
Patient outcomes number of drug-related adverse events 
 
Jones 123  
Design ITS 
Follow up of professionals NA 
Follow up of patients or episodes of care NA 
Blinded assessment of primary outcome(s) NA 
Baseline measurement NA 
Reliable primary outcome measure(s) NA 
Power calculation Done 
Concealment of allocation NA 
Protection against contamination NA 
Profession group Physicians, Nurses 
Patients - number 1481 
Patients - age (mean(yrs)) 65 
Patients - gender (% female) 47% 
Patients - predominant ethnic group (%) Not clear 
Total number of intervention groups 1 
Type of targeted behaviour Clinical prevention services, Diagnosis 
Control groups used historical 
type of intervention Professional 
intervention sub category Reminders 
intervention further details Use of automated early warning score alert to 
hospital doctors 
Primary outcome Clinical outcome 
Health professional outcomes/process 
measures 
Secondary - EWS accuracy, timeliness of obs 
recheck, clinical response to EWS alert 
Patient outcomes Primary - Length of stay 
Secondary - cardiac arrest, critical care bed days, 
deaths 
 
Kinn 107  
Design RCT 
Follow up of professionals Done 
Follow up of patients or episodes of care Done 
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Blinded assessment of primary outcome(s) Not clear 
Baseline measurement Done 
Reliable primary outcome measure(s) Not done 
Power calculation Not clear 
Concealment of allocation Not done 
Protection against contamination Done 
Profession group Physicians 
Patients - number 1799 
Patients - age (mean(yrs)) 69 
Patients - gender (% female) 32% 
Patients - predominant ethnic group (%) Not clear 
Total number of intervention groups 1 
Type of targeted behaviour Diagnosis, General management of a problem, 
Patient outcome 
Control groups used No intervention control group 
type of intervention Professional 
intervention sub category Audit and feedback 
intervention further details Computer assisted hypertension management 
programme 
Primary outcome Not stated 
Health professional outcomes/process 
measures 
Performance - likelihood of a patient receiving a 
diagnosis of hypertension from this professional 
Patient outcomes Likelihood to receive at least 1 antihypertensive 
drug 
Number of blood pressure medications per patient 
Use of combination therapy 
Systolic blood pressure 
Diastolic blood pressure 
Achieves blood pressure target 
 
McDonald 108  
Design RCT 
Follow up of professionals Not clear 
Follow up of patients or episodes of care Done 
Blinded assessment of primary outcome(s) Not clear 
Baseline measurement Done 
Reliable primary outcome measure(s) Done 
Power calculation Not done 
Concealment of allocation Not done 
 224 
Protection against contamination Not clear 
Profession group Physicians 
Patients - number 144 
Patients - age (mean(yrs)) 26 
Patients - gender (% female) 100% 
Patients - predominant ethnic group (%) African American (92%) 
Total number of intervention groups 1 
Type of targeted behaviour Clinical prevention services, Patient 
education/advice 
Control groups used Untargeted activity 
type of intervention Organisational 
intervention sub category Patient orientated intervention 
intervention further details Tailored information for parents based on beliefs 
and knowledge 
Primary outcome Not stated 
Health professional outcomes/process 
measures 
Not done 
Patient outcomes Parent safety knowledge, prevention beliefs, and 
safety behaviours 
 
Nagykaldy 109  
Design RCT 
Follow up of professionals Not clear 
Follow up of patients or episodes of care Not clear 
Blinded assessment of primary outcome(s) Not clear 
Baseline measurement Done 
Reliable primary outcome measure(s) Not clear 
Power calculation Done 
Concealment of allocation Not clear 
Protection against contamination Not clear 
Profession group Physicians, Nurses 
Patients - number 538 
Patients - age (mean(yrs)) 52 
Patients - gender (% female) 61% 
Patients - predominant ethnic group (%) White (82%) 
Total number of intervention groups 1 
Type of targeted behaviour Patient education/advice, Patient outcome 
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Control groups used Standard practice control group 
type of intervention Professional 
intervention sub category patient mediated interventions 
intervention further details Online clinical portal to upload clinical data, 
providing tailored information 
Primary outcome Not stated 
Health professional outcomes/process 
measures 
provision of preventative services 
Patient outcomes number of log ins to portal 
patient centredness 
 
Persell 118  
Design RCT 
Follow up of professionals Not clear 
Follow up of patients or episodes of care Not clear 
Blinded assessment of primary outcome(s) Not clear 
Baseline measurement Done 
Reliable primary outcome measure(s) Done 
Power calculation Done 
Concealment of allocation Not done 
Protection against contamination Not clear 
Profession group Physicians 
Patients - number 435 
Patients - age (mean(yrs)) 60 
Patients - gender (% female) 23% 
Patients - predominant ethnic group (%) White (50%) 
Total number of intervention groups 1 
Type of targeted behaviour Patient education/advice 
Control groups used Standard practice control group 
type of intervention Organisational 
intervention sub category Patient orientated intervention 
intervention further details provision of tailored CVS risk info mailed out to 
patients using automated data query to identify 
patients at risk 
Primary outcome Clinical outcome 
Health professional outcomes/process 
measures 
Prescription of a statin 
Number of office visits 
 226 
Patient outcomes Primary outcome - LDL cholesterol 
change in BP 
smoking cessation 
 
Persell 110  
Design ITS 
Follow up of professionals NA 
Follow up of patients or episodes of care NA 
Blinded assessment of primary outcome(s) NA 
Baseline measurement NA 
Reliable primary outcome measure(s) NA 
Power calculation Not done 
Concealment of allocation NA 
Protection against contamination NA 
Profession group Physicians 
Patients - number 106 - 7462 (varies with outcome) 
Patients - age (mean(yrs)) 60 
Patients - gender (% female) 43 - 75% 
Patients - predominant ethnic group (%) White (50%) 
Total number of intervention groups 1 
Type of targeted behaviour Clinical prevention services, Prescribing 
Control groups used No intervention control group 
type of intervention Professional 
intervention sub category Reminders  
Audit and feedback 
intervention further details Reminders provided to physicians via EHR.  
Quarterly QI reports to physicians (not new 
practice) 
Primary outcome Adherence - guidelines 
Health professional outcomes/process 
measures 
16 performance measures - prescribing for chronic 
disease and screening procedures 
Patient outcomes Not done 
 
Pinnock 120  
Design RCT 
Follow up of professionals Not clear 
Follow up of patients or episodes of care Done 
Blinded assessment of primary outcome(s) Done 
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Baseline measurement Done 
Reliable primary outcome measure(s) Done 
Power calculation Done 
Concealment of allocation Done 
Protection against contamination Not clear 
Profession group Physicians 
Patients - number 256 
Patients - age (mean(yrs)) 69.4 
Patients - gender (% female) 55% 
Patients - predominant ethnic group (%) Not clear 
Total number of intervention groups 1 
Type of targeted behaviour Clinical prevention services, Diagnosis 
Control groups used Standard practice control group 
type of intervention Professional 
intervention sub category Patient medicated intervention - new clinical 
information 
intervention further details New clinical information supplied by patient and 
HCP alerted to intervene based on automated 
algorithms 
Primary outcome Time to first hospital admission with a primary 
diagnosis of an exacerbation of COPD 
Health professional outcomes/process 
measures 
Patient contacts 
Duration of hospital admission 
Patient outcomes Duration of hospital admission 
Death 
Quality of life 
Number of COPD exacerbations 
 
Quinn 111  
Design RCT 
Follow up of professionals Not clear 
Follow up of patients or episodes of care Not done 
Blinded assessment of primary outcome(s) Not clear 
Baseline measurement Done 
Reliable primary outcome measure(s) Done 
Power calculation Not done 
Concealment of allocation Not done 
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Protection against contamination Not clear 
Profession group Physicians 
Patients - number 30 
Patients - age (mean(yrs)) 51 
Patients - gender (% female) 65% 
Patients - predominant ethnic group (%) African American (62%) 
Total number of intervention groups 1 
Type of targeted behaviour Patient education/advice, Professional-patient 
communication 
Control groups used Standard practice control group 
type of intervention Professional 
intervention sub category patient mediated interventions 
intervention further details new clinical data submitted by patient and 
recommendation made using automated 
algorithm 
Primary outcome Not stated 
Health professional outcomes/process 
measures 
Satisfaction 
Patient outcomes Diabetes self care 
Glycaemic control 
 
Raebel 112  
Design RCT 
Follow up of professionals Not done 
Follow up of patients or episodes of care Not done 
Blinded assessment of primary outcome(s) Not clear 
Baseline measurement Done 
Reliable primary outcome measure(s) Done 
Power calculation Not done 
Concealment of allocation Done 
Protection against contamination Not clear 
Profession group Pharmacists 
Patients - number 11100 
Patients - age (mean(yrs)) 29 
Patients - gender (% female) 100% 
Patients - predominant ethnic group (%) Not clear 
Total number of intervention groups 1 
 229 
Type of targeted behaviour Prescribing 
Control groups used Standard practice control group 
type of intervention Professional 
intervention sub category Reminders 
intervention further details Drug pregnancy alert to pharmacists dispensing 
medication that is contraindicated for pregnant 
women. 
Primary outcome Adverse drug event 
Health professional outcomes/process 
measures 
Not done 
Patient outcomes Proportion of pregnant women dispensed a 
category D or X medication 
 
Ross 119 (abstract only)  
Design RCT 
Follow up of professionals Not clear 
Follow up of patients or episodes of care Not clear 
Blinded assessment of primary outcome(s) Not clear 
Baseline measurement Not clear 
Reliable primary outcome measure(s) Not clear 
Power calculation Not clear 
Concealment of allocation Not clear 
Protection against contamination Not clear 
Profession group Not clear 
Patients - number 328 
Patients - age (mean(yrs)) 59 
Patients - gender (% female) 45% 
Patients - predominant ethnic group (%) Not clear 
Total number of intervention groups 1 
Type of targeted behaviour Patient education/advice 
Control groups used Untargeted activity 
type of intervention Professional 
intervention sub category patient mediated interventions 
intervention further details tailored education and reminders 
Primary outcome Not stated 
Health professional outcomes/process 
measures 
Not clear 
 230 
Patient outcomes system usage 
 
Sequist 114  
Design RCT 
Follow up of professionals Not clear 
Follow up of patients or episodes of care Not clear 
Blinded assessment of primary outcome(s) Not clear 
Baseline measurement Not clear 
Reliable primary outcome measure(s) Done 
Power calculation Done 
Concealment of allocation Not clear 
Protection against contamination Not clear 
Profession group Physicians 
Patients - number 6243 
Patients - age (mean(yrs)) 63 
Patients - gender (% female) 56% 
Patients - predominant ethnic group (%) White (50%) 
Total number of intervention groups 1 
Type of targeted behaviour Clinical prevention services, Test ordering, 
Prescribing 
Control groups used No intervention control group 
type of intervention Professional 
intervention sub category Reminders 
intervention further details Automated electronic reminders to adhere to 
guidelines 
Primary outcome Adherence - guidelines 
Health professional outcomes/process 
measures 
Perceptions surrounding guideline adherence 
Patient outcomes receipt of recommended care 
 
Tierney 115  
Design RCT 
Follow up of professionals Not clear 
Follow up of patients or episodes of care Not clear 
Blinded assessment of primary outcome(s) Not done 
Baseline measurement Not done 
Reliable primary outcome measure(s) Done 
 231 
Power calculation Done 
Concealment of allocation Done 
Protection against contamination Not clear 
Profession group Physicians, Pharmacists 
Patients - number 706 
Patients - age (mean(yrs)) 51 
Patients - gender (% female) 66% 
Patients - predominant ethnic group (%) White (60%) 
Total number of intervention groups 3 
Type of targeted behaviour General management of a problem, evidence 
based practice 
Control groups used No intervention control group 
type of intervention Professional 
intervention sub category Reminders 
intervention further details Group 1: electronic suggestions for care displayed 
to primary care physicians 
Group 2: reminder for community pharmacists 
only 
Group 3: reminder for physician and community 
pharmacists 
Primary outcome Adherence - guidelines 
Health professional outcomes/process 
measures 
Percentage of suggestions adhered to 
Patient outcomes Not done 
 
Vollmer 116  
Design RCT 
Follow up of professionals Not clear 
Follow up of patients or episodes of care Done 
Blinded assessment of primary outcome(s) Not clear 
Baseline measurement Not done 
Reliable primary outcome measure(s) Done 
Power calculation Not done 
Concealment of allocation Not clear 
Protection against contamination Not done 
Profession group Not clear 
Patients - number 14064 
Patients - age (mean(yrs)) 54 
 232 
Patients - gender (% female) 66% 
Patients - predominant ethnic group (%) NOT CLEAR 
Total number of intervention groups 1 
Type of targeted behaviour Prescribing, Patient education/advice 
Control groups used No intervention control group 
type of intervention Organisational 
intervention sub category patient orientated 
intervention further details automated phone calls reminding of need for 
inhaled corticosteroid prescription, based on data 
query from HER – tailored communication 
Primary outcome Adherence - patient 
Health professional outcomes/process 
measures 
Not done 
Patient outcomes medication adherence 
patient satisfaction - questionnaire 
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13. Appendix: EBMeDS script selection
13.1 Summary of scripts 
Script Title Aim Method Modifications made in light of 
feedback 
01299 TSH monitoring To ensure screening for 
hypothyroidism in risk group 
Checks most recent thyroid function and 
prompts user to consider checking where 
appropriate 
None 
01292 Laboratory follow-up in 
patients with type 1 diabetes 
To ensure adequate reactions to 
results of laboratory follow-up of 
type I diabetes 
Checks glycaemic control, renal function 
and BP and highlights need for 
appropriate intervention 
None 
01305 UKPDS Risk engine to calculate 
cardiovascular and stroke risk 
in patients with type 2 
diabetes 
To highlight when patient has high 
risk of cardiovascular event or 
stroke 
Calculates risk based on known risk 
factors and alerts user if risk is high 
Deleted 
01306 Weight gain in type 2 diabetes To remind users to highlight the 
importance of exercise 
Checks BMI through time and highlights 
upward trends 
None 
01307 Weight gain in type 1 diabetes To ensure that the correct insulin 
dose is being prescribed 
Checks BMI through time and highlights 
upward trends 
None 
01297 Nephropathy screening in type 
1 diabetes 
To promote regular screening for 
nephropathy  
Checks most recent UACR recording and 
prompts user to consider checking where 
appropriate 
Deleted 
01300 Screening for diabetic 
nephropathy in type 2 
diabetes 
To promote regular screening for 
nephropathy  
Checks most recent UACR recording and 
prompts user to consider checking where 
appropriate 
Deleted 
01301 Managing hypertension in 
diabetic nephropathy 
To encourage intervention for 
those with nephropathy and  
hypertension 
Checks BP and nephropathy status and 
prompts user to intervene as appropriate 
None 
01302 Intensifying diabetes 
treatment in recently 
diagnosed type 2 diabetes  
To ensure that pharmacological 
management has been considered 
Checks glycaemic control and current 
medications and gives appropriate advice 
in the event of poor control 
Amended – threshold raised 
(48mmol/mol increased to 
58mmol/mol) 
01303 ACE inhibitor or sartan for 
diabetic patients with 
albuminuria 
Secondary prevention of further 
renal insufficiency 
Checks for evidence of nephropathy and 
current medications and gives advice 
accordingly 
None 
01304 ACE inhibitors or angiotensin-
receptor blockers for patients 
with diabetes and 
hypertension but no 
microalbuminuria 
Primary prevention of renal 
insufficiency 
Checks for evidence of hypertension, 
nephropathy and current medications 
and gives advice accordingly 
None 
01296 Routine procedures when 
starting a glitazone 
To ensure that consideration is 
given to potential side effects or 
contraindications 
Checks current medications and for 
presence of anaemia.  Advice given for 
monitoring of potential side effects 
None 
01309 Glimepiride warning in renal 
insufficiency 
To avoid risks with glimepiride in 
patients with renal insufficiency 
Checks current medications and renal 
function and gives advice accordingly 
None 
01310 Glipizide warning in renal 
insufficiency 
To avoid risks with glipizide in 
patients with renal insufficiency 
Checks current medications and renal 
function and gives advice accordingly 
None 
01318 Recall of patients with type 1 
diabetes 
To ensure patients have had 
routine screening for 
complications of diabetes 
Checks when the following parameters 
were last checked and highlights those 
that fall out with guidelines: HbA1c; BMI; 
foot risk; BP; UACR; creatinine; and 
cholesterol. 
None 
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Script Title Aim Method Modifications made in light of 
feedback 
01319 Recall of patients with type 2 
diabetes 
To ensure patients have had 
routine screening for 
complications of diabetes 
Checks when the following parameters 
were last checked and highlights those 
that fall out with guidelines: HbA1c; BMI; 
foot risk; BP; UACR; creatinine; and 
cholesterol. 
None 
01320 Recall of patients for retinal 
screening 
To ensure patients have had 
routine screening for 
complications of diabetes 
Checks retinopathy status and date of 
last screening and gives advice 
accordingly 
Amended – temporary 
suspension enabled (based on 
clinical grounds) 
01312 Phosphodiesterase inhibitors 
for erectile dysfuntion in 
patients with diabetes mellitus 
To promote effective treatment of 
erectile dysfunction 
Checks for presence of erectile 
dysfuntion and current (and previous) 
medications and gives advice if indicated 
None 
01313 Metformin is the first choice 
oral hypoglycaemic agent in 
type 2 diabetes 
To promote improved glycaemic 
control 
Checks age; current medications; 
glycaemic control; and renal function and 
gives advice accordingly 
None 
13.2 01299 TSH monitoring 
13.2.1. Aim 
To ensure screening for hypothyroidism in risk group 
13.2.2. Method 
The script ensures that patients with diabetes are annually (children and young people (<18 years old) or bi-annually 
(adults aged ≥ 17 years old) screened for hypothyroidism.  This script runs for all patients, regardless of whether they 
have a current diagnosis of hypothyroidism. 
13.2.3. Decision Support Messages for Professionals 
1. Annual screening for hypothyroidism is recommended for children aged under 17 with diabetes. Consider
checking TSH even if asymptomatic (or currently being treated with thyroxine).5
2. Adults with diabetes are at increased risk of thyroid disease.  Please consider checking TSH if symptomatic
(or currently being treated with thyroxine)6
13.2.4. Short message
1. Type 1 diabetes - check TSH?
2. Type 1 diabetes - check TSH?
5
 http://www.sign.ac.uk/pdf/qrg116.pdf#page=44 
6
 http://www.sign.ac.uk/pdf/qrg116.pdf#page=44 
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13.3 01292 Laboratory follow-up in patients with type 1 diabetes 
13.3.1. Aim 
To ensure adequate reactions to results of laboratory follow-up of type I diabetes 
13.3.2. Method 
The script is launched if the patient has a previous diagnosis of type 1 diabetes and =>17yo. Subsequently, his/hers 
gender and the following last laboratory results are checked:  
B-HbA1c >= 58mmol/mol 
U ACR >= 2.5 (males) or 3.5 (females);  
eGFR-calculated <60. 
 If one or more are true, and the corresponding lab-tests are at most 13 months old, adequate reminders are shown. 
13.3.3. Decision Support Messages for Professionals 
1. This patient has type 1 diabetes and his/her glycaemic control is suboptimal (HbA1c = @1). Consider 
whether the diabetes treatment can be improved. 
2. This patient has type 1 diabetes and renal impairment (calculated GFR = @1 ml/min).  Please refer to local 
referral protocol7 
3. This patient has type 1 diabetes and proteinuria.  Please refer to local referral protocol8 
4. This patient has type 1 diabetes and microalbuminuria.  Please confirm with a repeat sample and optimise 
glycaemic and BP control.9 
13.3.4. Short message 
1. Type 1 diabetes with suboptimal glycaemic control 
2. Type 1 diabetes and renal impairment 
3. Type 1 diabetes and proteinuria 
 
 
                                                          
 
7
 http://www.diabetes-healthnet.ac.uk/Default.aspx?pageid=50#UrineProteinCreatinineRatio 
8
 http://www.diabetes-healthnet.ac.uk/Default.aspx?pageid=50#UrineProteinCreatinineRatio 
9
 http://www.sign.ac.uk/pdf/sign116.pdf#page=94 
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13.4 01305 UKPDS Risk Engine to calculate cardiovascular and stroke risk in patients 
with type 2 diabetes 
13.4.1. Aim 
The UKPDS calculators for cardiovascular and stroke risk are applied to the patient data. If the cardiovascular risk in 
10 years exceeds 10% or the stroke risk exceeds 5%, a reminder is shown. Given that the presence of atrial 
fibrillation is not known, the default setting “no atrial fibrillation” is applied and the reminder is shown if the risk 
exceeds 10% or 5%.  If the smoking status is not known, the reminder is shown if the risks exceed 10% or 5% by using 
the default settings "non-smoker".. If the 10-year risk of cardiovascular disease is above 10% reminder 1 (or 3) is 
shown. If the 10-year stroke risk is above 5% reminder 2 (or 4) is shown. 
13.4.2. Decision Support Messages for Professionals 
1. The risk of cardiovascular event is @1% in ten years according to the UKPDS risk engine.  This risk may be 
increased if this patient has atrial fibrillation.10 
2. This patient's ten-year risk of stroke is @1%, as calculated with the UKPDS Risk Engine.  This risk may be 
increased if this patient has atrial fibrillation.11 
3. This patient's ten-year risk of a cardiovascular event is @1%, as calculated with the UKPDS Risk Engine. Since 
information about this patient's smoking status was not found, the risk was calculated for a non-smoker. If 
the patient is a smoker, the ten-year risk is @2%.  This risk may be increased if this patient has atrial 
fibrillation.12 
4. This patient's ten-year risk of stroke is @1%, as calculated with the UKPDS Risk Engine. Since information 
about this patient's smoking status was not found, the risk was calculated for a non-smoker. If the patient is 
a smoker, the ten-year risk is @2%.  This risk may be increased if this patient has atrial fibrillation.13 
13.4.3. Short message 
1. Type 2 diabetes - increased cardiovascular risk (UKPDS) 
2. Type 2 diabetes - increased stroke risk (UKPDS). 
3. Type 2 diabetes, unknown smoking status - increased cardiovascular risk (UKPDS) 
4. Type 2 diabetes, unknown smoking status - increased stroke risk (UKPDS) 
13.4.4. Amendment 
Feedback from cycle 1 suggested that this alert was being triggered on almost all patients, resulting in user fatigue.  
                                                          
 
10
 http://www.dtu.ox.ac.uk/riskengine/ 
11
 http://www.dtu.ox.ac.uk/riskengine/ 
12
 http://www.dtu.ox.ac.uk/riskengine/ 
13
 http://www.dtu.ox.ac.uk/riskengine/ 
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Decision made to remove script from system. 
13.5 01306 Weight gain in type 2 diabetes 
13.5.1. Aim 
To remind of importance and effectiveness of exercise in the treatment of type 2 diabetes 
13.5.2. Method 
The purpose of the script is to ensure that weight gain in patients with type 2 diabetes is adequately noticed. The 
script applies to adults with type 2 diabetes. If BMI is above 25 and BMI change after previous measurement is above 
2 kg/m², the user is reminded of paying attention to weight control. 
13.5.3. Decision Support Messages for Professionals 
1. This patient with diabetes has gained weight @1 since the last visit. Pay special attention to weight control. 
Do you want to write a prescription for exercise?14 
13.5.4. Short message 
1. Weight gain noted? 
  
                                                          
 
14
 http://www.sign.ac.uk/pdf/sign116.pdf#page=27 
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13.6 01307 Weight gain in type 1 diabetes 
13.6.1. Aim 
To remind of checking insulin dose during weight gain  
13.6.2. Method 
The purpose of the script is to ensure, that in those patients with type 1 diabetes AGED => 17, who have put on 
weight, the insulin dosage is checked not to be too high. The script is applied in persons with type 1 diabetes AGED 
=> 17. The DS ensures that the patient is not underweight (BMI > 20 kg/m2 in patients 17 years of age or older; 
Subsequently, the DS calculates the BMI difference between now and at the time of last measurement (BMI now – 
BMI before). If the difference is > 2 kg/m2, the user is asked to check the insulin dosage (reminder 1). 
13.6.3. Decision Support Messages for Professionals 
1. This patient has gained weight significantly since the last visit. Is the insulin dose correct? Is hypoglycaemia 
an issue?15 Discuss calorie intake, exercise and lifestyle16. 
13.6.4. Short message 
1. Weight gain in a patient with diabetes 
  
                                                          
 
15
 http://www.sign.ac.uk/pdf/sign116.pdf#page=38 
16
 http://www.sign.ac.uk/pdf/sign116.pdf#page=24 
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13.7 01297 Nephropathy screening in type 1 diabetes 
13.7.1. Aim 
Promote regular screening for nephropathy in patients with type 1 diabetes. 
13.7.2. Method 
The script targets patients who are at least 12 years old and do not yet have laboratory evidence of 
microalbuminuria. If such a patient has not been screened for microalbuminuria during the last 13 months, reminder 
1 will be shown to remind of the need for regular screening. 
13.7.3. Decision Support Messages for Professionals 
1. This patient has type 1 diabetes and has not had urinary ACR measured during the last year. Annual 
screening for microalbuminuria by urine ACR measurement is recommended in type 1 diabetes17 
13.7.4. Short message 
1. Type 1 diabetes - time for nephropathy screening? 
13.7.5. Amendment 
Feedback from cycle 1 highlighted duplication between content of this script and that of script 01318, message 5.  
Decision made to delete this script from system. 
  
                                                          
 
17
 http://www.sign.ac.uk/pdf/sign116.pdf#page=93 
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13.8 01300 Screening for diabetic nephropathy in type 2 diabetes 
13.8.1. Aim 
Early detection of diabetic nephropathy by reminding of regular screening for microalbuminuria. 
13.8.2. Method 
The script targets patients with type 2 diabetes who do not yet have microalbuminuria. If albuminuria has not been 
screened for during the last 1 year for such a patient, a reminder to perform screening is shown. 
13.8.3. Decision Support Messages for Professionals 
1. This patient has type 2 diabetes, and has not had urinary ACR measured during the last year. Annual 
screening for microalbuminuria by urine ACR is recommended in type 2 diabetes.18 
13.8.4. Short message 
1. Type 2 diabetes - time for nephropathy screening? 
13.8.5. Amendment 
Feedback from cycle 1 highlighted duplication between content of this script and that of script 01319, message 5.  
Decision made to delete this script from system. 
  
                                                          
 
18
 http://www.sign.ac.uk/pdf/sign116.pdf#page=93 
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13.9 01301 Managing hypertension in diabetic nephropathy 
13.9.1. Aim 
In the case where the patient already has type 1 or 2 DM and has microalbuminuria, Blood pressure should be 
reduced to the lowest achievable level.  For the purposes of clinical alerts, BP thresholds are as follows: reminder 1 is 
shown about the ideal blood pressure of <130/80 mmHg. If the patient has macroalbuminuria (>300 mg/day) OR 
ACR>30 OR PCR>50, ideal blood pressure level is <125/75 mmHg (reminder 2). If the patient with diabetes has 
albuminuria, but no recent (< 9 months) blood pressure reported, reminder 3 is given about measuring blood 
pressure. 
13.9.2. Decision Support Messages for Professionals 
1. The patient has diabetes mellitus and microalbuminuria and the latest blood pressure for a patient with 
diabetes and microalbuminuria was @1 mmHg, Blood pressure should be reduced to the lowest achievable 
level19 
2. The patient has diabetes and proteinuria > 300 mg/day and the latest blood pressure was @1 mmHg. Blood 
pressure should be reduced to the lowest achievable level.20 
3. The patient has diabetes and albuminuria, and no recent blood pressure measurement results are found. A 
blood pressure measurement is recommended21 
13.9.3. Short message 
1. Diabetes mellitus and microalbuminuria - is the BP level optimal? 
2. Diabetes and proteinuria > 300 mg/day - is the blood pressure optimal? 
3. Diabetes with albuminuria - measure blood pressure? 
 
 
                                                          
 
19
 http://www.sign.ac.uk/pdf/sign116.pdf#page=96 
20
 http://www.sign.ac.uk/pdf/sign116.pdf#page=96 
21
 http://www.sign.ac.uk/pdf/sign116.pdf#page=96 
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13.10 01302 Intensifying diabetes treatment in recently diagnosed type 2 diabetes 
13.10.1. Aim 
If a patient with fresh (at most 2 years old) type 2 diabetes has an elevated HbA1c level >48 mmol/mol but no insulin 
or sulphonylurea treatment, the user is recommended to intensify hyperglycaemia treatment according to the SIGN 
Guidelines and local protocols 
13.10.2. Decision Support Messages for Professionals 
1. This patient has type 2 diabetes and the HbA1c value is high (@1). Consider intensifying diabetes 
treatment.22 
13.10.3. Short message 
1. Type 2 diabetes and high HbA1c - intensify diabetes treatment? 
13.10.4. Amendment 
Feedback from cycle 1 highlighted low threshold for HbA1c.  Current local practice aims to keep HbA1c <58 
mmol/mol.  Whilst it is desirable to aim for as low an HbA1c as possible, the original threshold resulted in alerts 
being triggered for the majority of patients, resulting in user fatigue. 
 
 
  
                                                          
 
22
 http://www.sign.ac.uk/pdf/sign116.pdf#page=46 
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13.11 01303 ACE inhibitor or sartan for diabetic patients with albuminuria 
13.11.1. Aim 
To prevent renal insufficiency in patients with diabetes 
13.11.2. Method 
This script is launched when albuminuria is detected (U ACR>= 2.5 (males) or 3.5 (females)), or microalbumin >30. 
First, the script checks diagnosis for diabetes. If the patient has diabetes, the script checks, whether medication list 
contains either ACE-inhibitor or ATRB. If the medication list does not contain drugs from either group, message (1) is 
shown. 
13.11.3. Decision Support Messages for Professionals 
1. This patient has microalbuminuria/proteinuria. Treatment with an ACE inhibitor or a sartan is recommended 
unless otherwise contraindicated23 
13.11.4. Short message 
1. Diabetes and microalbuminuria/proteinuria - start ACE inhibitor or sartan? 
  
                                                          
 
23
 http://www.sign.ac.uk/pdf/sign116.pdf#page=96 
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13.12 01304 ACE inhibitors or angiotensin-receptor blockers for patients with diabetes 
and hypertension but no microalbuminuria 
13.12.1. Aim 
Primary prevention of nephropathy in patients with diabetes and hypertension by promoting use of ACEI/ARB 
medication. 
13.12.2. Method 
If a patient with diabetes and hypertension, but no microalbuminuria or diabetic nephropathy, is not using an ACE 
inhibitor or an angiontensin-receptor blocker, a reminder on the benefit of these drugs is shown. 
13.12.3. Decision Support Messages for Professionals 
1. This patient has diabetes and hypertension, but is not using an ACE inhibitor or an angiotensin-receptor 
blocker. A Cochrane review found ACE inhibitors to significantly reduce the development of 
microalbuminuria when compared to treatment with placebo or calcium-channel blockers24 
13.12.4. Short message 
1. Diabetes and hypertension - start an ACE inhibitor or angiotensin-receptor blocker to prevent 
microalbuminuria? 
  
                                                          
 
24
 http://onlinelibrary.wiley.com/doi/10.1002/14651858.CD004136.pub3/abstract 
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13.13  01296 Routine procedures when starting a glitazone 
13.13.1. Aim 
The script guides the clinician to pay attention to relevant factors when initiating glitazone medication. 
13.13.2. Method 
This script is launched on initiation of glitazone treatment. First the script reviews current drug list for insulin use and 
if present, reminder (1) is shown. Next the script reviews the last B-Hb measurement and if it is less than 120 g/L (OR 
12g/dl), reminder (2) is shown. Next the script reviews drug list for any other drug which may cause hypoglycemia 
(coded as BNF 6.1.2 Antidiabetic drugs), in which case message (3) is shown. Message (4) is shown last and patient 
information for this drug is printed out. 
13.13.3. Decision Support Messages for Professionals 
1. This patient is receiving insulin treatment. The combined use of Glitazones and insulin therapy increases the 
risk of heart failure, especially in those with predisposing risk factors.25 
2. This patient is anaemic. Glitazones may decrease haemoglobin concentrations. The patient should be 
informed of this possibility and of the signs and symptoms of anaemia.26 
3. This patient has previously been prescribed a medicine which lowers the blood glucose. Glitazones may 
potentiate its effect. Should symptoms of hypoglycaemia occur, the dose of both medicines should be 
reduced.27 
4. Glitazones may cause fluid retention, which manifests itself through weight gain. The patient may be given 
printed information at the time of issuing the prescription. Liver enzyme values should be checked at regular 
intervals. The onset of action of glitazones is slow and often becomes evident only after several weeks.28 
13.13.4. Short message 
1. Glitazone treatment about to start - contraindicated due to insulin treatment? 
2. Glitazone treatment about to start - information given about the risk of anaemia? 
3. Glitazone treatment about to start - possible interactions noted? 
4. Glitazone treatment about to start - weight monitoring arranged? 
 
                                                          
 
25
 http://www.medicinescomplete.com/mc/bnf/current/PHP4194-pioglitazone.htm 
26
 http://www.medicinescomplete.com/mc/bnf/current/PHP4194-pioglitazone.htm 
27
 http://www.medicinescomplete.com/mc/bnf/current/PHP4194-pioglitazone.htm 
28
 http://www.medicinescomplete.com/mc/bnf/current/PHP4194-pioglitazone.htm 
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13.14 01309 Glimepiride warning in renal insufficiency 
13.14.1. Aim 
To avoid risks with glimepiride in patients with renal insufficiency 
13.14.2. Method 
The script is launched if the patient is on glimepiride. If the calculated glomerular filtration rate (GFR) is between 30 
and 50 ml/min, reminder (1) is shown. If the calculated GFR is less than 30 ml/min, reminder (2) is shown. 
13.14.3. Decision Support Messages for Professionals 
1. This patient’s calculated glomerular filtration rate (GFR) is between 30-49 ml/min (@1). Consider a lower 
than usual dose of glimepiride29 
2. This patient’s calculated glomerular filtration rate (GFR) is less than 30 ml/min (@1). Glimepiride is 
contraindicated30 
13.14.4. Short message 
1. Glimepiride treatment - impaired renal function noted? 
2. Discontinue glimepiride due to impaired renal function? 
  
                                                          
 
29
 http://www.medicinescomplete.com/mc/bnf/current/PHP4129-sulfonylureas.htm#PHP4134 
30
 http://www.medicinescomplete.com/mc/bnf/current/PHP4129-sulfonylureas.htm#PHP4134 
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13.15 01310 Glipizide warning in renal insufficiency 
13.15.1. Aim 
To avoid risks with glipizide in patients with renal insufficiency 
13.15.2. Method 
The script is launched if the patient is on glipizide. If the calculated glomerular filtration rate (GFR) is 30-50 ml/min, 
reminder (1) is shown. If the calculated GFR is less than 30 ml/min, reminder (2) is shown. 
13.15.3. Decision Support Messages for Professionals 
1. This patient’s calculated glomerular filtration rate (GFR) is between 30-49 ml/min (@1). Consider a lower 
than usual dose of glipizide31 
2. This patient’s calculated glomerular filtration rate (GFR) is less than 30 ml/min (@1). Glipizide is 
contraindicated32 
13.15.4. Short message 
1. Glipizide treatment - impaired renal function noted? 
2. Discontinue glipizide due to impaired renal function? 
  
                                                          
 
31
 http://www.medicinescomplete.com/mc/bnf/current/PHP4129-sulfonylureas.htm#PHP4134 
32
 http://www.medicinescomplete.com/mc/bnf/current/PHP4129-sulfonylureas.htm#PHP4134 
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13.16 01318 Recall of patients with type 1 diabetes 
13.16.1. Aim 
If none of the following laboratory tests has been taken during the last 11 months, a reminder on recalling the 
patient is shown. 
All patients: no HbA1c (message 1), no BMI (message 2), no foot risk score (message 3), 
Patients >11 years old: no blood pressure (message 4), U ACR (message 5), creatinine (message 6). 
Adults (≥17years old): no total cholesterol (message 7) 
13.16.2. Decision Support Messages for Professionals 
1. This patient has type 1 diabetes. More than 11 months have passed since HbA1c was measured.  Guidelines 
suggest that this should be checked at least 6 monthly. Consider rechecking at the next review 
appointment.33 
2. This patient has type 1 diabetes. More than 11 months have passed since BMI was measured.  Guidelines 
suggest that this should be checked at least 6 monthly. Consider rechecking at the next review 
appointment.34 
3. This patient has type 1 diabetes. More than 11 months have passed since a foot risk score was calculated.  
Guidelines suggest that this should be checked at least annually. Consider rechecking at the next review 
appointment.35 
4. This patient has type 1 diabetes. More than 11 months have passed since blood pressure was measured.  
Guidelines suggest that this should be checked at least annually. Consider rechecking at the next review 
appointment.36 
5. This patient has type 1 diabetes. More than 11 months have passed since U ACR was measured.  Guidelines 
suggest that this should be checked at least annually. Consider rechecking at the next review appointment.37 
6. This patient has type 1 diabetes. More than 11 months have passed since creatinine was measured.  
Guidelines suggest that this should be checked at least annually. Consider rechecking at the next review 
appointment.38 
7. This patient has type 1 diabetes. More than 11 months have passed since total cholesterol was measured.  
Guidelines suggest that this should be checked at least annually. Consider rechecking at the next review 
appointment.39 
13.16.3. Short message 
1. Diabetes - time for an HbA1c? 
2. Diabetes - time for a BMI check? 
3. Diabetes - time for an annual foot assessment? 
4. Diabetes - time for an annual BP check? 
5. Diabetes - time for an annual U ACR check? 
6. Diabetes - time for an annual creatinine check? 
7. Diabetes - time for an annual cholesterol check? 
                                                          
 
33
 http://publications.nice.org.uk/type-1-diabetes-cg15/guidance#blood-glucose-control-and-insulin-therapy 
34
 http://www.diabetes-healthnet.ac.uk/Default.aspx?pageid=42 
35
 http://www.sign.ac.uk/pdf/sign116.pdf#page=111 
36
 http://publications.nice.org.uk/type-1-diabetes-cg15/guidance#control-of-arterial-risk 
37
 http://www.sign.ac.uk/pdf/sign116.pdf#page=93 
38
 http://publications.nice.org.uk/type-1-diabetes-cg15/guidance#identification-and-management-of-complications 
39
 http://publications.nice.org.uk/type-1-diabetes-cg15/guidance#control-of-arterial-risk 
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13.17 01319  Recall of patients with type 2 diabetes 
13.17.1. Aim 
If none of the following laboratory tests has been taken during the last 11 months, a reminder on recalling the 
patient is shown. 
no HbA1c (message 1), no total cholesterol (message 2), no BMI (message 3), no blood pressure (message 4), no foot 
risk score (message 5), U ACR (message 6) and creatinine (message 7). 
13.17.2. Decision Support Messages for Professionals 
1. This patient has type 2 diabetes. More than 11 months have passed since HbA1c was measured.  Guidelines 
suggest that this should be checked at least 6 monthly. Consider rechecking at the next review 
appointment.40 
2. This patient has type 2 diabetes. More than 11 months have passed since BMI was measured.  Guidelines 
suggest that this should be checked at least 6 monthly. Consider rechecking at the next review 
appointment.41 
3. This patient has type 2 diabetes. More than 11 months have passed since a foot risk score was calculated.  
Guidelines suggest that this should be checked at least annually. Consider rechecking at the next review 
appointment.42 
4. This patient has type 2 diabetes. More than 11 months have passed since blood pressure was measured.  
Guidelines suggest that this should be checked at least annually. Consider rechecking at the next review 
appointment.43 
5. This patient has type 2 diabetes. More than 11 months have passed since U ACR was measured.  Guidelines 
suggest that this should be checked at least annually. Consider rechecking at the next review appointment.44 
6. This patient has type 2 diabetes. More than 11 months have passed since creatinine was measured.  
Guidelines suggest that this should be checked at least annually. Consider rechecking at the next review 
appointment.45 
7. This patient has type 2 diabetes. More than 11 months have passed since total cholesterol was measured.  
Guidelines suggest that this should be checked at least annually. Consider rechecking at the next review 
appointment.46 
13.17.3. Short message 
1. Diabetes - time for an HbA1c? 
2. Diabetes - time for a BMI check? 
3. Diabetes - time for an annual foot assessment? 
4. Diabetes - time for an annual BP check? 
5. Diabetes - time for an annual U ACR check? 
6. Diabetes - time for an annual creatinine check? 
7. Diabetes - time for an annual cholesterol check? 
                                                          
 
40
 http://publications.nice.org.uk/type-2-diabetes-cg87/guidance#glucose-control-levels 
41
 http://www.diabetes-healthnet.ac.uk/Default.aspx?pageid=42 
42
 http://www.sign.ac.uk/pdf/sign116.pdf#page=111 
43
 http://publications.nice.org.uk/type-2-diabetes-cg87/guidance#blood-pressure-therapy 
44
 http://www.sign.ac.uk/pdf/sign116.pdf#page=93 
45
 http://publications.nice.org.uk/type-2-diabetes-cg87/guidance#anti-thrombotic-therapy 
46
 http://publications.nice.org.uk/type-2-diabetes-cg87/guidance#cardiovascular-risk-estimation 
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13.18 01320 Recall of patients for retinal screening 
13.18.1. Aim 
This script checks for presence of previously diagnosed diabetic retinopathy and length of time since the patient was 
last screened.  This script applies only to patients >11 years old.  If there is previous retinopathy and there has been 
no diabetic retinal screening over the last 11 months, reminder (1) is shown.  If there is no previous retinopathy and 
there has been no retinal screening over the last 23 months, reminder (2) is shown  
13.18.2. Decision Support Messages for Professionals 
1. This patient has diabetes. More than 11 months have passed since eye screening was undertaken.  
Guidelines suggest that this should be checked at least annually if there is retinopathy.47 
2. This patient has diabetes. More than 23 months have passed since eye screening was undertaken.  
Guidelines suggest that patients with no previous retinopathy should be screened at least every 2 years.48 
13.18.3. Short message 
1. Diabetes - time for eye screening? 
2. Diabetes - time for eye screening? 
 
13.18.4. Amendment 
Feedback from cycle 1 highlighted that patients can be temporarily or permanently suspended from retinal screening 
programme due to a number of clinical reasons.  Additional rules have been added to the script to suppress 
reminders that are not applicable to individual patients. 
 
  
                                                          
 
47
 http://www.sign.ac.uk/pdf/sign116.pdf#page=104 
48
 http://www.sign.ac.uk/pdf/sign116.pdf#page=104 
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13.19 01312 Phosphodiesterase inhibitors for erectile dysfunction  
13.19.1. Aim 
Promote effective treatment of erectile dysfunction in men with diabetes. 
13.19.2. Method 
If a male patient with diabetes and a diagnosis of erectile dysfunction has never used phosphodiesterase inhibitors, a 
reminder on the effectiveness of these drugs is shown. However, if the patient is using nitrates, or has a registered 
adverse event for phosphodiesterase inhibitors, the reminder will not be shown. 
13.19.3. Decision Support Messages for Professionals 
1. This patient has been diagnosed with erectile dysfunction and diabetes. However, there is no record of 
previous treatment with a phosphodiesterase inhibitor or contraindications to the treatment, e.g. nitrate 
use. There is sufficient evidence on the effectiveness of phosphodiesterase inhibitors in improving erectile 
dysfunction in men with diabetes49 
13.19.4. Short message 
1. Erectile dysfunction and diabetes - try a phosphodiesterase inhibitor? 
  
                                                          
 
49
 http://www.medicinescomplete.com/mc/bnf/current/PHP5154-phosphodiesterase-type-5-inhibitors.htm 
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13.20 01313 Metformin in type 2 diabetes 
13.20.1. Aim 
Patients with Type 2 diabetes  should be on metformin if no contraindications exist 
13.20.2. Method 
The script is launched if the diagnosis is type 2 diabetes and the patient is under 80 years old. First, the script checks 
whether the drug list contains metformin and whether HbA1c is below 48 mmol/mol If not, the script checks for the 
plasma/serum creatinine value. If the GFR is in the normal range, reminder 1 is shown. If GFR is 30-45 ml/min, 
reminder 2 is shown. If GFR is missing or not checked within the last 12 months reminder 3 is shown. 
13.20.3. Decision Support Messages for Professionals 
1. This patient has type 2 diabetes. Metformin is the drug of choice for better glycaemic control50
2. This patient's glomerular filtration rate, calculated with the MDRD formula (@1), is at a level where a lower
than usual dose of metformin should be considered51
3. This patient has type 2 diabetes. Metformin is the drug of choice for better glycaemic control. Consider
checking renal function and starting metformin52
13.20.4. Short message 
1. Type 2 diabetes - start metformin?
2. Type 2 diabetes - start metformin? Note GFR.
3. Type 2 diabetes - check renal function and start metformin?
50
 http://www.sign.ac.uk/pdf/sign116.pdf#page=48 
51
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Dear	  sir/madam,	  
I	  would	  like	  to	  invite	  you	  to	  take	  part	  in	  a	  survey	  about	  
your	  experience	  of	  visiting	  the	  diabetes	  clinic.	  	  It	  is	  
important	  that	  we	  get	  the	  opinions	  of	  as	  many	  people	  
as	  possible,	  so	  please	  take	  a	  few	  minutes	  to	  complete	  
the	  survey	  if	  you	  can.	  
The	  questions	  in	  the	  survey	  are	  about	  your	  visit	  to	  the	  
diabetes	  clinic	  today.	  	  Please	  take	  a	  couple	  of	  minutes	  
to	  complete	  the	  survey	  after	  you	  have	  been	  seen	  -­‐	  we	  
would	  like	  you	  to	  think	  about	  your	  experience	  with	  
the	  doctor	  and/or	  nurse	  that	  you	  saw	  today	  when	  
answering	  the	  questions.	  
Nobody	  in	  the	  clinic	  or	  NHS	  board	  will	  know	  that	  you	  
have	  taken	  part	  in	  the	  survey,	  and	  they	  will	  only	  see	  
anonymous	  results.	  	  The	  information	  will	  help	  to	  
improve	  the	  service	  we	  provide	  at	  the	  diabetes	  clinic.	  
If	  you	  have	  any	  questions	  or	  need	  help	  filling	  in	  the	  
survey,	  please	  ask	  at	  the	  clinic	  reception	  desk.	  	  Please	  
take	  a	  few	  minutes	  to	  complete	  the	  survey	  at	  the	  end	  
of	  your	  appointment	  and	  return	  it	  in	  the	  box	  on	  your	  
way	  out.	  	  If	  you	  don’t	  have	  the	  time	  to	  complete	  it	  
today,	  you	  can	  return	  it	  to	  the	  address	  below	  in	  the	  
envelope	  provided	  or	  you	  can	  complete	  it	  on	  online	  at	  
http://tinyurl.com/obvvl93.	  	  
Thank	  you	  very	  much	  for	  your	  time.	  
Yours	  sincerely,	  
Dr	  Nicholas	  Conway	  
Senior	  clinical	  research	  fellow/honorary	  consultant	  
University	  of	  Dundee	  and	  NHS	  Tayside	  
MACHS	  building,	  Ninewells	  Hospital,	  	  	  
Dundee,	  DD1	  9SY.	  
Some	  Questions	  &	  Answers	  
What	  is	  this	  survey	  for?	  
The	  survey	  asks	  about	  your	  experiences	  with	  the	  
diabetes	  clinic	  during	  this	  most	  recent	  appointment.	  	  
We	  have	  recently	  changed	  some	  features	  of	  the	  
computer	  system	  used	  by	  the	  doctors	  and	  nurses	  and	  
we	  are	  interested	  in	  finding	  out	  if	  this	  has	  had	  any	  
effect	  on	  your	  appointment.	  	  The	  information	  that	  you	  
give	  is	  important	  because	  it	  will	  help	  us	  to	  understand	  
more	  about	  the	  quality	  of	  service,	  and	  what	  needs	  to	  
be	  improved.	  	  The	  University	  of	  Dundee	  Research	  
Ethics	  Committee	  has	  reviewed	  and	  approved	  this	  
study.	  
Can	  someone	  help	  me	  with	  this	  survey?	  
A	  relative,	  friend	  or	  carer	  may	  help	  you	  to	  fill	  in	  the	  
survey,	  but	  please	  remember	  that	  you	  should	  give	  all	  
of	  the	  answers	  from	  your	  own	  point	  of	  view.	  	  
Do	  I	  have	  to	  answer	  every	  question?	  
No,	  taking	  part	  is	  voluntary,	  and	  you	  don’t	  have	  to	  
answer	  every	  question	  if	  you	  don’t	  want	  to.	  	  Please	  fill	  
in	  as	  much	  as	  you	  can	  though,	  because	  the	  more	  that	  
people	  answer,	  the	  more	  we	  can	  understand	  about	  
the	  different	  experiences	  of	  people	  across	  Tayside.	  	  
Sometimes	  we	  will	  ask	  you	  to	  skip	  a	  question	  if	  it	  
doesn’t	  apply	  to	  you.	  
Will	  my	  doctor	  or	  nurse	  see	  my	  answers?	  
No.	  	  The	  staff	  at	  the	  clinic	  do	  not	  know	  who	  has	  filled	  
in	  the	  survey,	  and	  they	  will	  only	  see	  anonymous	  
results.	  
What	  happens	  to	  the	  results?	  
The	  survey	  results	  will	  be	  presented	  at	  local	  meetings	  
and	  will	  be	  included	  in	  a	  report	  to	  be	  published	  in	  a	  
medical	  journal	  that	  is	  available	  to	  the	  public.	  	  This	  
report	  will	  only	  contain	  anonymous	  results.	  
You	  can	  fill	  in	  the	  survey	  online	  at	  http://tinyurl.com/obvvl93	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1. What	  is	  your	  name?
2. Did	  you	  see	  a	  doctor	  when	  you	  visited	  the
diabetes	  clinic	  today?
No	   □ Go	  straight	  to	  question	  9
Yes	   □
Seeing	  the	  doctor	  
Thinking	  about	  the	  last	  time	  you	  saw	  a	  doctor	  at	  
the	  diabetes	  clinic,	  how	  much	  do	  you	  agree	  or	  
disagree	  with	  each	  of	  the	  following?	  
Please	  select	  one	  choice	  for	  each	  of	  the	  
following	  statements	  
3. The	  doctor	  listened	  to	  me
Strongly	  
agree	   Agree	   Neutral	   Disagree	  
Strongly	  
disagree	  
□	   □	   □	   □	   □	  
4. I	  felt	  that	  the	  doctor	  had	  all	  the
information	  needed	  to	  treat	  me
Strongly	  
agree	   Agree	   Neutral	   Disagree	  
Strongly	  
disagree	  
□	   □	   □	   □	   □	  
5. The	  doctor	  was	  considerate	  and
understanding
Strongly	  
agree	   Agree	   Neutral	   Disagree	  
Strongly	  
disagree	  
□	   □	   □	   □	   □	  
6. The	  doctor	  talked	  in	  a	  way	  that	  helped	  me
understand	  my	  condition	  and	  treatment
Strongly	  
agree	   Agree	   Neutral	   Disagree	  
Strongly	  
disagree	  
□	   □	   □	   □	   □	  
7. I	  felt	  confident	  in	  the	  doctor’s	  ability	  to
treat	  me
Strongly	  
agree	   Agree	   Neutral	   Disagree	  
Strongly	  
disagree	  
□	   □	   □	   □	   □	  
8. I	  had	  enough	  time	  with	  the	  doctor
Strongly	  
agree	   Agree	   Neutral	   Disagree	  
Strongly	  
disagree	  
□	   □	   □	   □	   □	  
9. Did	  you	  see	  a	  nurse	  when	  you	  visited	  the
diabetes	  clinic	  today?
No	   □ Go	  straight	  to	  question	  16
Yes	   □
Seeing	  the	  nurse	  
Thinking	  about	  the	  last	  time	  you	  saw	  a	  nurse	  at	  
the	  diabetes	  clinic,	  how	  much	  do	  you	  agree	  or	  
disagree	  with	  each	  of	  the	  following?	  
Please	  select	  one	  choice	  for	  each	  of	  the	  
following	  statements	  
10. The	  nurse	  listened	  to	  me
Strongly	  
agree	   Agree	   Neutral	   Disagree	  
Strongly	  
disagree	  
□	   □	   □	   □	   □	  
11. I	  felt	  that	  the	  nurse	  had	  all	  the	  information
needed	  to	  treat	  me
Strongly	  
agree	   Agree	   Neutral	   Disagree	  
Strongly	  
disagree	  
□	   □	   □	   □	   □	  
12. The	  nurse	  was	  considerate	  and
understanding
Strongly	  
agree	   Agree	   Neutral	   Disagree	  
Strongly	  
disagree	  
□	   □	   □	   □	   □	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13. The	  nurse	  talked	  in	  a	  way	  that	  helped	  me
understand	  my	  condition	  and	  treatment
Strongly	  
agree	   Agree	   Neutral	   Disagree	  
Strongly	  
disagree	  
□	   □	   □	   □	   □	  
14. I	  felt	  confident	  in	  the	  nurse’s	  ability	  to
treat	  me
Strongly	  
agree	   Agree	   Neutral	   Disagree	  
Strongly	  
disagree	  
□	   □	   □	   □	   □	  
15. I	  had	  enough	  time	  with	  the	  nurse
Strongly	  
agree	   Agree	   Neutral	   Disagree	  
Strongly	  
disagree	  
□	   □	   □	   □	   □	  
16. When	  you	  visited	  the	  diabetes	  clinic	  today,
were	  you	  started	  on	  any	  new	  medicines	  or
were	  your	  existing	  medicines	  changed?
No	   □ Go	  straight	  to	  question	  22
Yes	   □
Having	  your	  medicines	  changed	  
Thinking	  about	  the	  change	  in	  your	  medicines	  
made	  at	  the	  diabetes	  clinic,	  how	  much	  do	  you	  
agree	  or	  disagree	  with	  each	  of	  the	  following?	  
Please	  select	  one	  choice	  for	  each	  of	  the	  
following	  statements	  
17. I	  knew	  enough	  about	  what	  my	  medicines
were	  for
Strongly	  
agree	   Agree	   Neutral	   Disagree	  
Strongly	  
disagree	  
□	   □	   □	   □	   □	  
18. I	  knew	  enough	  about	  how	  and	  when	  to
take	  my	  medicines
Strongly	  
agree	   Agree	   Neutral	   Disagree	  
Strongly	  
disagree	  
□	   □	   □	   □	   □	  
19. I	  knew	  enough	  about	  possible	  side	  effects
of	  my	  medicines
Strongly	  
agree	   Agree	   Neutral	   Disagree	  
Strongly	  
disagree	  
□	   □	   □	   □	   □	  
20. I	  would	  know	  what	  to	  do	  if	  I	  had	  any
problems	  with	  my	  medicines
Strongly	  
agree	   Agree	   Neutral	   Disagree	  
Strongly	  
disagree	  
□	   □	   □	   □	   □	  
21. I	  took	  my	  prescription	  as	  I	  was	  supposed	  to
Strongly	  
agree	   Agree	   Neutral	   Disagree	  
Strongly	  
disagree	  
□	   □	   □	   □	   □	  
Your	  overall	  experience	  
How	  much	  do	  you	  agree	  or	  disagree	  with	  each	  of	  
the	  following	  about	  how	  you	  are	  treated	  by	  the	  
staff	  at	  the	  diabetes	  clinic?	  
Please	  select	  one	  choice	  for	  each	  of	  the	  
following	  statements	  
22. I	  am	  treated	  with	  dignity	  and	  respect
Strongly	  
agree	   Agree	   Neutral	   Disagree	  
Strongly	  
disagree	  
□	   □	   □	   □	   □	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23. I	  am	  treated	  with	  kindness	  and
understanding
Strongly	  
agree	   Agree	   Neutral	   Disagree	  
Strongly	  
disagree	  
□	   □	   □	   □	   □	  
24. Are	  you	  involved	  as	  much	  as	  you	  want	  to
be	  in	  decisions	  about	  your	  care	  and
treatment?
Please	  tick	  ONE	  choice	  only	  
I	  am	  involved	  more	  than	  I	  want	  to	  be	   □	  
I	  am	  involved	  as	  much	  as	  I	  want	  to	  be	   □
I	  am	  not	  involved	  enough	   □
I	  do	  not	  wish	  to	  be	  involved	   □
Not	  relevant	   □
25. Overall,	  how	  would	  you	  rate	  the	  care
provided	  by	  the	  diabetes	  clinic?
Excellent	   Good	   Fair	   Poor	   Very	  poor	  
□	   □	   □	   □	   □	  
26. If	  there	  is	  anything	  else	  you	  would	  like	  to
tell	  us	  about	  your	  experience	  at	  your	  most
recent	  visit	  to	  the	  diabetes	  clinic,	  please
feel	  free	  to	  add	  this	  below
About	  you	  
This	  information	  will	  help	  us	  to	  find	  out	  if	  different	  
groups	  of	  people	  in	  Tayside	  have	  different	  experience	  
of	  treatment	  at	  their	  outpatient	  clinic.	  Nobody	  at	  your	  
clinic	  will	  be	  able	  to	  see	  your	  answers.	  If	  you	  would	  
prefer	  not	  to	  answer	  a	  particular	  question	  then	  you	  
can	  miss	  it	  out.	  
27. Are	  you	  male	  or	  female?
Please	  tick	  ONE	  choice	  only	  
Male	   □
Female	   □
28. What	  year	  were	  you	  born?
29. What	  is	  your	  postcode?
30. How	  would	  you	  rate	  your	  health	  in
general?
Please	  tick	  ONE	  choice	  only	  
Good	   □	  
Fair	   □	  
Bad	   □	  
31. What	  is	  your	  ethnic	  group?
Tick	  ONE	  box	  which	  best	  describes	  your	  
ethnic	  group	  
White	   □
Mixed	  or	  multiple	  ethnic	  groups	   □	  
Asian,	  Asian	  Scottish	  or	  Asian	  British	   □	  
African,	  Caribbean	  or	  Black	   □	  
Other	  ethnic	  group	   □
32. Do	  you	  need	  an	  interpreter	  or	  other	  help
to	  communicate?
Please	  tick	  ONE	  choice	  only	  
No	   □
Yes	   □
This	  is	  the	  end	  of	  the	  questionnaire.	  	  Thank	  you	  
for	  taking	  the	  time	  to	  complete	  it.	  	  	  
Please	  return	  it	  in	  box	  in	  the	  clinic	  or	  post	  it	  to	  
the	  address	  at	  the	  front	  using	  the	  envelope	  
provided.	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Survey of attitudes towards 
clinical decision support systems 
Dear sir/madam, 
I would like to invite you to take part in a survey about 
your use of clinical guidelines and other evidence when 
making clinical decisions, and how this fits into your 
everyday working.  
It is important that we get the opinions of as many 
people as possible, so please take a few minutes to 
complete the survey if you can. 
I would be grateful if you could complete the following 
questions, regardless of whether or not you are a 
frequent user of SCI-Diabetes.  The questionnaire 
consists of 36 questions in total and should take you less 
than 5 minutes to complete.  Further information about 
the survey is available on the attached participant 
information sheet. 
You can fill in the survey in one of 3 ways: 
1. Print it out and post the completed form back to
the address below
2. Or, fill it in electronically and send it as an
attachment to n.z.conway@dundee.ac.uk
3. Or, complete the survey online by clicking on
this link: http://tinyurl.com/qgak7a9
If you have any questions about the survey or the 
project in general, please contact me via email at 
n.z.conway@dundee.ac.uk.  Thank you very much for 
your time. 
Yours sincerely, 
Dr Nicholas Conway 
Senior clinical research fellow/honorary consultant 
University of Dundee and NHS Tayside 
MACHS building, Ninewells Hospital,   
Dundee, DD1 9SY 
About you 
1. What is your age?
Please tick ONE choice only 
20-29 years □
30-39 years □ 
40-49 years □ 
50-59 years □ 
60+ years □
2. How many hours do you work on average
per week?
Please tick ONE choice only 
Up to 16 hours □
17-32 hours □ 
33 hours or more □ 
3. Where do you work?
Please tick ONE choice only 
Primary care □
Secondary care □ 
Both primary and secondary care □ 
Other □ 
4. What is the name of the practice in which
you are based?
5. Which of the following best describes your
job?
Please tick ONE choice only 
Doctor □
Nurse □ 
Allied heath professional □ 
Other □ 
You can fill in the survey online at http://tinyurl.com/qgak7a9 
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Your work with patients with diabetes 
6. Are you a registered user of SCI-Diabetes?
Yes □ No □ Don’t know □
7. How long have you worked with people
with diabetes?
Please tick ONE choice only 
Less than 5 years □
5 to 10 years □ 
More than 10 years □ 
8. Which, if any, protocols or guidelines do
you use when managing patients with
diabetes?
Select any number of the following choices 
NHS Tayside Diabetes Managed 
Clinical Network Handbook 
□
SIGN guideline □ 
NICE guideline □ 
None of the above □ 
Other □
9. In an average week, how long do you
spend searching and/or reading diabetes-
related literature (including guidelines)?
Please tick ONE choice only 
Less than 1 hour □
1 to 5 hours □ 
More than 5 hours □ 
Your use of guidelines and literature 
10. When do you access diabetes-related
guidelines and/or literature
For each column, please select any number of the 
following choices 
Guidelines Literature 
Before the consultation □ □
During the consultation □ □ 
After the consultation □ □ 
Unrelated to the 
consultation □ □ 
Never □ □ 
11. How do you access this diabetes-related
guidelines and/or literature?
For each column, please select any number of the 
following choices 
Guidelines Literature 
Textbooks (hard copy) □ □
Journals (hard copy) □ □ 
Computer at work □ □ 
Computer at home  □ □ 
Not applicable □ □ 
Other □ □ 
12. How often does your reading affect your
clinical practice?
For each column, please tick ONE choice only 
Guidelines Literature 
Never □ □
Seldom □ □ 
Sometimes □ □ 
Often  □ □ 
Not applicable □ □ 
13. What are the most common reasons for
choosing NOT to follow a guideline?
Select any number of the following choices 
Not applicable, I always follow guidelines □
Experience tells me the guideline is incorrect □ 
The guideline fails to take into account 
patient co-morbidities □ 
The guideline is difficult to access □ 
The guideline contradicts or is in conflict 
with guidelines for other conditions □ 
The guideline contradicts or is in conflict 
with local policy □ 
Other □ 
NHS Tayside Clinical Decision Support HCP 
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For each of the following statements, please select 
ONE response to show how much you agree or 
disagree with it.  
14. When I have a clinical query, I usually ask a
colleague for advice
Strongly 
agree Agree Neutral Disagree 
Strongly 
disagree 
□ □ □ □ □ 
15. When I have a clinical query, I usually look
for the answer in the literature and/or
guidelines.
Strongly 
agree Agree Neutral Disagree 
Strongly 
disagree 
□ □ □ □ □ 
16. When I have a clinical query, I usually
manage to find the time to find the
answer.
Strongly 
agree Agree Neutral Disagree 
Strongly 
disagree 
□ □ □ □ □ 
17. When I search for relevant literature
and/or guidelines, I usually find what I am
looking for.
Strongly 
agree Agree Neutral Disagree 
Strongly 
disagree 
□ □ □ □ □ 
18. I feel comfortable overriding a guideline if I
feel it is not in the patient's best interests.
Strongly 
agree Agree Neutral Disagree 
Strongly 
disagree 
□ □ □ □ □ 
19. When I search for relevant literature
and/or guidelines, I would like this to
count towards my continuing professional
development (CPD).
Strongly 
agree Agree Neutral Disagree 
Strongly 
disagree 
□ □ □ □ □ 
20. When I search for relevant literature
and/or guidelines, I always record it as
CPD.
Strongly 
agree Agree Neutral Disagree 
Strongly 
disagree 
□ □ □ □ □ 
21. I would like it if my CPD is automatically
recorded when I read literature and/or
guidelines.
Strongly 
agree Agree Neutral Disagree 
Strongly 
disagree 
□ □ □ □ □ 
Your attitude to decision support systems 
Decision support is when you are automatically 
alerted to the presence of an abnormal result or a 
potential problem.   This is usually when using an 
electronic health record (like SCI-Diabetes).  The alert 
might also suggest what might be appropriate 
management of the problem. 
22. Have you ever been aware of using a
decision support system in the past?
Please tick ONE choice only 
Yes □
No □ 
Don’t know □ 
23. If yes, when did you find it most useful
Select any number of the following choices 
Before the consultation □
During the consultation □ 
After the consultation □ 
Unrelated to the consultation □ 
Not applicable □ 
For each of the following statements, please select 
ONE response to show how much you agree or 
disagree with it. 
NHS Tayside Clinical Decision Support HCP 
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24. I would trust the advice given by an
automated message delivered by a clinical
decision support system (CDSS).
Strongly 
agree Agree Neutral Disagree 
Strongly 
disagree 
□ □ □ □ □ 
25. I would want to know the evidence behind
the advice given by the CDSS.
Strongly 
agree Agree Neutral Disagree 
Strongly 
disagree 
□ □ □ □ □ 
26. I think that CDSS could help me when
prescribing medication.
Strongly 
agree Agree Neutral Disagree 
Strongly 
disagree 
□ □ □ □ □ 
27. I think that CDSS could help me when
deciding when/when not to request
investigations.
Strongly 
agree Agree Neutral Disagree 
Strongly 
disagree 
□ □ □ □ □ 
28. I think that using a CDSS could lead to a
better quality of care.
Strongly 
agree Agree Neutral Disagree 
Strongly 
disagree 
□ □ □ □ □ 
29. I would find messages from a CDSS
annoying after a while
Strongly 
agree Agree Neutral Disagree 
Strongly 
disagree 
□ □ □ □ □ 
30. I would worry that some people might
come to rely on messages from the CDSS.
Strongly 
agree Agree Neutral Disagree 
Strongly 
disagree 
□ □ □ □ □ 
31. I would feel comfortable choosing to
ignore the advice from the CDSS if I felt it
was justified.
Strongly 
agree Agree Neutral Disagree 
Strongly 
disagree 
□ □ □ □ □ 
32. I worry that messages from a CDSS might
affect the consultation and/or my
relationship with the patient.
Strongly 
agree Agree Neutral Disagree 
Strongly 
disagree 
□ □ □ □ □ 
33. 4.12 If a CDSS was implemented, I would
like the option to turn it off.
Strongly 
agree Agree Neutral Disagree 
Strongly 
disagree 
□ □ □ □ □ 
Any other comments 
34. If you have previously used a CDSS, what
are the things you like best about them?
35. If you have previously used a CDSS, what
are the things you dislike most about
them?
36. Please feel free to tell us any other
concerns or suggestions that would help in
the development process.
This is the end of the questionnaire.  Thank you 
for taking the time to complete it.  Please return 
it to the box at the door. 
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  –	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  survey	  
Dear	  sir/madam,	  
Thanks	  for	  agreeing	  to	  take	  part	  in	  this	  survey.	  	  It	  is	  
designed	  to	  assess	  how	  well	  the	  EBMeDS	  clinical	  alert	  
system	  within	  SCI-­‐Diabetes	  is	  performing,	  and	  hopefully	  
help	  us	  improve	  it.	  
I	  would	  be	  grateful	  if	  you	  could	  complete	  the	  following	  
questions,	  regardless	  of	  whether	  or	  not	  you	  have	  
received	  any	  clinical	  alerts	  whilst	  working	  with	  SCI-­‐
Diabetes	  in	  the	  past	  couple	  of	  months.	  	  The	  
questionnaire	  is	  designed	  in	  6	  parts	  and	  should	  take	  you	  
less	  than	  5	  minutes	  to	  complete.	  	  	  
All	  of	  the	  information	  that	  you	  provide	  will	  be	  treated	  in	  
a	  confidential	  manner	  and	  we	  will	  always	  ensure	  that	  
your	  anonymity	  is	  protected.	  
You	  can	  fill	  in	  the	  survey	  in	  one	  of	  2	  ways:	  
1. Print	  it	  out	  and	  post	  the	  completed	  form	  back	  to
the	  address	  below
2. Or,	  complete	  the	  survey	  online	  by	  clicking	  on
this	  link:
If	  you	  have	  any	  questions	  about	  the	  survey	  or	  the	  
project	  in	  general,	  please	  contact	  me	  via	  email	  at	  
n.z.conway@dundee.ac.uk.	  	  Thank	  you	  very	  much	  for	  
your	  time.	  
Yours	  sincerely,	  
Dr	  Nicholas	  Conway	  
Senior	  clinical	  research	  fellow/honorary	  consultant	  
University	  of	  Dundee	  and	  NHS	  Tayside	  
MACHS	  building,	  Ninewells	  Hospital,	  	  	  
Dundee,	  DD1	  9SY	  
About	  you	  
1. Are	  you	  a	  registered	  user	  of	  SCI-­‐Diabetes?
Yes	   □ No	   □	   Don’t	  know	   □
If	  yes,	  proceed	  to	  
question	  2	  
If	  no,	  then	  please	  
forward	  this	  to	  a	  SCI-­‐
Diabetes	  user	  within	  
your	  workplace.	  Thanks.	  
2. What	  is	  your	  age?
Please	  tick	  ONE	  choice	  only	  
20-­‐29	  years	   □
30-­‐39	  years	   □	  
40-­‐49	  years	   □	  
50-­‐59	  years	   □	  
60+	  years	   □
3. How	  many	  hours	  do	  you	  work	  on	  average
per	  week?
Please	  tick	  ONE	  choice	  only	  
Up	  to	  16	  hours	   □
17-­‐32	  hours	   □	  
33	  hours	  or	  more	   □	  
4. Where	  do	  you	  work?
Please	  tick	  ONE	  choice	  only	  
Primary	  care	   □
Secondary	  care	   □	  
Both	  primary	  and	  secondary	  care	   □	  
Other	   □	  
5. What	  is	  the	  name	  of	  the	  practice/hospital
in	  which	  you	  are	  based?
6. Which	  of	  the	  following	  best	  describes	  your
job?
Please	  tick	  ONE	  choice	  only	  
Doctor	   □
Nurse	   □	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Allied	  heath	  professional	   □	  
Other	   □	  
Your	  work	  with	  patients	  with	  diabetes	  
	  
7. How	  long	  have	  you	  worked	  with	  people	  
with	  diabetes?	  
Please	  tick	  ONE	  choice	  only	  
Less	  than	  5	  years	   □	  
5	  to	  10	  years	   □	  
More	  than	  10	  years	   □	  
8. Which,	  if	  any,	  protocols	  or	  guidelines	  do	  
you	  use	  when	  managing	  patients	  with	  
diabetes?	  
Select	  any	  number	  of	  the	  following	  choices	  
NHS	  Tayside	  Diabetes	  Managed	  
Clinical	  Network	  Handbook	   □	  
SIGN	  guideline	   □	  
NICE	  guideline	   □	  
None	  of	  the	  above	   □	  
Other	   □	  
9. In	  an	  average	  week,	  how	  long	  do	  you	  
spend	  searching	  and/or	  reading	  diabetes-­‐
related	  literature	  (including	  guidelines)?	  
Please	  tick	  ONE	  choice	  only	  
Less	  than	  1	  hour	   □	  
1	  to	  5	  hours	   □	  
More	  than	  5	  hours	   □	  
10. Does	  your	  reading	  affect	  your	  clinical	  
practice?	  
Please	  tick	  ONE	  choice	  only	  
Never	   □	  
Seldom	   □	  
Sometimes	   □	  
Often	  	   □	  
Not	  applicable	   □	  
	  
11. Over	  the	  past	  couple	  of	  months,	  how	  often	  
have	  you	  received	  an	  EBMeDS	  clinical	  alert	  
whilst	  using	  SCI-­‐Diabetes?	  
Please	  tick	  ONE	  choice	  only	  
Seldom	   □	  
Sometimes	   □	  
Often	  	  □	  
Never	   □	  
Not	  applicable	   □	  
	   	  
	   	  
Your	  work	  and	  EBMeDS	  
	  
For	  each	  of	  the	  following	  statements,	  please	  select	  
ONE	  response	  to	  show	  how	  much	  you	  agree	  or	  
disagree	  with	  it.	  
12. The	  clinical	  alerts	  have	  changed	  my	  way	  of	  
working	  
Strongly	  
agree	   Agree	   Neutral	   Disagree	  
Strongly	  
disagree	  
□	   □	   □	   □	   □	  
	  
13. The	  clinical	  alerts	  have	  made	  me	  more	  
careful	  when	  prescribing	  medication.	  
Strongly	  
agree	   Agree	   Neutral	   Disagree	  
Strongly	  
disagree	  
□	   □	   □	   □	   □	  
	  
14. The	  clinical	  alerts	  have	  influenced	  my	  
decision	  when/when	  not	  to	  request	  
investigations.	  
Strongly	  
agree	   Agree	   Neutral	   Disagree	  
Strongly	  
disagree	  
□	   □	   □	   □	   □	  
	  
15. I	  think	  that	  using	  the	  EBMeDS	  system	  
improves	  my	  clinical	  knowledge.	  
Strongly	  
agree	   Agree	   Neutral	   Disagree	  
Strongly	  
disagree	  
If	  never	  or	  not	  applicable,	  please	  stop	  here	  and	  return	  
questionnaire	  to	  the	  address	  provided	  
EBMeDS	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□	   □	   □	   □	   □	  
	  
16. The	  use	  of	  the	  EBMeDS	  clinical	  alerts	  
system	  could	  lead	  to	  better	  quality	  of	  care.	  
Strongly	  
agree	   Agree	   Neutral	   Disagree	  
Strongly	  
disagree	  
□	   □	   □	   □	   □	  
Your	  overall	  opinion	  on	  the	  EBMeDS	  
clinical	  alert	  system	  
For	  each	  of	  the	  following	  statements,	  please	  select	  
ONE	  response	  to	  show	  how	  much	  you	  agree	  or	  
disagree	  with	  it.	  
17. I	  felt	  that	  I	  was	  given	  sufficient	  information	  
before	  the	  EBMeDS	  system	  was	  
introduced.	  
Strongly	  
agree	   Agree	   Neutral	   Disagree	  
Strongly	  
disagree	  
□	   □	   □	   □	   □	  
	  
18. Technical	  support	  is	  available	  when	  I	  need	  
it.	  
Strongly	  
agree	   Agree	   Neutral	   Disagree	  
Strongly	  
disagree	  
□	   □	   □	   □	   □	  
	  
19. Using	  the	  system	  fits	  in	  well	  with	  the	  way	  I	  
like	  to	  work.	  
Strongly	  
agree	   Agree	   Neutral	   Disagree	  
Strongly	  
disagree	  
□	   □	   □	   □	   □	  
	  
20. Overall,	  I	  am	  satisfied	  with	  the	  EBMeDS	  
system.	  
Strongly	  
agree	   Agree	   Neutral	   Disagree	  
Strongly	  
disagree	  
□	   □	   □	   □	   □	  
	  
21. I	  would	  recommend	  the	  use	  of	  the	  
EBMeDS	  system	  to	  others.	  
Strongly	  
agree	   Agree	   Neutral	   Disagree	  
Strongly	  
disagree	  
□	   □	   □	   □	   □	  
	  
22. I	  use	  the	  EBMeDS	  system	  mainly	  because	  
my	  colleagues	  do.	  
Strongly	  
agree	   Agree	   Neutral	   Disagree	  
Strongly	  
disagree	  
□	   □	   □	   □	   □	  
	  
23. Using	  the	  EBMeDS	  clinical	  alerts	  system	  
enables	  me	  to	  accomplish	  my	  tasks	  more	  
quickly.	  
Strongly	  
agree	   Agree	   Neutral	   Disagree	  
Strongly	  
disagree	  
□	   □	   □	   □	   □	  
	  
24. I	  intend	  to	  keep	  using	  the	  EBMeDS	  system.	  
Strongly	  
agree	   Agree	   Neutral	   Disagree	  
Strongly	  
disagree	  
□	   □	   □	   □	   □	  
Your	  interaction	  with	  EBMeDS	  
For	  each	  of	  the	  following	  statements,	  please	  select	  
ONE	  response	  to	  show	  how	  much	  you	  agree	  or	  
disagree	  with	  it.	  	  
25. The	  EBMeDS	  clinical	  alerts	  system	  is	  easy	  
to	  use.	  
Strongly	  
agree	   Agree	   Neutral	   Disagree	  
Strongly	  
disagree	  
□	   □	   □	   □	   □	  
26. I	  quickly	  adapted	  to	  using	  the	  EBMeDS	  
clinical	  alerts	  
Strongly	  
agree	   Agree	   Neutral	   Disagree	  
Strongly	  
disagree	  
□	   □	   □	   □	   □	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27. I	  always	  read	  the	  EBMeDS	  clinical	  alerts
(these	  are	  the	  messages	  shown	  in	  the	  pop-­‐
up	  box).
Strongly	  
agree	   Agree	   Neutral	   Disagree	  
Strongly	  
disagree	  
□	   □	   □	   □	   □	  
28. I	  always	  read	  the	  guidelines	  cited	  by
EBMeDS	  (these	  are	  accessed	  by	  using	  the
links	  contained	  within	  the	  case	  record
clinical	  alerts	  page).
Strongly	  
agree	   Agree	   Neutral	   Disagree	  
Strongly	  
disagree	  
□	   □	   □	   □	   □	  
29. The	  EBMeDS	  system	  is	  too	  slow.
Strongly	  
agree	   Agree	   Neutral	   Disagree	  
Strongly	  
disagree	  
□	   □	   □	   □	   □	  
30. I	  regularly	  experience	  technical	  problems
when	  using	  the	  EBMeDS	  system.
Strongly	  
agree	   Agree	   Neutral	   Disagree	  
Strongly	  
disagree	  
□	   □	   □	   □	   □	  
Your	  opinion	  on	  the	  content	  of	  the	  
messages	  
For	  each	  of	  the	  following	  statements,	  please	  select	  
ONE	  response	  to	  show	  how	  much	  you	  agree	  or	  
disagree	  with	  it.	  	  
31. The	  EBMeDS	  clinical	  alerts	  are	  relevant	  to
my	  practice.
Strongly	  
agree	   Agree	   Neutral	   Disagree	  
Strongly	  
disagree	  
□	   □	   □	   □	   □	  
32. I	  am	  satisfied	  with	  the	  clinical	  alerts	  that
EBMeDS	  gives.
Strongly	  
agree	   Agree	   Neutral	   Disagree	  
Strongly	  
disagree	  
□	   □	   □	   □	   □	  
33. I	  am	  satisfied	  with	  the	  reliability	  of	  the
EBMeDS	  system.
Strongly	  
agree	   Agree	   Neutral	   Disagree	  
Strongly	  
disagree	  
□	   □	   □	   □	   □	  
34. I	  am	  satisfied	  with	  the	  guidelines
suggested	  by	  EBMeDS.
Strongly	  
agree	   Agree	   Neutral	   Disagree	  
Strongly	  
disagree	  
□	   □	   □	   □	   □	  
35. The	  EBMeDS	  clinical	  alerts	  are	  not	  specific
enough.
Strongly	  
agree	   Agree	   Neutral	   Disagree	  
Strongly	  
disagree	  
□	   □	   □	   □	   □	  
36. I	  feel	  comfortable	  overriding	  the	  advice
given	  by	  the	  EBMeDS	  system	  if	  I	  feel	  it’s
not	  in	  the	  patient’s	  best	  interests.
Strongly	  
agree	   Agree	   Neutral	   Disagree	  
Strongly	  
disagree	  
□	   □	   □	   □	   □	  
37. I	  don't	  think	  the	  information	  provided	  by
EBMeDS	  is	  of	  sufficient	  quality.
Strongly	  
agree	   Agree	   Neutral	   Disagree	  
Strongly	  
disagree	  
□	   □	   □	   □	   □	  
38. The	  EBMeDS	  clinical	  alerts	  communicate
the	  message	  in	  a	  clear	  way.
Strongly	  
agree	   Agree	   Neutral	   Disagree	  
Strongly	  
disagree	  
□	   □	   □	   □	   □	  
39. I	  would	  prefer	  it	  if	  the	  guidelines	  referred
to	  by	  the	  clinical	  alert	  were	  available
within	  SCI-­‐Diabetes	  (as	  opposed	  to	  an
external	  site)
Strongly	  
agree	   Agree	   Neutral	   Disagree	  
Strongly	  
disagree	  
□	   □	   □	   □	   □	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40. What	  are	  the	  most	  common	  reasons	  for
choosing	  NOT	  to	  follow	  the	  advice	  given	  by
EBMeDS?
Yes	   No	  
Not	  applicable,	  I	  always	  follow	  the	  
advice	  given	  □	   □
Experience	  tells	  me	  that	  the	  advice	  
given	  is	  incorrect	  □	   □	  
The	  advice	  fails	  to	  take	  into	  account	  
patient	  co-­‐morbidities	  □	   □	  
The	  advice	  fails	  to	  take	  into	  account	  
patient	  circumstances	  	  □	   □	  
The	  advice	  is	  difficult	  to	  access	  □	   □	  
The	  advice	  contradicts	  or	  is	  in	  conflict	  
with	  guidelines	  for	  other	  conditions	  □	   □	  
The	  advice	  contradicts	  or	  is	  in	  conflict	  
with	  local	  policy	  □	   □	  
Other(please	  specify):_______________	  
Ways	  to	  make	  EBMeDS	  better	  
41. What	  are	  the	  things	  you	  like	  best	  about
EBMeDS?
42. What	  are	  the	  things	  you	  dislike	  most	  about
EBMeDS?
43. What	  are	  the	  most	  common	  reasons	  for
ignoring	  the	  EBMeDS	  clinical	  alerts?
44. What	  would	  help	  you	  in	  deciding	  to	  use
the	  EBMeDS	  clinical	  alerts	  more?
45. What	  improvements	  could	  be	  made	  to	  the
EBMeDS	  system?
This	  is	  the	  end	  of	  the	  questionnaire.	  	  Thank	  you	  
for	  taking	  the	  time	  to	  complete	  it.	  	  Please	  return	  
it	  to	  the	  address	  shown	  on	  page	  1.	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17. Appendix: Focus group topic guide
17.1 Part 1: Introductions 
Introduce self and current role within research team 
Reason for research 
o EBMeDS pilot – describe system
o Baseline data to evaluate attitudes to system
Objectives 
o Role of SCI-diabetes in participants’ everyday work
o Role of guidelines etc in management decisions
o Attitude to clinical decision support
o Potential barriers/facilitators to effective adoption
Housekeeping 
o Confidentiality of data and anonymisation process
o Recording of data and transcription
o Archiving
17.2 Part 2: Main discussion
Participant’s background 
o Role within MDT
 Examples of management decision that participant might have to make
 In the past week, how many drug changes/referrals to other
specialities/screening tests requested.
Use of Sci-Diabetes 
o Attitude to computers in general
 General attitude to computers at work
 Use of computers out with work space
o When is data entered – before/during/after consultation
o Other times when SCI-Diabetes is accessed
 When
 Purpose
o Barriers to current usage – time, context, doctor-patient relationship, UI, hardware
o Potential improvements to SCI-Diabetes?
How to apply best practice guidelines to the management of patients with diabetes 
o Overall attitude to current practice in general
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 What  works well
 What could be improved
o Resources currently used
 Tayside handbook, SIGN, NICE, google, websites (name), textbook, journals,
BNF, colleagues?
 How references are accessed – electronic, book
 When are these used – before/during/after
 Perceived need for references: “in the past week, how many times have you
felt the need to refer to....” 
 Actual use of references: “in the past week.....”
 What proportion of these was enquiry successful i.e. info found
 If discrepancy between perceived and actual – why?
o Role of guidelines when managing those with complex co-morbidities
 Do guidelines help or hinder?
 Need to over-ride guidelines – frequency, instances, problems with doing
this?
o Accreditation of CPD
 Attitude to automated system of collecting.
Attitude to decision support tools 
“Imagine you had a clinical query regarding a problem patient...” 
o Attitude to other colleagues’ recommendations
 Confidence and trust/acceptance in implementing advice directly
 Factors which influence decision – seniority of adviser, time, access
to appropriate resource, individual experience (trust judgment of
colleague)
o Attitude to automated recommendations
 Non-specific versus tailored – preference
 Value of non-specific advice – how often is it followed - some/all/never
 General opinion on the EBMeDS system as described
 Attitude to tailored advice – confidence and trust/acceptance
 More or less trusted than senior colleague
 Potential role in consultation
 Value placed in prompt
o Pay attention? Nuisance? Noise? Alert fatigue?
 Reassurance from lack of prompt
o Would you gain reassurance?
 Can you see it changing your practice?
o Perceived barriers to implementation
 Expand on each
 Strategies to overcome each
Conclude. 
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18. Appendix: SPSS syntax for data cleaning
The following is an account of the process used to clean SCI-Diabetes navigation data obtained for 
cycle 1 of the project. 
The following syntax was developed to initially clean the data: 
Number of rows of data (n)=760,666 
*Filter out all non-patient related activity.
FILTER OFF. 
USE ALL. 
SELECT IF (LinkId > 0). 
EXECUTE. 
n=684,601.  Saved as “…cleaning1.sav” 
*assign value to missing values in message by recoding into message_coded.
AUTORECODE VARIABLES=Message 
  /INTO message_coded 
  /PRINT. 
*Filter out all non-clicks - coding: 1=EBMeDS request, 10=page access successful i.e. clicked on a
page. 
FILTER OFF. 
USE ALL. 
SELECT IF (RANGE(message_coded,1,1,10,10)). 
EXECUTE. 
N=114,234 Saved as “…cleaning2.sav” 
*extract date numbers from string.
compute date=number(substr("Timestamp",1,23),f4). 
string n1 to n4 (a24). 
compute n1=char.substr(Timestamp,1,24). 
COMPUTE year=NUMBER(SUBSTR(n1,1,4),f4).  
COMPUTE month=NUMBER(SUBSTR(n1,6,2),f2).  
COMPUTE day=NUMBER(SUBSTR(n1,9,2),f2). 
COMPUTE hour=NUMBER(SUBSTR(n1,12,2),f4).  
COMPUTE minute=NUMBER(SUBSTR(n1,15,2),f2).  
COMPUTE second=NUMBER(SUBSTR(n1,18,5),f5). 
execute. 
* Date and Time Wizard: date_var.
COMPUTE  date_var=DATE.DMY(day, month, year) + TIME.HMS(hour, minute, second). 
VARIABLE LABELS  date_var "". 
VARIABLE LEVEL  date_var (SCALE). 
FORMATS  date_var (EDATE10). 
VARIABLE WIDTH  date_var(10). 
EXECUTE. 
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* Date and Time Wizard: Time. 
COMPUTE  Time=TIME.HMS(hour, minute, date_var). 
VARIABLE LABELS  Time "". 
VARIABLE LEVEL  Time (SCALE). 
FORMATS  Time (TIME8). 
VARIABLE WIDTH  Time(8). 
EXECUTE. 
 
*assign case number. 
COMPUTE id=$CASENUM. 
FORMAT id (F8.0). 
EXECUTE. 
 
*assign userid (NB anonymised for reporting purposes). 
RECODE User ('xxxx'=1) 
('xxxx'=2)….[repeat for each user]… 
…('xxxx'=63) INTO userid. 
execute. 
 
*recode events for merging with event types categorised. 
RECODE Event ('Active Clinical Domains'=1) 
('Acute Complications'=2) 
('Ad-Hoc Queries'=3) 
('Administration Facilities'=4) 
('Advice History'=5) 
('Audit Patient Contacts'=6) 
('Blood Pressure Summary'=7) 
('Body Mass Index & Smoking Summary'=8) 
('Carbohydrate Assessment'=9) 
('Cardiovascular System'=10) 
('Change Password'=11) 
('Change User Options'=12) 
('CHI Override'=13) 
('Clinic Information & Contacts'=14) 
('Clinic Letter History'=15) 
('Clinic Letter Management'=16) 
('Clinic Letters'=17) 
('Clinic Utilisation'=18) 
('Clinic/Practice Information & Contacts'=19) 
('Clinical Alerts'=20) 
('Clinical Comment Record'=21) 
('Clinical Domains History'=22) 
('Clinical Summary'=23) 
('Clinical Summary'=24) 
('Create New  PHS'=25) 
('Create User Account'=26) 
('Current Gestational Diabetes'=27) 
274 
('Current Retinal Screening Patients'=28) 
('Deceased Patients'=29) 
('Demographics'=30) 
('Diabetes in Remission'=31) 
('Diabetes Resolved'=32) 
('Diabetes Type Unknown'=33) 
('Diabetic Retinal Screening'=34) 
('Diagnostic Admin Form'=35) 
('Diagnostic Admin Form History'=36) 
('Diagnostic Information'=37) 
('Dietetic Patient Review'=38) 
('Discharge Patient'=39) 
('Discharge Patient (from a Clinic)'=40) 
('DRS Register'=41) 
('Drug Reactions/Allergies'=42) 
('DSN Form'=43) 
('DSN Form History'=44) 
('EBMeDS Request'=45) 
('Edit User Account'=46) 
('Education Establishment'=47) 
('Enrol Patient'=48) 
('Enrol Patient (into Clinic)'=49) 
('Erroneous Data'=50) 
('Exception'=51) 
('Eye Image'=52) 
('Eye Images - DRS'=53) 
('Eye Screening'=54) 
('Eye Screening Summary'=55) 
('Eye Summary'=56) 
('Find and Register a Patient'=57) 
('Find and Select a Patient'=58) 
('Foot Screening'=59) 
('Foot Screening History'=60) 
('Foot Screening Summary'=61) 
('Foot Screening Tool (Risk Stratification)'=62) 
('Foot Summary'=63) 
('General Audit'=64) 
('Glycaemic Control'=65) 
('Glycaemic Control Summary'=66) 
('Inpatient Episodes'=67) 
('Inpatient Overview'=68) 
('Insert New Comment'=69) 
('Insulin Pump Monitoring'=70) 
('Laboratory Results'=71) 
('Letters'=72) 
('Lifestyle'=73) 
('Login'=74) 
('Main Menu'=75) 
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('Manage Contacts'=76) 
('Manage Patient Consent'=77) 
('Manage User Population'=78) 
('Medical History'=79) 
('Neuropathy'=80) 
('No Diagnosis Made'=81) 
('Other Types of Diabetes'=82) 
('Paediatrics'=83) 
('Paediatrics'=84) 
('Patient Audit'=85) 
('Patient Diary'=86) 
('Patient Diet Assessment'=87) 
('Patient Education History'=88) 
('Patient List Management'=89) 
('Patient Record'=90) 
('Patient Record'=91) 
('Patient Search'=92) 
('Patient Status'=93) 
('Patients Pending Confirmation of  Unsuspension'=94) 
('Patients With Deteriorating Recordings'=95) 
('PHS History'=96) 
('Population Overview'=97) 
('Population Summary'=98) 
('Pre-Diabetic Conditions'=99) 
('Primary Care Prescribing Record'=100) 
('Recently Diagnosed Patients'=101) 
('Regional Comparison'=102) 
('Renal Care'=103) 
('Routine Clinic Recording'=104) 
('Routine Clinic Recording History'=105) 
('Scottish Diabetes Survey 2012'=106) 
('SDRN Admin '=107) 
('Search For A Patient Record'=108) 
('Search Results'=109) 
('Sexual Health'=110) 
('Specialist Prescribing Advice'=111) 
('Suspended Patients'=112) 
('System Maintenance Notification'=113) 
('Treatment Type'=114) 
('Type 1 Diabetes - Population Overview'=115) 
('Type 2 Diabetes - Population Overview'=116) 
('Ulcer Management'=117) 
('User Account Management'=118) 
('View My Contacts'=119) 
('View Patient Removal History'=120) into event_type_coded. 
Execute. 
N=114,234 Saved as “…cleaning3.sav” 
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*Count number of events for each patient record.  N.B. rename id in original file into EventID.
RECODE EventID (ELSE=1) INTO count. 
EXECUTE. 
SORT CASES BY LinkId userid. 
AGGREGATE 
  /OUTFILE=* MODE=ADDVARIABLES 
  /PRESORTED 
  /BREAK=LinkId userid 
  /linkID_events=SUM(count). 
EXECUTE. 
*Calculate number for each record in file.
SORT CASES BY EventID(A). 
COMPUTE RecordNumber=$CASENUM. 
EXECUTE. 
*Identify when patient record opened.
RECODE Event_type_coded (90=1) (48=1) (ELSE=0) INTO RecordOpen. 
EXECUTE. 
*Identfy record number for new login session, and then subtract 1 using LAG function.
IF  (RecordOpen=1) NumberRecordPreviousPatient=lag(RecordNumber). 
EXECUTE. 
*Identify data and time of record open.
IF  (RecordOpen=1) DateTimeRecordOpen=date_var. 
execute. 
*Identify start time when record opened.
IF  (RecordOpen=1) TimeRecordOpen=Time. 
EXECUTE. 
*Identify end time of session.
*Identify time of last record closed during previous session using LAG function.
*NB need to align times after DSS info aligned to login.
IF  (RecordOpen=1) TimePreviousRecordClosed=Lag(time). 
EXECUTE. 
*Associate RecordOpen with EBMeDS request.
CREATE DSSCodeRecordOpen = LEAD (DSSMessageLogId,2). 
EXECUTE. 
CREATE DSSCodeRecordOpenReminders = LEAD (Reminders,2). 
EXECUTE. 
RECODE DSSCodeRecordOpenReminders (SYSMIS=0) (0=0) (ELSE=1) INTO DSSpresentRecordOpen. 
EXECUTE. 
 
 
 
 
277 
 
*Select patientRecordOpen records. 
FILTER OFF. 
USE ALL. 
SELECT IF (RecordOpen=1). 
EXECUTE. 
N=19,994, Saved as “…cleaning4.sav” 
*Align patient record open and close times using LEAD. 
CREATE TimeRecordClose = LEAD(TimePreviousRecordClosed,1). 
EXECUTE. 
 
*Calculate duration of time for record being used. 
COMPUTE RecordDuration=(TimeRecordClose - TimeRecordOpen)/60. 
EXECUTE. 
 
*Delete instances <1sec duration as assumed to be system error rather than true user behaviour. 
FILTER OFF. 
USE ALL. 
SELECT IF (RecordDuration >= 1). 
EXECUTE. 
N=17,280, Saved as “…cleaning5.sav”
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19. Published conference abstracts relevant to the thesis
This work has directly contributed to the following abstracts being accepted for presentation at 
conferences (*denotes oral presentations): 
 *NT Conway, SG Cunningham, A Wales, DJ Wake.  Clinical Decision Support for Diabetes in 
Scotland: evaluation of user acceptance, clinical processes and outcomes.  International 
Diabetes Federation, World Diabetes Congress, Dubai 2017. 
 *NT Conway, SG Cunningham, A Wales, DJ Wake.  Clinical Decision Support for Diabetes in 
Scotland: evaluation of clinical processes and outcomes.  Informatics for Health conference, 
Manchester 2017. 
 NT Conway, K Adamson, SG Cunningham, A Emslie-Smith, A Wales, DJ Wake.  Clinical
Decision Support for Diabetes in Scotland: evaluation of user attitudes and system usage.
Diabetes UK conference, Manchester 2017
 NT Conway, K Adamson, SG Cunningham, A Emslie-Smith, A Wales, DJ Wake.  Clinical
Decision Support for Diabetes in Scotland: evaluation of clinical processes and outcomes.
Diabetes UK conference, Manchester 2017
 *Conway NT, Campbell I, Forbes P, Cunningham SG, Wake DJ. mHealth applications for 
diabetes – user preference and implications for app development..  Farr Institute 
International Conference, St Andrews 2015. 
 Conway NT, Campbell I, Forbes P, Cunningham SG, Wake DJ. mHealth applications for
diabetes – user preference and implications for app development..  International Diabetes
Federation, World Diabetes Congress, Vancouver 2015.
 Conway NT, Cunningham SG, Forbes P, Shaik F, Emslie-Smith A, Wales A, Wake DJ. Decision
Support for Diabetes: Implementation and evaluation of the EBMeDS project within NHS
Scotland. International Diabetes Federation, World Diabetes Congress, Vancouver 2015.
 *Conway NT, Wales A, Cunningham S, Walker J, Locke R, Emslie-Smith A, Shaik F, Wake DJ.  
Decision support for diabetes: embedding knowledge in care processes.  Health Informatics 
Scotland Conference, Glasgow 2014.  
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 Campbell IJM, Cunningham SG, Conway NT, Wake DJ.  Mobile technology as a tool for
patient education and self-management in the diabetic population. Diabetes UK Professional
Conference, Liverpool 2014
 Campbell IJM, Cunningham SG, Conway NT, Wake DJ.  Mobile technology as a tool for
patient education and self-management in the diabetic population. International Conference
on Advanced Technologies & Treatments for Diabetes, Vienna 2014.
The full text of each abstract is provided in the following pages 
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*NT Conway, SG Cunningham, A Wales, DJ Wake.  Clinical Decision Support for Diabetes in
Scotland: evaluation of user acceptance, clinical processes and outcomes.  International Diabetes 
Federation, World Diabetes Congress, Dubai 2017. 
Introduction 
Clinician Decision Support Systems (CDSS) are associated with improved adherence to clinical 
guidelines in the care of those with diabetes.  CDSS was implemented within the Scottish national 
electronic health record, SCI-Diabetes and has been live to users within NHS Tayside and Lothian 
since Dec’13, serving a combined diabetes population of ∼30,000.  This study aims to describe users’ 
attitudes and reactions to the system and to quantify impact on clinical processes and outcomes. 
Method 
Health care professional (HCP) opinion was sought via focus groups and questionnaires.  SCI-
Diabetes data were extracted for two time periods: Dec‘13-Feb’14 (Ninewells hospital, Dundee) and 
Aug’14-Nov’14 (St John’s hospital, Livingston). 
SCI-Diabetes usage was quantified using HCP interaction (“mouse-clicks”) and time spent within the 
patient record. HCP behaviour was compared between instances where CDSS messages were 
displayed, with instances where not (corrected for user-role, patient age, diabetes type/duration, co-
morbidity and deprivation). 
Case-control comparison was made to assess clinical processes and outcomes.  Cases were patients 
whose HCP received a CDSS message during the intervention period. Controls were matched for age; 
sex; diabetes type and duration; BMI and clinic attendance in areas outwith the pilot.  Clinical 
process measures were taken within 30 days of the clinic consultation and included screening for 
hypercholesterolaemia, kidney, foot and thyroid disease.  Additional process measures were the 
proportion of patients newly prescribed oral hypoglycaemic agents and angiotensin converting 
enzyme inhibitors (ACEI) or angiotensin receptor blockers (ARB) in the month following clinic.  
Clinical outcomes included HbA1c; cholesterol; blood pressure, and urinary albumin/creatinine 
(UACR) at 1 year.  Comparison was made using multivariable regression. 
Results 
Pre and post-intervention HCP questionnaire response rate was 57/105 (54%) and 39/105 (37%).  
Three focus groups were held (n=8-9/group).  The majority of respondents/participants had a 
positive or neutral response to the system.  Early-adopters reported usage within clinical workflow.  
CDSS messages were displayed on opening 6,665/17,280 (39%) records.  For nurses, presence of 
CDSS message was associated with increased SCI-Diabetes usage, compared with instances where no 
message was displayed (median “clicks” 19(IQrange:8-37) vs. 16(7-32), adj.p=0.014).  For doctors, 
CDSS messages were associated with reduced time within the patient record (median duration 33 
(IQrange:5-86) vs. 38(12-97) secs,adj.p=0.032).  
1,883 cases attended clinic, matched to 3,557 controls.  Probability of receiving screening more than 
doubled for hypercholesterolaemia (adjOR 2.4, (95%CI: 1.6-3.0)); creatinine (2.5(1.6-3.9)); UACR 
(2.3(1.9-2.8)); and foot screening (2.9(2.3-3.6)) – all p<0.001. Screening for hypothyroidism 
decreased slightly (0.8(0.7-1.0), p=0.035).  Prior to the intervention, 995/1883 (52.8%) cases and 
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1880/3557 (52.8%) controls were prescribed an oral hypoglycaemic agent.  Of those that were not 
previously on an oral hypoglycaemic agent, 15/888 (1.5%) cases and 40/1677 (2.4%) controls were 
commenced on one in the 30 days following their clinic appointment, with no significant difference 
noted after correcting for age, BMI, diabetes type and duration.  Prior to the intervention, 
1160/1,883 (61.6%) cases and 2196/3557 (61.7%) controls were prescribed an ACEI or ARB.  Of those 
not previously on an ACEI or ARB, 11/723 (1.5%) cases and 32/1361 (2.4%) controls were 
commenced on one in the 30 days following their clinic appointment.  There were no significant 
difference noted between groups after correcting for age; BMI; pre-intervention microalbuminuria 
or hypertension.   
Of all patients whose HCP received a CDSS prompt during the intervention period (i.e. not solely 
within the clinic environment, n=5,692), there were small improvements in mean HbA1c compared 
to controls (n=10,667) (baseline mean HbA1c 71.4 mmol/mol vs. 70.6, falling by -2.3 vs.-1.1, 
p=0.003).  Mean UACR increased in both groups but moreso in controls (baseline 8.7mg/mmol vs. 
9.3, increasing by +1.6 vs.+4.4, p=0.01).  Both serum cholesterol and blood pressure fell in both 
groups with no significant differences noted (with the exception of systolic BP – controls 
experienced significantly greater decrease (baseline mean SBP 137mmHg versus 138, falling by -1.3 
vs. -3.3, p<0.001)). 
Discussion/conclusion 
The CDSS was associated with improved efficiencies in working practices (dependent on role) and 
large improvements in guideline adherence.  If replicated nationally, thousands more individuals 
would receive appropriate screening tests. These evidence-based, early interventions can 
significantly impact on costly and devastating complications such as foot ulcers, amputations, 
cardiovascular disease, renal failure and death.  The potential benefits of this project extend beyond 
the Scottish diabetes population, as NHS Scotland considers how best to realise the full potential of 
CDSS. 
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*NT Conway, SG Cunningham, A Wales, DJ Wake.  Clinical Decision Support for Diabetes in
Scotland: evaluation of clinical processes and outcomes.  Informatics for Health conference, 
Manchester 2017. 
Introduction 
Nearly 3 million people in the UK have diabetes (>6% of adults), with prevalence expected to double 
over the next 2 decades.  Clinician Decision Support Systems (CDSS) are associated with improved 
adherence to clinical guidelines.  CDSS was implemented within the Scottish national electronic 
health record, SCI-Diabetes and has been live to users within NHS Tayside and Lothian since Dec’13, 
serving a combined diabetes population of ∼30,000.  This study aims to describe users’ attitudes and 
reactions to the system and to quantify impact on clinical processes and outcomes. 
Method 
Health care professional (HCP) opinion was sought via focus groups and questionnaires.  SCI-
Diabetes data were extracted for two time periods: Dec‘13-Feb’14 (Ninewells hospital, Dundee) and 
Aug’14-Nov’14 (St John’s hospital, Livingston). 
SCI-Diabetes usage was quantified using HCP interaction (“mouse-clicks”) and time spent within the 
patient record. HCP behaviour was compared between instances where CDSS messages were 
displayed, with instances where not (corrected for user-role, patient age, diabetes type/duration, co-
morbidity and deprivation). 
Case-control comparison was made to assess clinical processes and outcomes.  Cases were patients 
whose HCP received a CDSS message during the consultation. Controls were matched for age; sex; 
diabetes type and duration; BMI and clinic attendance in areas outwith the pilot.  Clinical process 
measures were screening for hypercholesterolaemia, kidney, foot and thyroid disease.  Clinical 
outcomes included HbA1c; cholesterol; blood pressure, and urinary albumin/creatinine (UACR) at 1 
year.  Comparison was made using multivariable regression. 
Results 
Pre and post-intervention HCP questionnaire response rate was 57/105 (54%) and 39/105 (37%).  
Three focus groups were held (n=8-9/group).  The majority of respondents/participants had a 
positive or neutral response to the system.  Early-adopters reported usage within clinical workflow.  
CDSS messages were displayed on opening 6,665/17,280 (39%) records.  For nurses, presence of 
CDSS message was associated with increased SCI-Diabetes usage, compared with instances where no 
message was displayed (median “clicks” 19(IQrange:8-37) vs. 16(7-32), adj.p=0.014).  For doctors, 
CDSS messages were associated with reduced time within the patient record (median duration 33 
(IQrange:5-86) vs. 38(12-97) secs,adj.p=0.032).  
1,883 cases attended clinic, matched to 3,557 controls.  Probability of receiving screening more than 
doubled for hypercholesterolaemia (adjOR 2.4, (95%CI: 1.6-3.0)); creatinine (2.5(1.6-3.9)); UACR 
(2.3(1.9-2.8)); and foot screening (2.9(2.3-3.6)) – all p<0.001. Screening for hypothyroidism increased 
slightly (0.8(0.7-1.0), p=0.035).  For those attending clinic, study group did not predict clinical 
outcomes at 1 year.  Post hoc analysis of all patients with a CDSS prompt (n=5,692) showed small 
improvements in mean HbA1c (-2.3mmol/mol vs.-1.1, B1.2(0.4-2.0),p=0.003) compared to controls 
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(n=10,667).  Mean UACR increased in both groups but moreso in controls (baseline 8.7mg/mmol vs. 
9.3, increasing by +1.6 vs.+4.4, B2.9(0.7-5.1),p=0.01). 
Discussion/conclusion 
The CDSS was associated with improved efficiencies in working practices (dependent on role) and 
large improvements in guideline adherence.  If replicated nationally, thousands more individuals 
would receive appropriate screening tests. These evidence-based, early interventions can 
significantly impact on costly and devastating complications such as foot ulcers, amputations, 
cardiovascular disease, renal failure and death.  The potential benefits of this project extend beyond 
the Scottish diabetes population, as NHS Scotland considers how best to realise the full potential of 
CDSS. 
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NT Conway, K Adamson, SG Cunningham, A Emslie-Smith, A Wales, DJ Wake.  Clinical Decision 
Support for Diabetes in Scotland: evaluation of user attitudes and system usage.  Diabetes UK 
conference, Manchester 2017 
Aims 
Clinician Decision Support Systems (CDSS) provide health care professionals (HCPs) with automated 
advice, resulting in improved adherence to guidelines.  CDSS was implemented within the Scottish 
national electronic health record, SCI-Diabetes, in NHS Tayside and Lothian.  This study aims to 
describe users’ attitudes and reactions to the system. 
Methods 
HCP opinion was sought via focus groups and questionnaires. SCI-Diabetes usage was quantified 
using data from Dec 13-Feb 14 (Ninewells hospital, Dundee) and Aug 14-Nov 14 (St John’s hospital, 
Livingston).  User behaviour was compared between instances where CDSS messages were displayed 
with instances where not (corrected for user-role, patient age, diabetes type/duration, co-morbidity 
and deprivation).  Quantitative outcomes were interaction (“mouse-clicks”) and time spent within 
the patient record. 
Results 
Pre and post-intervention questionnaire response rate was 57/105 (54%) and 39/105 (37%).  Three 
focus groups were held (n=8-9/group).  The majority of respondents/participants had a positive or 
neutral response to the system.  Early-adopters reported usage within clinical workflow, however 
most reported low use.  Worker role predicted users’ attitudes and system usage. CDSS messages 
were displayed on opening 6,665/17,280 (39%) records.  Presence of CDSS message was associated 
with increased SCI-Diabetes usage by nurses (median “clicks” 19(IQrange:8-37) vs. 16(7-32), 
adj.p=0.014).  For doctors, CDSS messages were associated with reduced time within the patient 
record (median duration 33sec(IQrange:5-86) vs. 38(12-97),adj.p=0.032).  
Conclusion 
The system was associated with improved efficiencies in working practices, dependent on role.  
Active users of the CDSS are in the minority, however user attitudes make it likely that usage will 
increase as content and functionality improve. 
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NT Conway, K Adamson, SG Cunningham, A Emslie-Smith, A Wales, DJ Wake.  Clinical Decision 
Support for Diabetes in Scotland: evaluation of clinical processes and outcomes.  Diabetes UK 
conference, Manchester 2017 
Aims 
Clinician Decision Support Systems (CDSS) provide health care professionals (HCPs) with automated 
advice, based on clinical guidelines.  CDSS was implemented within the Scottish national electronic 
health record, SCI-Diabetes.  This study aims to quantify impact on clinical processes and outcomes. 
Methods 
Cases were those where an HCP received a CDSS message during Dec 13-Feb 14 (Ninewells hospital, 
Dundee) and Aug 14-Nov 14 (St John’s hospital, Livingston). Controls were matched for age; sex; 
diabetes type and duration; BMI and clinic attendance in areas outwith the pilot.  Clinical process 
measures were screening for hypercholesterolaemia, kidney, foot and thyroid disease.  Clinical 
outcomes included HbA1c; cholesterol; blood pressure, and urinary albumin/creatinine (UACR) at 1 
year.  Comparison was made with multivariable regression. 
Results 
1,883 cases attended clinic, matched to 3,557 controls.  Probability of receiving screening more than 
doubled for hypercholesterolaemia (adjOR 2.4, (95%CI: 1.6-3.0)); creatinine (2.5(1.6-3.9)); UACR 
(2.3(1.9-2.8)); and foot screening (2.9(2.3-3.6)) – all p<0.001. Screening for hypothyroidism increased 
slightly (0.8(0.7-1.0), p=0.035).  Study group did not predict clinical outcomes at 1 year.  Secondary 
analysis of all patients with a CDSS prompt (n=5,692) showed small improvements in mean HbA1c (-
2.3mmol mol-1 vs.-1.1, B1.2(0.4-2.0),p=0.003) compared to controls (n=10,667).  Mean UACR 
increased in both groups but moreso in controls (baseline 8.7mg mmol-1 vs. 9.3, increasing by +1.6 
vs.+4.4, B2.9(0.7-5.1),p=0.01). 
Conclusion 
This low-cost intervention has demonstrated large improvements in adherence to guidelines with 
the potential for future improvement in clinical outcomes.  If replicated nationally, thousands more 
individuals would receive these evidence-based interventions resulting in avoidance of costly and 
devastating complications. 
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*Conway NT, Campbell I, Forbes P, Cunningham SG, Wake DJ. mHealth applications for diabetes –
user preference and implications for app development..  Farr Institute International Conference, St 
Andrews 2015. 
Background 
Increasing diabetes prevalence is driving a demand for more sustainable yet person-centred service.  
As the worldwide smartphone market continues to grow, the number of diabetes self care mHealth 
applications also grows exponentially.  mHealth can improve clinical outcomes, but current usage 
patterns, effectiveness and valued features are unclear.  This study sought to assess levels of 
engagement with mHealth technologies within a subset of the Scottish diabetes population; to 
identify specific demographic sub-groups of interest; and draw comparisons between desirable and 
currently available features of diabetes mHealth applications. 
Methods 
A snapshot analysis of the diabetes mHealth app marketplace was undertaken in July 2014.  
Available features were used to construct a questionnaire.  A random sample of 400 patients 
(stratified by diabetes type and age) was obtained from the Scottish Diabetes Research Network 
(n=200) and users of patient health record (MyDiabetesMyWay, n=200).  Demographic variables 
(age group, gender and diabetes type) were cross-tabulated with preference for mHealth 
technologies and loglinear analysis was used to identify significant interactions.  Desirable features 
of a diabetes mHealth app were compared with currently available diabetes apps. 
Results 
Available app features include: data storage/graphical presentation; integration with other apps; 
exercise tracking; health/diet tracking; reminders/alarms; and education.  59% (234/400) people 
responded to the questionnaire; 62% (144/233) owned a smartphone.  Most smartphone users 
expressed a preference towards mHealth apps (101/142 (71%)) (especially younger age groups), 
although mobile phone app use for diabetes self management was low (12/163 (7%)). Older women 
with T2D were significantly less likely to favour diabetes mHealth apps.  Respondents favoured a 
wide variety of potential features, contrasting with current availability: patient education – favoured 
by 45% (98/220) users but available in 14% (10/74) apps; personal health record - favoured by 40% 
(89/220) users but unavailable on apps reviewed. 
Discussion/conclusion 
mHealth has the potential to empower patients; improve outcomes; and provide service in a 
sustainable way.  This study demonstrates that mHealth acceptance is high, but current engagement 
is low and functionality does not match potential user preferences.  Engagement and functionality 
could perhaps be improved by including relevant stakeholders in future development, driven by 
clinical and user need. 
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Conway NT, Campbell I, Forbes P, Cunningham SG, Wake DJ. mHealth applications for diabetes – 
user preference and implications for app development..  International Diabetes Federation, World 
Diabetes Congress, Vancouver 2015. 
Background 
Increasing diabetes prevalence is driving a demand for more sustainable yet person-centred service.  
As the worldwide smartphone market continues to grow, the number of diabetes self care mHealth 
applications also grows exponentially.  mHealth can improve clinical outcomes, but current usage 
patterns, effectiveness and valued features are unclear.  This study sought to assess levels of 
engagement with mHealth technologies within a subset of the Scottish diabetes population; to 
identify specific demographic sub-groups of interest; and draw comparisons between desirable and 
currently available features of diabetes mHealth applications. 
Methods 
A snapshot analysis of the diabetes mHealth app marketplace was undertaken in July 2014.  
Available features were used to construct a questionnaire.  A random sample of 400 patients 
(stratified by diabetes type and age) was obtained from the Scottish Diabetes Research Network 
(n=200) and users of patient health record (MyDiabetesMyWay, n=200).  Demographic variables 
(age group, gender and diabetes type) were cross-tabulated with preference for mHealth 
technologies and loglinear analysis was used to identify significant interactions.  Desirable features 
of a diabetes mHealth app were compared with currently available diabetes apps. 
Results 
Available app features include: data storage/graphical presentation; integration with other apps; 
exercise tracking; health/diet tracking; reminders/alarms; and education.  59% (234/400) people 
responded to the questionnaire; 62% owned a smartphone.  Most smartphone users expressed a 
preference towards mHealth apps (especially younger age groups) although mobile phone app use 
for diabetes self management was low (12/163 (7%)). Older women with T2D were significantly less 
likely to favour diabetes mHealth apps.  Respondents favoured a wide variety of potential features, 
contrasting with current availability: patient education – favoured by 45% (98/220) users but 
available in 14% (10/74) apps; personal health record - favoured by 40% (89/220) users but 
unavailable on apps reviewed. 
Discussion/conclusion 
mHealth has the potential to empower patients; improve outcomes; and provide service in a 
sustainable way.  This study demonstrates that mHealth acceptance is high, but current engagement 
is low and functionality does not match potential user preferences.  Engagement and functionality 
could perhaps be improved by including relevant stakeholders in future development, driven by 
clinical and user need. 
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Conway NT, Cunningham SG, Forbes P, Shaik F, Emslie-Smith A, Wales A, Wake DJ. Decision 
Support for Diabetes: Implementation and evaluation of the EBMeDS project within NHS Scotland. 
International Diabetes Federation, World Diabetes Congress, Vancouver 2015. 
Introduction 
Over 80% of people with diabetes have co-morbidities, which increase in number with age.  
Evidence-based guidelines for these conditions are developed on a disease-specific basis, resulting in 
multiple guidelines.  Approximately half of Healthcare Professional (HCP) clinical decisions fail to 
take account of the best available evidence.  Clinical decision support systems (CDSS) within an 
electronic health record (EHR) can improve HCP performance by providing automated, tailored, 
evidence-based advice. This project aims to implement and evaluate the Evidence Based Medicine 
electronic Decision Support (EBMeDS) system within a national EHR for diabetes. 
Methods 
EBMeDS algorithms were developed with reference to national clinical guidelines and implemented 
within Scotland’s EHR for diabetes, SCI-Diabetes.  A cyclical, quality improvement approach was used 
to adapt the system in light of user feedback.  Evaluation used a mixed methods approach involving: 
HCP & patient questionnaires; focus groups; system navigational data; and case control comparisons 
of clinical processes & outcomes. 
Results 
19 EBMeDS scripts aimed at screening for complications and treatment optimisation were 
developed.  Improvement cycle 1 ran from Dec 13-Feb 14 involving a tertiary centre diabetes clinic 
(~500 patients/month).  The system was adapted prior to cycle 2 that involved primary and 
secondary care within a defined geographical area (pop. 412,160, number of people with diabetes 
22,033). 
17,280 patient EHRs were opened during cycle 1, 6665 (39%) of which triggered an EBMeDS 
message.  The median number of messages was 3 (IQ range 2-5).   The presence of a message was 
associated with a significant reduction in duration that the EHR was viewed: median duration 40 sec 
(IQ range 13-93) vs 32 sec (IQ range 7-84), p<0.001. 
User feedback was favourable with individuals reporting more efficient clinical practices.  Patient 
and HCP feedback did not identify any adverse effects on the consultation.  Users requested that 
messages are tailored to context and role. 
Discussion 
This service improvement project highlights the benefits of an iterative approach that adapts to 
users’ needs. The system has been well received and has the potential to improve efficiency in 
decision making with no reported adverse effects.  Evaluation of clinical processes and outcomes is 
ongoing.  Ultimately, the system has the potential to incorporate any number of relevant guidelines 
whilst tailoring messages to user role and clinical context. 
 
 
 
 
 
289 
*Conway NT, Wales A, Cunningham S, Walker J, Locke R, Emslie-Smith A, Shaik F, Wake DJ.  
Decision support for diabetes: embedding knowledge in care processes.  Health Informatics 
Scotland Conference, Glasgow 2014.  
Introduction 
Long term conditions affect one in five people, and account for 80% of general practice consultations 
in Scotland [Auditor General for Scotland 2007].  Approximately half of all clinical decisions made by 
Health Care Practitioners (HCPs) fail to take account of the best available evidence [McGlynn and 
Asch 2003] and guidelines often do not accommodate co-morbidities and multiple medications 
[Lugtenberg et al. 2011; Nobili et al. 2011].  There is a recognised need to find innovative ways of 
integrating knowledge into clinical workflow; to contextualise and personalise care; and to manage 
the complex care needs and human factors which contribute to unwanted variation in practice. 
Clinical decision support systems (CDSS) within an electronic health record (EHR) provide HCP’s with 
automated, tailored, evidence-based advice. This project aims to implement and evaluate the 
Evidence Based Medicine electronic Decision Support (EBMeDS) system [Duodecim Medical 
Publications Ltd. 2014] within SCI-Diabetes, the national EHR for diabetes in Scotland [Cunningham 
et al. 2011]. 
Methods 
EBMeDS  utilises structured patient data from EHRs and provides automated reminders, therapeutic 
suggestions and diagnosis-specific links to guidelines and literature [Duodecim Medical Publications 
Ltd. 2014].  EBMeDS scripts were adapted to the Scottish context and integrated within SCI-
Diabetes.  Implementation is following a phased approach - phase 1 involves NHS Tayside secondary 
care, phase 2 will include NHS Lothian and primary care. 
Ongoing evaluation is based upon the NES knowledge into action framework [NHSScotland 2012] 
and involves: user and patient questionnaires; HCP focus groups; quantitative analysis of usage data; 
and case control comparisons of guideline adherence and clinical outcomes.  User questionnaires 
were adapted from a previous evaluation of the EBMeDS system [Heselmans et al. 2012] which 
utilised the Unified Theory of User Acceptance of Technology (UTAUT) model [Venkatesh et al. 
2003]. 
Results 
19 EBMeDS scripts were developed for a variety of clinical situations e.g. optimising glycaemic 
control; uptake of screening services.  Alerts and reminders are displayed to users on opening the 
clinical record of an individual patient record. 
Phase 1 commenced December 2013 and involved 24 HCP’s within the diabetes clinic (approximately 
500 patients/month).  Questionnaire and focus group feedback suggests that users are receptive to 
using CDSS. However, self-reported system use is minimal. Barriers to adoption include: clinical time; 
low relevance to the secondary care context; and limited applicability to individual patient 
circumstances and co-morbidities.  There were no reported adverse effects, with high patient 
satisfaction recorded during the period of evaluation.  Scripts have been amended in light of user 
feedback – thresholds have been altered; additional rules created; and additional user-control has 
 
 
 
 
290 
been introduced.  Quantitative data analysis of user navigation data and quality performance 
indicators is ongoing. 
Discussion 
This service improvement project involves the implementation and evaluation of a CDSS.  The 
potential of the system is acknowledged but needs to adapt in response to user feedback.  Script 
development is ongoing with a view to phase 2 implementation in August 2014.  The ultimate aim is 
to develop a national system taking into account patient co-morbidities and clinical context. 
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Campbell IJM, Cunningham SG, Conway NT, Wake DJ.  Mobile technology as a tool for patient 
education and self-management in the diabetic population. Diabetes UK Professional Conference, 
Liverpool 2014 
Objectives 
This study aims to ascertain the desire for mobile technology, namely Smartphone apps (SA), which 
can support patient education, self-management and data sharing with the health-care team. 
Methods 
This prospective questionnaire study sampled 200 Patients from My Diabetes My Way (MDMW), an 
interactive database for patients in Scotland allowing access to personal online clinical information 
and educational resources. Questions for the survey were formed using a prior literature review and 
SA feature summary of 53 apps on the Apple platform (January 2013). The anonymous questionnaire 
explored areas of current management techniques, technology literacy, patient education, self-
management and desirable features for a future SA. Prior consent for patient contact had been 
agreed. 
Results 
200 patients from MDMW were contacted via email. 122/200 participants responded. Results below 
highlight response 1 or 2 versus response 4 or 5 on a likert scale (1=strongly agree and 5 =strongly 
disagree).  There is a strong desire for SA development (48/68, 71%, 95%CI 59-80). Half of the 
participants would use SA for education (60/119, 50%, 95%CI 42-59) and a similar number (54%) 
would prefer SA to current methods of self-management (37/68, 54%, 95%CI 42-66). Desirable 
features included social media integration (70/116, 6%, 95% CI 51-69). Carbohydrate tracking was 
undesirable (58/119, 52%, 95% CI, 42-61). 
Conclusions and Discussions 
Preliminary results from the study suggest that there is a desire for SA. In particular offering 
integration with health-care systems. Providing patients with contemporary methods to support 
their care will enable better health outcomes to be achieved and maintained. 
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Campbell IJM, Cunningham SG, Conway NT, Wake DJ.  Mobile technology as a tool for patient 
education and self-management in the diabetic population. International Conference on Advanced 
Technologies & Treatments for Diabetes, Vienna 2014. 
Objectives 
This study aims to ascertain the desire for mobile technology, namely Smartphone apps (SA), which 
can support patient education, self-management and data sharing with the health-care team. 
Methods 
This prospective questionnaire study sampled 200 Patients from My Diabetes My Way (MDMW), an 
interactive database for patients in Scotland allowing access to personal online clinical information 
and educational resources. Questions for the survey were formed using a prior literature review and 
SA feature summary of 53 apps on the Apple platform (January 2013). The anonymous questionnaire 
explored areas of current management techniques, technology literacy, patient education, self-
management and desirable features for a future SA. Prior consent for patient contact had been 
agreed. 
Results 
200 patients from MDMW were contacted via email. 122/200 participants responded. Results below 
highlight response 1 or 2 versus response 4 or 5 on a likert scale (1=strongly agree and 5 =strongly 
disagree). There is a strong desire for SA development (48/68, 71%, 95%CI 59-80). Half of the 
participants would use SA for education (60/119, 50%, 95%CI 42-59) and a similar number (54%) 
would prefer SA to current methods of self-management (37/68, 54%, 95%CI 42-66). Desirable 
features included social media integration (70/116, 6%, 95% CI 51-69). Carbohydrate tracking was 
undesirable (58/119, 52%, 95% CI, 42-61). 
Conclusions and Discussions 
Preliminary results from the study suggest that there is a desire for SA. In particular offering 
integration with health-care systems. Providing patients with contemporary methods to support 
their care will enable better health outcomes to be achieved and maintained. 
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Abstract
Tailored messages are those that specifically target individuals following an assessment of their unique 
characteristics. This systematic review assesses the evidence regarding the effectiveness of tailoring within 
eHealth interventions aimed at chronic disease management. OVID Medline/Embase databases were 
searched for randomised control trials, controlled clinical, trials, before -after studies, and time series 
analyses from inception - May 2014. Objectively measured clinical processes/outcomes were considered. 
Twenty-two papers were eligible for inclusion: 6/22 used fully tailored messaging and 16/22 used partially 
tailored messages. Two studies isolated tailoring as the active component. The remainder compared 
intervention with standard care. In all, 12/16 studies measuring clinical processes and 2/6 studies reporting 
clinical outcomes showed improvements, regardless of target group. Study quality was low and design did 
not allow for identification of interventions’ active component. Heterogeneity precluded meta-analysis. This 
review has demonstrated that there is a lack of evidence to suggest that tailoring within an eHealth context 
confers benefit over non-tailored eHealth interventions.
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Background
Long-term conditions affect one in five people, yet account for 80 per cent of general practice con-
sultations.1 More than half of all clinical decisions fail to take account of the best-available evi-
dence.2 In addition, evidence-based guidelines often do not accommodate co-morbidities and 
multiple medications.3–5 There is a recognised need to find innovative ways of integrating knowl-
edge into clinical workflow, to contextualise and personalise care, and to manage the complex care 
needs and human factors which contribute to unwanted variation in practice.6
Clinical decision support systems (CDSSs) utilise algorithms of varying complexity that are 
applied to existing eHealth systems. Typically, a CDSS within an electronic health record (EHR) 
will present the user of the EHR with a series of messages designed to improve clinical care, for 
example, identification of possible drug interactions or prompts to consider clinical investigations. 
The use of such automated reminders via CDSS has been shown to be one of the most consistently 
successful approaches to encourage clinicians to adopt evidence-based practice.7 In terms of effi-
cacy, a 2005 systematic review concluded that while a number of studies showed an improvement 
in clinical processes (e.g. adherence to guidelines), there was a lack of evidence demonstrating 
improved clinical outcomes.8 In the same year, a separate systematic review found that CDSSs, 
which incorporated contemporaneous recommendations (as opposed to simple summaries of data) 
and were available within the normal work stream, were more likely to result in improved clinical 
outcomes − 90 per cent (30/32) of interventions which included these features demonstrated 
improved outcomes.9
Communicating with messages that are specifically tailored to an individual has been found to 
be more effective than generic messages at changing behaviour.10 The theory underpinning the use 
of such methods draws heavily on a number of behaviour change theories, including the Health 
Belief Model,11 Prochaska and DiClemente’s12 Stages of Change, and Bandura’s13 Social Cognitive 
Theory. The tailoring of messages to specific individuals is viewed as the most sophisticated form 
of automated communication that can be used to deliver health education and material aimed at 
health promotion.14 Tailoring has been defined as ‘any combination of strategies and information 
intended to reach one specific person, based on characteristics that are unique to that person, related 
to the outcome of interest, and derived from an individual assessment’.15 This assessment is 
dependent on the type of intervention and the target audience, but could be based on routinely col-
lected data (e.g. professional role, socioeconomic status, health records or clinical parameters) or 
data collected from the individual with the specific intention of formulating a tailored message 
(e.g. health literacy, self-efficacy or pre-existing attitudes and knowledge). Interventions that uti-
lise tailored messages tend to involve the distribution of printed material aimed at primary health 
promotion, for example, dietary advice,16–18 smoking cessation,19,20 or uptake of screening.21
There is a lack of literature concerning the use of tailored messages aimed at changing health-
care practitioner (HCP) behaviour. There is also a lack of evidence to inform the design and modal-
ity of tailored messaging, and whether the effectiveness of existing eHealth technologies (e.g. 
CDSS) can be improved were they to incorporate tailored messaging.
Objective
This systematic review aimed to assess the published evidence regarding the effectiveness of 
eHealth interventions designed to improve the management of chronic diseases by providing infor-
mation or advice that has been tailored to the recipients, that is, HCPs or patients.
The research question was as follows: Does the cumulative published research evidence sup-
port the hypothesis that a system that incorporates messages specifically tailored to an individual 
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(HCP or patient) results in improved clinical processes or outcomes in the management of long-
term conditions?
Method
Types of studies
Randomised controlled trials (RCTs), controlled clinical trials (CCTs), controlled before and after 
studies, and interrupted time series (ITS) analyses were considered for inclusion in the review. 
Studies published in any language were considered.
Types of recipients
Studies that involved patients with a specified long-term condition receiving healthcare (any set-
ting), and/or HCPs responsible for the care of those with long-term conditions (any setting), were 
considered.
Types of interventions
We considered interventions that used eHealth technologies to deliver tailored information to 
patients or HCPs within the care setting. The search strategy, therefore, included a combination of 
terms relating to eHealth, health records, and communication strategies (including tailoring of 
information).
Types of outcomes
Any outcome was considered where a comparison was drawn between the intervention and no 
intervention and/or existing practice with regards to objectively measured professional perfor-
mance, clinical outcome, or patient behaviour. The study’s stated primary outcome was our main 
outcome of interest, with consideration also given to any stated secondary outcomes or post hoc 
analyses. Patient and professional satisfaction was also recorded, but studies were not included if 
this was the sole outcome.
Search strategy
A search strategy was devised to include keywords and text words relating to the following terms: 
chronic disease, methodology, eHealth, health records, communication, and user groups (available on 
request). Text words were appropriately truncated to maximise returns. Terms were combined using 
Boolean logic. There was no keyword identified for tailored messaging, and so we adopted a broad 
search strategy. As well as including variations of tailored messaging as text words, we included an 
exploded search of other communication-related keywords in an effort to capture studies that utilised 
tailored messages but did not refer to it as such. The search was run against both Ovid Medline 
(1946–present) and Embase (1974–present), with no restrictions placed on language.
Eligibility criteria for inclusion
Studies that were RCTs or CCTs were deemed eligible if the other criteria mentioned above were 
met. Additional methodologies (controlled before–after studies and interrupted time series 
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analyses) were considered if they met quality criteria specified by the Cochrane Effective Practice 
and Organisation of Care Group (EPOC) data collection checklist.22 In accordance with the EPOC 
criteria, the quality criteria for inclusion of both types of studies were as follows:
•• Controlled before–after studies were only eligible if the control site was deemed suitable; 
there was evidence of contemporaneous data collection, and there were ⩾2 intervention and 
⩾2 control sites.
•• Interrupted time series analyses were included if there was a clearly recorded point in time 
when the intervention began and where there were ⩾3 data points recorded both before and 
after the intervention commenced. Given the potential heterogeneity of the studies relevant to 
the review, study inclusion was not based on a minimum cut-off for methodological quality.
Data collection and analysis
Titles and abstracts were initially reviewed by a single reviewer (N.T.C.) and discarded if deemed 
not to be relevant to the research question. A shortlist was then compiled for which full-text articles 
were sought. These were independently reviewed by two reviewers (N.T.C. and C.W.). Any dis-
crepancies were resolved by consensus. An online data abstraction form (modified from the EPOC 
data collection checklist22) was used for data collection.23 An overall quality rating was assigned to 
RCTs based on the following criteria: allocation concealment, blinded or objective assessment of 
primary outcome(s), completeness of follow-up, reliable primary outcome, and protection against 
bias. In accordance with previously published EPOC systematic reviews,24,25 studies were rated as 
being of high quality if the first three criteria were met with no additional concerns. Studies were 
of moderate quality if ⩽2 criteria were ‘not done’ or ‘not clear’ and of low quality if this applied to 
>2 criteria.
Assessing tailoring
Kreuter et al.15 judged that an intervention incorporated tailored messaging if the intervention 
included both the following:
1. An assessment of individual patient characteristics;
2. Communication that was specifically targeted at that individual.
Owing to the limited number of published studies that the search strategy returned, we accepted 
interventions that included either of these criteria, as agreed by the two reviewers.
Protocol
A review protocol has not been published but is available from the corresponding author on enquiry.
Results
Search results
The search strategy was run twice – September 2013 and again in May 2014. The final yield from 
both searches was 1074 returns, of which 89 were duplicates. Of the remaining 985 studies, 818 
were initially rejected based on title alone, with a further 112 discarded after review of the abstract 
222 Health Informatics Journal 23(3)
(see Figure 1). Full-text papers were sought for the provisional shortlist of 55 studies and were 
available for 45 of these. The abstracts of the remaining 10 studies were assessed and included if 
there was sufficient information to meet the inclusion criteria. Owing to the absence of any tailor-
ing component in the intervention, 15 papers were rejected. The remaining 40 papers were then 
reviewed by the two reviewers. Furthermore, 18 papers were then rejected as they failed to meet 
(or had insufficient detail to satisfy) the eligibility criteria, leaving 22 papers to be considered in 
the review.
These 22 studies are shown in Table 1 (sorted by first author). All of the studies were pub-
lished since 2002 and most were conducted in North America.26–41 The majority were 
RCTs.26,28,30–34,36,37,39–45 The clinical problem addressed by the various interventions varied, but 
the most common applications were diabetes,26,27,35,36,39,44 cardiovascular disease,32,35,39,43 and 
the prescribing of medication.30,31,37,46
Setting and characteristics of the studies
Most studies were undertaken in either an outpatient or community-based setting and involved 
physicians (see Table 2). Other professional groups included nurses and pharmacists. The studies 
Figure 1. PRISMA diagram of literature search.
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were undertaken in both academic and non-academic settings. There was a general lack of infor-
mation describing the experience or qualifications of the various professional user groups. Thirteen 
of the studies directed the intervention at HCPs.28–32,35,37,39,40,45–48 The remainder directed the inter-
vention at patients,27,33,34,41–44 or at both HCPs and patients.36 Study quality is noted in Table 4. 
Further details on individual study characteristics are available on request.
Influence of tailoring component on intervention design
All of the studies included in the review incorporated some degree of individual patient assess-
ment. This assessment was made via automated data queries of routinely collected clinical datasets 
or via additional data entry completed by patient and/or HCP (see Table 3).
The use of individually tailored communication was only evident in a minority of 
studies.27,33,34,41,43,44 All of these studies delivered messages to individual patients based on data 
specific to that patient, for example, risk of illness/injury and how this might be modified for the 
individual;33,34,43 individualised educational content;41,44 or individualised clinical results.27 For 
the remainder of studies, the content of communication was dictated by automated algorithms 
based on the individual assessment rather than the specific circumstances of the end-user. For 
example, it was common that automated CDSS aimed at HCPs would provide prompts based on 
Table 1. Studies eligible for inclusion in the review.
First author (ref) Year Design Country Clinical speciality Clinical problem
Avery46 2012 RCT UK General/family practice Medication prescribing
Boukhors26 2003 RCT Canada General/family practice Diabetes
Cafazzo27 2012 ITS Canada Paediatrics Diabetes
Carroll28 2012 RCT USA Psychiatry Maternal depression
Cruz-Correia42 2007 RCT Portugal Other Asthma
Epstein29 2011 RCT USA Paediatrics ADHD
Field30 2009 RCT Canada General/family practice Medication prescribing
Fossum47 2011 CCT Norway Other Pressure ulcers
Gurwitz31 2008 RCT USA/Canada Other Medication prescribing
Jones48 2011 ITS UK General medicine Acute medicine
Kinn32 2002 RCT USA Other Hypertension
Mcdonald33 2005 RCT USA Paediatrics Preventative service
Nagykaldi34 2012 RCT USA General/family practice Preventative care
Persell35 2010 ITS USA General medicine CVD, diabetes, and cancer
Persell43 2013 RCT USA General/family practice CVD
Pinnock45 2013 RCT UK General medicine COPD
Quinn36 2008 RCT USA Other Diabetes
Raebel37 2007 RCT USA Obstetrics and 
gynaecology
Medication prescribing
Ross44 2006 RCT USA General medicine Diabetes
Sequist39 2005 RCT USA General medicine CVD and diabetes
Tierney40 2005 RCT USA General medicine Asthma
Vollmer41 2011 RCT USA Not clear Asthma
RCT: randomised controlled trial; ITS: interrupted time series; ADHD: attention-deficit hyperactivity disorder; CCT: 
controlled clinical trial; CVD: cardiovascular disease; COPD: chronic obstructive pulmonary disease.
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an assessment of a patient’s data, but the prompt provided by the system was generic to the system 
and not tailored to the HCP’s job-description or clinical context.
Of the six studies that fulfilled both criteria for having used tailored communication (as 
dictated by Kreuter et al.15), the primary outcomes (where stated) were patient self-care 
(improved),27 serum lipids (no difference),43 and medication adherence (better than control but 
reduced overall).41 The remainder of studies did not state the primary outcome, but reported on 
service uptake (improved in intervention group),44 patient knowledge (improved in intervention 
group, but multiple comparisons made),33 and patient centredness (improved in intervention 
group).34
Comparison – tailored intervention versus non-tailored intervention
Two studies compared an intervention which utilised tailoring with an intervention that included 
untargeted activity.33,44 Neither study specified the primary outcome of interest in the methods. 
Both studies provided tailored educational material to patients and compared outcomes with 
patients who had received non-tailored material. For example in one study,33 parents completed 
a questionnaire designed to assess previous injuries sustained by their child as well as parental 
perceptions of their child’s current risk of injury. The educational material then incorporated 
the events previously described as well as addressing any misconceptions in injury risk identi-
fied from parental responses. Tailoring resulted in an increase in patient service uptake in one 
study,44 with multiple comparisons being made in the other, introducing the possibility of a type 
1 error.33
Comparison – intervention versus no intervention
The primary outcome was not overtly stated in eight of the studies. Of the 22 studies included in 
the review, the main outcome of interest was related to clinical processes and performance in 14, 
with the remainder concerned with clinical outcomes (see Table 4).
Studies where the stated primary outcome related to clinical processes included HCP adherence 
to existing guidelines,29,35,39,40 avoidance of adverse drug events,30,31,37,46 patient adherence to med-
ication,41 and patients’ frequency of clinical testing.27 Of the six studies which failed to stipulate 
the primary outcome, one measured HCP adherence to an existing guideline aimed at improving 
diagnosis rates.36
A total of 12 among the 16 studies concerned with clinical processes reported a favourable 
outcome. For those studies aiming to assess HCP adherence to guidelines, most reported an 
improvement;28,29,32,35,39 however, one of these studies also noted a pre-intervention improvement 
in the ITS analysis, introducing the possibility that secular change was responsible for the 
observed improvement.35 The rate of potential adverse drug events was significantly reduced in 
half of the relevant studies.37,46 When compared with controls, patient medication adherence was 
said to be higher; however, the actual difference was small and both groups’ overall adherence fell 
during the study period.41 The other measures of patient-driven clinical processes also improved 
(blood sugar testing27 and service uptake44).
Two of the six studies concerned with clinical outcomes reported positive findings. Four studies 
measured clinical parameters as the primary outcome which included glycaemic control 
(unchanged),26 length of hospital stay (improved),48 change in serum lipids (unchanged),43 and 
time to admission to hospital (unchanged).45 Clinical parameters were also measured in two further 
studies and included glycaemic control (improved)36 and presence of malnourishment and/or pres-
sure ulcers (unchanged).47
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Comparing patient-orientated interventions with HCP-orientated interventions
Eight of the studies targeted patients with the intervention,26,27,33,34,41–44 one study involved an inter-
vention aimed at both HCPs and patients,36 and the remainder focussed solely on HCPs (see Table 3).
For the eight studies where the intervention targeted patients, five (63%) reported that the inter-
vention produced a positive effect. This included increased patient satisfaction,42 monitoring of 
blood glucose,27 adherence to medication,41 system usage,44 and knowledge33 (see Table 4).
For the 14 studies where the intervention was targeted at HCPs, a similar proportion reported 
positive findings (8/14, 57%). These included improved adherence to guidelines,29,35,39 detection of 
morbidity,28,32 decreased adverse drug events,37,46 and length of hospital stay48 (see Table 4).
Risk of bias in included studies
There was a high risk of bias for all studies included in the review, with the exception of one high-
quality study45 (see Table 4). Three studies were assessed as having concealed allocation ade-
quately.37,40,45 The remaining studies either failed to do so or did not provide sufficient information. 
Four studies reported that the assessors were sufficiently blinded to allocation group.30,31,40,45 Of 
the remainder, 10 studies derived outcome data from automated data queries, making assessment 
bias unlikely.28,29,32,37,39–41,43,44,47 Seven studies were assessed as having adequate follow-up of pro-
fessionals and/or patients.30,32,33,41,45–47
Three of the studies were ITS analyses.27,35,48 All three used a reliable outcome measure. It was 
unclear how either of these studies protected against detection bias (in terms of either data collec-
tion or blinded assessment) or secular changes in the population being studied. One study reported 
on the completeness of the dataset, which was assessed as being satisfactory.35
Discussion
In order to assess the effectiveness of tailored messages within eHealth interventions, a comparison 
needs to be made between outcomes of tailored interventions and non-tailored interventions. 
However, based on the results of this review, the research question remains incompletely answered 
for a number of reasons.
First, any direct comparison between tailored and non-tailored interventions was limited to a 
minority of the included studies. Nearly all studies compared the intervention to a no change/stand-
ard practice control group as opposed to a non-tailored intervention. This makes it impossible to 
ascertain whether any improvements were secondary to the tailoring component of the intervention 
per se.
Second, the outcome of either of these comparisons presented a mixed picture. A number of 
studies concluded that there was improvement in clinical processes, for example, adherence to 
guidelines, avoidance of prescription errors, and increased service uptake when compared to no 
intervention. However, most of these studies presented methodological weaknesses meaning that 
these conclusions should be met with caution.
Third, only a minority of studies included in the review included an intervention that fulfilled 
both criteria for what is considered to be tailoring of information. All of the other studies included 
in the review incorporated only one of the two components that define true tailoring. The adoption 
of studies meeting this less strict definition increased the number of studies eligible for inclusion 
but made it difficult to address the research question specifically.
Last, the quality of most of the included studies was assessed as low. However, the introduction 
of methodological quality as an eligibility criterion for inclusion would have excluded almost all 
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of the studies identified. Meta-analysis was not possible owing to the heterogeneous nature of the 
interventions and outcomes of the studies reviewed.
It should be noted that this review is limited to describing the effectiveness of tailored messages 
within eHealth systems and has done so by adopting a quantitative approach. For those studies that 
demonstrate improved outcomes, no attempt has been made to assess which components of the 
intervention were responsible. This will no doubt vary by setting (e.g. patient-orientated versus 
HCP-orientated interventions) and would require alternative methodologies.
Significance
Despite these limitations, some limited conclusions can be drawn. Irrespective of the degree to 
which the intervention incorporated tailoring, or the degree to which tailoring was responsible for 
the observed outcomes, it is notable that 14 of the 22 studies included reported positive findings. 
These improvements were largely limited to clinical processes as opposed to clinical outcomes and 
were observed in interventions aimed at both patients and HCPs. It is also notable that none of the 
included studies reported any harm. This would suggest that personalised eHealth interventions 
(aimed at either patients or HCPs) can safely effect behaviour change which may in turn reduce 
unwanted variation in practice. To what extent tailoring of messages is responsible for this effect is 
unknown.
The lack of studies that combine eHealth technologies with interventions that utilise tailoring of 
information is surprising, given the evidence that tailoring is effective when used in conjunction 
with traditional media, and the ease with which tailoring algorithms can be incorporated into new 
technologies. This may reflect the fact that both are relatively recent innovations. Given the exist-
ing evidence that tailored messages via traditional media can effect behaviour change, it would 
seem a logical extension to incorporate them into eHealth interventions. Clearly, there is a need for 
additional work in this area. Future research should delineate the role of tailoring in eHealth (e.g. 
by comparing it with non-tailored interventions as opposed to no intervention or standard care) as 
well as identifying which are the active components of such interventions (e.g. via future qualita-
tive studies).
Conclusion
Tailoring of information to recipients has previously been shown to be an effective way of chang-
ing behaviour when used with traditional media. This review suggests that eHealth-tailored infor-
mation delivery may improve clinical care, but there is currently a lack of evidence to conclude that 
the use of tailoring within an eHealth context confers any benefits over non-tailored eHealth inter-
ventions. This lack of evidence reflects the low number of good quality studies in this area. It is 
only by designing studies where the role of tailoring is isolated as the active component in the 
intervention, that the effectiveness of tailoring can be adequately assessed.
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User preference and implications for 
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Abstract
Increasing diabetes prevalence has led to the need for more sustainable and person-centred services. 
The diabetes self-care mHealth marketplace is growing, but most effective/valued features are unknown. 
This study gauges diabetes app user opinion to inform development work. An analysis of diabetes 
mHealth apps informed design of a questionnaire sent to a random sample of 400 patients stratified 
by diabetes type and age. Responses were analysed by sub-group, and preferences were compared 
with current diabetes apps. App features included data storage/graphics, exercise tracking, health/
diet, reminders/alarms, education. Questionnaire response rate was 59 per cent (234/400); 144/233 
(62%) owned smartphones. Smartphone users expressed preference towards mHealth (101/142 (71%)), 
although diabetes use was low (12/163 (7%)). Respondents favoured many potential features, with similar 
preferences between diabetes types. This study demonstrates that while mHealth acceptance is high, 
current engagement is low. Engagement and functionality could be improved by including stakeholders in 
future development, driven by clinical/user need.
Keywords
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Introduction
An estimated 385 million of the world’s 7 billion population have diabetes, over three quarters of 
whom live in low or middle income countries.1 Diabetes currently accounts for 11 per cent of 
worldwide healthcare spending with projected costs set to increase, as the numbers affected are 
estimated to reach nearly 600 million by the year 2035.1
The worldwide mobile phone market continues to grow year on year with over 1.3 billion units 
being shipped in 2014, 72 per cent of which were smartphones.2 The World Bank3 estimates 
that worldwide in 2013, there were 92 subscriptions to mobile phone providers per 100 people. 
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Developing countries have demonstrated the largest increase in ownership in the past few years, 
and it was anticipated that ownership in these countries would exceed those in developed countries 
for the first time by the end of 2014.4
The use of mobile devices to improve health outcomes, healthcare services or health related 
research has become known as mHealth.5 Many different smartphone and tablet apps are available 
for managing diabetes, the number of which is rising exponentially.6,7 Functionality that is most 
prevalent included insulin and medication recording, data export and communication, recording of 
dietary intake and weight monitoring.6 Very few apps are designed to improved diabetes knowl-
edge (in contrast to published guidelines which emphasise the need for patient education8–10), and 
there has been no identified formal evaluation of the role of social media in diabetes care.
In general, web-based interventions aimed at improving the management of diabetes have been 
shown to improve clinical outcomes.11,12 It is more difficult to establish which components are 
important to achieve these improvements, however, due to the complex nature of each interven-
tion. Published findings from studies that specifically report on mHealth-based interventions are 
mainly restricted to those interventions which predate the advent of smartphone technology, but 
have concluded that the use of mHealth can result in improved glycaemic control and patient self-
efficacy and knowledge.13
Local context
Diabetes care in Scotland relies on a series of managed clinical networks supported by a national 
informatics platform.14 Despite an increase in diabetes prevalence, there has been a sequential 
improvement in quality performance indicators and the incidences of diabetes-related complica-
tions have decreased.15–17 The informatics platform has also enabled the creation of the Scottish 
Diabetes Research Network (SDRN)18 – a national clinical trials infrastructure that comprises 
10,000 registered patients to date. My Diabetes My Way (MDMW) is a national electronic patient 
health record (ePHR) that is integrated with the national diabetes informatics platform.19 There are 
approximately 10,400 registered users to date.20 Registration for SDRN and MDMW is not mutu-
ally exclusive; however, the similarity between the numbers registered with both is purely 
coincidental.
Project aims
This project aims to utilise the SDRN and MDMW patient cohorts to
•• Assess levels of engagement with web-based and mHealth technologies within the Internet-
using Scottish diabetes population,
•• Identify demographic sub-groups that are more or less likely to use such technologies,
•• Draw comparisons between features that are currently available within the app market and 
features that are most desirable to those with diabetes.
Methods
Review of available diabetes mobile apps
Prior to questionnaire  design, a search was conducted of the Apple app store in July 2014. This 
snapshot search was limited to the search term ‘glucose tracking’ and was principally aimed at 
developing a broad understanding of the diabetes app market; therefore, informing questionnaire 
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content. Apps were included (regardless of price) if they specifically targeted diabetes. Search 
results were then downloaded and reviewed by a single reviewer (I.C.), who identified and catego-
rised available features. The identified features were then incorporated into the questionnaire to 
assess user preference (see below). User preference was also sought for features not identified from 
the snapshot analysis, but thought to be relevant for future app development.
Diabetes patient mHealth Questionnaire
A 39-item questionnaire was designed in four parts: demographics, current use of technology in 
diabetes self-care, preference for mHealth and preferred features/functionality of mHealth applica-
tions developed in the future (questionnaire available on request). The questionnaire was written in 
an electronic format and posted online. No identifiable data were collected. All items utilised a 
categorical response in order to improve response rate and quality of data. Permissions to gather 
data were obtained from the local Caldicott Guardian. All patients contacted had previously given 
consent to be contacted via unsolicited email during the enrolment process for both SDRN and/or 
MDMW. Ethics permission was sought and deemed unnecessary as this work was related to ongo-
ing service improvement.
The MDMW and SDRN datasets were randomly sampled in a stratified way (via a random number 
generator) to return 200 patients, consisting of 50 patients from the following four groups: T1D < 50 years 
old; T1D ⩾ 50 years old; T2D < 50 years old; T2D ⩾ 50 years old. Both samples were also mutually 
exclusive, that is, individuals in the MDMW sample were excluded prior to sampling the SDRN data-
set. All individuals were resident in Scotland and had an active email address that was used to invite 
them to take part in the survey. This invitation email contained a link to the online questionnaire. The 
MDMW survey took place between August–October 2013 and formed the basis of an undergraduate 
student project. The SDRN survey took place between April and June 2014, in an effort to draw com-
parisons between the findings of the MDMW survey and the wider diabetes community.
Statistical analysis
Initial analysis demonstrated that mHealth preference was the same across both groups (see results) 
and so responses from both surveys were combined into one dataset. Preference for mHealth apps 
was measured via two questionnaire items that were conditional on the respondent owning a smart-
phone (respondents were asked to reflect on current diabetes management and were asked to agree 
with the following statements: ‘A smartphone app to manage my diabetes would be a positive 
development’ and ‘I would prefer to use a smartphone app to manage my diabetes’. Both items 
were agree/disagree questions that utilised a 5-point scale). The internal consistency of these items 
as a measure of preference for an mHealth app was tested using the Kappa statistic. The two items 
were then summed to produce a score (out of 10) that was used as a summary of an individual’s 
preference for the use of mHealth technologies – the mHealth preference scale. A higher score on 
the scale (0–10) was interpreted as an individual being enthusiastic about using mHealth tech-
nologies. Demographic variables (age group, gender and diabetes type) were crosstabulated with 
mHealth preference to identify sub-groups of interest. Categories within the demographic variables 
and mHealth preference were collapsed as appropriate, in order to achieve representation in each 
of the cells (see results). Denominators were adjusted to take into account missing data. Loglinear 
analysis was used to identify interactions between demographic sub-groups and mHealth prefer-
ence. Cases with missing data were excluded from analysis of that data field. Significant inter-
actions identified in the loglinear analysis were then explored in greater depth using Chi Square 
and odds ratios.
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In addition to mHealth preference, respondents were asked about current use of technology. 
Responses were analysed with respect to demographic sub-groups that were found to be signifi-
cantly associated with mHealth preference. Finally, all respondents were asked which of the fea-
tures commonly found in mHealth diabetes apps would be most desirable with responses stratified 
according to diabetes type.
Results
mHealth apps
A total of 74 diabetes-related apps were identified through the Apple Store and analysed. 
Approximately half (39/74, 53%) were free, while the others ranged in price from £0.69 to £6.99 
(€0.87–€8.83, US$1.09–US$11.06). In all, 16 separate features were identified. The median num-
ber of features was 5 (range 2–11). All apps had the facility to record blood glucose results, while 
only one incorporated a blood glucose monitor. The available features and the frequency with 
which they were available are listed in Table 1.
Demographics
Responses to the questionnaire were received by 121/200 (60.5%) of the MDMW sample and 
113/200 (56.5%) of the SDRN sample. Data quality was good with very little missing data – for 
example, completion rate was 98–100 per cent for gender, diabetes type, duration of diabetes, treat-
ment and phone ownership. Age group was completed by 218/234 (93%). When compared with 
MDMW respondents, the SDRN group were more likely to be older (SDRN median age group 
56–65 years compared to MDMW median age group 46–55 years, U = 4232, z = −3.771, p < 0.001), 
male (SDRN: 79/112 (70.5%) male c.f. MDMW: 66/117 (56.4%) male, p = 0.029) and have T2D 
Table 1. Frequency of mHealth app features identified during snapshot analysis. Total apps analysed was 74.
Feature Available
 n %
Password protection 9 12
Graphic display/analysis 56 76
Education 10 14
CHO counter 26 35
Data backup 14 19
Email backup 47 64
Glucose monitor 74 100
Physiology tracker 32 43
Download meter 1 1
Weight tracker 33 45
Medication log 24 32
Activity tracker 25 34
Reminders/alarms 21 28
Insulin logger 31 42
Ratio wizard 0 0
Social media 11 15
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(SDRN: 80/109 (73.4%) T2D c.f. MDMW: 59/121 (48.8%), p < 0.001) (age categories were dec-
ades from the age of 16, i.e., 16–25, 26–35, etc.). There was no significant difference in smart-
phone ownership between both groups (SDRN: 75/112 (67%) c.f. MDMW: 69/121 (57%), 
p = 0.077). Similarly, there was no significant difference in prevalence of smartphone ownership 
when those with T1D (55/91, 60.4%) were compared with T2D (85/138, 61.6%). These similarities 
allowed for data to be pooled for subsequent analysis. The majority of respondents (176/229, 77%) 
use self-monitored blood glucose (SMBG) levels in their diabetes management.
mHealth preference
In all, 144/233 (62%) people owned a smartphone, of which 142 gave their preference for mHealth 
technologies. The majority expressed an interest in the use of mHealth apps to manage their diabe-
tes – 101/142 (70.1%) agreed or strongly agreed with the statement a smartphone app to manage 
my diabetes would be a positive development, and 79/142 (54.9%) agreed or strongly agreed with 
the statement I would prefer to use a smartphone app to manage my diabetes. As expected, there 
was a statistically significant correlation between responses for each of these statements, which 
demonstrated moderate agreement (Kappa = 0.45, p < 0.001, 95% confidence interval (CI): 0.35–
0.56). The responses to both of these items were then summed to calculate an individual’s mHealth 
preference score, available for 127/144 (88%) of respondents.
mHealth preference was skewed towards high preference (see Figure 1). The score was there-
fore collapsed into high (7–10) and low (2–6) preference categories in order to combine the low 
numbers of respondents at the lower end of the scale. When comparing mHealth preference catego-
ries for each of the demographic groups (age category, gender and diabetes type), there were no 
Figure 1. mHealth preference scale by respondents’ group. Percentages calculated using group totals 
(MDMW: n = 67, SDRN n = 75) as denominator.
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significant differences noted, although there was a trend for people ⩾56 years to express less pref-
erence (data not shown).
The four-way loglinear analysis produced a final model that retained the interaction between 
gender, mHealth preference and age (χ2 (1) = 4.16, p = 0.04) as well as diabetes type and age (χ2 
(1) = 9.58, p = 0.02). The former was explored in greater detail. There was a highly significant asso-
ciation between age and mHealth preference for women with T2D (p = 0.002) but not T1D, whereas 
there was no such association in men – see Table 2. Odds ratios indicated that women ⩾56 years of 
age (with T1D or T2D) were 28 times less likely than younger women to express a preference for 
mHealth applications to help with their diabetes. In comparison, older men (with T1D or T2D) 
were only two times less likely to express a preference when compared to younger men.
Smartphones and use of technology for diabetes
With regard to current use of technology, of the 144 people who owned a smartphone, 121 (84%) 
used their phone more than once a day. The use of the two main operating systems was roughly 
equivalent (Android: 69/144, 48%; iOS: 57/144, 40%). Both men and women ⩾56 years of age 
were significantly less likely to find the use of smartphone apps ‘enjoyable’ when compared with 
younger adults (females who found apps enjoyable: ⩾56 years 1/8 (12.5%) vs 26/41 
(63.4%) < 56 years, p = 0.001; males who found apps enjoyable: ⩾56 years 20/44 (45.5%) vs 28/39 
(71.7%) < 56 years, p = 0.042).
In all, 176/229 (76.9%) respondents reported that they needed to check blood glucose regularly 
as part of their diabetes self-care, including the majority of those with T2D (T1D: 89/90, 98%; 
T2D: 87/139, 63%). Of those who did use blood glucose monitoring as part of their diabetes self-
management, the majority did not use any device to remind them to do so (116/163, 71.8% (NB. 
13 individuals did not respond)) (response to the question: How do you remind yourself to take 
medication and/or check blood sugars? Tick all that apply from the following: Just remember with-
out aids/I use an alarm/I have a set routine/I use my phone to set reminders/Someone Reminds Me/
Somebody (carer, relative or friend) does it for me), with no significant differences between demo-
graphic sub-groups (data not shown). The most common way of recording the result was via the 
monitor device (87/163, 53.4%) or a written diary (56/163, 34.4%). Use of other technologies was 
minimal – 12/163 (7.4%) used their phone and 17/163 (10.4%) used their home computer (via a 
Table 2. mHealth preferences stratified by demographic sub-groups.
Gender Diabetes type Age (years) mHealth preference scale 
(collapsed)
Total p value
 Low High  
 n % n %  
Female Type 1 <56 6 28.6 15 71.4 21 0.138
 ⩾56 1 100.0 0 0.0 1  
 Type 2 <56 3 15.8 16 84.2 19 0.002
 ⩾56 6 85.7 1 14.3 7  
Male Type 1 <56 2 11.8 15 88.2 17 0.561
 ⩾56 2 20.0 8 80.0 10  
 Type 2 <56 4 19.0 17 81.0 21 0.351
 ⩾56 11 34.4 21 65.6 32  
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spreadsheet). The only significant difference between age categories for either gender was that 
women ⩾56 years were significantly less likely to use their home blood glucose monitor (HBGM) 
to record results (9/24, 37.5% women ⩾56 years vs 28/43, 65.1% women < 56 years, p = 0.027).
Preferences for mobile technology use and app features
Preferences were analysed with respect to diabetes type. Response rates for each of the suggested 
features varied between 84–87/91 (92–96%) for those with type 1 diabetes and 123–135/139 
(88%–97%) for those with type 2 diabetes. If available, the feature that both types of users would 
most commonly use was password protection (47/84, 56% for T1D and 89/129, 69% for T2D) – 
see Figure 2. Thereafter, approximately 40–50 per cent of respondents indicated that they would 
use the various suggested features, irrespective of diabetes type, for example, preference for fea-
tures relating to activity and exercise did not differ markedly between those with T1D and T2D.
Diabetes type did have some influence on the types of features that would be desirable, for 
example, those with T1D showed higher preference for a ratio wizard (39/87, 45% vs 25/122, 21%; 
p < 0.001) and logging of insulin (38/88, 43% vs 33/123, 27%; p = 0.02). If this comparison was 
restricted to only those who used insulin, this significance was lost or reduced (ratio wizard: 39/87 
vs 10/40 p < 0.05; insulin logger 38/88 vs 13/39, p = 0.07). Preference for a glucose-monitoring 
feature was also higher for those with T1D (T1D: 46/87, 53%; T2D 50/135, 37%; p = 0.03). Again, 
there was no such difference between diabetes types if analysis was restricted to those who self-
monitor blood glucose (46/87 vs 32/85, p = 0.1).
The lowest rated feature was social media integration (positive response: T1D 17/87, 20%; T2D 
26/131, 20%). Preference for social media integration was compared with respect to age group, with 
those < 56 years demonstrating higher preference (30/97, 30.9% positive) to those ⩾56 years (14/108, 
13.0%, p = 0.008). This significance was lost when stratified by gender, owing to smaller numbers.
Figure 2. Preferred features of an mHealth app, stratified by diabetes type. Features are arranged in 
descending order of preference (T1D and T2D combined). Denominators for preference vary depending 
on number of respondents to each item (total n = 213–226). ‘Strongly agree’ and ‘agree’ were categorised 
as being positive responses. ‘Strongly disagree’ or ‘disagree’ responses were categorised as being 
negative.
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Discussion
This study has demonstrated interesting insights regarding the use and preferences for mobile tech-
nology in a diverse diabetes population. In general, smartphone ownership and use was high and 
in keeping with UK usage.21 However, users did not tend to use these or other technologies when 
managing their diabetes. For example, for those who use SMBG, approximately a quarter used 
some form of reminder (e.g. alarm on phone) to do so. Half of this group used their blood glucose 
monitor to record their results and a small minority used some form of other technology (e.g. 
spreadsheet on desktop computer). It is perhaps unsurprising, therefore, that when asked about 
preferences for app development, a minority felt that reminders and alarms in an app would be 
useful, and less than half felt similarly for the inclusion of the facility to record blood glucose data 
using an app. This contrasts with Dobson and Hall22 who concluded that the majority of respond-
ents would welcome the ability to track blood glucose data.
A comprehensive review of app features currently available concluded that usability is inversely 
correlated with number of features contained within the app.7 In our study, there was a marked 
contrast between the availability of features on the apps included in the snapshot analysis and the 
features that users showed greater preference for. For example, the majority of respondents indi-
cated that patient education would be a useful addition to an app, whereas this feature is currently 
only available in a minority of apps. There was a notable lack of enthusiasm for social media inte-
gration with any future app development – while younger people were significantly more likely to 
show preference for this feature, only one-fifth of respondents were positive overall.
The digital diabetes landscape has grown rapidly over the past decade and there is evidence that 
web-based interventions can lead to improved clinical outcomes.11,12 The use of mHealth applica-
tions has the potential to improve access to such services, thereby addressing a key component of 
the ‘digital divide’.23 However, there is increasing evidence that Internet usage patterns reflect 
underlying demographic and socioeconomic differences, with the potential to increase health ine-
qualities.24 In this study, most respondents expressed a preference for mHealth apps to manage 
their diabetes; however, gender, diabetes type and age were significant confounders – women 
⩾56 years were significantly less likely to express a preference for mHealth apps. This is in keep-
ing with findings from elsewhere22 Again, this has implications for future app development in 
terms of ensuring that population sub-groups do not feel alienated or become disenfranchised.
Limitations
There are a number of limitations acknowledged in this study. The sample size was one of conveni-
ence as opposed to the result of a power calculation. The use of stratified sampling from more than 
one dataset ensured that the respondents included sub-groups of the wider diabetes community in 
terms of diabetes type and age, although the number of those with T1D was over-represented when 
compared with national data.20 In addition, low numbers in certain demographic sub-groups (e.g. 
older women) make it difficult to make robust statistical inference. Young people < 16 years old 
were not included, and it could be argued that this user group would provide a very different per-
spective on the use of mHealth technologies. It should also be noted that the MDMW and SDRN 
cohorts may have some inherent biases in that both datasets may represent a more engaged section 
of the diabetes community – they have all given prior consent to be contacted for research and all 
those contacted were Internet users (contact was via email address). In addition, subscribers to the 
online MDMW portal are probably more likely to be engaged with modern technology, tend to be 
younger and, by implication, have less comorbidities. While not being representative of the wider 
diabetes community, it could be argued that the sample demographic is a potential strength of the 
study as this population is more likely to use mHealth technologies. We did not gather data on 
 at University of Dundee on December 16, 2015jhi.sagepub.comDownloaded from 
Conway et al. 9
questionnaire respondents’ ethnicity. The sample was drawn from a population who are 96 per cent 
White.25 This limits the generalisability to other populations, given that ethnicity is associated with 
the likelihood of engaging with mHealth technologies.26 Another potential shortcoming is that the 
use of categorical responses introduced limitations to the analysis. However, the relatively high 
response rate can in part be attributable to the ease in which the questionnaire can be completed, 
and so we believe this design was justified. The search strategy of available apps was limited in 
terms of search terms and marketplace (iOS apps only). The decision to limit the search in this way 
was a pragmatic choice that was primarily intended to inform questionnaire design. We believe the 
results to be representative of the wider app market.
Conclusion
The growing prevalence of diabetes accounts for an ever-increasing proportion of healthcare 
spending. There is a recognised need to improve the way that care is delivered to provide a more 
sustainable and person-centred service. The integration of mHealth technologies within existing 
informatics systems has the potential to empower patients, increase patient choice, improve out-
comes and provide service in a different and sustainable way.
This study has demonstrated that in this sample of people with diabetes, most would welcome 
the development of mHealth technologies to help manage their condition. However, we have also 
shown that the functionality of existing apps does not currently meet the preferences of this poten-
tial user group. Both functionality and user engagement could be improved by including relevant 
stakeholders in future app development, which should be driven by clinical and user need as 
opposed to what is easiest to develop.
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Abstract
Background: Automated clinical decision support systems (CDSS) are associated with improvements in health care
delivery to those with long-term conditions, including diabetes. A CDSS was introduced to two Scottish regions (combined 
diabetes population ∼30 000) via a national diabetes electronic health record. This study aims to describe users’ reactions 
to the CDSS and to quantify impact on clinical processes and outcomes over two improvement cycles: December 2013 to 
February 2014 and August 2014 to November 2014. 
Methods: Feedback was sought via patient questionnaires, health care professional (HCP) focus groups, and
questionnaires. Multivariable regression was used to analyze HCP SCI-Diabetes usage (with respect to CDSS message 
presence/absence) and case-control comparison of clinical processes/outcomes. Cases were patients whose HCP received 
a CDSS messages during the study period. Closely matched controls were selected from regions outside the study, 
following similar clinical practice (without CDSS). Clinical process measures were screening rates for diabetes-related 
complications. Clinical outcomes included HbA1c at 1 year. 
Results: The CDSS had no adverse impact on consultations. HCPs were generally positive toward CDSS and used it
within normal clinical workflow. CDSS messages were generated for 5692 cases, matched to 10 667 controls. Following 
clinic, the probability of patients being appropriately screened for complications more than doubled for most measures. 
Mean HbA1c improved in cases and controls but more so in cases (–2.3 mmol/mol [–0.2%] versus –1.1 [–0.1%], P = .003). 
Discussion and Conclusions: The CDSS was well received; associated with improved efficiencies in working
practices; and large improvements in guideline adherence. These evidence-based, early interventions can significantly 
reduce costly and devastating complications. 
Keywords
decision support systems, clinical, diabetes mellitus, guideline adherence, process assessment (health care) 
Best practice in the management of diabetes has been 
established by the use of national guidelines based on an 
appraisal of the available evidence.1-3 Diabetes care in 
Scotland relies on a series of managed clinical networks 
supported by a national informatics platform—the Scottish 
Care Information Diabetes Collaboration (SCI-Diabetes).4 
Regional and national audits of clinical practice are 
published on an annual basis using data extracted from SCI-
Diabetes.5 Despite the rising prevalence of diabetes in 
Scotland there has been a sequential improvement in QPIs 
and the incidences of diabetes-related complications have 
decreased.6-8 However, there is room for improvement in 
adherence to guidelines, as evident when comparing with 
the international community.9 
It is estimated that more than half of all clinical decisions 
fail to take account of the best available evidence.10 In 
addition, evidence-based guidelines often do not 
accommodate comorbidities and multiple medications.11-13 
There is a recognized need to find innovative ways of 
integrating knowledge into clinical workflow, to 
contextualize and personalize care, and to manage the 
complex care needs and human factors that contribute to 
unwanted variation in practice.14,15 
Clinical decision support systems (CDSS) utilize 
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algorithms of varying complexity that are applied to 
existing eHealth systems. The use of automated reminders 
via CDSS has been shown to be one of the most 
consistently successful approaches to encourage clinicians 
to adopt evidence-based practice,16 although there is a lack 
of evidence to demonstrate that this translates into 
improved clinical outcomes.17 
This study reports on a project that aimed to pilot a 
CDSS within the SCI-Diabetes system within two regions 
in Scotland. The evaluation aimed to assess users’ and 
patients’ reaction to the CDSS, to demonstrate whether 
there were no unintended adverse effects attributable to the 
system, and to quantify any change in clinical processes or 
outcomes. 
Methods 
The CDSS was based on the Evidence Based Medicine 
electronic Decision Support (EBMeDS) system developed 
by the Finnish Medical Society—Duodecim Medical 
Publications Ltd, who collaborated on the project.18 The 
various algorithms used to generate CDSS messages were 
amended to conform to Scottish national guidelines,1 with 
full details of the final scripts available via the EBMeDS 
website.19 EBMeDS is accredited by the UK National 
Institute for Health and Care Excellence (NICE),20 and is 
currently being evaluated in a number of settings.21-25 
Messages could be grouped into 3 main categories: 
1. Reminders of pending investigations, eg, screening
tests for diabetes-related complications
2. Prompts to consider intervention, eg, initiating a
treatment associated with improved long-term
outcomes
3. Alerts to a potentially deleterious situation, eg,
prescribing of a contra-indicated medication or
inappropriate dose
The SCI-Diabetes user interface (UI) was adapted to 
display these messages within a “pop-up” dialogue box that 
appears on opening an individual patient record, the 
appearance and behavior of which was adapted in light of 
user feedback (see Figure 1). 
All people with diabetes in Scotland are registered to 
SCI-Diabetes (approximately 280 000 individuals).5 The 
system encrypts and transmits compressed, coded data via 
the NHS N3 network. HCP access is dependent on which 
health care domain the user is employed. All study data 
were extracted in a pseudo-anonymized format. Data 
controllers retained the cipher and all data was transferred 
to the researchers using a secure NHS file sharing network. 
Permission to access these data was granted via the national 
Caldicott Guardian, in accordance with the UK Data 
Protection Act 1998.26 The service improvement nature of 
the project precluded the need for formal research ethics 
review. 
Implementation of the CDSS within SCI-Diabetes 
adopted a quality improvement approach whereby the 
system was introduced to a limited number of health care 
domains; evaluated for acceptability; adapted in light of 
user feedback; and then introduced more widely. Two such 
“improvement cycles” ran over the course of an 18-month 
period. Cycle 1 was conducted in Tayside, Scotland, and 
included Ninewells hospital diabetes clinic plus one general 
practice. Cycle 2 widened coverage to include St John’s 
hospital, Livingston diabetes clinic. The system was then 
implemented for the whole of NHS Tayside (including 
primary care) to cover a combined diabetes population of 
∼30 000. This study reports on data obtained from
improvement cycles 1 and 2 (see Figure 2). 
Patient Reaction 
A patient-reported experience measures (PREMs) 
questionnaire was devised and distributed to patients 
attending diabetes clinics at two time points: December 
2013-February 2014 (cycle 1) and August 2014-February 
2015 (cycle 2). The questionnaire was adapted from the 
NHS Scotland Patient Survey27,28 and consisted of a series 
of closed, 5-point Likert-type scale items grouped within 
different domains: interaction with doctors and nurses, use 
of medication, and general satisfaction. A copy of the 
questionnaire is available within the supplementary files. 
Scores were calculated for each domain. The domain scores 
served as dependent variables in a multivariable linear 
regression analysis. Patient demographics and 
presence/absence of a CDSS message displayed to the HCP 
were entered as independent predictors. 
Health Care Professional Reaction 
Two questionnaires were developed for distribution to 
health care professional (HCP) users of SCI-Diabetes and 
distributed prior to, and at the end of each 3-month quality 
improvement cycle in both primary and secondary care. 
The questionnaires were available in electronic and paper 
versions and consisted of a series of closed 5-point Likert-
type scale questions grouped by theoretical construct, 
derived from the Unified Theory of Acceptance and Use 
of Technology (UTAUT) model,29 and adapted from the 
work of Heselmans et al.30 Construct scores served as 
dependent variables in a multivariable linear regression 
analysis. HCP demographics were entered as the 
independent predictors. 
Three HCP focus groups were conducted, each 
comprising 8-9 HCPs of varying roles within the diabetes 
departments taking part in the study. The first focus group 
explored attitudes to CDSS prior to implementation. The 
second group gave reaction and feedback following the first 
improvement cycle. The system was amended in light of 
this feedback and the third focus group gave their reaction 
to these changes. A constant comparative approach 
identified emergent themes describing the differing 
attitudes to CDSS adoption. 
For the quantitative analysis of HCP system usage, data 
were extracted from the SCI-Diabetes audit trail for 
improvement cycle 1. The outcomes of interest were the 
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number of user “clicks” within patient record and the 
duration of time that the patient record was viewed. 
Figure 1. Screenshot of SCI-Diabetes user interface showing CDSS short message pop up dialogue box within a test page.
Figure 2. Project timeline showing the 2 improvement cycles.
NWH, Ninewells Hospital; GP, General Practice; SJH, St John’s 
Hospital. 
Comparison was made between presence or absence of a 
CDSS message using multivariable generalized estimating 
equations, correcting for number of CDSS messages; 
patient comorbidity score; diabetes type; insulin therapy 
and socioeconomic status. 
Clinical Processes 
The outcomes of interest included adherence to guideline 
recommendations (as measured by QPIs). The QPIs 
included screening for foot disease (standardized foot 
screening in accordance with Scottish diabetes group 
guidance);31 hyperlipidemia (serum cholesterol); thyroid 
disease (serum thyroid stimulating hormone [TSH]); and 
kidney disease (serum creatinine and urinary albumin/ 
creatinine ratio [UACR]). 
Cases were defined as those patients where the HCP 
received a CDSS message during the period of study. Cases 
were matched to controls residing in regions within 
Scotland that were not taking part in the study (ie, their 
HCP did not receive any CDSS messages), and who had 
attended their local diabetes clinic during the period of 
study. Controls were matched in a ratio of 2:1 based on the 
following criteria: age (±2 years); gender; diabetes type; 
duration of diabetes (±2 years); BMI (±2 kg/m2); and 
attendance at clinic during the study period. 
Cases and controls were included in the analysis of each 
QPI if there were no recorded screening tests within the 
previous 15 months (24 months for TSH). In each instance, 
cases’ HCP received a CDSS message alerting them to this 
fact, whereas no such message was displayed to controls’ 
HCP. Adherence was considered improved if those patients 
with no recorded screening activity proceeded to have the 
screening test done within 30 days postappointment. Cases 
and controls were compared by multivariable linear 
regression taking into account potential demographic 
confounders (user role, patient age, diabetes type/duration, 
comorbidity, and deprivation). 
Power was calculated using the foot disease screening 
primary outcome. Based on national data, 82% of patients 
would have received foot screening in the preceding 15 
months.32 Approximately 1200 patients would attend clinic 
during the period of study, 216 (18% of 1200) of whom 
would have had no foot screening in the past 15 months. 
With no intervention, it was assumed that 12 of these 
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patients would receive foot screening every month (ie, 
background screening rate: 82% of 216 divided by 15 
months = 11.8). If the CDSS resulted in the HCP screening 
an additional 8 patients per month then over the course of 
the 3-month study period, 60 patients who had not received 
foot screening for 15-months (ie, 3*(8+12)) would receive 
foot screening in the intervention clinic (60/1200 = 5%). It 
was assumed that the control patient group (anticipated 
n = 2400) was subject to the same background rate of foot 
screening, resulting in 24 patients per month who had not 
received screening in the past 15-months receiving foot 
screening through routine care—equivalent to 72/2400 
(3%) over the three-month period. The resulting difference 
between the 2 samples (5% of 1200 vs 3% of 2400) would 
allow the null hypothesis that there is no difference between 
the 2 groups to be rejected with 90% power. 
Clinical Outcomes 
This analysis considered all cases in whom a CDSS 
message was displayed to HCPs (ie, including those 
instances outside the diabetes clinic environment) during 
improvement cycles 1 and 2, matched in the same way to 
controls living outside the study area, that is, the controls 
had attended the diabetes clinic but the decision support 
system was not available. The main clinical outcome of 
interest was change in glycemic control (HbA1c) at one 
year following the initial CDSS message (cases) or one year 
following the initial consultation (controls). 
Secondary outcomes included change in serum 
cholesterol, blood pressure (systolic [SBP] and diastolic 
[DBP]) and urinary albumin/creatinine ratio (UACR). All 
samples were processed and analyzed by local NHS 
biochemistry laboratories (fully accredited to ISO 15189 by 
the United Kingdom Accreditation Service). Paired data 
were obtained for each dependent variable from baseline 
and follow-up at 9-15 months. Comparison of baseline data 
was made using Student’s T test. The difference between 
baseline and follow-up values were calculated and then 
cases and controls were compared by multivariable linear 
regression, taking into account potential demographic 
confounders. Independent variables with significance of 
P < .3 on initial univariate regression were retained in the 
final model. 
Power calculations were based on 1200 patients 
attending clinic during the study period, of which it was 
assumed that a prompt would be displayed to the HCP in 
20% of cases (n = 240). Prior to the study, the mean HbA1c 
for patients in Tayside was 59 mmol/mol.32 A 2 mmol/mol 
reduction in mean HbA1c in cases, with no observed 
difference in controls at follow-up would result in the 
rejection of the null hypothesis that there was no difference 
between the groups with 81% power (assuming SD = 10). 
Results 
Patient Reaction 
A total of 359 questionnaire responses were received from 
cycles 1 and 2 combined, from a total population of 2072 
clinic attendances (17%). Response rates were higher for 
cycle 2 (281/471, 60%), following the introduction of 
dedicated research staff to improve distribution. Responses 
to all domains were overwhelmingly favorable with >90% 
or respondents reporting positively to each item. There was 
no significant association between presence or absence of a 
CDSS message and score in any of the domains, suggesting 
that the CDSS had no impact on patient satisfaction with 
the consultation. 
Health Care Professional Reaction 
The response rate for pre and post intervention 
questionnaires was 57/105 (54%) and 39/105 (37%), 
respectively. Attitudes to the CDSS were mixed. The 
majority of respondents had a positive or neutral response 
to the content of the reminders (in terms of relevance, 
clarity, and quality) and ease of use. Despite this, self-
reported use of the system was low. Work role predicted 
users’ performance expectancy (ie, the degree to which an 
individual believes the system will help them with their 
work), which was significantly higher for nurses. 
The focus groups demonstrated that HCPs were 
generally receptive to the idea of a CDSS and could 
appreciate its utility. There were concerns regarding user 
fatigue; insufficient tailoring to role; covert surveillance of 
system use; and the applicability of guidelines in general to 
a complex patient population. Following implementation, 
there was evidence of some users using the system within 
their normal clinical workflow to improve the efficiency of 
their use of SCI-Diabetes. System behavior was amended in 
light of feedback prior to the second improvement cycle and 
subsequent feedback was positive. 
With regards to system usage, there were 5355 unique 
patient records opened during improvement cycle 1, each 
record being opened a median of 3 times (range 2 to 56, 
interquartile range (IQR) 4). The total number of records 
opened was 17 280. CDSS messages were displayed on 
opening 6665/17 280 patient records (39%). When 
displayed, the median number of CDSS messages was 3 
(range 1 to 12, IQR 3). Presence of a CDSS message had no 
association with the duration that the record was viewed by 
nurses, however the number of mouse clicks made by 
nurses within the patient record was significantly increased 
when a CDSS message was displayed (median number of 
clicks (IQR) 19 (29) versus 16 (25), adjusted P = .014). 
Among doctors, the duration that the record was viewed 
was significantly reduced when a CDSS message was 
displayed (median duration (IQR) 33 sec (81) vs 38 sec 
(85), adjusted P = .032), with no other significant 
confounders. The presence or absence of a CDSS message 
had no relationship with number of mouse clicks made by 
doctors. 
Clinical Processes 
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A CDSS message was displayed to an HCP in 1883 cases 
attending the diabetes clinic (cycle 1 = 1116, cycle 2 = 767 
cases), of which 1749 were matched to two controls. An 
additional 59 cases were matched to one control, resulting 
in a comparator group of 1808 controls. The remaining 
75 cases were unable to be matched on the defined criteria 
and so were excluded from analysis. There were no 
significant differences between cases and controls for any 
of the matching criteria, that is, age, gender, diabetes type 
and duration, and BMI. 
Prior to the intervention, adherence to each of the QPIs 
was greater than 60% (Table 1). The proportion of all cases 
that had had foot screening in the previous 15 months was 
significantly greater amongst cases than amongst controls 
(76.5% versus 73.4%, P < .001), whereas controls had 
significantly greater adherence to screening for TSH, 
creatinine and cholesterol. There was no difference between 
groups in previous adherence to UACR screening (see 
Table 1). 
In the month following a clinic appointment, a 
significantly greater proportion of cases than controls 
received appropriate screening for foot disease, kidney 
disease and hypercholesterolemia (Table 1). After adjusting 
for potential confounders, patient group (ie, case or control) 
was a significant predictor of whether or not a patient 
received appropriate screening following a clinic 
appointment for each QPI. The size of this effect varied by 
hospital site. During improvement cycle 1, the intervention 
was significantly associated with increased uptake of 
screening for foot disease (adjusted OR 1.4, 95% CI: 1.0 to 
2.1, P = .045) and urinary protein (2.0 (1.5 to 2.7), 
P < .001) but decreased uptake of thyroid disease screening 
(0.2 (0.1 to 0.2) P < .001). During improvement cycle 2, 
cases were significantly more likely than matched controls 
to undergo screening for all of the outcomes, the odds of 
which were far greater than those observed in cycle 
1. Cases were over 4 times more likely than cases to have
their feet, cholesterol and creatinine checked (adjusted OR 
(95% CI): 4.5 (3.2 to 6.3); 4.5 (2.3 to 8.6); 4.2 (2.7 to 6.5) 
respectively, all P < .001); 9 times more likely to have TSH 
checked (9.1 (6.2 to 13.2) P < .001); and twice as likely to 
have UACR checked (2.7 (2.0 to 3.6) P < .001). The overall 
probability of receiving screening more than doubled for 
hypercholesterolemia (adjusted OR 2.4 (95% CI: 1.6 to 
3.0)); creatinine (2.5 (1.6 to 3.9)); UACR (2.3 (1.9 to 2.8)); 
and foot screening (2.9 (2.3 to 3.6)), all P < .001. Screening 
for hypothyroidism decreased slightly (0.8 (0.7 to 1.0), 
P = .035) (see Figure 3).	  
Clinical Outcomes 
A CDSS message was generated for 5692 cases in total 
(including the 1883 cases visiting clinic). Of these, 5245 
were successfully matched to two controls. An additional 
187 cases were matched to one control, resulting in a total 
control population of 10 677. The remaining 260 cases were 
unable to be matched on the defined criteria and so were 
excluded from analysis. 
There were no significant differences between cases and 
controls in terms of demographic variables nor HbA1c 
baseline (71.4 mmol/mol (6.5%) vs 70.6 (6.5%), P = .086). 
Baseline cholesterol, SBP and UACR were significantly 
greater in controls (P < .001, P < .001, P = .028 
respectively) and baseline DBP was significantly higher in 
cases (P < .001) (see Table 2). 
Paired baseline-follow-up HbA1c values were available 
for 2662/5432 (47%) cases and 6203/10 677 (58%) 
controls. Both cases and controls showed small, but 
significant improvements in HbA1c (mean change in 
HbA1c: ,2.3 mmol/l (–0.2%) vs –1.1 (–0.1%), B 1.2 95% 
CI 0.4 to 2.0, P = .003). There were no significant 
differences in change in cholesterol and DBP between the 
groups. SBP improved more among controls (mean change 
in SBP: –1.3 mmHg vs –3.3, B –2.0, 95% CI: –3.0 to –1.0, 
P < .001). UACR increased in both groups but significantly 
more in the control group (mean change in UACR: 1.6 vs 
4.4, B 2.9, 95% CI 0.7 to 5.1, P = .01) (see Table 2). 
Discussion 
This study showed that the use of the CDSS has not had any 
demonstrable adverse effects on patient experience, clinic 
consultation or working practices. In addition, this study has 
demonstrated improved HCP adherence to guideline-driven 
care. There may also be potential efficiencies and wider cost 
savings by decision prompts which negate the need for wider 
interrogation of the medical record. The modest 
improvements demonstrated in glycemic control have the 
potential to reduce diabetes-related complications in the long 
term. These findings are in keeping with other smaller studies 
assessing the effects of CDSS on the management of long-
term conditions, including diabetes.17 This study further adds 
to the evidence base by demonstrating how an iterative, 
quality improvement approach can lead to effective 
implementation at a population level with large 
improvements in adherence to guidelines. 
This study has also identified differences in working 
patterns between members of the multidisciplinary team. 
When subject to a CDSS prompt, on average, doctors would 
spend less time within the patient record. This may reflect 
focus group findings that the system enables a more 
targeted approach to consultations. In contrast to doctors, 
nurses’ time within the clinical record was unchanged by 
the CDSS, however their interaction with the system 
increased (as measured by user clicks). In this case, the 
CDSS may be acting as a catalyst for users to increase their 
data entry and is consistent with the questionnaire findings 
that nurses had greater performance expectancy. Regardless 
of such supposition, it is worth noting that any change in 
consultation style or efficiencies had no demonstrable 
negative impact on patients’ experience of the consultation, 
as measured by PREMs. 
Diabetes-related complications place a substantial 
burden on health care services. It has been estimated that 
the overall cost of diabetes within the United Kingdom in 
2010/11 was £23.7 billion, with direct costs equivalent to 
approximately 10% of NHS annual spending.33 As disease 
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prevalence increases, it is estimated that by 2035 this 
proportion will rise to 17% of health spending in the United 
Kingdom. Small improvements in glycemic control are 
associated with considerable long-term savings due to 
reduced complications.34 
Table 1. Adherence to Guidelines in Cases and Controls, Before and After Clinic Appointment.
Preclinic Postclinic 
Cases (n = 1883) Controls (n = 3557) P Cases, n(%) Controls, n(%) P 
Foot screening 1440 (76.5%) 2612 (73.4%) .008 243/443 (54.9%) 281/945 (29.7%) <.001 
TSH 1176 (62.5%) 2457 (69.1%) <.001 229/707 (32.4%) 408/1100 (37.1%) .02 
Creatinine 1677 (89.1%) 3305 (92.9%) <.001 168/206 (81.6) 162/252 (64.3%) <.001 
Cholesterol 1541 (81.8%) 3115 (87.6%) <.001 236/342 (69.0%) 213/442 (48.2%) <.001 
UACR 1205 (64.0%) 2305 (64.8%) .287 277/678 (40.9%) 287/1252 (22.9%) <.001 
Preclinic data are those patients who have had a screening test in the preceding 15 months (or TSH within 24 months). Postclinic data relate to patients 
who did not have screening test prior to clinic but went on to receive test in 30 days following clinic appointment. 
Figure 3. Adjusted odds ratios for each of the primary outcomes, stratified by site. Odds represent the probability of a case receiving
screening for the complications of diabetes following a clinic appointment, compared with controls. Adjusted for age, diabetes type and 
duration, gender and BMI. NWH, Ninewells hospital; SJH, St John’s hospital; OR, Odds ratio (log scale); TSH, Thyroid stimulating 
hormone; UACR, urinary albumin/creatinine ratio. 
Table 2. Linear Regression Used to Determine Significance of Patient Group as a Predictor of Clinical Outcomes.
Cases, mean (SD) Controls, mean (SD) 
Mean difference (95% CI), 
univariable P Multivariable P 
Baseline Follow-up Change Baseline Follow-up Change 
HbA1c 
(mmol/mol) 
71.4 (19.7) 69.1 (17.9) –2.3 (16.8) 70.6 (19.8) 69.5 (18.2) –1.1 (17.3) –1.2 (–2.0 to –0.4), P = .002 P = .003 
Cholesterol 
(mmol/l) 
4.2 (1.1) 4.1 (1.1) –0.1 (0.8) 4.3 (1.1) 4.3 (1.1) –0.05 (0.0) 0.0 (–0.1 to 0.0), P = .549 — 
SBP (mmHg) 136.5 (18.5) 135.2 (17.6) –1.3 (19.5) 137.8 (19.9) 134.5 (8.1) –3.3 (20.4) 2.0 (1.0 to 2.9), P < .001 P < .001 
DBP (mmHg) 75.7 (10.8) 75.0 (10.6) –0.8 (11.2) 74.5 (12.0) 73.4 (10.9) –1.1 (12.4) 0.4 (–0.2 to 0.9), P = .244 P = .226 
UACR 8.7 (20.2) 10.3 (24.4) 1.6 (19.8) 9.3 (18.6) 13.7 (37.3) 4.4 (30.0) –2.7 (–5.0 to –0.5), P = .015 P = .01 
All predictors with P < .3 entered into multivariable model. Potential confounders entered into multivariable model included patient age, diabetes type, 
gender, duration of diabetes, and BMI. 
As the prevalence of diabetes grows, so too does the role 
of primary care in delivering care.35 Primary care HCPs are 
tasked with navigating between multiple guidelines in an 
effort to deliver effective care to a population with 
increasing comorbidities.13 In this context, the potential 
utility of decision support systems becomes increasingly 
apparent. 
There are a number of limitations in study design that 
limit the generalizability of our findings. Questionnaire 
response rate was generally low and focus groups were based 
on convenience samples of HCPs. The proxy measures of 
user-interaction with the system (mouse “clicks” and time 
spent within the case record) were blunt instruments. When 
analyzing QPIs, controls were closely matched to cases by 
demographic variables, but there was no ability to match 
local clinical practice. All centers follow the same national 
guidance,1 however it is acknowledge that practice will likely 
vary by center, as borne out by the comparison of guideline 
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adherence at baseline. It is notable that these observed 
differences in adherence at baseline were often in the 
opposite direction to the differences observed at follow-up, 
suggesting that the intervention had a real impact. 
Future work should include further analysis of emergent 
data; widening the scope of the investigation to cover 
additional clinical outcomes (eg, prescribing practices); the 
development and implementation of additional rule-based 
algorithms based on further user feedback and emerging 
literature/guidelines; and the effect of tailoring of messages 
to user group (HCPs and patients). 
Conclusions 
The diabetes digital landscape is evolving at a rapid pace. 
Scotland’s national informatics platform for diabetes 
ensures that widespread implementation of a CDSS is 
technically straightforward. This work could easily be 
adapted to systems within other countries as well as other 
chronic diseases. This project can be viewed as an exemplar 
for other health care organizations considering such 
innovations with the potential to improve the safety, 
quality, and standardization of diabetes care. 
Abbreviations 
ACE, angiotensin converting enzyme; BMI, body mass index; 
CDSS, clinical decision support systems; CI, confidence 
interval; DBP, diastolic blood pressure; EBMeDS, evidence-
based medicine electronic decision support; GP, general 
practitioner; HbA1c, hemoglobin A1c; HCP, health care 
professional; IDF, International Diabetes Federation; IQR, 
interquartile range; NHS, National Health Service; NWH, 
Ninewells Hospital; OR, odds ratio; PREMs, patient-reported 
experience measures; QPI, quality performance indicator; SBP, 
systolic blood pressure; SD, standard deviation; SJH, St John’s 
Hospital; TSH, thyroid stimulating hormone; UACR, urinary 
albumin/creatinine ratio; UI, user interface; UK, United 
Kingdom; UTAUT, unified theory of acceptance and use of 
technology. 
Acknowledgments 
We acknowledge the help and support of staff and patients of NHS 
Tayside and NHS Lothian. 
Declaration of Conflicting Interests 
The author(s) declared the following potential conflicts of interest 
with respect to the research, authorship, and/or publication of this 
article: PN is employed by Duodecim Medical Publications, 
developers and owners of the EBMeDS proprietary system that 
was used in this study. 
Funding 
The author(s) disclosed receipt of the following financial support 
for the research, authorship, and/or publication of this article: This 
work was supported by a grant from the Digital Health & Care 
Institute.	  
References
1. Scottish Intercollegiate Guidelines Network. 116. Management
of Diabetes. A National Clinical Guideline. 2010. Available at:
http://www.sign.ac.uk/pdf/sign116.pdf. [AQ2]
2. National Institute for Health and Care Excellence. Diagnosis
and Management of Type 1 Diabetes in Children, Young
People and Adults (CG15). 2004. Available at:
http://guidance.nice.org.uk/CG15.
3. National Institute for Health and Care Excellence. Type 2
Diabetes: The Management of Type 2 Diabetes (CG87).
2009. Available at: http://publications.nice.org.uk/type-2-
diabetes-cg87. [AQ3]
4. Cunningham S, McAlpine R, Leese G, et al. Databases for
diabetes epidemiology: using web technology to support
population-based diabetes care. J Diabetes Sci Technol.
2011;5(3):523.
5. Scottish Diabetes Survey Monitoring Group. Scottish
Diabetes Survey 2015. 2015. Available at:
http://diabetesinscotland.org.uk/Publications/SDS2015.pdf.
Accessed July 26, 2017.
6. Scottish Diabetes Survey Monitoring Group. Scottish
Diabetes Survey 2014. 2014. Available at:
http://www.diabetesinscotland.org.uk/Publications/SDS20
14.pdf.
7. Schofield CJ, Yu N, Jain AS, Leese GP. Decreasing
amputation rates in patients with diabetes—a
population-­‐based study. Diabet Med. 2009;26(8):773-777.
8. Vallance JH, Wilson PJ, Leese GP, McAlpine R, MacEwen
CJ, Ellis JD. Diabetic retinopathy: more patients, less laser: a
longitudinal population-based study in Tayside, Scotland.
Diabetes Care. 2008;31(6):1126-1131.
9. McKnight JA, Wild SH, Lamb MJE, et al. Glycaemic control
of Type 1 diabetes in clinical practice early in the 21st
century: an international comparison. Diabet Med.
2015;32(8):1036-1050.
10. McGlynn E, Asch S. The quality of health care delivered to
adults in the United States. N Engl J Med. 2003;348:2635-
2645. 
11. Lugtenberg M, Burgers J, Clancy C, Westert G, Schneider E.
Current guidelines have limited applicability to patients with
comorbid conditions: a systematic analysis of evidence-based
guidelines. PLOS ONE. 2011;6(10):e25987.
12. Nobili A, Garattini S, Mannucci P. Multiple diseases and
polypharmacy in the elderly: challenges for the internist of
the third millennium. J Comorbidity. 2011;1:28-44.
13. Guthrie B, Payne K, Alderson P, McMurdo MET, Mercer
SW. Adapting clinical guidelines to take account of
multimorbidity. BMJ. 2012;345:e6341.
14. Scottish Government. The Healthcare Quality Strategy for
NHS Scotland. 2010. Available at: http://www.scotland.gov.
uk/Resource/Doc/311667/0098354.pdf.
15. Scottish Government. NHS Scotland eHealth Strategy 2014-
2017. 2015. Available at: http://www.gov.scot/Resource/
0047/00472754.pdf.
16. Bero L, Grilli R, Grimshaw J, Harvey E, Oxman A, MA T.
Closing the gap between research and practice: an overview
of systematic reviews of interventions to promote the
implementation of research findings. BMJ. 1998;317:465.
17. Garg AX, Adhikari NKJ, McDonald H, et al. Effects of
computerized clinical decision support systems on
practitioner performance and patient outcomes. JAMA.
2005;293(10):1223-1238.
18. Duodecim Medical Publications Ltd. EBMeDS clinical
decision support. 2014. Available at: http://www.ebmeds.org/
8 Journal of Diabetes Science and Technology 
web/guest/home?p_id=129190&b_id=129273&s_id=129273
&lang=en. 
19. Duodecim Medical Publications Ltd. Scripts—EBMeDS.
2015. Available at: http://www.ebmeds.org/web/guest/
scripts?p_id=130805&b_id=130801&s_id=130801&lang=en.
Accessed July 26, 2017.
20. UK National Institute for Health and Care Excellence. NICE
Accreditation. 2017. Available at: https://www.nice.org.uk/
about/what-we-do/accreditation. Accessed July 30, 2017.
21. Sönnichsen A, Trampisch US, Rieckert A, et al.
Polypharmacy in chronic diseases—reduction of
inappropriate medication and adverse drug events in older
populations by electronic decision support (PRIMA-eDS):
study protocol for a randomized controlled trial. Trials.
2016;17(1):57.
22. Moja L, Polo Friz H, Capobussi M, et al. Implementing an
evidence-based computerized decision support system to
improve patient care in a general hospital: the CODES study
protocol for a randomized controlled trial. Implement Sci.
2015;11(1):89.
23. Kortteisto T, Raitanen J, Komulainen J, et al. Patient-specific
computer-based decision support in primary healthcare—a
randomized trial. Implement Sci. 2014;9(1):15.
24. Heselmans A, Van de Velde S, Ramaekers D, Vander
Stichele R, Aertgeerts B. Feasibility and impact of an
evidence-based electronic decision support system for
diabetes care in family medicine: protocol for a cluster
randomized controlled trial. Implement Sci. 2013;8(1):83.
25. Moja L, Passardi A, Capobussi M, et al. Implementing an
evidence-based computerized decision support system linked
to electronic health records to improve care for cancer
patients: the ONCO-CODES study protocol for a randomized
controlled trial. Implement Sci. 2016;11(1):153.
26. GOV.UK. UK Caldicott Guardian Council. Available at:
https://www.gov.uk/government/groups/uk-caldicott-
guardian-council. Accessed July 26, 2017.
27. Department of Health. Outpatients Questionnaire. 2011:1-19. 
Available at: http://www.nhssurveys.org/Filestore//documents/ 
Outpatient_allquestions.pdf.
28. Scottish Government. Patient Experience Survey of GP and
Local NHS Services 2011/12 volume 2: technical report.
2011. Available at: http://www.gov.scot/Publications/
2012/05/1477/12.
29. Venkatesh V, Morris MG, Davis GB, Davis FD. User
acceptance of information technology: toward a unified view.
MIS Q. 2003:425-478.
30. Heselmans A, Aertgeerts B, Donceel P, Geens S, Van de
Velde S, Ramaekers D. Family physicians’ perceptions and
use of electronic clinical decision support during the first year
of implementation. J Med Syst. 2012;36(6):3677-3684.
31. Diabetes in Scotland. Foot Action Group. Available at:
http://www.diabetesinscotland.org.uk/Groups.aspx?catId=C4.
Accessed December 15, 2016.
32. Scottish Diabetes Survey Monitoring Group. Scottish
Diabetes Survey 2012. 2012. Available at:
http://www.diabetesinscotland.org.uk/Publications/SDS
2012.pdf.
33. Hex N, Bartlett C, Wright D, Taylor M, Varley D. Estimating
the current and future costs of type 1 and type 2 diabetes in
the UK, including direct health costs and indirect societal and
productivity costs. Diabet Med. 2012;29(7):855-862.
34. Baxter M, Hudson R, Mahon J, et al. Estimating the impact
of better management of glycaemic control in adults with
type 1 and type 2 diabetes on the number of clinical
complications and the associated financial benefit. Diabet
Med. 2016;33(11):1575-1581.
35. Care Quality Commission. My Diabetes, My Care. 2016.
Available at: http://www.cqc.org.uk/sites/default/files/
20160907_CQC_Diabetes_final_copyrightnotice.pdf.
